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Abstract 
The aim of this research thesis was to explore the structure-activity relationship (SAR) of 
ferrocenyl-peptide bioconjugates, a novel class of potential anti-cancer agents. A series of 
N-(ferrocenyl)naphthoyl amino acid and dipeptide derivatives were synthesised by coupling 
3-ferrocenylnaphthalene-2-carboxylic acid and 6-ferrocenylnaphthalene-2-carboxylic acid 
to α-amino acid ethyl esters and dipeptide ethyl esters in the presence of N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC) and 1-
hydroxybenzotriazole (HOBt). The compounds were fully characterised by a wide range of 
spectroscopic techniques, including 
1
H and 
13
C NMR, IR, UV-Vis, MS and CV. X-ray 
crystallographic studies of intermediate compounds were also performed.  
 
Biological evaluation of the N-(ferrocenyl)naphthoyl amino acid and dipeptide derivatives 
was performed in vitro. These novel derivatives exhibited a strong anti-proliferative effect 
in the H1299 non-small cell lung cancer cell line, whilst the Sk-Mel-28 melanoma cell line 
was slightly more resistant to these compounds. N-(6-ferrocenyl-2-naphthoyl)-glycine-L-
alanine ethyl ester and N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester were 
identified as the most potent compounds. In particular, a remarkable inhibitory effect on 
H1299 cell proliferation was observed for N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine 
ethyl ester (IC50 = 0.13 ± 0.02 μM). 
 
Based on these findings, a secondary SAR study was undertaken. The focus of this study 
was directed to the peptide chain, whereby isosteric replacements were employed to 
generate an additional series of N-(ferrocenyl)naphthoyl dipeptide derivatives. In addition, 
N-naphthoyl analogues of the two most potent compounds and a homologous series of N-
(ferrocenyl)naphthoyl amino acid derivatives were prepared. The compounds were fully 
characterised and biological evaluation identified three more compounds that displayed a 
potent anti-proliferative effect in both cell lines: N-(6-ferrocenyl-2-naphthoyl)-sarcosine-
glycine ethyl ester, N-(6-ferrocenyl-2-naphthoyl)-glycine-D-alanine ethyl ester and N-(6-
ferrocenyl-2-naphthoyl)-γ-aminobutryic acid ethyl ester. The N-naphthoyl analogues were 
shown to be inactive.  
vii 
 
In total, the five most active compounds have an equivalent or more potent anti-
proliferative effect in the H1299 cell line than cisplatin. Furthermore, four of these 
compounds possess IC50 values that lie in the nanomolar range. In the Sk-Mel-28 cell line, 
significant IC50 values ranging from 1.06 ± 0.05 to 3.74 ± 0.37 μM were determined for the 
five compounds. Cell cycle analysis in the H1299 cell line has shown N-(6-ferrocenyl-2-
naphthoyl)-glycine-glycine ethyl ester and N-(6-ferrocenyl-2-naphthoyl)-sarcosine-glycine 
ethyl ester to cause a significant increase in the sub-G0/G1 peak, which is suggestive of 
apoptosis.  
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Chapter 1  
Cancer, chemotherapy and bioorganometallic anti-cancer agents 
1.1. Cancer and cancer chemotherapy 
1.1.1. Introduction 
The term “cancer” is used to describe a disease distinguishable by the abnormal growth of 
cells which ultimately evolves into a population of cells that can invade tissues and spread 
to other parts of the body. It is a Latin term, literally translated from the Greek “Karkinos” 
meaning crab, which refers to the metaphorical claws reaching out to invade surrounding 
tissues. At a molecular level, cancer cells are characterised by numerous alterations in 
multiple gene expression which leads to deviation from the normal program for cell 
division and cell differentiation.
1
 The growth of the tumour cell population is promoted by 
an imbalance between cell replication and cell death. Over time, this aberrant growth of 
cancer cells progresses to form a malignant tumour capable of invading locally, spreading 
to regional lymph nodes and metastasising to distant organs within the body. Thus, if 
cancer cell growth is allowed to continue unchecked over a prolonged period, this disease 
can prove to be life threatening and even fatal to the patient.     
Cancers arise from a single cell which undergoes mutation; consequently, cancer may 
develop in any region within the body. In terms of nomenclature, it is common practice to 
name cancers according to the location of the tumour growth and the type of cell from 
which they were originally derived e.g. lung carcinoma. Carcinoma refers to cancers that 
begin in the skin or in tissues that line or cover internal organs. Similarly, cancers that 
originate in bone, cartilage, fat, muscle, blood vessels or other connective tissues are 
sarcomas. Lymphoma and multiple myeloma arise from cells of the immune system. 
Lastly, leukaemia develops from blood-forming tissue such as the bone marrow, causing 
large numbers of abnormal blood cells to be produced and enter the blood.  
Cancer is a major cause of death and disease worldwide. It is estimated that in 2002 alone, 
there were 10.9 million new cases of cancer and 6.7 million deaths from cancer.
2
 In Ireland 
there were over 21,000 new cases of cancer reported each year up to 2004 and over 11,261 
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cancer deaths annually.
3
 Although incidence rates have increased between 1994 and 2004, 
cancer death rates have fallen during this period, indicating an improvement in cancer 
survival either through early detection, improved treatment or both. Cancer is more 
common with increasing age; half of the patients diagnosed in Ireland between 2000 and 
2004 were over 68 years of age.
3
 Given the fact that more and more people are living 
beyond 65 years, the number of cancer cases is sure to continue to rise.  
The possibility of developing cancer is dependent on a number of risk factors which can 
vary according to the tumour location e.g. there is an increased risk of developing 
melanoma following over-exposure to ultraviolet (UV) radiation. Tobacco is the greatest 
risk factor in the development of many cancers (lung, larynx, oesophagus, stomach, 
pancreas, kidney, liver and bladder). Other factors include genetic predisposition, lack of 
balanced diet and physical activity, obesity, alcohol consumption, exposure to certain 
chemicals and gases (asbestos, benzene and radon gas), exposure to ultraviolet or ionising 
radiation, infections such as the human papillomavirus (HPV) and treatments such as 
exposure to estrogen through Hormone Replacement Therapy (HRT).
4
  
In Ireland, the most common forms of cancer in males are cancers of the prostate, colon, 
lung and lymphoma whereas among women cancers of the breast, colon, lung and ovaries 
are the most common.
3
 Five-year survival rates can be used to gain a more accurate picture 
of the most lethal forms of cancer that affect the Irish population. Survival rates are 
primarily dependent on the location of the tumour, since this influences the ease with which 
the tumour can be detected, which in turns aids detection and treatment at an early stage. As 
a consequence, survival rates for the many distinct forms of cancer show a large variation. 
Perhaps the most striking example is the survival rate for males diagnosed with pancreatic 
cancer (5.4%) compared to that observed for males diagnosed with testicular cancer 
(96.9%).
3
 Lung cancer and advanced metastatic melanoma are two forms of cancer for 
which survival rates remain critically low. Consequently, the research within this project is 
focussed on the synthesis of N-(ferrocenyl)naphthoyl amino acid and dipeptide derivatives 
and their biological evaluation as potential chemotherapeutic agents for the treatment of 
lung cancer and advanced melanoma. 
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1.1.2. Lung cancer 
Lung cancer is a devastating disease and has been the most common cancer in the world 
since 1985. Approximately 1.35 million new cases of lung cancer (12.4% of total cancers) 
occur worldwide every year.
2
 Lung cancer is the leading cause of cancer mortality both 
worldwide and in Europe.
5
 In Ireland, lung cancer is the 3
rd
 most common cancer in men 
and women, is responsible for 20.8% of all cancer-related deaths and has a five-year 
relative survival of only 10.4% for patients diagnosed between 2000 and 2004.
4
 Such low 
survival rates can be attributed to poor detection at the early stage of the disease, which 
severely hinders treatment. In 2001, 47.6% of Irish patients diagnosed with lung cancer, 
presented at an advanced stage (III/IV) and almost the same percentage of patients (46.3%) 
only received palliative treatment.
4
  
Cigarette smoke is the primary environmental cause of lung cancer and is responsible for 
85% of all cases in men and 47% of all cases in women worldwide. However, in Europe 
and North America this figure rises to as high as 90-95% and 74-85% of all cases in men 
and women, respectively.
2
 Other causes include exposure to chemicals such as asbestos as 
well as the naturally occurring radioactive gas, radon. 
Lung cancer is divided into two major types based on histological appearance: small cell 
lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Approximately 20% of all 
lung cancers are SCLC, which is a very aggressive form of cancer due to early metastasis 
(both local and distant).
6
 Chemotherapy is the most common treatment for SCLC because 
of early metastatic spread. However, even with treatment, long-term survival remains poor. 
The remaining 80% of all lung cancers are NSCLC, comprising adenocarcinomas, 
squamous cell and large cell carcinomas.
7
 Surgery is generally regarded as the best 
treatment option for NSCLC. However, 75% of NSCLC tumours are inoperable at the time 
of diagnosis.
7
 A further 20% of patients with locally advanced disease receive radiotherapy. 
In these cases, chemotherapy following standard treatment has been shown to help patients 
live longer.
8
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1.1.3. Melanoma 
Worldwide, malignant melanoma of the skin accounts for 160,000 new cases annually, with 
slightly more cases occurring in women than in men.
2
 Over the past two decades, European 
National Cancer Registries show a rising incidence of melanoma.
9
 In Ireland, the number of 
melanoma cases rose by approximately 50% between 1994 and 2004, making this the 
fastest rising preventable cancer.
3
 Relative survival figures from malignant melanoma are 
relatively high, with 86.3% of patients surviving five years.
4
 This is primarily due to 
increased awareness and detection at an early stage, which is crucial for surgical resection 
of the tumour.  
The principal risk factor associated with melanoma is exposure to UV radiation from 
sunshine or UV-emitting tanning devices. The level of risk of developing melanoma 
through over-exposure to UV radiation depends upon skin type; those with fairer skin that 
sunburns easily are more at risk.
4
 Recently, UV-emitting tanning devices have been 
classified as “carcinogenic to humans” following studies that showed the risk of developing 
melanoma increases by 75% when the use of tanning devices starts before 30 years of 
age.
10
  
Malignant melanoma has the potential to metastasise to any organ within the body, and 
common sites of dissemination include the skin, lymph nodes, liver, bone, lungs and 
brain.
11
 Patients with advanced disease such as those with distant metastasis have a poor 
prognosis, with a one-year survival rate of less than 5%. Advanced metastatic melanoma is 
almost uniformly fatal, with the median survival standing at only nine months. This poor 
prognosis is due, at least in part, to the fact that metastatic melanoma is notoriously 
resistant to all current forms of treatment.  
 
1.1.4. Cancer chemotherapy 
Chemotherapy is the most effective treatment for metastatic tumours. It is the treatment of 
choice for patients who have cancers that do not respond to surgery or radiation. 
Chemotherapy impedes the growth and spread of the tumour by utilising drugs that are 
capable of killing cancer cells. Most conventional chemotherapeutic drugs are cytotoxic 
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agents; they elicit cancer cell death by interfering with the cell replication process. This can 
be accomplished by disrupting the function of DNA, either by acting directly on DNA or by 
inhibiting the enzymes involved in DNA synthesis e.g. topoisomerase II.
12
 Alternatively, 
drugs may act by interfering with the mechanics of cell division e.g. by binding to 
microtubules.
13
 Cytotoxic agents aim to target cancer cells in a selective manner. Their 
selectivity is based primarily on the fact that cancer cells divide more rapidly than normal 
cells. Unfortunately, there are also cells in the bone marrow, digestive tract and hair 
follicles that divide rapidly under normal circumstances. Most cytotoxic agents also act on 
these cells and for this reason myelosuppression (decreased production of blood cells), 
mucositis (inflammation of lining of the digestive tract) and hair loss are all common side 
effects.  
The appearance of cancer cells resistant to a range of cytotoxic drugs is also a serious 
problem in cancer chemotherapy. Clinical drug resistance represents a major barrier to be 
overcome before chemotherapy can become curative for patients presenting with metastatic 
cancer. There are two main types of cancer resistance. Intrinsic drug resistance is present at 
the time of diagnosis in tumours that fail to respond to first-line chemotherapy. In contrast, 
acquired drug resistance occurs in tumours that can often be highly responsive to initial 
treatment, but present with strong resistance to the original treatment upon tumour 
recurrence.
12
 In such cases, the tumour becomes resistant to previously used drugs, as well 
as new agents that possess both different structures and modes of action. A number of 
specific resistance mechanisms that occur at a molecular level have been described in vivo 
and in vitro. The three main proposed mechanisms include the reduction of intracellular 
accumulation of anti-cancer drugs by increased drug efflux (MDR), alterations in drug 
targets (topoisomerase II) or activation of detoxifying systems (glutathione-S-transferases).  
To this day, traditional cytotoxic drugs form the cornerstone of clinical chemotherapy for 
lung cancer and melanoma patients. This is despite the inherent problems associated with 
these agents, including their toxicity, harsh side effects and acquired drug resistance. A 
brief overview of the main anti-cancer agents employed in the treatment of lung cancer and 
melanoma follows. 
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1.1.4.1. Platinum agents 
Cisplatin 1 is a very effective, but highly toxic, anti-tumour drug. Its clinical use was 
initiated in the early 1970s, and it is one of the most widely employed anti-cancer agents, 
useful in ovarian, testicular, small cell lung and other cancers.
14
 It is a square-planar 
complex containing two relatively inert ammonia molecules and two labile chloride ions 
coordinated to the central Pt(II) atom in a cis configuration. The in vivo anti-cancer activity 
of cisplatin is due to the replacement of the chloride ligands by neutral water ligands to give 
reactive positively charged species (Figure 1.1).
12
 This process is facilitated within the cell 
by the relatively low cellular concentration of chloride ions.
15
 The platinum atom of these 
positively charged species binds strongly to DNA, forming covalent bonds with the N-7 
positions of purine bases to yield 1,2- and 1,3-intrastrand DNA crosslinks.      
 
Figure 1.1 Cellular activation of cisplatin 
12
. 
 
The 2
nd
 and 3
rd
 generation platinum drugs carboplatin 2 and oxaliplatin 3 were developed in 
later years to address the severe side effects (nephrotoxicity, neurotoxicity and 
emetogenesis) associated with cisplatin. These derivatives contain different leaving groups 
(cyclobutane-1,1-dicarboxylate and oxalate in the cases of 2 and 3, respectively) in place of 
the chloride ions which aid solubility, increase stability and reduce toxicity.  
 
The platinum agents are some of the most frequently employed anti-cancer agents. 
Chemotherapy with platinum agents is widely used and is regarded as a first line treatment 
for SCLC, either as a single agent or in combination with etopside.
6
 The standard therapy 
for patients with NSCLC is a platinum agent in combination with a second agent, typically 
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gemcitabine, paclitaxel, vinorelbine, and docetaxel.
16
 This is despite the fact that NSCLC is 
known to be inherently resistant to platinum therapy.
17
 Platinum agents are also used as 
single agents for the chemotherapy of metastatic melanoma, although studies have shown 
cisplatin to induce only a 15% response rate.
18
 Another accepted treatment for melanoma 
includes a platinum agent in combination with vinblastine 9 and dacarbazine 4.  
 
1.1.4.2. Alkylating agents 
Alkylating agents are highly electrophilic compounds that attach alkyl groups to DNA by 
reacting at the nucleophilic sites present in the DNA bases. The main nucleophilic sites are 
the N-1 and N-3 of adenine, N-3 of cytosine and in particular, the N-7 of guanine.
12
 Some 
alkylating agents possess two alkylating groups so that following initial reaction with a 
DNA base, the remaining alkylating group can react with another base contained either 
within the same DNA strand or within the complementary DNA strand. Thus, alkylation 
prevents DNA replication and RNA transcription from the affected DNA. It also leads to 
the fragmentation of DNA by hydrolytic reactions and by the action of repair enzymes that 
attempt to remove the modified bases. In addition, alkylation can lead to the mispairing of 
DNA nucleotides, since the normal hydrogen bonding pattern between bases becomes 
altered.  
Dacarbazine 4 and temozolomide 5 are two structurally related prodrugs; both drugs are 
metabolised in vivo to MTIC 6, which spontaneously degrades to form diazomethane, a 
potent alkylating agent. The single-agent chemotherapy of metastatic melanoma depends 
primarily on these two drugs which typically produce response rates that range from 15% to 
25%.
18
 Other examples of alkylating agents sometimes used in the treatment of SCLC and 
melanoma are cyclophosphamide 7 and carmustine 8. 
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1.1.4.3. Anti-microtubule agents 
Anti-microtubule agents prevent cell mitosis by interfering with the formation of the 
mitotic spindle required for cell division. The main cellular target of these compounds is 
the structural protein tubulin. During mitosis, tubulin undergoes polymerisation to form the 
mitotic spindle. The vinca alkaloids, of which vinblastine 9, vincristine 10 and vinorelbine 
are the main examples, bind to tubulin and prevent polymerisation from occurring. 
Taxanes, such as paclitaxel 11 and docetaxel, bind to the β-subunit of tubulin, accelerating 
polymerisation and stabilising the resultant microtubules to prevent depolymerisation.
12
 
Both classes of compounds are frequently used in combination therapies for the treatment 
of lung cancer and melanoma. 
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1.1.4.4. Anti-metabolites 
Anti-metabolites are agents which inhibit the enzymes involved in the synthesis of DNA or 
its building blocks. Gemcitabine 12 is a pyrimidine based anti-metabolite prodrug; it is a 
fluorinated analogue of the natural DNA building block 2-deoxycytidine. Inside the cell, 
the active triphosphate analogue is formed following several enzymatic reactions. The 
cytotoxicity of gemcitabine results from the incorporation of this active triphosphate 
derivative into a growing DNA chain, which causes the addition of a single 
deoxynucleotide and chain termination.
19
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1.1.4.5. DNA topoisomerase inhibitors 
Etopside 13 is a semi-synthetic derivative of the naturally occurring podophyllotoxins, and 
exerts its anti-cancer activity by stabilising the DNA-topoisomerase II complex, preventing 
the resealing of DNA strands which have been cleaved by the enzyme.
12
   
 
 
1.2. Bioorganometallic anti-cancer agents  
1.2.1. Introduction 
Interest in metal complexes with biological applications has grown at a phenomenal rate 
since the serendipitous discovery of the inhibition of cell division by Pt complexes in 1965, 
and the subsequent identification of cis-dichlorodiamineplatinum(II) or cisplatin 1 as an 
effective anti-cancer drug.
20,21
 Research in this area is thriving; so much so that Gainferrara 
et al have recently proposed a system of categorising the diverse range of metal anti-cancer 
compounds according to their mode of action.
22
 Five distinct categories have been proposed 
for these compounds wherein: 
 The metal has a functional role i.e. the activity is derived from direct binding of the 
metal fragment to the biological target. 
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 The metal has a structural role i.e. it is important in determining the shape of the 
compound and binding to the biological target occurs through non-covalent 
interactions. 
 The metal is a carrier for active ligands that are delivered in vivo. 
 The metal compound behaves as a catalyst in vivo e.g. through the production of 
reactive oxygen species (ROS) that cause cell damage. 
 The metal compound is photoactive and behaves as a photosensitiser. 
 
Some of the most promising novel non-platinum metal anti-cancer agents are emerging 
from the field of bioorganometallic chemistry. “Bioorganometallic chemistry” is a term 
first coined by Gérard Jaouen in 1985 to describe the discipline dedicated to the study of 
biomolecules or biologically active molecules that contain at least one direct metal-carbon 
bond.
23
 Organometallic complexes have received much attention, due to the large diversity 
of structure and bonding modes on offer (e.g. π-coordination, multiple M-C bonds).24 
Organometallic compounds containing transition metals, such as Co, Cu, Fe, Ga, Ge, Mo, 
Pt, Sn, Rh, Ru, Ti and V are known to have anti-proliferative (in vitro) and anti-neoplastic 
(in vivo) activities.
25
 In particular, early transition metal compounds belonging to a group of 
metallocene dichlorides (Cp2MCl2) with M = Ti, V, Nb, Mo, have all showed remarkable 
anti-tumour activity.
26
 These derivatives were originally investigated in the hope that the 
cis-MCl2 motif would react with DNA in a similar manner to cisplatin.
24
 In fact, these 
complexes bind only weakly to DNA and more strongly to the phosphate backbone, and 
there is no evidence that they exhibit similar mechanisms of action. The most noteworthy 
of these metallocene compounds is titanocene dichloride 14; the first non-platinum 
organometallic compound to enter clinical trials in 1993. Unfortunately, Phase II clinical 
trials of titanocene dichloride were abandoned when its efficacy as an anti-cancer 
therapeutic against metastatic renal cell carcinoma and metastatic breast cancer proved too 
low to warrant further trials.
27
 
Ferrocene is perhaps the quintessential organometallic molecule, and indeed was the first 
example of the well known “metallocene” compounds to be discovered.28,29 The elucidation 
of this novel π-complexed “sandwich” structure revolutionised the field of organometallic 
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chemistry and resulted in the Nobel Prize in Chemistry being awarded to G. Wilkinson and 
E. O. Fischer in 1973. There now exists an entire class of metallocenes containing various 
transition metals such as V(II), Cr(II), Mn(II), Co(II), Ru(II) and Ni(II), however ferrocene 
is still the main focus of research primarily due to its remarkable stability and ease of 
preparation.
30
 Ferrocene is also a particularly attractive candidate for incorporation into 
biomolecules and biologically active compounds due to its aromatic character, redox 
properties and low toxicity. The medicinal application of ferrocene derivatives is currently 
a thriving area of research, with countless reports showing their activity in vitro and in vivo 
and potential as anti-cancer, anti-malarial, anti-fungal, anti-viral and anti-bacterial agents.
31
 
Most promisingly, phase II clinical trials have commenced with the anti-malarial compound 
ferroquine 15 (SR97193) in combination with artesunate as recommended by the World 
Health Organisation (WHO).
32
 
 
 
1.2.2. Ferricenium salts 
One of the most important properties of ferrocene is the ease by which it undergoes 
oxidation to form the ferricenium cation (Fc → Fc+). This occurs in a reversible manner 
and is demonstrated in Figure 1.2. Oxidation/reduction is accommodated readily by the 
loss/gain of an electron from a high energy, non-bonding orbital and can occur both 
chemically and electrochemically. The oxidation potential of ferrocene is sensitive to the 
nature of its substituents: electron donating substituents such as alkyl groups tend to aid 
oxidation, whereas electron withdrawing substituents such as aryl groups tend to hinder 
oxidation.
30
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Figure 1.2 Oxidation/reduction of ferrocene. 
 
The redox properties of ferrocene have often been implicated in its cytotoxicity.
25
 The anti-
tumour properties of ferricenium salts were first reported by Kopf-Maier et al in 1984.
33
 
These ionic, water soluble complexes were found to exhibit high cure rates in tests against 
fluid Ehrlich ascites tumour. Ferricenium picrate 16 and trichloroacetate salts were found to 
elicit 100% cure rates using an optimal dose of 220-300 mg kg
-1
.   
In vivo studies were conducted by Osella et al to assess the ability of ferricenium salts, e.g. 
[FcCOOH]
+
[PF6]
-
, to inhibit the growth of Ehrlich ascites tumours.
34
 It was observed that 
only Fe(III) ferricenium salts inhibited tumour cell growth; the corresponding Fe(II) 
ferrocene derivatives, e.g. FcCOOH, failed to display any inhibitory activity. Thus, 
inhibitory activity is independent of redox potential, at least in the range 175 to 330 mV. It 
was also observed that ferricenium species do not undergo intercalation with DNA. 
1
H and 
31
P NMR studies suggest that interaction with DNA occurs primarily via an electrostatic 
interaction with the phosphate backbone. Using electron spin resonance (ESR) experiments, 
it was proposed that the ferricenium salts produced hydroxyl radicals (HO
•
) under 
physiological conditions, which in turn resulted in DNA damage. Subsequent studies were 
conducted wherein different ferricenium salts were prepared and evaluated in vitro in the 
MCF-7 breast cancer cell line.
35
 Decamethylferricenium tetrafluoroborate 17 was revealed 
as the most active of these salts, displaying an IC50 value of 37 μM.  
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ESR experiments confirmed that reactive oxygen species (ROS) are produced when 
compound 17 is dissolved in aqueous media. From the ESR pattern it is suggested that this 
occurs via a Haber-Weiss like process, followed by a Fenton reaction to yield the hydroxyl 
radical. Fluorescence Activated Cell Sorting (FACS) measurements of 8-oxo-7,8-
dihydroguanine (8-oxo-Gua), the biomarker for oxidative stress on DNA, also revealed that 
compound 17 was able to increase the 8-oxo-Gua level and induce oxidative stress in cells 
in a dose-dependent manner.    
Preliminary studies by Kowalski et al demonstrated the in vitro cytotoxic activity of 
azaferrocenes in the HeLa cervical cancer cell line.
36
 In particular, compound 18 was found 
to show selectivity for the cancerous HeLa cell line over the non-cancerous NIH 3T3 cell 
line. Although in this study the compounds were evaluated at millimolar concentrations, 
these results were adequate to warrant further investigation of azaferrocene derivatives. 
Subsequent studies showed that azaferrocenes such as compound 19 can induce DNA 
scission, mainly by causing single strand DNA breaks.
37
 Even at the lowest concentrations 
tested, namely 6.25 μM, compound 19 caused complete degradation of the DNA plasmid. 
ESR experiments suggest a free radical mechanism of DNA scission by azaferrocenes. The 
strength of the iron-heteroatom ring bonding and the release of redox active metal cations 
that can generate ROS were found to be important in DNA scission.      
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1.2.3. Metallocene-based selective estrogen receptor modulators (SERMs) and anti-
androgens 
Tamoxifen is a widely prescribed selective estrogen receptor modulator (SERM). It is 
employed in the treatment of hormone-dependent breast cancer, where the estrogen 
receptor (ER) is present. These are known as ER positive cells, ER(+).
38
 SERMs are 
capable of interacting with the estrogen binding sites, despite their non-steroidal structure. 
The anti-proliferative effect of tamoxifen is due to the hydroxylated form 20 produced in 
vivo. 4-Hydroxytamoxifen 20 binds competitively to the estrogen receptor binding site, to 
produce an anti-estrogenic effect.
39
 However, some breast cancer cells do not express ER. 
These are referred to as ER negative cells, ER(-) and are resistant to tamoxifen. Also, some 
cells may develop resistance to tamoxifen following prolonged exposure.
38
  
Over the past decade, Jaouen et al have extensively studied a series of ferrocene substituted 
tamoxifen derivatives. The first of these derivatives, ferrocenyl hydroxytamoxifen 
(hydroxyferrocifen) 21, was reported in 1996 by Top et al.
40
 It was postulated that the 
replacement of the β-aromatic ring of 4-hydroxytamoxifen 20 with ferrocene could produce 
a single molecule possessing both anti-estrogenic and anti-tumour properties. The target 
compound 21 was synthesised as a mixture of (Z)- 21a and (E)- 21b isomers, which were 
separated prior to biological testing. The anti-proliferative effect of both isomers was 
evaluated in the ER(+) MCF-7 breast cancer cell line. IC50 values of 3.4 and 4.9 μM were 
obtained for 21a and 21b, respectively. Tamoxifen was found to exhibit an IC50 of 6.4 μM 
under the same conditions. A DNA damage assay indicated that the ferrocenic compounds 
show genotoxic activity at low micromolar concentrations, whilst tamoxifen does not have 
any effect.   
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Altering the length of the dimethylamino side chain was found not to dramatically 
influence the anti-proliferative activity of ferrocenyl tamoxifen compounds.
41
 Compounds 
such as 21 and 22 (n=3, 5 or 8) displayed a strong anti-proliferative effect in the MCF-7 
cell line when tested at a concentration of 1 μM. However, this effect does weaken when 
the chain is lengthened to n=8.  Extending the biological evaluation to include the ER(-) 
MDA-MB231 breast cancer cell line revealed some interesting results. At 1 μM, compound 
20 had no effect on cell proliferation, whereas the ferrocenyl tamoxifen derivatives 21 and 
22 showed a strong anti-proliferative effect, except for when n=8.     
Pigeon et al prepared the ruthenocene analogue of hydroxytamoxifen, compound 23. In 
vitro, compound 23 displays an anti-proliferative effect similar to compound 20 on ER(+) 
MCF-7 cells, whilst these compounds have no effect on the ER(-) MDA-MB231 cell line.
42
 
Thus, these compounds act in an anti-estrogenic manner similar to compound 20. These 
results contrast surprisingly with those observed for the ferrocenyl derivatives. 
Electrochemical experiments revealed that oxidation leads to rapid decomposition of the 
ruthenocene radical cation. This is a possible explanation for the difference in activity 
between the two analogues, 22 and 23.   
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The activity of compound 21 had been attributed to intracellular oxidation to the 
ferricenium ion, leading to hydroxyl radical formation and oxidative stress. Thus, the 
ability of 21 to induce oxidative stress via the Fenton reaction was investigated by Osella 
and Jaouen.
43
 The level of oxidative stress was assessed by measuring the production of 8-
oxo-Gua, the first product of oxidative attack to DNA and hence, a marker for nucleobase 
oxidative damage. Interestingly, compound 21 did not significantly increase 8-oxo-Gua 
levels, in either hormone-dependent or hormone-independent cells and thus the growth 
inhibition observed cannot be attributed to oxidative stress. 
Hillard et al used cyclic voltammetry to propose another possible mechanism of 
cytotoxicity for the ferrocenyl tamoxifen derivatives.
44
 Cyclic voltammograms of several 
derivatives were obtained in methanol, and then pyridine was added to determine the 
reactivity of the electrochemically generated cations towards nucleophiles. Addition of 
pyridine caused two major changes to the voltammograms. The Fc/Fc
+
 couple became 
irreversible, indicating that the Fc
+
 was scavenged chemically and the Fc oxidation wave 
increased, indicating a secondary electron transfer. Any phenol-oxidation waves also 
underwent a dramatic cathodic shift. They proposed that following oxidation to Fc
+
, the 
electron becomes delocalised over the π-system, imparting a slight positive charge on the 
hydroxyl group. The acidified hydroxyl proton is easily abstracted in the presence of 
pyridine. The resulting phenoxy radical can then be oxidised. Another proton abstraction, 
this time from the ethyl group, results in the formation of a quinone methide. In the 
presence of basic species like DNA, the quinone methide species 24 will be formed which 
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in turn will lead to cell death. The oxidation of tamoxifen and other SERMs to quinoids is 
also a recognised pathway for their cytotoxicity.
45
  
 
This mechanism of action was further validated by studies of derivatives bearing a 
hydroxyl group in the meta-position of the phenol.
46
 For example, compound 25 maintains 
the ferrocene-π-system-phenol motif but the m-phenol prevents quinone methide formation. 
Cyclic voltammograms of 25 show no electrochemical changes upon addition of pyridine to 
solution. In addition, the IC50 value of 25 against MDA-MB231 cells (hormone-
independent) is more than twice that of the p-phenol analogue.  
Nguyen et al have prepared further ferrocenyl tamoxifen derivatives. Compound 26 
maintains the three aromatic rings of the hydroxytamoxifen skeleton, however, a lipophilic 
ferrocenyl group has been appended to this skeleton in place of the dimethyl amino side 
chain.
47
 The IC50 value of compound 26 was 10.4 μM when tested in the ER(+) MCF-7 cell 
line. Interestingly, compound 26 also showed activity in the ER(-) PC-3 prostate cancer cell 
line (IC50 value = 8.9 μM). This suggests that the cytotoxic character of the ferrocenyl 
group is responsible for the observed anti-proliferative activity as the generation of a 
quinone methide species is impossible.  
The structure-activity relationship (SAR) of compound 26 was investigated by varying 
three parameters: the length of the side chain, the presence of one or two phenolic groups, 
and the presence or absence of a ketone group adjacent to the ferrocene moiety.
48
 Removal 
of the ketone functionality and variation of the side chain from one carbon to four carbons 
in length had little effect on the anti-proliferative activity in the PC-3 cell line; IC50 values 
were found to be around 10 μM for each derivative. Conversely, in the MCF-7 cell line 
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each derivative displayed a proliferative effect. Derivatives that possessed only one 
phenolic group and lacked the ketone functionality, showed a proliferative effect in the 
MCF-7 cell line, and had little effect in the PC-3 cell line, when tested at 10 μM. The loss 
of one of the phenolic groups from compound 26 was also found to significantly weaken 
the cytotoxic activity.   
 
Vessières et al have prepared a series of diphenolic compounds derivatised with ferrocene 
and studied their anti-cancer activity in both hormone dependent and independent breast 
cancer cell .
49
 Derivative 27 was found to show strong anti-proliferative activity against 
MCF-7 and MDA-MB231 cell lines, with IC50 values of 0.7 μM and 0.6 μM, respectively. 
Conversely, compound 28, which is a regioisomer of compound 27, displays only modest 
activity against both cell lines.  
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In terms of structure, there are two main differences between compound 27 and 28. In 
compound 27 one of the two phenol groups is always oriented trans to the ferrocenyl 
group, whereas in compound 28 there is a cis relationship between the ferrocenyl and 
phenol groups. Secondly, in compound 27 the two phenol rings are bonded to the same 
carbon of the alkene, whereas in compound 28 each carbon of the alkene is attached to a 
phenol ring. The difference in biological activity of these two compounds indicates that the 
ferrocene moiety is not solely responsible for cytotoxicity. The relationship between the 
ferrocenyl group and the rest of the molecule must also be taken into consideration. 
Derivatives of 27 and 28, where one -OH group has been replaced by an –OMe group, were 
studied by cyclic voltammetry.
44
 Only the compound in which the ferrocene and ethyl 
groups were attached to the same carbon showed irreversible redox activity upon addition 
of pyridine to solution. Therefore, the position of the ferrocenyl group in relation to the 
ethyl group is essential for formation of a quinone methide species. 
 
The in vitro formation of quinone methide species from ferrocenyl phenol derivatives was 
investigated by Hamels et al.
50
 Rat liver microsomes, which contain the main enzymes 
involved in xenobiotic metabolism, were incubated with either compound 22 or 27. 
Analysis by HPLC-MS of a sample taken following incubation for 30 minutes, 
demonstrated the formation of the corresponding quinone methide species as the major 
product of metabolism. The quinone methide species 29 formed from compound 22 (n=3), 
was prepared by chemical oxidation and tested in the ER(-) MDA-MB231 cell line. An IC50 
value of 4.2 ± 1 μM was determined for compound 29. This value is higher than that of 
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compound 22 (IC50 value = 0.5 μM), although this may be due to the instability in the 
incubation medium.  
Compounds 26 and 27 have been successfully incorporated into two types of nanoparticles, 
namely nanocapsules and PEG/PLA (polyethyleneglycol/poly-D-lactic acid) nanospheres 
with the aim of finding an in vivo drug delivery model.
51
 These nanoparticles can improve 
the bioavailability of these compounds by protecting them from hydrolysis, oxidation and 
degradation. Cell cycle analysis revealed that compounds 26 and 27 both increase apoptosis 
in MCF-7 cells when administered freely at a concentration of 10 μM. Upon entrapment in 
PEG/PLA nanospheres, this ability to induce apoptosis is enhanced. At a concentration of 1 
μM, whether free or encapsulated in nanocapsules, compound 27 causes an arrest in S-
phase of the cell cycle, and to a more limited extent in the G2/M phase. No significant 
effect was observed for compound 26 at this low concentration. Further studies performed 
in the presence of α-tocopherol 30, a well known anti-oxidant, showed a decrease in the 
levels of apoptotic cells found in the sub-G0/G1 phase. These results suggest that the anti-
oxidant may prevent oxidation of ferrocene to the ferricenium ion and therefore prevent the 
formation of the quinone methide species, leading to a loss in anti-proliferative effect.  
 
Lipid nanocapsules and swollen micelles containing compound 27 have been prepared by 
Allard et al and studied as a treatment for malignant gliomas.
52
 In vitro survival assays 
were performed on 9L glioma cell and on newborn rat astrocyte primary cultures. An IC50 
value of 0.5 μM was determined for compound 27 when tested in the 9L glioma cells, 
whereas the IC50 value for hydroxytamoxifen 20 was 35 μM and ferrocene was totally 
inactive. Encapsulation in lipid nanocapsules did not alter the anti-proliferative activity of 
compound 27. In contrast, the micelles loaded with compound 27 showed only a toxicity 
related to the nanocarrier, implying inefficient release of the compound to the surrounding 
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environment. When tested on astrocytes, either freely or bound within lipid nanocapsules, 
compound 27 was found to be much less cytotoxic, suggesting selectivity towards cancer 
cells alone. In vivo studies conducted on a 9L subcutaneous glioma model in rats showed a 
significant reduction in tumour mass following treatment with the loaded lipid 
nanocapsules.       
The importance of the ferrocenyl group to the activity of this series of compounds was 
demonstrated by Hillard et al. A series of organometallic analogues of compound 27 were 
prepared wherein the ferrocenyl moiety was replaced by pentamethylferrocene, 
ruthenocene, cyclopentadienyl rhenium tricarbonyl and cyclopentadienyl manganese 
tricarbonyl units.
53
 Incorporation of these units resulted in the loss of anti-proliferative 
effect in the ER(-) MDA-MB231 cell line and an estrogenic effect in the ER(+) MCF-7 cell 
line. Substitution of the ethyl group of compound 27 with chlorine to give compound 31 
decreased the anti-proliferative effect slightly, with the IC50 value increasing to 1 μM 
against MDA-MB231 cells. Cyclic voltammetry experiments indicate that the chloro 
substituent increases the ferrocene redox potential by +40 mV in methanol and +73 mV 
upon addition of pyridine.  
 
The importance of conjugation to the activity of these compounds is evident from the 
biological results obtained for a series of unconjugated ferrocenyl phenols, for example 
compound 32.
54
  IC50 values were determined for compound 32 in ER(-) MDA-MB231 and 
PC-3 cell lines and averaged around 3-3.5 μM. Activity was best when the hydroxyl group 
was in the para-position. In comparison to compound 27, these derivatives are around five 
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to seven times less cytotoxic. Cyclic voltammetry experiments revealed no major change in 
the ferrocene/ferricenium redox couple upon addition of pyridine to a solution of compound 
32. These results indicate that conjugated π-system of compound 27 facilitates the 
generation of a reactive quinone methide species. Due to the absence of a π-system in 
compound 32 it is unable to mediate electron transfer. However, the significant IC50 values 
obtained for this compound indicates that Fenton chemistry may be responsible for the 
observed cytotoxicity.  
 
The importance of the phenol groups of this class of compounds was investigated in a 
number of studies. Initially, Heilmann et al prepared thioether and thioester analogues of 
compound 27, for example compound 33.
55
 When tested at 1 μM, these compounds 
displayed a strong proliferative effect in the ER(+) MCF-7 cell line, and failed to show any 
anti-proliferative effect in the ER(-) MDA-MB231 cell line. The ester analogue of 
compound 33 was also prepared, namely compound 34. At 1 μM, compound 34 displayed 
an anti-proliferative effect equalling that of compound 27. This suggests that the ester 
moiety is hydrolysed by enzymes to generate compound 27 in situ. Since thioesterases are 
known to be present in breast cancer cells, it can be expected that hydrolysis also occurs for 
compound 33. The lack of anti-proliferative activity for compound 33 suggests that the 
corresponding ferrocenyl thiophenol is also not cytotoxic.   
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Pigeon et al have replaced the phenol group with an aniline or acetanilide group to give 
compounds 35 and 36, respectively.
56
 Both compounds were found to show a strong anti-
proliferative effect in the ER(-) MDA-MB231 cell line, with IC50 values of 0.8 μM for 
compound 35 and 0.65 μM for compound 36. Cyclic voltammetry experiments indicate that 
both compounds can be transformed into oxidised products via the ferricenium-mediated 
proton-coupled electron transfer mechanism. It is likely that the reactive species generated 
is an imino methide species, which has been implicated in cytotoxic processes.  
 
Zekri et al studied the effect of incorporating Br, Cl, CF3 and CN groups in place of the 
amino group of compound 35.
57
 No anti-proliferative effect was observed for the Br, Cl and 
CF3 derivatives when tested at a concentration of 10 μM in the ER(-) MDA-MB231 cell 
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line. The cyano analogue 37 of compound 35, was the only derivative to show an anti-
proliferative effect in this cell line. IC50 values of 11 and 60 μM were determined for the 
(Z)- and (E)- isomers of compound 37, respectively. Cyclic voltammograms obtained for 
each derivative lack any features other than the reversible ferrocene/ferricenium redox 
wave. The absence of other oxidation waves indicates the inability of these compounds to 
undergo ferricenium-mediated proton-coupled electron transfer. QSAR studies reveal that 
the cytotoxicity observed for this class of compounds is primarily dependent on the 
presence of a protic substituent in the para-position of the phenyl ring. The resonance 
donating ability of this substituent may also be important for cytotoxicity. 
 
Evaluation of the two lead ferrocenyl phenol compounds in primary and metastatic 
melanoma cell lines was conducted by Michard et al.
58
 Compound 22 (n=3) and 27 were 
tested in a panel of four cell lines, a normal cell line (NHEM), two primary melanoma cell 
lines (WM35 and WM793) and one metastatic melanoma cell line (WM9). At a 
concentration of 1 μM, compound 22 displayed selectivity towards the three melanoma cell 
lines, inducing a strong anti-proliferative effect whilst the normal melanocytes remained 
relatively unharmed. Compound 27 also displayed selectivity for cancerous cells and 
inhibited the growth of the primary melanoma cell lines at a concentration of 0.1 μM. 
However, it was ineffective in the metastatic cell line. Increasing the concentration of 
compound 27 to 1 μM increased the anti-proliferative effect in all four cell lines. An assay 
using the H2DCF-DA fluorescent probe to monitor the production of reactive oxygen 
species (ROS) showed that neither compound induced ROS production in any cell line.    
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Compounds 38 and 39, which possess the [3]ferrocenophane motif incorporated into the 
ferrocenyl phenol structure were prepared and studied by Plazuk et al.
59
 In the ER(+) MCF-
7 cell line, compounds 38 and 39 exhibited IC50 values of 4 μM and 1 μM, respectively. In 
the ER(-) MDA-MB231 and PC-3 cell lines, the anti-proliferative effect of compound 38 
increases dramatically, with an IC50 value of 0.09 μM. This compound is ten times more 
active than compound 39, for which IC50 values of around 1 μM were obtained in both cell 
lines. Conjugation between the ferrocenyl and phenol groups is absent from compound 39, 
which may explain the difference in cytotoxicity. Cyclic voltammetry experiments 
performed in the presence of imidazole show the formation of a quinone methide species 
from both compounds 38 and 39. In the case of compound 39, the required intramolecular 
electron transfer may proceed either “through space” or via the formation of an 
intermediate α-methylene radical, which can delocalise over the π-system and undergo an 
additional oxidation step to yield the quinone methide species.   
 
Gormen et al prepared the monophenol analogue of compound 38, namely compound 40.
60
 
In the ER(-) MDA-MB231 cell line the IC50 value was determined to be 0.47 ± 0.01 μM, 
corresponding to a five-fold decrease in activity. Replacement of the phenol group with an 
acetanilide group does not alter the IC50 value however replacement with an aniline group 
reduces the IC50 value to 0.21 ± 0.03 μM. 
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Tamoxifen has also been appended to other known cytotoxic compounds. For example, the 
cytotoxic (DACH)Pt fragment of oxaliplatin 3 has been attached to the β-aromatic ring of 
tamoxifen molecule via a malonato moiety to give compound 41.
61
 In the ER(+) MCF-7 
cell line, compound 41 had an IC50 value of 4.0 μM, whereas oxaliplatin had an IC50 value 
of 7.4 μM.  Therefore the anti-proliferative effect of 41 is similar to that observed for the 
parent platinum complex. 
 
Top et al also selected titanocene dichloride 14 for attachment to the tamoxifen skeleton.
62
 
However, the most important finding of this study was that the resulting compound 42 
exerted a powerful estrogenic effect on MCF-7 cells. Compound 14 was also found to exert 
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an estrogenic effect, which implies that any anti-proliferative effect due to the tamoxifen 
fragment of 42 is concealed by the strength of the estrogenic effect. The proliferative effect 
caused by 14 has been attributed to the Ti(IV) ion. The parent molecule undergoes 
hydrolysis of the chloride ligands and the cyclopentadienyl groups leading to the complete 
release of Ti(IV). A molecular modelling study indicated that the Ti(IV) ion had a similar 
effect to estradiol on the estrogen receptor (ER).   
 
Raloxifene 43 is a SERM approved for the treatment of postmenopausal osteoporosis. 
Whilst compound 43 is an estrogen agonist in bone tissue, its acts as an anti-estrogen in 
mammary tissue, and has been found to decrease breast cancer risk in postmenopausal 
women. Ferreira et al have prepared a series of organometallic benzo[b]thiophene 
derivatives inspired by the structure of 43.
63
 These 2-benzoyl-3-
ferrocenylbenzo[b]thiophene compounds contain various tertiary alkylamino groups 
substituted at the para-position of the benzoyl moiety. The anti-proliferative activity of this 
series was evaluated in vitro in a panel of human tumour cell lines containing examples of 
ovarian (2008, C13*, RH4), cervical (A431), lung (A549), colon (HCT-15), and breast 
(MCF-7, MCF-7 ADR) cancers. The piperazinyl derivative 44 showed the greatest anti-
proliferative effect across the panel of cell lines, with IC50 values ranging from 0.74 to 3.85 
μM. The anti-proliferative effect of compound 44 was more marked against the breast, 
cervical and ovarian cell lines. A correlation between anti-proliferative effect and redox 
potential of the ferrocene/ferricenium couple is observed for this series of compounds, with 
compound 44 being the most easily oxidised member of the series. 
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Payen et al have prepared ferrocenyl derivatives of the non-steroidal anti-androgen 
nilutamide, used in the treatment of prostate cancer.
64
 Analogues of nilutamide were 
prepared where the C-5 position of the hydantoin ring was substituted with ferrocene 45 
and a para-anisyl group, 46. Both analogues showed negligible binding affinity for the 
androgen receptor (AR), which is claimed to play a vital role in cancer development. The in 
vitro anti-proliferative effect of both compounds was strongest in the hormone independent 
PC-3 prostate cancer cell line. IC50 values of 5.4 ± 0.5 μM and 5.6 ± 0.4 μM were obtained 
for compounds 45 and 46, respectively. These results indicate that any anti-proliferative 
effect is due solely to the aromatic character of ferrocene and is independent of its 
organometallic nature.  
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Organometallic derivatives of the steroidal androgens, testosterone and dihydrotestosterone 
(DHT), have been prepared by Top et al.
65
 Substitution with an ethynylferrocene group was 
carried out at the 17α position of the steroid, to give compounds such as 47. All of the 
compounds were found to show only a negligible binding affinity for the androgen receptor 
(AR). In the hormone independent PC-3 cell line, compound 47 and the corresponding 
DHT derivative displayed a strong anti-proliferative effect, with IC50 values of 4.7 and 8.3 
μM, respectively. As expected, both testosterone and DHT had no effect in this AR 
negative cell line. 
 
 
1.2.4. Ferrocenyl-peptide conjugates 
A series of N-(ferrocenylmethyl)fluorobenzene-carboxamide derivatives were prepared by 
Kelly et al using standard peptide coupling procedures.
66
 The strategic replacement of 
hydrogen with fluorine is a recognised strategy in the development of various drug types. In 
vitro evaluation in the ER(-) MDA-MB-435-S-F breast cancer cell line revealed the 4-
fluoro derivative 48 as the compound showing the strongest anti-proliferative effect. An 
IC50 value of between 11 and 14 μM was determined for compound 48. As the 
concentration of 48 increased, the anti-proliferative effect increased, indicating a dose-
dependent relationship.   
N-(ferrocenyl)benzoyl dipeptide esters have also been shown to be highly active in 
vitro.
67,68,69
 Initially, N-{ortho-(ferrocenyl)-benzoyl}-glycine ethyl ester was tested for in 
vitro anti-proliferative activity in the H1299 non-small cell lung cancer (NSCLC) cell line. 
This compound was found to be cytotoxic, with an IC50 value of 48 μM, whilst the starting 
material, ortho-ferrocenyl ethyl benzoate, was completely inactive in this cell line. 
Therefore, other derivatives were evaluated for their anti-proliferative effect in the H1299 
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cell line. Savage et al prepared a series of N-{meta-(ferrocenyl)-benzoyl} dipeptide 
derivatives containing L-alanine as the first α-amino acid in the peptide chain.67 The L-
alanine-glycine ethyl ester derivative 49 was found to have an IC50 value of 26 μM in the 
H1299 cell line, whilst an IC50 value of 21 μM was calculated for the corresponding ortho- 
analogue.  
 
A series of N-{ortho-(ferrocenyl)-benzoyl} dipeptide derivatives containing glycine as the 
first α-amino acid in the peptide chain were prepared by Corry et al.68 The glycine-L-
alanine ethyl ester derivative 50 was shown to exhibit a strong anti-proliferative effect in 
the H1299 cell line, with an IC50 value of 5.3 μM. Subsequently, the in vitro anti-
proliferative effect of the meta- and para- analogues of 50 was investigated, and the IC50 
values determined were 4.0 and 6.6 μM, respectively.69 These results indicate that 
orientation around the central benzoyl moiety is not a crucial factor for biological activity. 
However, the order of the α-amino acids in the dipeptide chain was found to influence the 
biological activity. N-(ferrocenyl)benzoyl dipeptide derivatives that contained glycine as 
the N-terminal amino acid had a greater anti-proliferative effect in the H1299 cell line than 
derivatives that contained L-alanine as the N-terminal amino acid.  
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The biological activity of these compounds is possibly due to their low redox potentials and 
their ability to form reactive oxygen species (ROS) under physiological conditions. The 
anti-proliferative effect of 50 is not solely due to ferrocene so it is plausible that the peptide 
chain is involved in a secondary mode of action.
67
 Cell cycle analysis was performed on a 
control sample and on cells treated with N-{ortho-(ferrocenyl)-benzoyl}-glycine-L-alanine 
ethyl ester (compound 50) at concentrations of 5 μM, 10 μM, 20 μM and 40 μM. As the 
concentration of compound 50 increases, the percentage of cells in the G1 phase of the cell 
cycle decreases, suggesting a block in the G2/M phase, preventing the cells re-entering the 
G1 phase.
69
    
Corry et al prepared a N-(ferrocenyl)benzoyl tripeptide and tetrapeptide ethyl ester 
derivatives, using standard peptide coupling procedures.
70
 The N-{ortho-(ferrocenyl)-
benzoyl}-glycine-glycine-glycine ethyl ester was tested in vitro for anti-proliferative effect 
in the H1299 cell line and an IC50 value of 63 μM was determined. The tetra-glycine 
analogue was also tested, however, it did not register an IC50 value in the concentration 
range tested (1-100 μM). Thus, it can be concluded that a dipeptide chain is required for 
optimum activity.  
The importance of the benzoyl linker in this series of compounds was investigated by 
Mooney et al.
71
 The benzoyl unit that links the redox active ferrocene group to the peptide 
chain was replaced by a naphthoyl unit to give a series of N-(ferrocenyl)naphthoyl 
dipeptide ethyl esters. The naphthoyl unit employed contained the dipeptide chain 
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substituted in the 2-position and the ferrocene moiety substituted in either the 3- or 6-
position. Assessment of in vitro anti-proliferative effect in the H1299 cell line, revealed this 
series of compounds to be more potent than the benzoyl analogues, with IC50 values below 
10 μM determined for each compound. The N-(6-ferrocenyl-2-naphthoyl)-glycine-L-
alanine ethyl ester 51 exhibited the strongest anti-proliferative effect, with an IC50 value of 
1.3 ± 0.1 μM. Cisplatin 1 was found to have an IC50 value of 1.5 ± 0.1 μM, thus compound 
1 and 51 are equipotent in this cell line. 
 
Joksović et al appended a ferrocenyl pyrazole unit to the N-terminal of α-amino acids.72 
The in vitro anti-proliferative effect of these modified amino acids was evaluated in cervix 
adenocarcinoma (HeLa), melanoma (Fem-x) cells and myelogenous leukaemia (K562) cell 
lines. IC50 values were found to vary from >60 μM to around 6 μM across the range of cell 
lines. The L-tryptophan derivative 52 showed the strongest overall anti-proliferative effect, 
with IC50 values of 7.95 ± 1.42 μM, 9.78 ± 0.27 μM and 6.34 ± 1.24 μM for each respective 
cell line.  
Subsequently, Ratković et al prepared a series of compounds wherein the ferrocenyl 
pyrazole unit was appended to various chalcones.
73
 In vitro evaluation in the same three 
cell lines (HeLa, Fem-x and K562) revealed compound 53 to be the most active ferrocenyl 
chalcone. The strongest anti-proliferative effect for 53 was observed in the myelogenous 
leukaemia K562 cell line. An IC50 value of 5.42 ± 0.53 μM was determined for 53, and is 
comparable with cisplatin in this cell line (IC50 value = 5.90 ± 0.20 μM). 
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Working towards the aim of incorporating an unnatural ferrocene amino acid into a nucleic-
acid-binding protein in order to confer nucleolytic activity, Gellett et al prepared a N
α
-N
ε
-
(ferrocene-1-acetyl)-L-lysine conjugate 54.
74
 The ability of this ferrocene amino acid to 
cleave DNA was studied by incubation of 54 with supercoiled pUC19 DNA. At low 
concentrations, compound 54 predominantly induced single strand cleavage to give circular 
nicked DNA. At higher concentrations, the levels of double strand cleavage were found to 
increase to give 47% linear DNA. In contrast, assays performed with ferroceneacetic acid 
showed no DNA cleavage. It is possible that the amine group of the lysine zwitterion 
present in compound 54 may bring the redox centre of the ferrocene moiety into close 
proximity of the negatively charged DNA backbone.  
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1.2.5. Other metallocene complexes as anti-cancer agents 
Topoisomerases are enzymes that are crucial in DNA replication, transcription and repair. 
They can be divided into two categories, topoisomerase I and topoisomerase II. Due to their 
crucial role in DNA function, topoisomerase I and topoisomerase II inhibitors have become 
important targets for researchers. Several ferrocenyl derivatives have been prepared as 
topoisomerase II inhibitors. The carboxaldoxime derivative 55 had a strong anti-
proliferative effect when tested in vitro in the Colo-205 colon carcinoma cell line.
75
 It is 
proposed that complexation with the topoisomerase II enzyme is as a result of nitrogen and 
oxygen interaction between 55 and the topoisomerase. The azalactone derivative 56 allows 
ATP binding to the topoisomerase enzyme and induces the formation of cleavable 
complexes, while thiomorpholide amido methyl ferrocene 57 competes with ATP binding 
and inhibits the catalytic activity of the enzyme.
76
 The exact role of ferrocene in these 
examples is unclear.    
 
A series of ferrocenyl-aryl-chalcones were prepared by Zsoldos-Mády et al and evaluated 
in vitro in the human leukaemia (HL-60) cell line.
77
 Compound 58 showed the strongest 
anti-proliferative effect (IC50 value = 1.75 μM). Substitution of the phenolic hydroxyl group 
of 58 with either an acetyl or methyl group did not alter the anti-proliferative effect 
significantly. Neither did the attachment of a bulky acetylated glucose or galactose moiety. 
Removal of the phenyl ring to give the acrylic acid derivative 59 resulted in a decrease in 
anti-proliferative effect. Compound 59 was found to display an IC50 value of 9.4 ± 3 μM in 
the HL-60 cell line.
78
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Cyclodextrin (CD) inclusion complexes have been shown to be useful in enhancing the 
solubility, stability and bioavailability of drug molecules. Petrovski et al have studied the 
effect of CD inclusion complexes on the in vitro anti-proliferative activity of a group of 
1,2-disubstituted ferrocenes in the Ehrlich ascites tumour (EAT) cell line.
79
 Compound 60 
was found to display an IC50 value of 71.2 ± 1.1 μM. Upon inclusion in TRIMEB and 
HPβCD, the IC50 value decreases to 25.2 ± 1.0 μM and 20.0 ±1.1 μM, respectively.  
Xie et al prepared a series of novel 5-alkyl-2-ferrocenyl-6,7-dihydropyrazolo[1,5-
a]pyrazin-4(5H)-one derivatives.
80
 In vitro evaluation in the A549 lung cancer cell line, 
revealed compound 61 to be the most active derivative, with an IC50 value of 10 μM after 
48 hours of treatment. Examination of cells treated with 20 μM of compound 61 under a 
phase contrast microscope, revealed the occurrence of morphological changes associated 
with apoptosis, particularly when R = t-Bu.
81
 Compound 61 was also found to significantly 
increase the levels of intracellular reactive oxygen species (ROS). 
 
13-cis-Retinoic acid possesses potential as a chemotherapeutic agent, but harsh side effects 
at the therapeutically required dosage levels prevent it from being of practical value. Long 
et al have prepared a series of organometallic derivatives consisting of 13-cis-retinoic acid 
appended to a ferrocenyl group via either alkyl or aryl linkers.
82
 These derivatives were 
evaluated in vitro for anti-proliferative activity against three cancer cell lines: lung (A549), 
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liver (BEL7404) and tongue (Tca). All the compounds tested were found to have moderate 
anti-cancer activity, with IC50 values typically varying from 42 μM to 18.6 μM. Compound 
62 showed the best anti-proliferative effect, with IC50 values in the range of 18.6 to 22.3 
μM against all cell lines. 
 
The methylidene-1,3-dihydro-2H-indol-2-one (oxindole) skeleton is found in a number of 
compounds with promising anti-cancer activity. It was therefore of interest to Spencer et al. 
to investigate the anti-cancer potential of a ferrocene-substituted oxindole, compound 63.
83
 
Both the (Z)- and (E)- isomers of compound 63 were evaluated against B16 (Murine 
Melanoma) and Vero (African Green Monkey Kidney Epithelia) cell lines and were found 
to exhibit strong anti-proliferative activities. An IC50 value of 0.7 ± 0.2 μM was obtained 
for the (Z)-isomer in both cell lines and IC50 values of 0.9 ± 0.05 μM and 1.2 ± 0.3 μM 
were obtained for the (E)-isomer in each cell line, respectively.  
 
Metallocene dichlorides with Ti, V and Nb metal centres have also shown anti-tumour 
activity.
84
 Titanocene dichloride 14 reached phase II clinical trials for patients with renal 
cell carcinoma and metastatic breast cancer. Substituted titanocene dichlorides have been 
prepared by Tacke et al as potential anti-cancer drugs.
27
 The anti-proliferative activity of 
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these derivatives has been consistently evaluated in the pig kidney cell line LLC-PK. In 
addition, the two most promising compounds 64 and 65 have been evaluated in 36 human 
tumour cell lines.
84
 
 
Prostate, cervix and renal cell cancer were all shown to be prime targets for these novel 
titanocenes. In vivo experiments with these two derivatives showed the successful treatment 
of xenografted Caki-1 tumours and xenografted Ehrlich’s ascites tumour in mice. 
Surprisingly, a change in the substitution pattern of titanocenes can also lead to 
proliferative effects, as observed by Strohfeldt et al for compound 66.
85
  
 
Considering that Top et al had previously observed a strong estrogenic/proliferative effect 
for the titanocene dichloride tamoxifen derivative 42, compounds 65 and 66 were evaluated 
in vitro in the ER(+) MCF-7 breast cancer cell line.
86
 Compound 66 exhibited a strong 
proliferative effect in this cell line when tested at 10 μM. On the other hand, compound 65 
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does not exhibit a significant effect at 10 μM, suggesting that this molecule is more stable 
to total hydrolysis than compound 66. The ferrocenyl analogue 67 of compound 65 was 
also prepared as part of this study and evaluated in vitro in both the ER(+) MCF-7 cell line 
and the ER(-) MDA-MB231 cell line. At a concentration of 10 μM, compound 67 shows a 
slight anti-proliferative effect in the MCF-7 cell line. In the MDA-MB231 cell line, an IC50 
value of 95 μM was determined for 67. 
 
Mixed binuclear ferrocene/ruthenium organometallic species, for example compound 68, 
have been shown to exhibit anti-proliferative effects in colon carcinoma (HT-29) and breast 
cancer (MCF-7) cell lines.
87
 The PF6
-
 salt of compound 68 displayed a slightly stronger 
anti-proliferative effect compared to 68, with IC50 values of 9.2 ± 0.4 μM and 4.8 ± 0.2 μM 
in the HT-29 and MCF-7 cell line, respectively. The mononuclear analogue 69 was 
completely inactive in the HT-29 cell line and displayed only a weak anti-proliferative 
effect in the MCF-7 cell line, with an IC50 value of 54.8 ± 14.5 μM.  These results suggest 
that the presence of the ruthenium centre may play an important role in triggering anti-
proliferative effect. 
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1.3. Conclusions 
Cancer is a devastating disease that can affect any part of the human anatomy. Lung cancer 
and metastatic melanoma are two forms of cancer for which survival rates remain critically 
low. The current chemotherapeutic treatments for these diseases are largely ineffective, due 
to their reliance on traditional chemotherapeutic drugs, for which there are widespread 
resistance problems and severe toxic side effects.   
Research in the area of metal anti-cancer drugs is flourishing, with metallocenes receiving 
much attention. Ferrocene is the archetypal metallocene; it is a small, rigid, lipophilic 
molecule that can easily penetrate the cell membrane. Over the past decade, ferrocene 
derivatives have shown great promise in the area of medicinal organometallic chemistry. 
For example, ferroquine (SR97193), a unique anti-malarial drug candidate has commenced 
phase II clinical trials in combination with artesunate.
32
 Biologically active ferrocene 
derivatives can be divided into two groups, namely, novel ferrocenyl derivatives found to 
exert a biological effect and ferrocenyl analogues of known drugs. In the second case, 
ferrocene is frequently used as a bioisostere for a phenyl ring contained in the original drug 
molecule. This strategy was devised to overcome problems related to drug resistance and 
the ferrocifens (ferrocenyl tamoxifen derivatives) represent the most successful application 
of this approach in cancer research. Ferrocifens have shown promising results in vitro in 
both ER(+) and ER(-) breast cancer cell lines, whereas the parent molecule tamoxifen only 
expresses an anti-proliferative effect in ER(+) cells.  
The reversible redox properties of ferrocene have been strongly associated with the 
biological activity of ferrocenyl compounds. Ferricenium salts known to inhibit tumour 
growth have been shown to produce hydroxyl radicals (HO
•
) via the Fenton reaction under 
physiological conditions. Ferrocenyl derivatives have also been shown to significantly 
increase the levels of intracellular reactive oxygen species (ROS) in vitro. High levels of 
intracellular ROS can lead to oxidative damage to DNA and subsequent cell death.  
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Chapter 2  
Synthesis and structural characterisation of N-(ferrocenyl)naphthoyl amino acid and 
dipeptide derivatives which contain α-amino acids 
2.1. Introduction 
Amino acids are one of nature’s most essential building blocks; they are naturally occurring 
organic compounds with an amino group at one terminus and a carboxylic acid group at the 
other. In nature, individual α-amino acid units are linked together by an amide bond to form 
peptides, and much larger macromolecules known as proteins. Peptides and proteins form 
an essential part of any biological system and are involved in many diverse processes e.g. 
proteins known as enzymes are responsible for catalysing a vast range of specific chemical 
reactions within the cell. This remarkable variety in protein function is due to the versatile 
nature of α-amino acids; there are 20 “essential” α-amino acids, each containing a side 
chain functional group that varies in size, shape, charge, hydrogen-bonding capacity, 
hydrophobic character, and chemical reactivity.
1
  
The α-amino acids L-tryptophan and L-tyrosine are also key precursors in the biosynthesis 
of many important neurotransmitters and hormones. Clearly, this group of basic building 
blocks is indispensable in nature. The increasing volume of drug molecules that contain α-
amino acids and peptide-based drugs on the market is a testament to the utility of these 
multifunctional units (Figure 2.1).  
 
Figure 2.1 Drug molecules that contain α-amino acids currently on the market. 
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Organometallic compounds are versatile species due to the range of both structure and 
bonding modes that are accessible. As a consequence, they have been incorporated in a 
wide variety of materials that have diverse applications. Ferrocene is a particularly useful 
organometallic compound for biological applications since it is stable in aqueous and 
aerobic media, is easy to use and exhibits interesting spectroscopic and electrochemical 
properties.  Bioconjugates of ferrocene with amino acids and peptides have been the subject 
of much research towards the development of novel sensor compounds, peptide mimetic 
models, and unnatural drugs.
2
 Ferrocenyl-peptide bioconjugates have been investigated as 
anti-bacterial agents, however only a limited toxicity was observed.
3,4
 N-benzoyl peptides 
have been shown to have a wide range of biological activity that includes the treatment of 
diabetes
5
 and rheumatoid arthritis.
6,7
 The benzoylation of an N-terminal amino acid 
increases the lipophilicity of the amino acid and substitution on such a group is often 
crucial for its biological activity. Appending a ferrocenyl unit to N-benzoyl peptides is an 
appealing approach in the design of ferrocenyl-peptide bioconjugates that act as unnatural 
drugs. Not only will the combination of both aromatic moieties aid in increasing the 
lipophilicity of the peptide, the presence of the benzoyl unit between the ferrocene and the 
peptide should lower the redox potential of these bioconjugates, thereby making them 
easier to oxidise. Ferricenium salts known to inhibit tumour growth have been shown to 
produce hydroxyl radicals under physiological conditions, leading to oxidatively damaged 
DNA.
8
 Thus, ferrocenyl derivatives that possess redox potentials which fall within the 
range of biologically accessible potentials offer an attractive and alternative method to 
target and kill cancer cells.  
Previous work in this laboratory has shown this approach to be particularly fruitful. A 
series of novel N-(ferrocenyl)benzoyl peptide derivatives were synthesised and selected 
compounds were tested for in vitro anti-cancer activity in the non-small cell lung cancer 
(NSCLC) derived H1299 cell line. The effect of these compounds on cell proliferation was 
expressed as an IC50 value, which corresponds to the concentration of the drug required for 
50% inhibition of cell growth (Table 2.1). The N-ortho, N-meta and N-{para-(ferrocenyl)-
benzoyl}-glycine-L-alanine ethyl esters were identified as the most potent members of this 
series, with a remarkable anti-proliferative effect of on average 5.3 µM. 
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Table 2.1 IC50 values for N-(ferrocenyl)benzoyl peptide derivatives in the H1299 cell line. 
Compound IC50 value (µM) 
N-{ortho-(ferrocenyl)-benzoyl}-Gly-OEt 
9
 48 
 N-{meta-(ferrocenyl)-benzoyl}-L-Ala-Gly-OEt 
9
 26 
 N-{ortho-(ferrocenyl)-benzoyl}-L-Ala-Gly-OEt 
9
  21 
 N-{ortho-(ferrocenyl)-benzoyl}-Gly-L-Ala-OEt 
10
 5.3 
N-{meta-(ferrocenyl)-benzoyl}-Gly-L-Ala-OEt 
11
 4.0 
 N-{para-(ferrocenyl)-benzoyl}-Gly-L-Ala-OEt 
11
  6.6 
N-{meta-(ferrocenyl)-benzoyl}-Gly-L-2-aminobutyric acid-OEt 
11
 10.5 
 N-{meta-(ferrocenyl)-benzoyl}-Gly-L-norvaline-OEt 
11
 19.1 
 N-{meta-(ferrocenyl)-benzoyl}-Gly-L-norleucine-OEt 
11
 18.9 
N-{ortho-(ferrocenyl)-benzoyl}-Gly-Gly-OEt 
12
 20 
 N-{ortho-(ferrocenyl)-benzoyl}-Gly-Gly-Gly-OEt 
12
 63 
 N-{ortho-(ferrocenyl)-benzoyl}-Gly-Gly-Gly-Gly-OEt 
12
 >100 
 
The primary objective of this research thesis is to explore the structure-activity relationship 
(SAR) of these novel ferrocenyl-peptide bioconjugates in order to enhance their in vitro 
anti-proliferative effect. Since the precise biological target of these compounds is unknown 
at this point in time, the best approach is to perform enough syntheses to identify the 
molecular features which are favourable and those which are detrimental to the activity. 
With this in mind, the lead compound was divided into four distinct regions for SAR 
evaluation (Figure 2.2).  
 
Figure 2.2 SAR regions of N-(ferrocenyl)benzoyl-glycine-L-alanine ethyl ester. 
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The first region consists of the ferrocene electroactive core, which could be varied by 
replacing ferrocene with an alternative metallocene. The most common approach reported 
in the literature is the incorporation of ruthenocene in place of ferrocene.
13,14
 This would be 
a logical step since in this case, a low oxidation potential is believed to be important for 
anti-proliferative effect and ruthenocene undergoes electrochemical oxidation more readily 
than ferrocene. Nonetheless, there is some controversy surrounding the oxidation of 
ruthenocene, as some reports suggest a one-electron oxidation process, whilst other studies 
have indicated that ruthenocene undergoes a two-electron irreversible oxidation process.
15
 
Studies conducted by Jaouen et al concerning organometallic tamoxifen derivatives 
reported a loss of activity in the ER(-) breast cancer cell line when the ferrocenyl group was 
replaced with ruthenocene.
13
 Since the reversible redox properties displayed by the N-
(ferrocenyl)benzoyl peptide derivatives are believed to play an integral role in the mode of 
action of these novel drugs, it was concluded that any ruthenocenyl analogues would not 
display the same biological activity.  
The three remaining regions all offer excellent starting points for introducing diversity into 
this series of ferrocenyl-peptide bioconjugates. The conjugated linker was considered to be 
the most fundamental region that may be altered, since the conjugating ability of the linker 
is important in determining the redox potential of the derivative. There is an abundance of 
aromatic and hetero-aromatic ring systems that could potentially be incorporated in place of 
the benzene ring. Perhaps the simplest alteration is to employ a naphthalene ring as the 
conjugated linker. Following a search of commercially available chemicals, two 
disubstituted naphthalene compounds were selected for this purpose: 3-amino-2-naphthoic 
acid and 6-amino-2-naphthoic acid. These compounds are amenable to the synthetic route 
employed in the synthesis of the N-(ferrocenyl)benzoyl peptide derivatives, which should 
allow for the facile synthesis of a series of N-(ferrocenyl)naphthoyl analogues. 
In relation to the peptide chain, limiting the amino acids at this point in time to the 20 
essential α-amino acids still provides a great assortment of side chain functional groups. 
Since the IC50 values determined for the selected N-(ferrocenyl)benzoyl peptide derivatives 
indicate that the presence of either a tripeptide or tetrapeptide chain has a negative effect on 
biological activity, the peptide chain length was limited to dipeptides and single α-amino 
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acids for this study. Even by imposing these restrictions, there are still a substantial number 
of derivatives that could be synthesised, since it is possible to form 400 different dipeptide 
chains from the 20 essential α-amino acids. The previous study indicated that anti-
proliferative effect is best when the small, neutral α-amino acids glycine and L-alanine are 
present in the peptide chain. However, the effect of branched alkyl groups and aromatic 
groups on biological activity has never been investigated. For this reason, L-leucine and L-
phenylalanine were also selected from the 20 essential α-amino acids for this initial study.   
There is a variety of different alkyl and aromatic groups that could be introduced in the 
ester functionality. However, alteration of the ester group is more of a concern at the later 
stages of drug design and development, when factors such as oral absorption and 
biodistribution are being taken into consideration. Since this is a primary SAR exploration, 
the ester group was unaltered during these studies. 
 
2.2. The synthesis of N-(ferrocenyl)naphthoyl amino acid and dipeptide derivatives 
which contain α-amino acids 
Peptide coupling reactions allow the facile introduction of the ferrocenyl naphthoyl group 
onto an amino acid or dipeptide. Thus, the ferrocenyl naphthoyl moiety was appended to a 
series of amino acid and dipeptide ethyl esters under solution phase peptide coupling 
conditions. A solution of ferrocenylnaphthalene-2-carboxylic acid in dichloromethane at 
0
o
C, was treated with N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride 
(EDC), 1-hydroxybenzotriazole (HOBt) and triethylamine (Et3N). An equimolar amount of 
the required amino acid ethyl ester hydrochloride or the dipeptide ethyl ester hydrochloride 
was then added to this stirred solution. The procedure is similar to that used for the 
synthesis of the N-(ferrocenyl)benzoyl peptide derivatives.
16
 Scheme 2.1 outlines the 
synthetic route employed in the synthesis of the N-(3-ferrocenyl-2-naphthoyl) amino acid 
derivatives, whilst Scheme 2.2 outlines the synthetic route employed in the synthesis of the 
N-(6-ferrocenyl-2-naphthoyl) dipeptide derivatives. 
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 (i) NaNO2, HCl, 5 
o
C; (ii) NaOH/MeOH, H2O; (iii) EDC, HOBt, Et3N, amino acid ethyl 
ester. 
Scheme 2.1 The general reaction scheme for the synthesis of N-(3-ferrocenyl-2-naphthoyl) 
amino acid derivatives. 
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(i) NaNO2, HCl, 5 
o
C; (ii) NaOH/MeOH, H2O; (iii) EDC, HOBt, Et3N, dipeptide ethyl 
ester. 
Scheme 2.2 The general reaction scheme for the synthesis of N-(6-ferrocenyl-2-naphthoyl) 
dipeptide derivatives.  
 
2.2.1. The preparation of methyl ferrocenylnaphthalene-2-carboxylate 
Ferrocene reacts 3 x 10
6
 times faster than benzene towards electrophilic substitution, hence, 
this class of reactions dominates the chemistry of ferrocene.
15
 Thus, the arylation of 
ferrocene is readily achieved by reacting ferrocene with an aryl diazonium salt. In this case, 
the appropriate methyl aminonaphthalene-2-carboxylate was treated with sodium nitrite in 
the presence of hydrochloric acid at a temperature below 5 
o
C to yield the diazonium salt. 
Above 5 
o
C the diazonium salt decomposes resulting in the formation of an aryl carbocation 
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and evolution of nitrogen gas.  Ferrocene present in situ reacts with this unstable aryl cation 
via electrophilic aromatic substitution to furnish the methyl ferrocenylnaphthalene-2-
carboxylate as an orange/red solid.  
There is still debate as to the mechanism by which ferrocene undergoes electrophilic 
aromatic substitution. A reaction mechanism where the initial interaction occurs between 
the electrophile and the weakly bonding electrons of the iron atom was proposed by 
Rosenblum et al in 1963.
17
 This initial interaction is followed by a transfer of the 
electrophile to the endo face of the η5-C5H5 i.e. the side nearest the iron atom. Subsequent 
proton elimination gives the substituted product (Figure 2.3). Alternatively, it has been 
proposed that the electrophile can react directly with the cyclopentadienyl ring and does not 
have any direct interaction with the iron atom. In this case the electrophile can be added to 
either the exo or endo face of the ferrocene molecule (Figure 2.4).  
 
Figure 2.3 Possible reaction mechanism that proceeds via the transition states in which the 
electrophile is bonded to the iron atom.
15
 
 
Figure 2.4 Possible reaction mechanism for the electrophilic substitution of ferrocene 
where the electrophile reacts directly with the cyclopentadienyl ring via the exo or endo 
transition state. 
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2.2.2. The preparation of ferrocenylnaphthalene-2-carboxylic acid 
Hydrolysis of methyl ferrocenylnaphthalene-2-carboxylate in 10% sodium hydroxide 
solution effectively removes the ester group to produce ferrocenylnaphthalene-2-carboxylic 
acid. In the 
1
H NMR spectra a broad singlet between δ 12.7 to δ 13 indicates the presence 
of the carboxylic acid proton. Hydrolysis can also be monitored by the disappearance of the 
methyl ester peak from the 
1
H and 
13
C NMR spectra.  
 
2.2.3. Amino acids 
Proteins and peptides are comprised of individual amino acids linked together via an amide 
or peptide bond. The synthetic value of amino acids as building blocks stems from the fact 
that they can be linked together by an amide bond to form peptide chains or linked to other 
suitable compounds e.g. ferrocenylnaphthalene-2-carboxylic acid. In the formation of an 
amide bond between two amino acids protection of the N-terminus of one amino acid and 
the C-terminus of the other amino acid is required to ensure regiospecific coupling. For this 
reason, it was necessary to protect the C-terminus of the amino acids and dipeptides prior to 
condensation with ferrocenylnaphthalene-2-carboxylic acid.  
 
2.2.4. Carboxyl protecting groups 
The most typical means of protection is esterification, which not only aids solubility in 
organic solvents but also ensures that (i) an amide bond and not an anhydride is formed and 
(ii) that only the product of mono-addition is formed.
18
 Thus, conversion of the carboxylic 
acid group to the ester was achieved by treatment of the amino acid or peptide with thionyl 
chloride and ethanol to give the corresponding ethyl ester hydrochloride salt (Figure 2.5). 
The hydrochloride salts can be neutralised to give the corresponding free bases, however 
these decompose quite rapidly at room temperature. The free base forms are therefore 
generated in situ only when required, by neutralisation with a tertiary amine such as 
triethylamine.
19
 The hydrochloride salt can be easily identified in the 
1
H NMR spectrum as 
a broad singlet integrating for three protons. In DMSO-d6 this peak is present between δ 8 
and δ 9. 
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Figure 2.5 The protection of the carboxyl terminus of an amino acid by conversion to an 
ethyl ester. 
 
Ethyl esters are completely stable towards HBr, acetic acid, trifluoroacetic acid (TFA) or 
catalytic hydrogenolysis and therefore the selective removal of amino protecting groups 
from peptide ethyl ester derivatives presents no difficulties. Due to the stability of the ethyl 
ester protecting group, its own removal may present difficulties. Saponification is 
sometimes satisfactory however the base that is required for this process may cause 
racemisation (Figure 2.6). 
 
Figure 2.6 The process of racemisation that may occur instead of the desired cleavage 
reaction due to the presence of base required for saponification. 
 
2.3. Amide Bond Formation 
The key step in peptide synthesis is the condensation of distinct carboxylic acid and amine 
moieties to form the amide bond. For this purpose, it is necessary to activate the carboxylic 
acid, since (i) carboxylic acids simply form salts with amines at ambient temperatures
19
 and 
(ii) high temperature (> 200 
o
C) reaction conditions are typically detrimental to the integrity 
of the substrates. The activation process occurs by converting the –OH of the acid into a 
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good leaving group prior to treatment with the amine.
20
 This is achieved by employing 
peptide coupling reagents.  
 
2.3.1. Acyl chlorides 
The most simple and straightforward way to activate a carboxylic acid is to convert it into 
its corresponding acyl chloride prior to coupling to the amine. However, acyl chlorides 
have a limited value in peptide coupling due to the danger of hydrolysis, racemisation, 
cleavage of protecting groups and other side reactions.
21
 Harsh reagents such as thionyl 
chloride (SOCl2) or phosphorous pentachloride (PCl5) are commonly used to generate acyl 
chlorides. These reagents have proven to be too vigorous for some substrates and in 
particular, are not compatible with acid-sensitive substrates. Coupling to the amine moiety 
is typically performed under basic conditions to trap any HCl formed and thus avoid the 
conversion of the amine into its unreactive HCl salt. Unfortunately, acyl chlorides display a 
tendency to racemise under such basic conditions, via the formation of a ketene (Figure 
2.7). The ketene may react with a nucleophile such as an amine to yield the corresponding 
addition product with an obvious loss of chiral integrity.
21
  
 
Figure 2.7 Potential racemisation under basic conditions via ketene formation. 
 
2.3.2. Anhydrides 
Symmetric anhydrides can be prepared from the corresponding carboxylic acid by reacting 
two molecules of acid in the presence of one equivalent of 1,3-dicyclohexylcarbodiimide 
(DCC) under mild conditions. In a second step the anhydride is reacted with the appropriate 
amine to form the required amide. The main limitation of this method is that only half of 
the acid used is effectively incorporated into the product. To overcome this problem, mixed 
anhydrides were developed where the second carboxylic moiety is cheap and easy to couple 
onto the acid.
21
 Mixed pivalic anhydrides are the most favoured, as the presence of the 
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bulky t-Bu group directs the attack of the amine to the required carboxy component (Figure 
2.8).   
 
 
Figure 2.8 Amide bond formation via a mixed pivalic anhydride. 
 
An alternative strategy involves the generation and aminolysis of a carboxylic-carbonic 
anhydride e.g. ethoxycarbonyl anhydrides. Since one of the carbonyl groups in the 
activated intermediate is bonded to two oxygen atoms, its reactivity is diminished and 
nucleophilic attack is directed towards the other more reactive carbonyl.
19
 Ethoxycarbonyl 
anhydrides can be generated using ethyl chloroformate or 2-ethoxy-1-ethoxycarbonyl-1,2-
dihydroquinoline 76 (EEDQ) (Figure 2.9). 
 
Figure 2.9 Ethoxycarbonyl anhydride preparation using EEDQ 76. 
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2.3.3. Phosphonium Reagents 
Phosphonium cations may undergo attack from carboxylate anions to form 
acyloxyphosphonium species, which can react readily with nucleophiles at the acyl 
carbon.
19
 Since these phosphonium cations hold promise as direct coupling reagents, a 
number of phosphonium salts have been developed for this purpose. Benzotriazol-1-yl-oxy-
tris-(dimethylamino)-phosphonium hexafluorophosphate 77 (BOP) was the first of these 
reagents to be introduced. The BOP reagent reacts with the carboxylate anion to generate 
both the activated acylphosphonium species and HOBt. HOBt reacts with the activated acid 
to give a reactive benzotriazole ester that readily undergoes aminolysis (Figure 2.10). 
However, the use of BOP has been limited due to the carcinogenicity and respiratory 
toxicity associated with the by-product hexamethylphosphoramide (HMPA).
20
 
Phosphonium derivatives that generate less toxic by-products e.g. benzotriazol-1-yl-oxy-
tris-pyrrolidino-phosphonium hexafluorophosphate 78 (PyBop) have been developed, 
although the success of these reagents is now overshadowed by reagents such as O-(1H-
benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate 79 (HBTU).     
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Figure 2.10 Amide bond formation using BOP reagent. 
 
2.3.4. Carbodiimides 
The use of carbodiimides as efficient peptide coupling reagents is commonplace ever since 
Hess and Sheehan first demonstrated the usefulness of 1,3-dicyclohexylcarbodiimide 
(DCC) in activating carboxyl groups towards nucleophilic attack. The first step towards 
peptide coupling involves addition of the carboxyl group to the carbodiimide to give an O-
acylisourea intermediate. This is a potent acylating agent, and will react rapidly to form the 
required peptide product either through direct aminolysis or via a symmetrical anhydride 
intermediate (Figure 2.11).
19
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Figure 2.11 Amide bond formation using DCC. 
 
These intermediates are highly reactive and thus, side-reactions can pose a serious problem 
and can result in extensive racemisation. In particular, the O-acylisourea can undergo an 
intramolecular acyl transfer to form the much less reactive N-acylurea (Figure 2.12). This 
side-reaction can sometimes compete significantly with the desired attack by external 
nucleophiles and can also occur intermolecularly between the urea and a symmetrical 
anhydride.
19
 Thus, formation of the inert N-acylurea can lead to considerably lower yields 
and may also give rise to problems during purification.  
 
Figure 2.12 Acyl transfer of O-acylisourea to N-acylurea. 
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These issues can be eliminated by performing the coupling reaction in the presence of an α-
nucleophile, most commonly HOBt. This α-nucleophile reacts very rapidly with the O-
acylisourea before any side-reactions can occur, resulting in an acylating agent of lower 
potency, which favours aminolysis and thus eliminates other side-reactions. The 
participation of HOBt in the formation of the amide bond can be seen in Figure 2.13. EDC 
was employed in the synthesis of the N-(ferrocenyl)naphthoyl amino acid and dipeptide 
ethyl esters since the 1-{3-(dimethylamino)propyl}-3-ethyl urea by-product is completely 
water-soluble, which aids purification.
18
  
 
Figure 2.13 Amide bond formation using EDC and HOBt. 
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2.4. Purification and yields of N-(ferrocenyl)naphthoyl amino acid and dipeptide 
derivatives 
The N-(ferrocenyl)naphthoyl amino acid derivatives were synthesised by the condensation 
of 3-ferrocenylnaphthalene-2-carboxylic acid and 6-ferrocenylnaphthalene-2-carboxylic 
acid, with the α-amino acid ethyl esters of glycine, L-alanine, L-leucine and L-
phenylalanine, under the peptide coupling conditions outlined in Section 2.2. The N-
(ferrocenyl)naphthoyl dipeptide derivatives were similarly prepared by the condensation of 
the ferrocenylnaphthalene-2-carboxylic acid units with the free N-terminal dipeptide ethyl 
esters. In the case of the dipeptide derivatives, glycine and L-alanine were employed as the 
N-terminal α-amino acid, whilst glycine, L-alanine, L-leucine and L-phenylalanine were 
employed as the C-terminal α-amino acids. Crude N-(ferrocenyl)naphthoyl amino acid or 
dipeptide derivatives were isolated following the coupling procedure and purified by 
column chromatography, using a mixture of hexane and ethyl acetate as the eluant. The 
pure N-(ferrocenyl)naphthoyl amino acid and dipeptide derivatives were furnished as 
orange or red solids, with yields in the range of 18% to 95%. All compounds gave 
spectroscopic and analytical data in accordance with their proposed structures.  
The yields for the N-(3-ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives were 
generally lower than those for the N-(6-ferrocenyl-2-naphthoyl) amino acid and dipeptide 
derivatives. In the case of the N-(3-ferrocenyl-2-naphthoyl) series, low yields are a result of 
steric hindrance around the carboxylic acid functionality, due to the presence of the bulky 
ferrocenyl group in the ortho-position. This assertion is supported by similar observations 
for the N-(ferrocenyl)benzoyl peptide derivatives.
16
 The side chain of the reacting α-amino 
acid can also have an influence on the overall yield. Yields are lower in cases where the 
side chain of the α-amino acid is large enough to exert a steric effect, e.g. the benzyl side 
chain of L-phenylalanine. In combination, these steric effects account for the difference in 
yield observed for N-(3-ferrocenyl-2-naphthoyl)-L-phenylalanine ethyl ester 83 (40%), 
compared to that obtained for N-(6-ferrocenyl-2-naphthoyl)-L-phenylalanine ethyl ester 95 
(78%). Table 2.2 summarises the yields for all of the N-(ferrocenyl)naphthoyl amino acid 
and dipeptide derivatives.  
62 
 
Table 2.2 Percentage yields for N-(ferrocenyl)naphthoyl amino acid and dipeptide 
derivatives. 
Compound No. % Yield 
N-(3-ferrocenyl-2-naphthoyl)-Gly-OEt 80 83 
N-(3-ferrocenyl-2-naphthoyl)-L-Ala-OEt 81 95 
N-(3-ferrocenyl-2-naphthoyl)-L-Leu-OEt 82 32 
N-(3-ferrocenyl-2-naphthoyl)-L-Phe-OEt 83 40 
N-(3-ferrocenyl-2-naphthoyl)-Gly-Gly-OEt 84 60 
N-(3-ferrocenyl-2-naphthoyl)-Gly-L-Ala-OEt 85 55 
N-(3-ferrocenyl-2-naphthoyl)-Gly-L-Leu-OEt 86 42 
N-(3-ferrocenyl-2-naphthoyl)-Gly-L-Phe-OEt 87 29 
N-(3-ferrocenyl-2-naphthoyl)-L-Ala-Gly-OEt 88 59 
N-(3-ferrocenyl-2-naphthoyl)-L-Ala-L-Ala-OEt 89 28 
N-(3-ferrocenyl-2-naphthoyl)-L-Ala-L-Leu-OEt 90 18 
N-(3-ferrocenyl-2-naphthoyl)-L-Ala-L-Phe-OEt 91 45 
N-(6-ferrocenyl-2-naphthoyl)-Gly-OEt 92 62 
N-(6-ferrocenyl-2-naphthoyl)-L-Ala-OEt 93 83 
N-(6-ferrocenyl-2-naphthoyl)-L-Leu-OEt 94 33 
N-(6-ferrocenyl-2-naphthoyl)-L-Phe-OEt 95 78 
N-(6-ferrocenyl-2-naphthoyl)-Gly-Gly-OEt 96 83 
N-(6-ferrocenyl-2-naphthoyl)-Gly-L-Ala-OEt 51 79 
N-(6-ferrocenyl-2-naphthoyl)-Gly-L-Leu-OEt 97 58 
N-(6-ferrocenyl-2-naphthoyl)-Gly-L-Phe-OEt 98 56 
N-(6-ferrocenyl-2-naphthoyl)-L-Ala-Gly-OEt 99 67 
N-(6-ferrocenyl-2-naphthoyl)-L-Ala-L-Ala-OEt 100 29 
N-(6-ferrocenyl-2-naphthoyl)-L-Ala-L-Leu-OEt 101 23 
N-(6-ferrocenyl-2-naphthoyl)-L-Ala-L-Phe-OEt 102 23 
Footnote: Compounds 70-75 are intermediates and hence, are not included in Table 2.2. 
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2.5.
 1
H NMR studies of N-(ferrocenyl)naphthoyl amino acid and dipeptide derivatives 
All of the 
1
H NMR experiments were performed in DMSO-d6 as the N-
(ferrocenyl)naphthoyl amino acid and dipeptide derivatives showed limited solubility in 
other deuterated solvents. In the 
1
H NMR spectra of the N-(ferrocenyl)naphthoyl amino 
acid and dipeptide derivatives, the aromatic signal pattern varied depending on the 
substitution pattern of the naphthalene ring. For the N-(3-ferrocenyl-2-naphthoyl) amino 
acid and dipeptide derivatives, a singlet, doublet, doublet, singlet, triplet, triplet pattern may 
be observed, with each peak integrating for one proton. More often than not though, several 
of these signals may overlap due to their close proximity in chemical shift. In the 
1
H NMR 
spectra of the N-(6-ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives, the 
aromatic region generally shows a singlet, singlet, multiplet, and double doublet splitting 
pattern, integrating for one, one, three and one proton, respectively. 
The chemical shift of the amide proton that forms the amide bond between the naphthoyl 
group and the peptide appears from δ 8.82-9.08 for the N-(ferrocenyl)naphthoyl amino acid 
derivatives, whilst in the 
1
H NMR spectra of the N-(ferrocenyl)naphthoyl dipeptide 
derivatives this signal appears from δ 8.47-8.94. The appearance of these signals in the low 
field region of the 
1
H NMR spectra is due to hydrogen bond interactions between the amide 
proton and the S=O bond of DMSO-d6. If CDCl3 was used to obtain the spectra, the amide 
protons would most likely appear more upfield since CDCl3 does not possess the same 
ability to form hydrogen bonds. 
The aromatic peaks of the ferrocene moiety appear upfield of the aromatic region between 
δ 4.02 and δ 5.01. Since ferrocene is more electron dense than benzene, the ferrocenyl 
protons experience an increased shielding effect. Characteristic peaks in this region confirm 
the presence of a mono-substituted ferrocene moiety. However, there is a notable difference 
in the chemical shift of the ferrocenyl peaks in accordance with the substitution pattern 
around the central naphthoyl linker.  
For the N-(6-ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives, a singlet due to 
the unsubstituted cyclopentadienyl ring (η5-C5H5) typically appears from δ 4.05-4.10. This 
signal integrates for five protons. The ortho hydrogens on the cyclopentadienyl (η5-C5H4) 
ring appear in the range δ 4.95-5.01 as a fine triplet or a singlet, each integrating for two 
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protons. The meta hydrogens of the (η5-C5H4) ring appear from δ 4.45-4.50, also as a fine 
triplet or a singlet that integrates for two protons.  
In the 
1
H NMR spectra of the N-(3-ferrocenyl-2-naphthoyl) amino acid and dipeptide 
derivatives, these signals are shifted slightly upfield. The ortho (η5-C5H4) protons appear 
from δ 4.71-4.83; the meta (η5-C5H4) protons appear from δ 4.21-4.38. The five protons of 
the unsubstituted (η5-C5H5) ring are located from δ 4.01-4.09, and are sometimes observed 
as part of a multiplet with overlapping signals.  
In some cases, the ferrocenyl region of the 
1
H NMR spectra of N-(3-ferrocenyl-2-
naphthoyl) amino acid and dipeptide derivatives was found to be more complex than first 
expected. This complexity is due to magnetic inequivalence and is exemplified in the case 
of the N-(3-ferrocenyl-2-naphthoyl) amino acid derivatives (Figure 2.14). The 
1
H NMR 
spectrum of N-(3-ferrocenyl-2-naphthoyl)-glycine ethyl ester 80 shows the typical signal 
pattern observed for a mono-substituted ferrocene moiety. The ortho (η5-C5H4) protons 
appear at δ 4.83, the meta (η5-C5H4) protons appear at δ 4.32 and the five protons of the 
(η5-C5H5) ring are shown at δ 4.07. For N-(3-ferrocenyl-2-naphthoyl)-L-alanine ethyl ester 
81 and N-(3-ferrocenyl-2-naphthoyl)-L-leucine ethyl ester 82, there are two signals 
observed for the meta hydrogens, which integrate for one proton each. In the case of N-(3-
ferrocenyl-2-naphthoyl)-L-phenylalanine ethyl ester 83, four signals are observed between 
δ 4.15 and δ 4.75 and correspond to the four protons of the (η5-C5H4) ring. There is also a 
discernable upfield shift for these resonances, e.g. the ortho protons of the glycine 
derivative 80 come into resonance at δ 4.83, whilst those of the L-phenylalanine derivative 
83 appear from δ 4.75-4.76 (Figure 2.14).  
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Figure 2.14 Ferrocenyl region (3.8-5.0 ppm) of the 
1
H NMR spectra of: (a) N-(3-
ferrocenyl-2-naphthoyl)-glycine ethyl ester 80; (b) N-(3-ferrocenyl-2-naphthoyl)-L-alanine 
ethyl ester 81; (c) N-(3-ferrocenyl-2-naphthoyl)-L-leucine ethyl ester 82; (d) N-(3-
ferrocenyl-2-naphthoyl)-L-phenylalanine ethyl ester 83. 
 
Table 2.3 Selected 
1
H NMR spectral data (δ, DMSO-d6) for N-(ferrocenyl)naphthoyl amino 
acid and dipeptide derivatives. 
Compound No. NH’s αH ortho (η5-C5H4) meta (η
5
-C5H4) 
81 8.94 4.45 4.78-4.80 4.33-4.35, 4.29-4.31 
85 8.72, 8.38 4.31-4.36 4.81 4.31-4.36 
87 8.67, 8.43 4.53 4.80 4.30 
89 8.54, 8.34 4.49, 4.28-4.33 4.74 4.28-4.33 
93 8.96 4.57 5.01 4.50 
51 8.84, 8.41 4.30 4.95 4.44 
99 8.67, 8.38 4.60 4.96 4.45 
102 8.58, 8.36 4.60, 4.43-4.50 4.96 4.43-4.50 
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2.5.1.  
1
H NMR study of N-(3-ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl ester 
(85) 
 
Figure 2.15 N-(3-ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl ester 85. 
 
In the 
1
H NMR spectrum of N-(3-ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl ester 85 
the naphthoyl amide proton peak appears downfield at δ 8.72. This signal integrates for one 
proton and appears as a triplet due to coupling with the adjacent methylene protons of the 
glycine residue. The remaining amide proton is observed as a doublet at δ 8.38, due to 
coupling with the α-hydrogen of the L-alanine residue, and integrates for one proton. The 
2,3-disubstituted naphthoyl group appears as a singlet at δ 8.32, two doublets at δ 7.99 and 
δ 7.90, a singlet at δ 7.83 that all integrate for one proton. Between δ 7.49 and δ 7.57 there 
is a multiplet that integrates for two protons. In the ferrocenyl region, the peak due to the 
ortho protons on the (η5-C5H4) ring appears as a singlet at δ 4.81 that integrates for two 
protons. The peak due to the meta protons of the (η5-C5H4) ring is observed in a multiplet 
with a quintet representing the α-proton of the L-alanine residue. An integration of three is 
observed for this multiplet which appears from δ 4.31-4.36. The singlet due to the 
unsubstituted (η5-C5H5) ring appears in a multiplet with a quartet representing the 
methylene protons of the ethyl ester. This multiplet occurs from δ 4.02-4.14 and integrates 
for seven protons. The methylene protons of glycine residue are observed as two doublets 
of doublets at δ 3.96 and δ 3.87, with both these signals integrating for one proton each. 
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This splitting pattern is due to the presence of a chiral centre in the molecule. The 
methylene protons of the glycine residue are diastereotopic, and hence, geminal coupling is 
observed with a coupling constant of 16.4 Hz, together with coupling to the amide proton, 
with a coupling constant of 5.6 Hz. The peak due to the L-alanine methyl group appears as 
a doublet at δ 1.32, and the peak due to the methyl group of the ethyl ester appears as a 
triplet at δ 1.21.     
 
Figure 2.16 
1
H NMR spectrum of N-(3-ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl 
ester 85. 
 
2.5.2. 
1
H NMR study of N-(6-ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl ester 
(51) 
 
Figure 2.17 N-(6-ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl ester 51. 
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The amide protons of N-(6-ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl ester 51 are 
positioned downfield at δ 8.84 and δ 8.41, and appear as a triplet and doublet, respectively. 
Both of these signals integrate for one proton. The triplet is due to coupling of the 
naphthoyl amide proton to the methylene protons of glycine, and the doublet is due to 
coupling with the α-hydrogen of L-alanine. The aromatic region confirms the presence of 
six protons, which appear from δ 7.82-8.44. As is typical with a 2,6-disubstituted naphthyl 
group, the spectrum shows two singlets at δ 8.44 and δ 8.06, a multiplet from δ 7.92-7.97 
(three overlapping signals) and a doublet of doublets at δ 7.82. In the ferrocenyl region, the 
peak due to the ortho (η5-C5H4) protons appears as the furthest downfield signal. This 
signal appears as a fine triplet at δ 4.95 with a coupling constant of 1.6 Hz. Similarly, the 
meta (η5-C5H4) protons appear as a fine triplet at δ 4.44. Both these peaks integrate for two 
protons. The singlet due to the unsubstituted (η5-C5H5) ring is observed in a multiplet with 
a doublet of doublets representing one of the methylene protons of glycine. An integration 
of six protons is shown for this signal, which is observed from δ 4.00-4.05. The other 
methylene proton can be observed as a doublet of doublets at δ 3.93. The signal due to the 
L-alanine methyl group appears as a doublet at δ 1.31. The characteristic ethyl ester signals 
appear as a triplet at δ 1.19 and a multiplet from δ 4.06-4.12, respectively. 
 
Figure 2.18 
1
H NMR spectrum of N-(6-ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl 
ester 51. 
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2.6. 
13
C and DEPT 135 NMR studies of N-(ferrocenyl)naphthoyl amino acid and 
dipeptide derivatives 
13
C and DEPT 135 NMR studies were carried out on all compounds. In a DEPT 135 
spectrum, methine and methyl carbons appear as positive peaks, whereas methylene 
carbons appear as negative peaks i.e. below the resonance line. Carbonyl and quaternary 
carbons are absent in a DEPT 135 spectrum. 
In the 
13
C spectra of the N-(ferrocenyl)naphthoyl amino acid and dipeptide derivatives, the 
amide and ester carbonyl carbons appear downfield in the range of δ 166.0-172.7. In the 
aromatic region ten carbon signals are observed, since the carbon atoms of the naphthalene 
ring system are non-equivalent. The four aromatic quaternary carbons can be identified 
with the aid of DEPT 135 spectra.  
Signals due to the ferrocenyl carbons occur from δ 66.6-84.7 in the 13C NMR spectra. As 
observed for the 
1
H NMR spectra of the N-(ferrocenyl)naphthoyl amino acid and dipeptide 
derivatives, there are slight differences in the chemical shift of the ferrocenyl carbons 
depending on the substitution pattern around the aromatic linker. For the N-(6-ferrocenyl-2-
naphthoyl) amino acid and dipeptide derivatives, the ipso carbon on the substituted 
cyclopentadienyl (η5-C5H4) ring appears from δ 83.9-84.1, whilst the unsubstituted 
cyclopentadienyl ring (η5-C5H5) appears as an intense peak at approximately δ 69.5. The 
signal due to the meta (η5-C5H4) carbons generally overlaps with this peak or appears in 
close proximity at δ 69.4, whilst the ortho (η5-C5H4) peak appears slightly upfield at δ 66.6. 
In the case of the N-(3-ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives, the 
signal due to the ortho (η5-C5H4) carbons is shifted downfield to between δ 68.4 and δ 69.4. 
This indicates that these carbons have become deshielded with respect to the ortho (η5-
C5H4) carbons of the N-(6-ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives. 
The meta (η5-C5H4) carbons of the N-(3-ferrocenyl-2-naphthoyl) amino acid and dipeptide 
derivatives come into resonance from δ 68.1-68.6. Two individual peaks corresponding to 
the meta (η5-C5H4) carbons were also observed in close proximity in some 
13
C NMR 
spectra, e.g. in the spectrum obtained for N-(3-ferrocenyl-2-naphthoyl)-L-leucine ethyl 
ester 82, indicating the magnetic inequivalence of these species. The ipso carbon on the 
substituted cyclopentadienyl (η5-C5H4) ring and the unsubstituted (η
5
-C5H5) ring carbons of 
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the N-(3-ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives remain largely 
unaffected. 
The methylene group of the ethyl ester appears in the very narrow range of δ 60.3-60.6 and 
is easily identifiable due to the negative resonance in the DEPT 135 spectrum. The methyl 
carbon comes into resonance at approximately δ 14. 
 
Table 2.4 Selected 
13
C NMR data (δ, DMSO-d6) for N-(ferrocenyl)naphthoyl amino acid 
and dipeptide derivatives. 
Compound 
No. 
 
C=O 
Ipso  
(η5-C5H4) 
ortho 
(η5-C5H4) 
meta  
(η5-C5H4) 
 
(η5-C5H5) 
81 172.5-169.3 84.3 68.5 68.3, 68.2 69.5 
84 169.9-169.3 84.4 68.9 68.3 69.5 
87 171.4-168.9 84.3 68.9 68.3 69.5 
94 172.7-166.7 84.0 66.6 69.4 69.5 
95 171.7-166.5 83.9 66.6 69.4 69.5 
98 171.4-166.4 84.1 66.6 69.5 69.5 
99 173.0-166.1 84.1 66.6 69.4 69.5 
100 172.5-166.0 84.1 66.6 69.4 69.5 
101 172.7-166.0 84.1 66.6 69.5 69.5 
 
 
2.6.1.
 13
C and DEPT 135 NMR study of N-(6-ferrocenyl-2-naphthoyl)-glycine-L-
leucine ethyl ester (97) 
 
Figure 2.19 N-(6-ferrocenyl-2-naphthoyl)-glycine-L-leucine ethyl ester 97. 
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The 
13
C NMR spectrum of N-(6-ferrocenyl-2-naphthoyl)-glycine-L-leucine ethyl ester 97 
displays three carbonyl carbon atoms at δ 172.5, δ 169.1 and δ 166.5. These are absent from 
the DEPT 135 spectrum. The aromatic region shows ten individual signals, representing the 
ten non-equivalent carbon atoms of the 2,6-disubstituted naphthalene group. The absence of 
the carbon atoms at δ 138.8, δ 134.5, δ 130.7 and δ 130.5 in the DEPT 135 spectrum 
indicates their quaternary nature. The six remaining carbon atoms appear at δ 128.7, δ 
127.5, δ 127.3, δ 125.9, δ 124.5 and δ 122.7, respectively. The signal at δ 84.1 is not 
present in the DEPT 135 spectrum and therefore it is assigned as the ipso ferrocenyl carbon. 
Upfield from the ferrocenyl ipso carbon signal, an intense signal is observed for the 
unsubstituted (η5-C5H5) ring carbons and the meta (η
5
-C5H4) carbons at δ 69.4. The signal 
due to the ortho (η5-C5H4) carbons appears at δ 66.6. The methylene groups can be 
assigned from the DEPT 135 spectrum due to the negative peak. The methylene carbons of 
the ethyl ester, glycine and L-leucine moieties are easily assigned as they show negative 
resonance peaks in the DEPT 135 spectrum at δ 60.4, δ 42.2 and δ 40.1, respectively. The 
α-carbon of the L-leucine residue comes into resonance at δ 50.3. The methine carbon of 
the L-leucine side chain is observed at δ 24.2. The methyl groups of the L-leucine residue 
are present at δ 22.7 and δ 21.4 and the methyl group of the ethyl ester is present at δ 14.0. 
 
Figure 2.20 
13
C NMR spectrum of N-(6-ferrocenyl-2-naphthoyl)-glycine-L-leucine ethyl 
ester 97. 
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Figure 2.21 DEPT 135 spectrum of N-(6-ferrocenyl-2-naphthoyl)-glycine-L-leucine ethyl 
ester 97. 
 
2.7. HMQC study of N-(6-ferrocenyl-2-naphthoyl)-L-alanine-glycine ethyl ester (99) 
HMQC (Heteronuclear Multiple Quantum Coherence) is a 2D NMR technique that 
correlates each 
13
C atom to the proton to which it is directly attached. Thus, HMQC allows 
for the complete assignment of proton and carbon spectra, and hence total structure 
elucidation. In addition, the carbon dimension is frequently utilised to resolve the 
overlapping proton signals in complex spectra. Since this technique correlates a carbon 
signal to any directly associated protons, no signals are observed for those carbon atoms 
lacking protons i.e. carbonyl or quaternary carbon atoms. The structure and HMQC 
spectrum of N-(6-ferrocenyl-2-naphthoyl)-L-alanine-glycine ethyl ester 99 is shown in 
Figures 2.22 and 2.23, respectively. 
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Figure 2.22 N-(6-ferrocenyl-2-naphthoyl)-L-alanine-glycine ethyl ester 99. 
 
 
Figure 2.23 HMQC spectrum of N-(6-ferrocenyl-2-naphthoyl)-L-alanine-glycine ethyl 
ester 99. 
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Table 2.5 HMQC data for N-(6-ferrocenyl-2-naphthoyl)-L-alanine-glycine ethyl ester 99. 
Site 
1
H NMR 
13
C NMR HMQC 
1  84.1  
2, 5 4.96  66.6 
3, 4 4.45  69.4 
6 to 10 4.05  69.5 
11  138.8  
12 8.06  122.7 
13  130.6
a
  
14 7.94  127.2 
15 7.94  127.7 
16  134.5  
17 8.48  128.7 
18  130.4
b
  
19 7.94  124.8 
20 7.82  125.9 
21  166.1  
22 4.60  48.8 
23 1.41  17.9 
24  169.7  
25 3.89, 3.82  40.7 
26  173.0  
27 4.12  60.3 
28 1.19  14.0 
a,b
 Signals may be reversed. 
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2.8. Infra red studies of N-(ferrocenyl)naphthoyl amino acid and dipeptide derivatives 
Infra red (IR) spectroscopy is a spectroscopic method by which many functional groups can 
be identified. Compounds can absorb IR radiation and hence various molecular vibrations 
are induced e.g. stretching, bending, rocking etc. These localised vibrations are very useful 
for the identification of key functional groups.
22
  
The region of the spectrum above 1500 cm
-1
 gives the most information on the structure of 
the molecule, while the fingerprint region (less than 1500 cm
-1
) contains numerous 
absorption bands and is of less consequence. The IR spectra of the N-(ferrocenyl)naphthoyl 
amino acid and dipeptide derivatives were obtained either as KBr discs or as pure solids. 
The spectra of these compounds generally show two bands above 3000 cm
-1 
that correspond 
to the secondary amide groups. In the carbonyl region it is usual to observe at least two 
bands for primary and secondary amides.  The one at higher frequency is the stretching 
vibration of the C=O bond; it is called the amide I band and typically appears between 1680 
and 1630 cm
-1
. The amide II band is found between 1570 and 1515 cm
-1
 and is the localised 
bending vibration of the N-H bond. The ester carbonyl band usually appears at higher 
frequency, between 1750 and 1735 cm
-1
.  Bands due to aryl rings are present in the 1225-
950 cm
-1
 region but are not very informative, as are a group of weak overtone and 
combination bands in the 2000-1600 cm
-1
 region. 
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Figure 2.24 IR spectrum of N-(6-ferrocenyl-2-naphthoyl)-L-alanine-L-leucine ethyl ester 
101. 
 
Table 2.6 Selected IR data for N-(ferrocenyl)naphthoyl amino acid and dipeptide 
derivatives. The values quoted are in cm
-1
. 
Compound No. N-H C=O amide I C=O amide II C=O ester 
82 3322 1649 1544 1735 
83 3342 1645 1544 1734 
88 3397 1646 1544 1748 
93 3442 1638 1542 1734 
96 3407, 3340 1654, 1650 1558 1732 
100 3448, 3288 1636 1546 1735 
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2.9. UV-Vis studies of N-(ferrocenyl)naphthoyl amino acid and dipeptide derivatives 
The visible and ultraviolet spectra of organic compounds are associated with transitions 
between electronic energy levels. The transitions are usually between a bonding or a lone 
pair orbital and an unfilled non-bonding or anti-bonding orbital. The wavelength is then a 
measure of the separation of the energy levels of the orbitals concerned. The most 
informative region in the UV-Vis range occurs above 200 nm, as this is where excitation of 
electrons from p- and d-orbitals, π-orbitals and particularly, π-conjugated systems, gives 
rise to readily measured and informative spectra.
22
  
The UV-Vis spectra of N-(ferrocenyl)naphthoyl amino acid and dipeptide derivatives differ 
significantly. The N-(6-ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives give 
the strongest absorptions in the visible region, with local maxima at 375 nm and 450 nm, 
respectively. The strength of these absorbances is an indication of the degree of conjugation 
between the naphthoyl group and the (η5-C5H4) group i.e. a strong absorbance indicates that 
these two groups lie roughly in the same plane creating a large chromophore. The 
absorbance at 375 nm can be assigned to a π to π* transition of the aromatic spacer group 
and the absorbance at 450 nm is attributed to a metal to ligand charge transfer band 
(MLCT). In Figure 2.25, it can be seen that upon substitution of the ferrocene moiety, the 
MLCT band undergoes a red shift from 420 nm to 450 nm, this is also indicative of 
conjugation.   
The corresponding values in the UV-Vis spectra of the N-(ferrocenyl)benzoyl derivatives, 
show that the absorbances are not as intense as is the case with the N-(6-ferrocenyl-2-
naphthoyl) amino acid and dipeptide derivatives, and they typically appear at shorter 
wavelengths.
23
 In the case of the N-(3-ferrocenyl-2-naphthoyl) amino acid and dipeptide 
derivatives, the absorbance due to the π to π* transition of the aromatic spacer group is 
much weaker, and there is only one absorbance with a local maximum of around 450 nm 
due to the MLCT band. The weakness of this absorption suggests that the (η5-C5H4) and 
naphthoyl groups do not lie in the same plane, hence presenting an increasing barrier to 
efficient conjugation. 
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Figure 2.25 UV-Vis spectra of ferrocene, N-(3-ferrocenyl-2-naphthoyl)-glycine-glycine 
ethyl ester 84 and N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 96. 
 
These absorbances also yield other interesting information. Extinction coefficients are a 
function of how efficiently a chromophore absorbs UV or visible radiation. Therefore, the 
extent of conjugation is an important consideration. The UV-Vis spectra show a large 
disparity in the intensity of the absorbances between the N-(6-ferrocenyl-2-naphthoyl) 
amino acid and dipeptide derivatives, and the corresponding N-(3-ferrocenyl-2-naphthoyl) 
analogues. Since the former compounds are more conjugated than the latter compounds, the 
bands in the visible region go from being relatively intense for the first group of 
compounds to much less intense for the second group. This is in accordance with the 
observations made for the N-(ferrocenyl) benzoyl peptide derivatives.
23
 Extinction 
coefficients are given by ε and can be calculated from the Beer-Lambert Law i.e. A=εCl, 
where A is absorbance, C is concentration, l is the path length of the cell. In this UV-Vis 
study, the spectra of all compounds were obtained at a concentration of 4 x 10
-4
 M. 
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Table 2.7 Selected UV-Vis data (nm) for N-(ferrocenyl)naphthoyl amino acid and 
dipeptide derivatives. 
Compound No. λmax1 (nm) ε1 λmax2 (nm) ε2 
81 - - 450 512 
94 375 3256 450 1395 
84 - - 445 572 
51 375 3451 450 1482 
100 375 3233 450 1349 
p-Fc-Bz-Ala-Gly-OEt* 352 2400 450 720 
* N-{para-(ferrocenyl)-benzoyl}-L-alanine-glycine ethyl ester as prepared by David 
Savage.
23
 
 
2.10. Cyclic voltammetry studies of N-(ferrocenyl)naphthoyl amino acid and dipeptide 
derivatives 
Cyclic Voltammetry (CV) is a versatile electroanalytical technique for studying 
electroactive molecules.
24
 It has been employed extensively to evaluate the redox properties 
of organometallic compounds, including ferrocene.
25
 In a CV experiment, the voltage 
applied to the working electrode is scanned from an initial position, A, to a predetermined 
endpoint, D (Figure 2.26), the scan is then reversed. This forward and reverse scanning can 
be repeated as many times as is necessary. The potential of the working electrode is 
controlled versus a reference electrode. For the electrochemistry experiments reported 
Ag|AgCl is used as the reference electrode. This reference is used in preference to other 
reference electrodes, namely, the normal hydrogen electrode (NHE) and the saturated 
calomel electrode (SCE). The Ag|AgCl electrode is more robust and is easier to maintain. 
In addition, it does not have the toxicity and safety problems associated with the SCE and 
NHE.
26
 
A cyclic voltammogram is obtained by measuring the current at the working electrode 
during a potential scan. The voltammogram, such as that in Figure 2.26, is a plot of current 
(vertical axis) versus potential (horizontal axis). 
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Figure 2.26 Cyclic voltammogram of ferrocene in ACN with glassy carbon working 
electrode, platinum wire counter electrode and Ag|AgCl reference electrode. 
 
A.  The initial potential is applied at 0 V. The potential is then scanned in a positive 
direction. 
B.  When the potential is sufficiently positive, the ferrocenyl compound is oxidised to 
the ferricenium compound, Fc → Fc+. The anodic current then begins to increase.  
C.  The anodic current continues to increase until the system surrounding the electrode 
is depleted of ferrocenyl compound due to its conversion to ferricenium species.  
D-G.  At this stage the ferricenium species begins to get reduced back to the ferrocenyl 
species, thus the cathodic current begins. As is the case with a redox system that 
behaves in an ideal fashion, the reverse scan roughly mirrors the forward scan. The 
reverse scan ends when the current reaches the start point, 0 V. 
 
The N-(ferrocenyl)naphthoyl amino acid and dipeptide derivatives exhibit one electron, 
reversible, redox waves similar to ferrocene, under the same conditions. The E
0
´ (oxidation 
potential) values for the N-(3-ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives 
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were in the range of 5-29 mV, whilst the N-(6-ferrocenyl-2-naphthoyl) amino acid and 
dipeptide derivatives showed values in the 42-60 mV range versus the 
ferrocene/ferricenium redox couple (Fc/Fc
+
). Figure 2.27 illustrates the difference in 
potential of the CVs obtained for N-(3-ferrocenyl-2-naphthoyl)-L-alanine-L-phenylalanine 
ethyl ester 91 and N-(6-ferrocenyl-2-naphthoyl)-L-alanine-L-phenylalanine ethyl ester 102.  
 
Figure 2.27 Cyclic voltammograms of N-(3-ferrocenyl-2-naphthoyl)-L-alanine-L-
phenylalanine ethyl ester 91 and N-(6-ferrocenyl-2-naphthoyl)-L-alanine-L-phenylalanine 
ethyl ester 102 (0.1 M TBAP in ACN, Ag|AgCl, 0.1 V s
-1
). 
 
The E
0
´ values for the N-(6-ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives 
are comparable with those reported for the N-(ferrocenyl)benzoyl peptide derivatives (33 to 
78 mV vs. Fc/Fc
+
).
16
 These E
0
´ values are much lower than those observed for N-
ferrocenoyl peptide esters, for example N-Fc-Ala-Ala-OMe shows a E
0
´ of 190 mV vs. 
Fc/Fc
+
, while N-Fc-Ala-Phe-OMe has a E
0
´ of 230 mV vs. Fc/Fc
+
.
27
 The amide carboxyl 
group is strongly electron withdrawing and consequently N-ferrocenoyl peptide esters are 
difficult to oxidise. The presence of a naphthoyl linker between the ferrocene moiety and 
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the peptide chain provides extended conjugation to the π-electrons of the Cp rings making 
initial oxidation of the iron centre easier.  
The E
0
´ values determined for the N-(3-ferrocenyl-2-naphthoyl) amino acid and dipeptide 
derivatives are more comparable to that determined for ferrocene itself. The ortho-
relationship between the two naphthyl substituents imposes a steric restriction on the bulky 
ferrocene group, forcing it to adopt a position out-of-plane with respect to the naphthoyl 
ring. Consequently, efficient overlap between the naphthoyl p-orbitals and the p-orbitals of 
the Cp ring is prevented in the N-(3-ferrocenyl-2-naphthoyl) amino acid and dipeptide 
derivatives; only minimal conjugation is occurring. 
 
2.11. Mass spectrometric studies of N-(ferrocenyl)naphthoyl amino acid and dipeptide 
derivatives 
Mass spectrometry enables the determination of the relative molecular mass of many 
different types of compounds.
28
 The mass spectrometer is composed of three distinct parts, 
namely the ion source, the analyser and the detector. After the sample has been introduced 
into the ion source ionisation occurs. These ions are then extracted into the analyser, where 
they are separated according to their mass (m) to charge (z) ratios (m/z). The separated ions 
are detected and displayed as a mass spectrum.  
Since the N-(ferrocenyl)naphthoyl amino acid and dipeptide derivatives are non-volatile, a 
soft ionisation technique such as electrospray ionisation must be employed in their analysis. 
Thus, the N-(ferrocenyl)naphthoyl amino acid and dipeptide derivatives were analysed by 
electrospray ionisation (ESI) mass spectrometry, which confirmed the correct relative 
molecular mass for each compound. Examination of the mass spectra revealed the presence 
of both radical cation species, [M]
+•
 as well as [M+H]
+
 species at one mass unit higher. 
Intense adducts due to sodium and potassium were also present 22 and 38 mass units higher 
than the protonated molecular ion species. Sequence specific fragment ions were not 
observed or were of low intensity in the mass spectra and therefore tandem mass 
spectrometry (MS/MS) experiments were performed for several compounds.   
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2.11.1. Tandem Mass Spectrometry (MS/MS) 
Tandem mass spectrometry (MS/MS) is a well-established analytical technique for the 
determination of the primary sequence of peptides and proteins.
29
 A tandem mass 
spectrometer is a mass spectrometer that has more than one analyser, in practice usually 
two. A collision cell (which functions by fragmenting the ions that were selected by the 
first analyser) is positioned between the two analysers. The first analyser is used to select 
user specified sample ions arising from a particular component; usually the (M+H)
+
 or (M-
H)
-
 ions. These chosen ions pass into the collision cell and are bombarded by the gas 
molecules, which cause fragment ions to be formed. The resultant fragment ions are 
analysed according to their mass to charge ratios, by the second analyser. All of the 
fragment ions arise directly from the precursor ions specified in the experiment. Thus, a 
fingerprint pattern specific to the compound under investigation is produced.  
The identification of fragment ions arising from MS/MS analysis of peptides has been 
facilitated by a nomenclature system which was devised by Roepstorff.
30
 This 
nomenclature system differentiates fragment ions according to the amide bond that 
fragments and the end of the peptide that retains a charge after fragmentation. The 
appearance of a, b or c ions suggest that charge retention has occurred at the N-terminal, 
while the appearance of x, y or z ions are consistent with charge retention at the C-terminal. 
A schematic depiction of this system is shown in Figure 2.28. 
 
Figure 2.28 The suggested nomenclature for peptide fragment ions produced during 
MS/MS.
30
 
 
Positive-ion mode MS/MS data was obtained for N-(3-ferrocenyl-2-naphthoyl)-glycine-L-
alanine ethyl ester 85 and N-(6-ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl ester 51 
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(Figure 2.29). It can be seen that the fragmentation pattern for the two compounds is 
completely different. The MS/MS spectrum of N-(3-ferrocenyl-2-naphthoyl)-glycine-L-
alanine ethyl ester 85 shows a major product ion at m/z 447, which corresponds to the loss 
of the unsubstituted (η5-C5H5) ring. The formation of this fragment ion is possibly due to 
steric hindrance between the ortho substituted naphthoyl substituents and the (η5-C5H5) 
ring. This fragment ion was also observed for the N-ortho-(ferrocenyl)-benzoyl amino acid 
and dipeptide derivatives.
31,10
 The product ion at m/z 373 is due to [M-65-H2O-Fe]
+
.  
 
Figure 2.29 MS/MS spectrum of (a) N-(3-ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl 
ester 85 and (b) N-(6-ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl ester 51. 
 
In the MS/MS spectrum of N-(6-ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl ester 51 
sequence specific ions were observed, which confirm that the glycine residue was linked to 
the naphthoyl spacer group. A product ion present at m/z 311 confirms the presence of a 
ferrocenyl naphthyl subunit and the signal at m/z 339 is due to cleavage at the naphthoyl 
carbonyl group (Figure 2.30). However, the expected a1 and b1 product ions at m/z 368 and 
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m/z 396 were not observed. Instead a1-1 and b1-1 product ions were observed at m/z 367 
and m/z 395, respectively, thus, a hydrogen atom has also been lost during the 
fragmentation process. This is unusual as these a1 and b1 fragment ions are usually 
produced without loss of a hydrogen atom.
32
 Recently, the formation of a1-1 and b1–1 ions 
in the mass spectra of N-{para-(ferrocenyl)-benzoyl}-glycine-L-alanine ethyl ester has 
been investigated by tandem mass spectrometry and deuterium labelling studies. The results 
showed that b1-1 product ions arise from the loss of a hydrogen atom attached to the 
nitrogen and not to the -carbon of the glycine residue.
33
 
 
Figure 2.30 Product ions observed in the MS/MS spectrum of N-(6-ferrocenyl-2-
naphthoyl)-glycine-L-alanine ethyl ester 51. 
 
2.12. X-ray crystallography study of methyl ferrocenylnaphthalene-2-carboxylate 
Crystals suitable for X-ray crystallographic determination of methyl 3-
ferrocenylnaphthalene-2-carboxylate 71 and methyl 6-ferrocenylnaphthalene-2-carboxylate 
74 were grown from hexane/ethyl acetate yielding red block shaped crystals. Selected bond 
distances and angles of non hydrogen atoms are given in Table 2.8 and all pertinent 
crystallographic information is summarised in Table 2.9.  
Figure 2.31 shows the molecular structures and asymmetric unit of methyl 3-
ferrocenylnaphthalene-2-carboxylate 71. Compound 71 crystallises in the monoclinic space 
group P21/c with one molecule in the asymmetric unit. The principal dimensions are 
carboxylate ester C=O 1.199(3) Å, C-O 1.335(2) Å and O-CH3 1.449(3) Å and O=C-O 
123.6(2) 
o
. The cyclopentadienyl rings of the ferrocene unit (Cp1 and Cp2) are almost 
eclipsed with C1n…Cg1…Cg2…C2n torsion angles (n = 1-5) in the -0.7(42) to 1.3(3) o 
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range. Centroids Cg1 and Cg2 are equidistant from the iron core, with Fe…Cg1/Cg2 
distances of 1.643(3)/1.646(2), respectively, while the Cg1…Fe…Cg2 angle is almost 
linear at 178.3(3) 
o
. There are no classical hydrogen bonds present; however, there is a short 
contact between a (Cp2) ring carbon C3 and a (Cp1) ring hydrogen H20 of another 
molecule, contact distance being 2.73(1) Å. There is also a short contact of 2.86(4) Å 
between a (Cp1) ring carbon C5 of one molecule and (Cp2) ring hydrogen H11 of the 
neighbouring molecule. There are no significant C-H…π(arene) or π…π stacking 
interactions.  
In compound 71, the C10H6 ring and the four-atom O=C-O-CH3 plane are oriented at 
54.45(12) 
o
 and the C10H6/(η
5
-C5H4) rings at 28.27(15) 
o
, whereas the angle between the 
(η5-C5H4) ring and the O=C-O-CH3 plane is 68.87(4) 
o
. This data demonstrates the 
existence of a large distortion in the molecule, which is evident in Figure 2.31. Steric 
hindrance has forced the atoms of this molecule to adopt this strained conformation in the 
solid state, resulting is a loss of co-planarity of the conjugating groups. This is supported by 
the torsion angles for the O25-C14-C19-C15 bonds and C20-C21-C15-C19 bonds which 
were calculated to be 54.2(3) and 149.5(2) 
o
, respectively. 
 
Figure 2.31 Molecular drawing of methyl 3-ferrocenylnaphthalene-2-carboxylate 71 using 
ORTEP: displacement ellipsoids are drawn at the 50% probability level. 
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Methyl 6-ferrocenylnaphthalene-2-carboxylate 74 crystallises in the monoclinic space 
group P21/n with one molecule in the asymmetric unit: the molecular structure is depicted 
in Figure 2.32. The principal dimensions are carboxylate ester C=O 1.198(4) Å, C-O 
1.343(4) Å and O-CH3 1.438(4) Å and O=C-O 122.5(4)
 o
. In the case of compound 74, the 
cyclopentadienyl rings of the ferrocene unit (Cp1 and Cp2) are slightly staggered with 
C1n…Cg1…Cg2…C2n torsion angles (n = 1-5) in the -12.2(4) to -14.9(2)o range. 
Centroids Cg1 and Cg2 are equidistant from the iron core, with Fe…Cg1/Cg2 distances of 
1.650(3)/1.657(4), respectively, while the Cg1…Fe…Cg2 angle is almost linear at 178.1(3) 
o
. There are no classical hydrogen bonds present; however, there is a significant 
intermolecular contact between a (Cp2) ring hydrogen H3 and a (Cp2) ring hydrogen H4, 
contact distance being 2.38(2) Å. There is also a short contact of 2.83(3) Å between a (Cp2) 
ring carbon C1 and (naphthyl) ring hydrogen H18. There are no significant C-H…π(arene) 
or π…π stacking interactions.  
The C10H6 ring and the four-atom O=C-O-CH3 plane of compound 74 are oriented at 
4.45(15) 
o
 and the C10H6/(η
5
-C5H4) rings at 3.13(16) 
o; whereas the angle between (η5-
C5H4) ring and the O=C-O-CH3 plane is 1.97(5) 
o
. Calculated torsion angles in compound 
74 between the O1-C21-C16-C17 bonds and C10-C9-C11-C12 bonds are minimal at 2.9(5) 
and -4.3(5) 
o
, respectively. Thus, the conjugating groups in this molecule lie almost 
completely within the same plane in the solid state (Figure 2.32). A similar observation has 
been reported for the para-substituted ferrocenyl methyl benzoate.
34
 
 
Figure 2.32 Molecular drawing of methyl 6-ferrocenylnaphthalene-2-carboxylate 74 using 
ORTEP: displacement ellipsoids are drawn at the 50% probability level. 
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Table 2.8 Representative bond lengths (Å) and angles (
o
) for methyl 3-
ferrocenylnaphthalene-2-carboxylate 71 and methyl 6-ferrocenylnaphthalene-2-carboxylate 
74. 
 71  74 
Bond Distances/Å  Bond Distances/Å  
Fe2…Cg1 1.643(2) Fe…Cg1 1.650(3) 
Fe2…Cg2 1.646(3) Fe…Cg2 1.657(4) 
Cg1…Fe…Cg2 178.31(3) Cg1…Fe…Cg2 178.1(3) 
C14-O25 1.199(3) C21-O1 1.198(4) 
C14-O24 1.335(2) C21-O2 1.343(4) 
O24-C2 1.449(3) O2-C22 1.438(4) 
    
Bond Angles/
o
  Bond Angles/
o
  
Fe2-C21-C15 125.9(1) Fe-C9-C11 126.4(6) 
C17-C19-C14 115.8(2) C15-C16-C21 122.5(3) 
C15-C19-C14 123.8(2) C17-C16-C21 118.2(3) 
O25-C14-O24 123.6(2) O1-C21-O2 122.5(4) 
O25-C14-C19 125.0(2) O2-C21-C16 112.4(3) 
C14-O24-C2 116.2(2) C21-O2-C22 116.5(3) 
O24-C14-C19 111.3(2) O1-C21-C16 125.1(4) 
C20-C21-C15-C19 149.5(2) Fe-C9-C11-C20 86.7(3) 
C28-C21-C15-C19 156.5(2) C8-C9-C11-C20 -2.5(3) 
Fe2-C21-C15-C19 63.3(2) C10-C9-C11-C12 -4.3(4) 
O24-C14-C19-C15 -129.8(2) C15-C16-C21-O2 3.7(3) 
C14-C19-C15-C21 11.6(3) C17-C16-C21-O1 2.9(5) 
    
Where Cg1 and Cg2 are the centroids of the (η5-C5H4) and (η
5
-C5H5) rings, respectively. 
 
 
 
89 
 
Table 2.9 Pertinent crystal structure data. 
Details 71 74 
Empirical formula C22H18O2Fe C22H18O2Fe 
M/g mol
-1
 370.21 370.21 
Crystal colour, habit Red block Red block 
Crystal system Monoclinic Monoclinic 
Space group P21/c P21/n 
a/Å 13.9797(15) 14.7851(17) 
b/Å 8.7249(9) 6.1301(7) 
c/Å 13.9843(15) 18.161(2) 
β/o 103.111(2) 92.273(3) 
V/Å
3
 1661.2(3) 1644.8(3) 
Z 4 4 
Temperature/K 273 298 
Dcalc/g cm
-3
 1.480 1.495 
μ/mm-1 0.920 0.929 
F000 768 768 
Crystal dimensions/mm 0.25 x 0.18 x 0.13 0.27 x 0.19 x 0.13 
Max. and min. transmission 0.8898 – 0.8027 0.8888 – 0.7876 
Refinement method SHELXL97 SHELXL97 
Reflections collected/unique 17252/2927 9115/2883 
Final R indices [I > 2ζI] R1 = 0.0285 wR2 = 0.0796 R1 = 0.0469 wR2 = 0.1146 
R indices [all data] R1 = 0.0314 wR2 = 0.0819 R1 = 0.0627 wR2 = 0.1220 
Goodness of fit 1.018 1.02 
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2.13. Conclusions 
N-(ferrocenyl)benzoyl peptide derivatives have been identified as potential anti-cancer 
agents following in vitro testing in the H1299 NSCLC cell line.
10
 This project sought to 
explore the structure-activity relationship (SAR) of these derivatives, in order to enhance 
the anti-proliferative effect. The primary focus of this SAR study was centred on altering 
the conjugating linker, by extending the aromatic framework. Thus, the synthesis of a series 
of N-(ferrocenyl)naphthoyl amino acid and dipeptide derivatives which contain α-amino 
acids was undertaken. These novel compounds were prepared by condensation of 3-
ferrocenylnaphthalene-2-carboxylic acid and 6-ferrocenylnaphthalene-2-carboxylic acid 
with the appropriate amino acid or dipeptide ethyl ester under solution phase peptide 
coupling conditions. Purification by column chromatography furnished the required 
compounds as orange or red solids, in moderate to good yields (18% to 95%).  
The N-(ferrocenyl)naphthoyl amino  acid and dipeptide derivatives were characterised by a 
range of spectroscopic techniques including 
1
H NMR, 
13
C NMR, DEPT 135, HMQC, IR, 
UV-Vis, MS and CV. The UV-Vis spectra of the N-(6-ferrocenyl-2-naphthoyl) amino acid 
and dipeptide derivatives showed an intense absorbance at 375 nm due to a π to π* 
transition of the aromatic spacer group. This absorbance was too weak to be observed in the 
UV-Vis spectra of the N-(3-ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives. 
Cyclic voltammetry experiments showed the N-(ferrocenyl)naphthoyl amino  acid and 
dipeptide derivatives to exhibit one electron, reversible, redox waves similar to ferrocene, 
under the same conditions. E
0’ values for the N-(6-ferrocenyl-2-naphthoyl) amino acid and 
dipeptide derivatives (42-60 mV vs. Fc/Fc
+
) were much lower than those observed for N-
ferrocenoyl peptide esters. However, the E
0’ values for the N-(3-ferrocenyl-2-naphthoyl) 
amino acid and dipeptide derivatives (5-29 mV vs. Fc/Fc
+
) were more comparable to that 
determined for ferrocene itself. The MS/MS spectrum of N-(3-ferrocenyl-2-naphthoyl)-
glycine-L-alanine ethyl ester 85, showed a major product ion at m/z 447, which corresponds 
to the loss of the unsubstituted (η5-C5H5) ring. This product ion is absent from the MS/MS 
spectrum of N-(6-ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl ester 51.  
This data provides evidence that π conjugation is occurring between the ferrocene and 
naphthalene units in the N-(6-ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives. 
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In contrast, π conjugation between these two units is minimal in the N-(3-ferrocenyl-2-
naphthoyl) amino acid and dipeptide derivatives. In the latter case, the ortho-relationship of 
the two naphthyl substituents imposes a steric restriction on the bulky ferrocene group, 
forcing it to adopt a position out-of-plane with respect to the naphthalene ring. Thus, 
effective π conjugation is prevented. An X-ray crystallography study illustrates the out-of-
plane position adopted by the ferrocene group in methyl 3-ferrocenylnaphthalene-2-
carboxylate 71. In contrast, the molecular structure of methyl 6-ferrocenylnaphthalene-2-
carboxylate 74 shows the ferrocene group to lie almost completely within the same plane as 
the naphthalene unit.  
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Experimental Procedures 
 
Experimental Note 
All chemicals were purchased from Sigma-Aldrich, Lennox Chemicals, Fluorochem 
Limited or Tokyo Chemical Industry UK Limited; and used as received. Commercial grade 
reagents were used without further purification. When necessary, all solvents were purified 
and dried prior to use. Riedel-Haën silica gel was used for thin layer and column 
chromatography. Melting points were determined using either a Griffin melting point 
apparatus or a Stuart melting point (SMP3) apparatus and are uncorrected. Optical rotation 
measurements were made on a Perkin Elmer 343 Polarimeter and are quoted in units of 10
-1
 
deg cm
2
 g
-1
. Infrared spectra were recorded on either a Perkin Elmer Spectrum GX FT-IR 
or a Perkin Elmer Spectrum 100 FT-IR with ATR. UV-Vis spectra were recorded on a 
Hewlett Packard 8452 A diode array UV-Vis spectrophotometer. 
1
H and 
13
C NMR spectra 
were recorded in deuterated solvents on a Bruker Avance 400 NMR. The 
1
H and 
13
C NMR 
chemical shifts are reported in ppm (parts per million). Tetramethylsilane (TMS) or the 
residual solvent peaks have been used as an internal reference. All coupling constants (J) 
are in Hertz. The abbreviations for the peak multiplicities are as follows: s (singlet), d 
(doublet), dd (doublet of doublets), t (triplet), q (quartet), qt (quintet), m (multiplet) and br 
(broad). Electrospray ionisation mass spectra were performed on a Micromass LCT mass 
spectrometer or a Brüker Daltonics Esquire-LC ion trap mass spectrometer. Tandem mass 
spectra were obtained on a Micromass Quattro micro
TM
 LC-MS/MS triple quadrupole mass 
spectrometer. Elemental analysis was carried out by the microanalytical laboratory at 
University College Dublin. 
Cyclic voltammograms were recorded in anhydrous acetonitrile (Sigma-Aldrich), with 
0.1 M tetrabutylammonium perchlorate (TBAP) as a supporting electrolyte, using a CH 
Instruments 600a electrochemical analyzer (Pico-Amp Booster and Faraday Cage). The 
experiments were carried out at room temperature. A three-electrode cell consisting of a 
glassy carbon working-electrode, a platinum wire counter-electrode and an Ag|AgCl 
reference electrode was used. The glassy carbon electrode was polished with 0.3 μm 
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alumina followed by 0.05 μm alumina, between each experiment to remove any surface 
contaminants. The scan rate was 0.1 V s
-1
. The concentration range of the ferrocene 
compounds was 1.0 mM in acetonitrile. The E
0
´ values obtained for the test samples were 
referenced relative to the ferrocene/ferricenium redox couple. 
 
General procedure for the preparation of starting materials for N-(ferrocenyl)naphthoyl 
peptide derivatives. 
Methyl 3-aminonaphthalene-2-carboxylate hydrochloride 70 
3-Amino-2-naphthoic acid (1.51 g, 8.1 mmol) was added 
slowly to a solution of methanol (50 ml) and thionyl chloride 
(8 ml) at 0 
o
C and then refluxed for 24 h. The solution was 
cooled and the product was isolated by filtration as a pale 
pink/brown solid (1.45 g, 75%), mp 185-187 
o
C; 
δH (400 MHz, DMSO-d6): 8.61 (1H, s, ArH), 8.03 (1H, d, J 
8.0, ArH), 7.84 (1H, d, J 8.0, ArH), 7.76 (1H, s, ArH), 7.60 (1H, t, J 8.0, ArH), 7.46 (1H, t, 
J 8.0, ArH), 3.92 (3H, s, -OCH3); 
δC (100 MHz, DMSO-d6): 166.2 (C=O), 135.7 (Cq), 135.3 (Cq), 133.1, 129.5, 129.2, 128.4 
(Cq), 126.4, 125.4, 118.4 (Cq), 117.6, 52.4 (-OCH3). 
 
Methyl 3-ferrocenylnaphthalene-2-carboxylate 71 
Concentrated hydrochloric acid (4 ml) was added with 
intermittent cooling to a solution of methyl 3-
aminonaphthalene-2-carboxylate hydrochloride (2.62 g, 
11 mmol) in 15 ml of water. A solution of sodium nitrite 
(0.9 g, 13 mmol) in 15 ml of deionised water was then 
added slowly to this mixture with stirring, keeping the 
temperature below 5 
o
C to furnish a pale brown/yellow 
solution. The resulting diazo salt was added to a solution of ferrocene (2.42 g, 13 mmol) in 
diethyl ether (90 ml) and allowed to react for 18 h. The reaction was then washed with 
water, the ether layer was dried over MgSO4 and the solvent was removed in vacuo to yield 
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the crude product. The crude product was purified using column chromatography {eluant 
3:2 petroleum ether (40-60
o
C): diethyl ether} to obtain an orange solid (1.23 g, 30%), mp 
119-120 
o
C; 
Anal. Calc. for C22H18O2Fe: C, 71.4; H, 4.9%. Found: C, 71.35; H, 4.9; 
m/z (ESI) 370.4 [M]
+•
. C22H18O2Fe requires 370.2; 
λmax(EtOH)/nm 440 (ε/dm
3
 mol
-1
 cm
-1
 574); 
νmax(KBr)/cm
-1
 1720, 1494, 1201; 
δH (400 MHz, DMSO-d6): 8.40 (1H, s, ArH), 8.07 (1H, s, ArH ), 8.05 (1H, d, J 8.0, ArH), 
7.97 (1H, d, J 8.0, ArH), 7.61 (1H, t, J 8.0, ArH), 7.54 (1H, t, J 8.0, ArH), 4.59 {2H, t, J 
1.6, ortho on (η5-C5H4)}, 4.35 {2H, t, J 1.6, meta on (η
5
-C5H4)}, 4.10 (5H, s, η
5
-C5H5), 
3.77 (3H, s, -OCH3); 
δC (100 MHz, DMSO-d6): 169.4 (C=O), 134.2 (Cq), 133.5 (Cq), 130.4 (Cq), 130.3 (Cq), 
129.2, 128.1, 128.0, 127.9, 127.5, 126.4, 85.0 (Cipso η
5
-C5H4), 69.6 (η
5
-C5H5), 68.9 (Cortho 
η5-C5H4), 68.3 (Cmeta η
5
-C5H4), 52.2 (-OCH3). 
 
3-Ferrocenylnaphthalene-2-carboxylic acid 72 
Sodium hydroxide (0.1 g, 2.5 mmol) was added to 
methyl 3-ferrocenylnaphthalene-2-carboxylate (0.92 g, 
2.5 mmol) in a 1:1 mixture of water/methanol and was 
refluxed for 12 h. Concentrated HCl was added until pH 
2 was reached. The solution was allowed to cool and 
filtered to obtain an orange/brown solid (0.81 g, 92%), 
mp (decomp.) at 145 
o
C;  
m/z (ESI) 356.4 [M]
+•
. C21H16O2Fe requires 356.2; 
λmax(EtOH)/nm 445 (ε/dm
3
 mol
-1
 cm
-1
 568); 
νmax(KBr)/cm
-1
 3430, 1698; 
δH (400 MHz, DMSO-d6): 12.8 (1H, br.s, -COOH), 8.33 (1H, s, ArH), 8.00 (1H, d, J 8.0, 
ArH), 7.99 (1H, s, ArH), 7.95 (1H, d, J 8.0, ArH), 7.57 (1H, t, J 8.0, ArH), 7.52 (1H, t, J 
8.0, ArH), 4.70 {2H, t, J 1.6, ortho on (η5-C5H4)}, 4.34 {2H, t, J 1.6, meta on (η
5
-C5H4)}, 
4.10 (5H, s, η5-C5H5); 
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δC (100 MHz, DMSO-d6): 170.8 (C=O), 134.3 (Cq), 133.9 (Cq), 133.1 (Cq), 130.5 (Cq), 
128.8, 127.9, 127.4, 127.0, 126.1, 85.2 (Cipso η
5
-C5H4), 69.6 (η
5
-C5H5), 69.1 (Cmeta η
5
-
C5H4), 68.2 (Cortho η
5
-C5H4). 
 
Methyl 6-aminonaphthalene-2-carboxylate hydrochloride 73 
6-Amino-2-naphthoic acid (1.54 g, 8.2 mmol) was 
added slowly to a solution of methanol (50 ml) and 
thionyl chloride (8 ml) at 0 
o
C and then refluxed for 
24 h. The solution was cooled and the product was 
isolated by filtration as a brown solid (1.43 g, 73%), mp 156-158 
o
C; 
δH (400 MHz, DMSO-d6): 8.56 (1H, s, ArH), 8.09 (1H, d, J 8.8, ArH), 7.93 (1H, dd, J 2.0 
and 8.8, ArH), 7.90 (1H, d, J 8.8, ArH), 7.56 (1H, s, ArH), 7.38 (1H, dd, J 2.0 and 8.8, 
ArH), 3.90 (3H, s, -OCH3); 
δC (100 MHz, DMSO-d6): 166.2 (C=O), 135.9 (Cq), 135.4 (Cq), 131.2, 130.5, 129.6 (Cq), 
127.6, 126.1 (Cq), 125.7, 121.8, 117.6, 52.2 (-OCH3). 
 
Methyl 6-ferrocenylnaphthalene-2-carboxylate 74 
Concentrated hydrochloric acid (4 ml) was 
added with intermittent cooling to a solution 
of methyl 6-aminonaphthalene-2-carboxylate 
hydrochloride (2.7 g, 11.5 mmol) in 15 ml of 
water. A solution of sodium nitrite (1.0 g, 
14.5 mmol) in 15 ml of deionised water was 
then added slowly to this mixture with stirring, keeping the temperature below 5 
o
C 
furnishing a pale brown/yellow solution. The resulting diazo salt was added to a solution of 
ferrocene (2.8 g, 14.5 mmol) in diethyl ether (90 ml) and allowed to react for 18 h. The 
reaction mixture was then washed with water, the ether layer was dried over MgSO4, and 
the solvent removed in vacuo to yield the crude product. The crude product was purified 
using column chromatography {eluant 3:2 petroleum ether (40-60
o
C): diethyl ether} to 
obtain a red solid (0.88 g, 21%), mp 158-159 
o
C; 
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Anal. Calc. for C22H18O2Fe: C, 71.4; H, 4.9%. Found: C, 71.6; H, 5.2; 
m/z (ESI) 370.4 [M]
+•
. C22H18O2Fe requires 370.2; 
λmax(EtOH)/nm 380 (ε/dm
3
 mol
-1
 cm
-1
 3211), 455 (1523); 
νmax(KBr)/cm
-1
 1708, 1494, 1450, 1219; 
δH (400 MHz, DMSO-d6): 8.58 (1H, s, ArH), 8.09 (1H, s, ArH), 8.07 (1H, d, J 8.8, ArH), 
7.93-7.98 (2H, m, ArH), 7.85 (1H, dd, J 1.6 and 8.8, ArH), 4.99 {2H, t, J 1.6, ortho on (η5-
C5H4)}, 4.47 {2H, t, J 1.6, meta on (η
5
-C5H4)}, 4.05 (5H, s, η
5
-C5H5), 3.92 (3H, s, -OCH3); 
δC (100 MHz, DMSO-d6): 166.4 (C=O), 140.0 (Cq), 135.4 (Cq), 130.6 (Cq), 130.4, 129.2, 
127.8, 126.1, 125.8 (Cq), 125.1, 122.7, 83.7 (Cipso η
5
-C5H4), 69.6 (Cmeta η
5
-C5H4), 69.5 (η
5
-
C5H5), 66.8 (Cortho η
5
-C5H4), 52.2 (-OCH3). 
 
6-Ferrocenylnaphthalene-2-carboxylic acid 75 
Sodium hydroxide (0.08 g, 2.0 mmol) was 
added to methyl 6-ferrocenylnaphthalene-2-
carboxylate (0.70 g, 1.9 mmol) in a 1:1 
mixture of water/methanol and was refluxed 
for 12 h. Concentrated HCl was added until 
pH 2 was reached. The solution was allowed 
to cool and filtered to obtain an orange solid (0.63 g, 93%), mp (decomp.) at 205 
o
C; 
m/z (ESI) 356.4 [M]
+•
. C21H16O2Fe requires 356.2; 
λmax(EtOH)/nm 375 (ε/dm
3
 mol
-1
 cm
-1
 2635), 450 (1296); 
νmax(KBr)/ cm
-1
 3435, 1682; 
δH (400 MHz, DMSO-d6): 12.8 (1H, br.s, -COOH), 8.57 (1H, s, ArH), 8.07 (1H, s, ArH), 
8.03 (1H, d, J 8.4, ArH), 7.94 (2H, s, ArH), 7.83 (1H, dd, J 1.6 and 8.4, ArH), 4.97 {2H, t, 
J 1.6, ortho on (η5-C5H4)}, 4.45 {2H, t, J 1.6, meta on (η
5
-C5H4)}, 4.04 (5H, s, η
5
-C5H5); 
δC (100 MHz, DMSO-d6): 167.5 (C=O), 139.7 (Cq), 135.3 (Cq), 130.6 (Cq), 130.4, 129.1, 
127.6, 127.0 (Cq), 125.9, 125.5, 122.7, 83.8 (Cipso η
5
-C5H4), 69.6 (Cmeta η
5
-C5H4), 69.5 (η
5
-
C5H5), 66.7 (Cortho η
5
-C5H4). 
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General procedure for the preparation of N-(ferrocenyl)naphthoyl amino acid and 
dipeptide derivatives. 
N-(3-ferrocenyl-2-naphthoyl)-glycine ethyl ester 80 
Glycine ethyl ester hydrochloride (0.17 g, 1.2 mmol) 
was added to a solution of 3-ferrocenylnaphthalene-2-
carboxylic acid (0.43 g, 1.2 mmol), 1-
hydroxybenzotriazole (0.22 g, 1.6 mmol), triethylamine 
(0.5 ml) and N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (0.3 g, 1.6 mmol) in 
50 ml of dichloromethane at 0 
o
C. After 30 minutes the 
solution was raised to room temperature and the 
reaction was allowed to proceed for 48 h. The reaction 
mixture was then washed with water. The 
dichloromethane layer was dried over MgSO4 and the solvent was removed in vacuo. The 
product was purified by column chromatography (eluant 1:1 hexane:ethyl acetate) to give 
the title compound as an orange solid (0.44 g, 83%), mp 105-106 
o
C; E
0
´/mV 13 vs. Fc/Fc
+
;  
Anal. Calc. for C25H23NO3Fe: C, 68.0; H, 5.25; N, 3.2%. Found: C, 67.7; H, 5.5; N, 3.25;  
m/z (ESI) 441.4 [M]
+•
. C25H23NO3Fe requires 441.3;  
λmax(EtOH)/nm 450 (ε/dm
3
 mol
-1
 cm
-1
 466);  
νmax(KBr)/cm
-1
 3296, 1736, 1647, 1544, 1191; 
δH (400 MHz, DMSO-d6): 8.98 (1H, t, J 5.6, -CONH-), 8.35 (1H, s, ArH), 8.01 (1H, d, J 
8.0, ArH), 7.93 (1H, d, J 8.0, ArH), 7.82 (1H, s, ArH), 7.56 (1H, t, J 8.0, ArH), 7.52 (1H, t, 
J 8.0, ArH), 4.83 {2H, t, J 1.6,  ortho on (η5-C5H4)}, 4.32 {2H, t, J 1.6, meta on (η
5
-C5H4)}, 
4.18 (2H, q, J 7.2, -OCH2CH3), 4.07 (5H, s, η
5
-C5H5), 4.03 (2H, d, J 5.6, -NHCH2-), 1.27 
(3H, t, J 7.2, -OCH2CH3); 
δC (100 MHz, DMSO-d6): 170.1 (C=O), 169.8 (C=O), 134.6 (Cq), 134.3 (Cq), 133.0 (Cq), 
130.4 (Cq), 128.1, 127.7, 127.4, 127.1, 126.8, 126.1, 84.1 (Cipso η
5
-C5H4), 69.6 (η
5
-C5H5), 
68.9 (Cortho η
5
-C5H4), 68.3(Cmeta η
5
-C5H4), 60.6 (-OCH2-, -ve DEPT), 41.1 (-NHCH2-, -ve 
DEPT), 14.1 (-OCH2CH3). 
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N-(3-ferrocenyl-2-naphthoyl)-L-alanine ethyl ester 81 
The synthesis followed that of 80 using the following 
reagents: 3-ferrocenylnaphthalene-2-carboxylic acid 
(0.36 g, 1.0 mmol), 1-hydroxybenzotriazole (0.14 g, 1.0 
mmol), triethylamine (0.5 ml), N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.19 g, 1.0 mmol) and L-alanine ethyl 
ester hydrochloride (0.19 g, 1.2 mmol). The product was 
purified by column chromatography (eluant 1:1 
hexane:ethyl acetate) to give the title compound as an 
orange solid (0.24 g, 95%), mp 49 
o
C;  
E
0
´/mV 8 vs. Fc/Fc
+
;  
[α] 20
D
 +13 (c 0.01 in EtOH);  
Anal. cald. for C26H25NO3Fe: C, 68.6; H, 5.5; N, 3.1%. Found: C, 68.8; H, 5.8; N, 3.3;  
m/z (ESI) 455.5 [M]
+•
. C26H25NO3Fe requires 455.3;  
λmax(EtOH)/nm 450 (ε/dm
3
 mol
-1
 cm
-1
 512);  
νmax(KBr)/cm
-1
 3288, 1734, 1647, 1544, 1494, 1200; 
δH (400 MHz, DMSO-d6): 8.94 (1H, d, J 7.2, -CONH-), 8.34 (1H, s, ArH), 8.00 (1H, d, J 
8.0, ArH), 7.93 (1H, d, J 8.0, ArH), 7.80 (1H, s, ArH), 7.50-7.58 (2H, m, ArH), 4.78-4.80 
{2H, m, ortho on (η5-C5H4)}, 4.45 (1H, qt, J 7.2, -NHCH-), 4.33-4.35 {1H, m, meta on (η
5
-
C5H4)}, 4.29-4.31 {1H, m, meta on (η
5
-C5H4)}, 4.16 (2H, q, J 7.2, -OCH2CH3), 4.09 (5H, s, 
η5-C5H5), 1.38 (3H, d, J 7.2, -CH3), 1.27 (3H, t, J 7.2, -OCH2CH3); 
δC (100 MHz, DMSO-d6): 172.5 (C=O), 169.3 (C=O), 134.7 (Cq), 134.3 (Cq), 132.9 (Cq), 
130.4 (Cq), 128.2, 127.7, 127.4, 127.1, 126.8, 126.1, 84.3 (Cipso η
5
-C5H4), 69.5 (η
5
-C5H5), 
68.5 (Cortho η
5
-C5H4), 68.3 (Cmeta η
5
-C5H4), 68.2 (Cmeta η
5
-C5H4), 60.6 (-OCH2-, -ve DEPT), 
48.0 (α-C), 16.7 (-CH3), 14.1 (-OCH2CH3).
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N-(3-ferrocenyl-2-naphthoyl)-L-leucine ethyl ester 82 
The synthesis followed that of 80 using the following 
reagents: 3-ferrocenylnaphthalene-2-carboxylic acid 
(0.36 g, 1.0 mmol), 1-hydroxybenzotriazole (0.22 g, 1.6 
mmol), triethylamine (0.5 ml), N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.29 g, 1.5 mmol) and L-leucine ethyl 
ester hydrochloride (0.23 g, 1.2 mmol). The product was 
purified by column chromatography (eluant 1:1 
hexane:ethyl acetate) to give the title compound as an 
orange solid (0.16 g, 32%), mp 75-76 
o
C;  
E
0
´/mV 16 vs. Fc/Fc
+
;  
[α] 20
D
+6 (c 0.01 in EtOH); 
m/z (ESI) 498.1714 [M+H]
+
. C29H33NO3Fe requires 498.1732; 
λmax(EtOH)/nm 445 (ε/dm
3
 mol
-1
 cm
-1
 627); 
νmax(KBr)/cm
-1
 3322, 1735, 1649, 1544, 1494, 1209; 
δH (400 MHz, DMSO-d6): 8.87 (1H, d, J 7.6, -CONH-), 8.36 (1H, s, ArH), 8.01 (1H, d, J 
8.0, ArH), 7.94 (1H, d, J 8.0, ArH), 7.74 (1H, s, ArH), 7.50-7.58 (2H, m, ArH), 4.75-4.76 
{2H, m, ortho on (η5-C5H4)}, 4.39-4.44 (1H, m, -NHCH-), 4.32-4.33 {1H, m, meta on (η
5
-
C5H4)}, 4.28-4.29 {1H, m, meta on (η
5
-C5H4)}, 4.16 (2H, q, J 7.2, -OCH2CH3), 4.08 (5H, s, 
η5-C5H5), 1.65-1.76 (2H, m, -CH2CH-) 1.50-1.58 (1H, m, -CH2CH-), 1.26 (3H, t, J 7.2, -
OCH2CH3), 0.91-0.94 {6H, m, -CH(CH3)2}; 
δC (100 MHz, DMSO-d6): 172.5 (C=O), 169.7 (C=O), 134.9 (Cq), 134.2 (Cq), 132.9 (Cq), 
130.4 (Cq), 128.2, 127.7, 127.4, 127.1, 126.5, 126.1, 84.3 (Cipso η
5
-C5H4), 69.5 (η
5
-C5H5), 
68.4 (Cortho η
5
-C5H4), 68.2 (Cmeta η
5
-C5H4), 68.1 (Cmeta η
5
-C5H4), 60.5 (-OCH2-, -ve DEPT), 
50.8 (α-C), 39.4 (-CH2-, -ve DEPT), 24.3 (-CH-), 22.9 (-CH3), 21.2 (-CH3), 14.1(-
OCH2CH3). 
 
 
 
100 
 
N-(3-ferrocenyl-2-naphthoyl)-L-phenylalanine ethyl ester 83  
The synthesis followed that of 80 using the following 
reagents: 3-ferrocenylnaphthalene-2-carboxylic acid 
(0.36 g, 1.0 mmol), 1-hydroxybenzotriazole (0.22 g, 1.6 
mmol), triethylamine (0.5 ml), N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.29 g, 1.5 mmol) and L-phenylalanine 
ethyl ester hydrochloride (0.24 g, 1.0 mmol). The 
product was purified by column chromatography (eluant 
1:1 hexane:ethyl acetate) to give the title compound as 
an orange solid (0.21 g, 40%), mp 48-49 
o
C;  
E
0
´/mV 10 vs. Fc/Fc
+
;  
[α] 20
D
 
-24 (c 0.01 in EtOH); 
Anal. Calc. for C32H29NO3Fe: C, 72.3; H, 5.5; N, 2.6%. Found: C, 72.15; H, 5.7; N, 2.6; 
m/z (ESI) 532.1572 [M+H]
+
. C32H30NO3Fe requires 532.1575; 
λmax(EtOH)/nm 450 (ε/dm
3
 mol
-1
 cm
-1
 582); 
νmax(KBr)/cm
-1
 3342, 1734, 1645, 1544, 1494, 1193; 
δH (400 MHz, DMSO-d6): 9.01 (1H, d, J 7.6, -CONH-), 8.29 (1H, s, ArH), 7.98 (1H, d, J 
8.0, ArH), 7.82 (1H, d, J 8.0, ArH), 7.49-7.57 (2H, m, ArH), 7.47 (1H, s, ArH), 7.34-7.43 
(5H, m, -CH2Ph), 4.71-4.75 (2H, m, -NHCH-), (η
5
-C5H4)}, 4.32-4.34 (1H, m, η
5
-C5H4), 
4.22-4.24 (1H, m, η5-C5H4), 4.15-4.21 {3H, m, -OCH2CH3, (η
5
-C5H4)}, 4.01 (5H, s, η
5
-
C5H5), 3.22 (1H, dd, J 7.6 and 13.6, -CH2Ph), 3.01 (1H, dd, J 7.6 and 13.6, -CH2Ph), 1.25 
(3H, t, J 7.2, -OCH2CH3); 
δC (100 MHz, DMSO-d6): 171.5 (C=O), 169.4 (C=O), 137.5 (Cq), 134.7 (Cq), 134.3 (Cq), 
132.9 (Cq), 130.3 (Cq), 129.3, 128.3, 128.1, 127.5, 127.4, 127.1, 126.6, 126.5, 126.1, 83.9 
(Cipso η
5
-C5H4), 69.5 (η
5
-C5H5), 68.9 (η
5
-C5H4), 68.8 (η
5
-C5H4), 68.3 (η
5
-C5H4), 68.1 (η
5
-
C5H4), 60.7 (-OCH2-, -ve DEPT), 53.7 (α-C), 36.4 (-CH2Ph, -ve DEPT), 14.1 (-OCH2CH3). 
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N-(3-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 84 
The synthesis followed that of 80 using the 
following reagents: 3-ferrocenylnaphthalene-2-
carboxylic acid (0.32 g, 0.9 mmol), 1-
hydroxybenzotriazole (0.22 g, 1.6 mmol), 
triethylamine (0.5 ml), N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.3 g, 1.6 mmol) and glycine-
glycine ethyl ester hydrochloride (0.18 g, 0.9 
mmol). The product was purified by column 
chromatography (eluant 1:1 hexane:ethyl 
acetate) to give the title compound as an orange 
solid (0.27 g, 60%), mp 136-137 
o
C;  
E
0
´/mV 8 vs. Fc/Fc
+
; 
Anal. cald. for C27H26N2O4Fe: C, 65.1; H, 5.3; N, 5.6%. Found: C, 64.8; H, 5.3; N, 5.5; 
m/z (ESI) 499.1342 [M+H]
+
. C27H27N2O4Fe requires 499.1320; 
λmax(EtOH)/nm 445 (ε/dm
3
 mol
-1
 cm
-1
 572); 
νmax(KBr)/cm
-1
 3360, 1730, 1671, 1655, 1541, 1495, 1219; 
δH (400 MHz, DMSO-d6): 8.74 (1H, t, J 5.6, -CONH-), 8.29-8.32 (2H, m, ArH, -CONH-), 
8.00 (1H, d, J 8.0, ArH), 7.90 (1H, d, J 8.0, ArH), 7.87 (1H, s, ArH), 7.50-7.58 (2H, m, 
ArH), 4.79 {2H, t, J 1.6, ortho on (η5-C5H4)}, 4.31 {2H, t, J 1.6, meta on (η
5
-C5H4)}, 4.12 
(2H, q, J 7.2, -OCH2CH3), 4.08 (5H, s, η
5
-C5H5), 3.91-3.94 (4H, m, -NHCH2-), 1.22 (3H, t, 
J 7.2, -OCH2CH3); 
δC (100 MHz, DMSO-d6): 169.9 (C=O), 169.8 (C=O), 169.3 (C=O), 134.9 (Cq), 134.2 (Cq), 
132.9 (Cq), 130.5 (Cq), 128.1, 127.6, 127.4, 127.0, 126.7, 126.0, 84.4 (Cipso η
5
-C5H4), 69.5 
(η5-C5H5), 68.9 (Cortho η
5
-C5H4), 68.3 (Cmeta η
5
-C5H4), 60.5(-OCH2-, -ve DEPT), 41.9(-
NHCH2-, -ve DEPT), 40.7(-NHCH2-, -ve DEPT), 14.1 (-OCH2CH3). 
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N-(3-ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl ester 85 
The synthesis followed that of 80 using the 
following reagents: 3-ferrocenylnaphthalene-2-
carboxylic acid (0.53 g, 1.5 mmol), 1-
hydroxybenzotriazole (0.30 g, 2.2 mmol), 
triethylamine (0.5 ml), N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.38 g, 2.0 mmol) and glycine-L-
alanine ethyl ester hydrochloride (0.32 g, 1.5 
mmol). The product was purified by column 
chromatography (eluant 1:1 hexane:ethyl acetate 
- 100% ethyl acetate) to give the title compound 
as an orange solid (0.42 g, 55%), mp 70-71 
o
C;  
E
0
´/mV 5 vs. Fc/Fc
+
;  
[α] 20
D
-35 (c 0.01 in EtOH); 
m/z (ESI) 513.1487 [M+H]
+
. C28H29N2O4Fe requires 513.1477; 
λmax(EtOH)/nm 450 (ε/dm
3
 mol
-1
 cm
-1
 525); 
νmax(KBr)/cm
-1
 3393, 3291, 1734, 1646, 1544, 1494, 1205; 
δH (400 MHz, DMSO-d6): 8.72 (1H, t, J 5.6, -CONH-), 8.38 (1H, d, J 6.8, -CONH-), 8.32 
(1H, s, ArH), 7.99 (1H, d, J 8.0, ArH), 7.90 (1H, d, J 8.0, ArH), 7.83 (1H, s, ArH), 7.49-
7.57 (2H, m, ArH), 4.81 {2H, s, ortho on (η5-C5H4)}, 4.31-4.36 {3H, m, -NHCH-, meta on 
(η5-C5H4)}, 4.02-4.14 (7H, m, -OCH2CH3, η
5
-C5H5), 3.96 (1H, dd, J 5.6 and 16.4, -NHCH2-), 
3.87 (1H, dd, J 5.6 and 16.4, -NHCH2-), 1.32 (3H, d, J 7.2, -CH3), 1.21 (3H, t, J 7.2, -
OCH2CH3); 
δC (100 MHz, DMSO-d6): 169.8 (C=O), 169.4 (C=O), 168.7 (C=O), 135.0 (Cq), 134.3 (Cq), 
132.9 (Cq), 130.5 (Cq), 128.1, 127.6, 127.4, 127.0, 126.7, 126.0, 84.3 (Cipso η
5
-C5H4), 69.5 
(η5-C5H5), 69.0 (Cortho η
5
-C5H4), 68.3 (Cmeta η
5
-C5H4), 60.5 (-OCH2-, -ve DEPT), 47.7 (α-
C), 41.8 (-NHCH2-, -ve DEPT), 17.1 (-CH3), 14.1 (-OCH2CH3). 
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N-(3-ferrocenyl-2-naphthoyl)-glycine-L-leucine ethyl ester 86 
The synthesis followed that of 80 using the 
following reagents: 3-ferrocenylnaphthalene-2-
carboxylic acid (0.36 g, 1.0 mmol), 1-
hydroxybenzotriazole (0.16 g, 1.2 mmol), 
triethylamine (0.5 ml), N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.23 g, 1.2 mmol) and glycine-L-
leucine ethyl ester hydrochloride (0.25 g, 1.0 
mmol). The product was purified by column 
chromatography (eluant 1:1 hexane: ethyl 
acetate) to give the title compound as an orange 
solid (0.23 g, 42%), mp 69-70 
o
C;  
E
0
´/mV 26 vs. Fc/Fc
+
;  
[α] 20
D
 +8 (c 0.06 in CH3CN);  
Anal. cald. for C31H34N2O4Fe: C, 67.15; H, 6.2; N, 5.05%. Found: C, 66.7; H, 6.3; N, 4.8;  
m/z (MALDI-TOF) 554.3 [M]
+•
. C31H34N2O4Fe requires 554.5; 
λmax(CH3CN)/nm 450 (ε/dm
3
 mol
-1
 cm
-1
 526);  
νmax(neat)/cm
-1
 3285, 2959, 1732, 1645, 1516, 1261, 1193; 
δH (400 MHz, DMSO-d6): 8.69 (1H, t, J 5.6, -CONH-), 8.31-8.33 (2H, m, -CONH-, ArH), 
7.99 (1H, d, J 8.0, ArH), 7.90 (1H, d, J 8.0, ArH), 7.83 (1H, s, ArH), 7.49-7.57 (2H, m, 
ArH), 4.81 {2H, s, ortho on (η5-C5H4)}, 4.33-4.39 (1H, m, -NHCH-), 4.30 {2H, s, meta on 
(η5-C5H4)}, 4.08-4.14 (7H, m, -OCH2CH3, η
5
-C5H5), 3.97 (1H, dd, J 5.6 and 16.4, -
NHCH2-), 3.89 (1H, dd, J 5.6 and 16.4, -NHCH2-), 1.50-1.73 (3H, m, -CH2CH-), 1.21 (3H, 
t, J 7.2, -OCH2CH3), 0.88-0.93 {6H, m, -CH(CH3)2}; 
δC (100 MHz, DMSO-d6): 172.5 (C=O), 169.8 (C=O), 168.9 (C=O), 135.0 (Cq), 134.3 (Cq), 
133.0 (Cq), 130.5 (Cq), 128.1, 127.6, 127.4, 127.0, 126.7, 126.0, 84.3 (Cipso η
5
-C5H4), 69.5 
(η5-C5H5), 68.9 (Cortho η
5
-C5H4), 68.3 (Cmeta η
5
-C5H4), 60.5 (-OCH2-, -ve DEPT), 50.4 (α-
C), 41.8 (-NHCH2-, -ve DEPT), 40.1 (-CH2-, -ve DEPT), 24.2 (-CH-), 22.7 (-CH3), 21.4 (-
CH3), 14.0 (-OCH2CH3). 
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N-(3-ferrocenyl-2-naphthoyl)-glycine-L-phenylalanine ethyl ester 87 
The synthesis followed that of 80 using the 
following reagents: 3-ferrocenylnaphthalene-2-
carboxylic acid (0.36 g, 1.0 mmol), 1-
hydroxybenzotriazole (0.18 g, 1.3 mmol), 
triethylamine (0.9 ml), N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.25 g, 1.3 mmol) and glycine-L-
phenylalanine ethyl ester hydrochloride (0.29 g, 
1.0 mmol). The product was purified by column 
chromatography (eluant 1:1 hexane: ethyl 
acetate) to give the title compound as an orange 
solid (0.17 g, 29%), mp 67-68 
o
C;  
E
0
´/mV 24 vs. Fc/Fc
+
);  
[α] 20
D
 +10 (c 0.06 in CH3CN);  
m/z (MALDI-TOF) 588.3 [M]
+•
. C34H32N2O4Fe requires 588.5; 
λmax(CH3CN)/nm 450 (ε/dm
3
 mol
-1
 cm
-1
 518);  
νmax(neat)/cm
-1
 3280, 3059, 1734, 1645, 1513, 1261, 1197; 
δH (400 MHz, DMSO-d6): 8.67 (1H, t, J 5.6, -CONH-), 8.43 (1H, d, J 7.6, -CONH-), 8.31 
(1H, s, ArH), 7.99 (1H, d, J 8.0, ArH), 7.90 (1H, d, J 8.0, ArH), 7.80 (1H, s, ArH), 7.49-
7.57 (2H, m, ArH), 7.21-7.32 (5H, m, -CH2Ph), 4.80 {2H, t, J 1.6, ortho on (η
5
-C5H4)}, 
4.51-4.57 (1H, m, -NHCH-),  4.30 {2H, t, J 1.6, meta on (η5-C5H4)}, 4.01-4.10 (7H, m, -
OCH2CH3, η
5
-C5H5), 3.85-3.96 (2H, m, -NHCH2-), 3.05 (1H, dd, J 7.6 and 13.6, -CH2Ph), 
2.98 (1H, dd, J 7.6 and 13.6, -CH2Ph), 1.13 (3H, t, J 7.2, -OCH2CH3); 
δC (100 MHz, DMSO-d6): 171.4 (C=O), 169.8 (C=O), 168.9 (C=O), 136.9 (Cq), 135.0 (Cq), 
134.2 (Cq), 133.0 (Cq), 130.5 (Cq), 129.1, 128.3, 128.1, 127.6, 127.4, 127.0, 126.7, 126.6, 
126.0, 84.3 (Cipso η
5
-C5H4), 69.5 (η
5
-C5H5), 68.9 (Cortho η
5
-C5H4), 68.3 (Cmeta η
5
-C5H4), 60.6 
(-OCH2-, -ve DEPT), 53.8 (α-C), 41.8 (-NHCH2-, -ve DEPT), 37.0 (-CH2Ph, -ve DEPT), 
14.1 (-OCH2CH3). 
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N-(3-ferrocenyl-2-naphthoyl)-L-alanine-glycine ethyl ester 88 
The synthesis followed that of 80 using the 
following reagents: 3-ferrocenylnaphthalene-2-
carboxylic acid (0.36 g, 1.0 mmol), 1-
hydroxybenzotriazole (0.16 g, 1.2 mmol), 
triethylamine (0.5 ml), N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.23 g, 1.2 mmol) and L-alanine-
glycine ethyl ester hydrochloride (0.32 g, 1.5 
mmol). The product was purified by column 
chromatography (eluant 1:1 hexane:ethyl 
acetate) to give the title compound as an orange 
solid (0.30 g, 59%), mp 63-64 
o
C;  
E
0
´/mV 10 vs. Fc/Fc
+
;  
[α] 20
D
 -75 (c 0.01 in EtOH); 
m/z (ESI) 513.1453 [M+H]
+
. C28H29N2O4Fe requires 513.1477; 
λmax(EtOH)/nm 445 (ε/dm
3
 mol
-1
 cm
-1
 483) nm; 
νmax(KBr)/cm
-1
 3397, 3291, 1748, 1646, 1544, 1494, 1197; 
δH (400 MHz, DMSO-d6): 8.64 (1H, d, J 7.2, -CONH-), 8.38 (1H, s, ArH), 8.35 (1H, t, J 
5.6, -CONH-), 8.06 (1H, d, J 8.0, ArH), 7.97 (1H, d, J 8.0, ArH), 7.92 (1H, s, ArH), 7.49-
7.58 (2H, m, ArH), 4.79 {2H, t, J 1.6, ortho on (η5-C5H4)}, 4.56 (1H, qt, J 7.2, -NHCH-), 
4.32-4.35 {1H, m, meta on (η5-C5H4)}, 4.29-4.32 {1H, m, meta on (η
5
-C5H4)}, 4.01-4.14 
(7H, m, -OCH2CH3, η
5
-C5H5), 3.99 (1H, dd, J 5.6 and 17.6, -NHCH2-), 3.89 (1H, dd, J 5.6 
and 17.6, -NHCH2-), 1.37 (3H, d, J 7.2, -CH3), 1.27 (3H, t, J 7.2, -OCH2CH3); 
δC (100 MHz, DMSO-d6): 169.7 (C=O), 169.5 (C=O), 169.2 (C=O), 135.1 (Cq), 134.2 (Cq), 
132.9 (Cq), 130.5 (Cq), 128.2, 127.6, 127.4, 126.9, 126.7, 126.0, 84.7 (Cipso η
5
-C5H4), 69.5 
(η5-C5H5), 68.6 (Cortho η
5
-C5H4), 68.2 (Cmeta η
5
-C5H4), 60.4 (-OCH2-, -ve DEPT), 48.4 (α-
C), 40.7 (-NHCH2-, -ve DEPT), 17.7 (-CH3), 14.0 (-OCH2CH3). 
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N-(3-ferrocenyl-2-naphthoyl)-L-alanine-L-alanine ethyl ester 89 
The synthesis followed that of 80 using the 
following reagents: 3-ferrocenylnaphthalene-2-
carboxylic acid (0.43 g, 1.2 mmol), 1-
hydroxybenzotriazole (0.22 g, 1.6 mmol), 
triethylamine (0.5 ml), N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.29 g, 1.5 mmol) and L-alanine-
L-alanine ethyl ester hydrochloride (0.29 g, 1.3 
mmol). The product was purified by column 
chromatography (eluant 1:1 hexane:ethyl acetate) 
to give the title compound as an orange solid 
(0.18 g, 28%), mp 59-60 
o
C;  
E
0
´/mV 9 vs. Fc/Fc
+
;  
[α] 20
D
 -122 (c 0.02 in EtOH); 
m/z (ESI) 527.1649 [M+H]
+
. C29H31N2O4Fe requires 527.1633; 
λmax(EtOH)/nm 445 (ε/dm
3
 mol
-1
 cm
-1
 498); 
νmax(KBr)/cm
-1
 3448, 3292, 1733, 1638, 1550, 1495, 1202; 
δH (400 MHz, DMSO-d6): 8.54 (1H, d, J 7.2, -CONH-), 8.34 (1H, d, J 7.2, -CONH-), 8.32 
(1H, s, ArH), 7.99 (1H, d, J 8.0, ArH), 7.91 (1H, d, J 8.0, ArH), 7.81 (1H, s, ArH), 7.49-
7.57 (2H, m, ArH), 4.74-4.75 {2H, m, ortho on (η5-C5H4)}, 4.49 (1H, qt, J 7.2, -NHCH-), 
4.28-4.33 {3H, m, meta on (η5-C5H4), -NHCH-}, 4.09-4.10 (7H, m, -OCH2CH3, η
5
-C5H5), 
1.30-1.33 (6H, m, -CH3), 1.19 (3H, t, J 7.2, -OCH2CH3); 
δC (100 MHz, DMSO-d6): 172.5 (C=O), 172.2 (C=O), 169.1 (C=O), 135.1 (Cq), 134.2 (Cq), 
132.9 (Cq), 130.5 (Cq), 128.2, 127.6, 127.4, 126.9, 126.7, 126.0, 84.6 (Cipso η
5
-C5H4), 69.5 
(η5-C5H5), 68.6 (Cortho η
5
-C5H4), 68.2 (Cmeta η
5
-C5H4), 68.1 (Cmeta η
5
-C5H4), 60.4 (-OCH2-, -
ve DEPT), 48.3 (α-C), 47.7 (α-C), 17.8 (-CH3), 16.9 (-CH3), 14.0 (-OCH2CH3). 
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N-(3-ferrocenyl-2-naphthoyl)-L-alanine-L-leucine ethyl ester 90 
The synthesis followed that of 80 using the 
following reagents: 3-ferrocenylnaphthalene-2-
carboxylic acid (0.43 g, 1.2 mmol), 1-
hydroxybenzotriazole (0.22 g, 1.6 mmol), 
triethylamine (0.5 ml), N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.29 g, 1.5 mmol) and L-alanine-
L-leucine ethyl ester hydrochloride (0.32 g, 1.2 
mmol). The product was purified by column 
chromatography (eluant 1:1 hexane:ethyl 
acetate) to give the title compound as an orange 
solid (0.12 g, 18%), mp 64-65 
o
C;  
E
0
´/mV 29 vs. Fc/Fc
+
;  
[α] 20
D
 -63 (c 0.06 in CH3CN); 
m/z (ESI) 568.0 [M]
+•
. C32H36N2O4Fe requires 568.5; 
λmax(CH3CN)/nm 450 (ε/dm
3
 mol
-1
 cm
-1
 479); 
νmax(neat)/cm
-1
 3285, 3092, 1734, 1637, 1510, 1259, 1195; 
δH (400 MHz, DMSO-d6): 8.54 (1H, d, J 7.2, -CONH-), 8.32 (1H, s, ArH), 8.27 (1H, d, J 
7.2, -CONH-), 7.99 (1H, d, J 7.6, ArH), 7.90 (1H, d, J 7.6, ArH), 7.80 (1H, s, ArH), 7.49-
7.57 (2H, m, ArH), 4.75 {2H, s, ortho on (η5-C5H4)}, 4.51 (1H, qt, J 7.2, -NHCH-), 4.26-
4.36 {3H, m, meta on (η5-C5H4), -NHCH-}, 4.07-4.14 (7H, m, -OCH2CH3,  η
5
-C5H5), 1.47-
1.75 (3H, m, -CH2CH-), 1.31 (3H, d, J 7.2, -CH3), 1.19 (3H, t, J 7.2, -OCH2CH3), 0.87-0.93 
{6H, m, -CH(CH3)2}; 
δC (100 MHz, DMSO-d6): 172.5 (C=O), 172.4 (C=O), 169.1 (C=O), 135.1 (Cq), 134.2 (Cq), 
132.9 (Cq), 130.5 (Cq), 128.1, 127.6, 127.4, 127.0, 126.7, 126.0, 84.5 (Cipso η
5
-C5H4), 69.5 
(η5-C5H5), 68.5 (Cortho η
5
-C5H4), 68.2 (Cmeta η
5
-C5H4), 60.4 (-OCH2-, -ve DEPT), 50.3 (α-
C), 48.3 (α-C), 36.9 (-CH2-, -ve DEPT), 24.2 (-CH-), 22.8 (-CH3), 21.4 (-CH3), 17.8 (-
CH3), 14.0 (-OCH2CH3). 
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N-(3-ferrocenyl-2-naphthoyl)-L-alanine-L-phenylalanine ethyl ester 91 
The synthesis followed that of 80 using the 
following reagents: 3-ferrocenylnaphthalene-2-
carboxylic acid (0.36 g, 1.0 mmol), 1-
hydroxybenzotriazole (0.23 g, 1.7 mmol), 
triethylamine (0.5 ml), N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.29 g, 1.5 mmol) and L-alanine-
L-phenylalanine ethyl ester hydrochloride (0.35 
g, 1.2 mmol). The product was purified by 
column chromatography (eluant 1:1 
hexane:ethyl acetate) to give the title compound 
as fine yellow needles (0.27 g, 45%), mp 78-79 
o
C; E
0
´/mV 24 vs. Fc/Fc
+
;  
[α] 20
D
 -72 (c 0.06 in CH3CN);  
Anal. Calc. for C35H34N2O4Fe: C, 69.8; H, 5.7; N, 4.65%. Found: C, 69.75; H, 5.7; N, 4.5;  
m/z (ESI) 602.0 [M]
+•
. C35H34N2O4Fe requires 602.5; 
λmax(CH3CN)/nm 450 (ε/dm
3
 mol
-1
 cm
-1
 510);  
νmax(neat)/cm
-1
 3361, 3058, 1736, 1679, 1637, 1530, 1245, 1197; 
δH (400 MHz, DMSO-d6): 8.47 (1H, d, J 7.2, -CONH-), 8.32-8.35 (2H, m, -CONH-, ArH), 
8.00 (1H, d, J 8.0, ArH), 7.90 (1H, d, J 7.6, ArH), 7.77 (1H, s, ArH), 7.50-7.58 (2H, m, 
ArH), 7.21-7.31 (5H, m, -CH2Ph), 4.72-4.73 {2H, m, ortho on (η
5
-C5H4)}, 4.46-4.53 (2H, 
m, -NHCH-, -NHCH-), 4.29-4.31 {1H, m, meta on (η5-C5H4)}, 4.26-4.28 {1H, m, meta on 
(η5-C5H4)}, 4.02-4.09 (7H, m, -OCH2CH3, η
5
-C5H5), 2.97-3.07 (2H, m, -CH2Ph), 1.27 (3H, 
d, J 7.2, -CH3), 1.11 (3H, t, J 7.2, -OCH2CH3); 
δC (100 MHz, DMSO-d6): 172.4 (C=O), 171.3 (C=O), 169.1 (C=O), 136.9 (Cq), 135.1 (Cq), 
134.2 (Cq), 132.9 (Cq), 130.5 (Cq), 129.1, 128.2, 128.1, 127.6, 127.4, 130.0, 126.7, 126.5, 
126.0, 84.6 (Cipso η
5
-C5H4), 69.5 (η
5
-C5H5), 69.4 (Cortho η
5
-C5H4), 68.6 (Cmeta η
5
-C5H4), 68.2 
(Cmeta η
5
-C5H4), 60.5 (-OCH2-, -ve DEPT), 53.7 (α-C), 48.4 (α-C), 36.7 (-CH2Ph, -ve 
DEPT), 17.8 (-CH3), 13.9 (-OCH2CH3). 
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N-(6-ferrocenyl-2-naphthoyl)-glycine ethyl ester 92 
The synthesis followed that of 80 
using the following reagents: 6-
ferrocenylnaphthalene-2-
carboxylic acid (0.36 g, 1.0 mmol), 
1-hydroxybenzotriazole (0.20 g, 
1.5 mmol), triethylamine (0.5 ml), 
N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (0.3 g, 1.6 mmol) and glycine ethyl ester hydrochloride 
(0.1 g, 0.7 mmol). The product was purified by column chromatography (eluant 1:1 
hexane:ethyl acetate) to give the title compound as an orange solid (0.19 g, 62%), mp 114-
115 
o
C;  
E
0
´/mV 42 vs. Fc/Fc
+
; 
Anal. Calc. for C25H23NO3Fe: C, 68.0; H, 5.25; N, 3.2%. Found: C, 67.8; H, 5.4; N, 3.1; 
m/z (ESI) 441.4 [M]
+•
. C25H23NO3Fe requires 441.3; 
λmax(EtOH)/nm 375 (ε/dm
3
 mol
-1
 cm
-1
 2683), 450 (1149); 
νmax(KBr)/cm
-1
 3306, 1745, 1638, 1545, 1494, 1215; 
δH (400 MHz, DMSO-d6): 9.08 (1H, t, J 5.6, -CONH-), 8.44 (1H, s, ArH), 8.07 (1H, s, 
ArH), 7.97 (1H, d, J 8.8, ArH), 7.94 (1H, d, J 8.4, ArH), 7.92 (1H, dd, J 1.6 and 8.4, ArH), 
7.83 (1H, dd, J 1.6 and 8.8, ArH), 4.96 {2H, t, J 1.6, ortho on (η5-C5H4)}, 4.45 {2H, t, J 
1.6, meta on (η5-C5H4)}, 4.15 (2H, q, J 7.2, -OCH2CH3), 4.04-4.07 (7H, m, -NHCH2-, η
5
-
C5H5), 1.22 (3H, t, J 7.2, -OCH2CH3); 
δC (100 MHz, DMSO-d6): 169.9 (C=O), 166.7 (C=O), 138.9 (Cq), 134.6 (Cq), 130.6 (Cq), 
130.1 (Cq), 128.8, 127.6, 127.5, 125.9, 124.3, 122.7, 84.0 (Cipso η
5
-C5H4), 69.5 (η
5
-C5H5), 
69.4 (Cmeta η
5
-C5H4), 66.6 (Cortho η
5
-C5H4), 60.5 (-OCH2-, -ve DEPT), 41.4 (-NHCH2-, -ve 
DEPT), 14.1 (-OCH2CH3). 
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N-(6-ferrocenyl-2-naphthoyl)-L-alanine ethyl ester 93  
The synthesis followed that of 80 
using the following reagents: 6-
ferrocenylnaphthalene-2-
carboxylic acid (0.36 g, 1.0 mmol), 
1-hydroxybenzotriazole (0.20 g, 
1.5 mmol), triethylamine (0.5 ml), 
N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (0.29 g, 1.5 mmol) and L-alanine ethyl ester 
hydrochloride (0.14 g, 0.9 mmol). The product was purified by column chromatography 
(eluant 1:1 hexane:ethyl acetate) to give the title compound as an orange solid (0.34 g, 
83.3%), mp 57-58 
o
C;  
E
0
´/mV 42 vs. Fc/Fc
+
;  
[α] 20
D
 
+32 (c 0.01 in EtOH); 
Anal. Calc. for C26H25NO3Fe: C, 68.6; H, 5.5; N, 3.1%. Found: C, 68.1; H, 5.8; N, 2.95; 
m/z (ESI) 456.1265 [M+H]
+
. C26H26NO3Fe requires 456.1262; 
λmax(EtOH)/nm 375 (ε/dm
3
 mol
-1
 cm
-1
 3636), 450 (1614); 
νmax(KBr)/cm
-1
 3442, 1734, 1638, 1542, 1494, 1204;  
δH (400 MHz, DMSO-d6): 8.96 (1H, d, J 7.2, -CONH-), 8.51 (1H, s, ArH), 8.12 (1H, s, 
ArH), 8.02 (1H, d, J 8.8, ArH), 7.99-8.00 (2H, m, ArH), 7.88 (1H, dd, J 1.6 and 8.8, ArH), 
5.01 {2H, t, J 2.0, ortho on (η5-C5H4)}, 4.57 (1H, qt, J 7.2, -NHCH-), 4.50 {2H, t, J 2.0, 
meta on (η5-C5H4)}, 4.19 (2H, q, J 7.2, -OCH2CH3), 4.10 (5H, s, η
5
-C5H5), 1.51 (3H, d, J 
7.2, -CH3), 1.27 (3H, t, J 7.2, -OCH2CH3); 
δC (100 MHz, DMSO-d6): 172.7 (C=O), 166.4 (C=O), 138.9 (Cq), 134.6 (Cq), 130.6 (Cq), 
130.1 (Cq), 128.7, 127.6, 127.4, 126.0, 124.6, 122.7, 84.0 (Cipso η
5
-C5H4), 69.5 (η
5
-C5H5), 
69.4 (Cmeta η
5
-C5H4), 66.6 (Cortho η
5
-C5H4), 60.4 (-OCH2-, -ve DEPT), 48.5 (α-C), 16.7 (-
CH3), 14.1 (-OCH2CH3).      
 
 
 
111 
 
N-(6-ferrocenyl-2-naphthoyl)-L-leucine ethyl ester 94 
The synthesis followed that of 80 
using the following reagents: 6-
ferrocenylnaphthalene-2-
carboxylic acid (0.32 g, 0.9 
mmol), 1-hydroxybenzotriazole 
(0.14 g, 1.0 mmol), triethylamine 
(0.5 ml), N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (0.21 g, 1.1 mmol) and L-
leucine ethyl ester hydrochloride (0.2 g, 1.0 mmol). The product was purified by column 
chromatography (eluant 1:1 hexane:ethyl acetate) to give the title compound as an orange 
solid (0.14 g, 33.3%), mp 109 
o
C;  
E
0
´/mV 42 vs. Fc/Fc
+
;  
[α] 20
D
 
+12 (c 0.01 in EtOH); 
Anal. Calc. for C29H31NO3Fe: C, 70.0; H, 6.3; N, 2.8%. Found: C, 70.35; H, 6.7; N, 2.6; 
m/z (ESI) 498.1712 [M+H]
+
. C29H32NO3Fe requires 498.1732; 
λmax(EtOH)/nm 375 (ε/dm
3
 mol
-1
 cm
-1
 3256), 450 (1395); 
νmax(KBr)/cm
-1
 3437, 1733, 1638, 1544, 1493, 1200;  
δH (400 MHz, DMSO-d6): 8.82 (1H, d, J 7.2, -CONH-), 8.45 (1H, s, ArH), 8.06 (1H, s, 
ArH), 7.97 (1H, d, J 8.4, ArH), 7.93 (2H, s, ArH), 7.83 (1H, dd, J 1.6 and 8.4, ArH), 4.96 
{2H, t, J 1.6, ortho on (η5-C5H4)}, 4.52-4.57 (1H, m, -NHCH-), 4.45 {2H, t, J 1.6, meta on 
(η5-C5H4)}, 4.09-4.17 (2H, m, -OCH2CH3), 4.05 (5H, s, η
5
-C5H5), 1.73-1.88 (2H, m, -
CH2CH-), 1.58-1.65 (1H, m, -CH2CH-), 1.21 (3H, t, J 7.2, -OCH2CH3), 0.96 {3H, d, J 6.4, 
-CH(CH3)2}, 0.91 {3H, d, J 6.4, -CH(CH3)2}; 
δC (100 MHz, DMSO-d6): 172.7 (C=O), 166.7 (C=O), 138.9 (Cq), 134.6 (Cq), 130.6 (Cq), 
130.2 (Cq), 128.7, 127.6, 127.3, 125.9, 124.6, 122.7, 84.0 (Cipso η
5
-C5H4), 69.5 (η
5
-C5H5), 
69.4 (Cmeta η
5
-C5H4), 66.6 (Cortho η
5
-C5H4), 60.4 (-OCH2-, -ve DEPT), 51.1 (α-C), 39.3 (-
CH2-, -ve DEPT), 24.5 (-CH-), 22.9 (-CH3), 21.2 (-CH3), 14.1 (-OCH2CH3). 
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N-(6-ferrocenyl-2-naphthoyl)-L-phenylalanine ethyl ester 95  
The synthesis followed 
that of 80 using the 
following reagents: 6-
ferrocenylnaphthalene-2-
carboxylic acid (0.32 g, 
0.9 mmol), 1-
hydroxybenzotriazole 
(0.14 g, 1.0 mmol), triethylamine (0.5 ml), N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (0.21 g, 1.1 mmol) and L-phenylalanine ethyl ester 
hydrochloride (0.26 g, 1.1 mmol). The product was purified by column chromatography 
(eluant 1:1 hexane:ethyl acetate) to give the title compound as an orange solid (0.38 g, 
77.8%), mp 151-152 
o
C;  
E
0
´/mV 46 vs. Fc/Fc
+
;  
[α] 20
D
 
+52 (c 0.01 in EtOH); 
Anal. Calc. for C32H29NO3Fe: C, 72.3; H, 5.5; N, 2.6%. Found: C, 72.3; H, 5.55; N, 2.6; 
m/z (ESI) 532.1552 [M+H]
+
. C32H30NO3Fe requires 532.1575; 
λmax(EtOH)/nm 375 (ε/dm
3
 mol
-1
 cm
-1
 3696), 450 (1582); 
νmax(KBr)/cm
-1
 3435, 1741, 1623, 1544, 1494, 1208; 
δH (400 MHz, DMSO-d6): 8.95 (1H, d, J 7.6, -CONH-), 8.38 (1H, s, ArH), 8.05 (1H, s, 
ArH), 7.95 (1H, d, J 8.4, ArH), 7.92 (1H, d, J 8.4, ArH), 7.86 (1H, dd, J 1.6 and 8.4, ArH), 
7.82 (1H, dd, J 1.6 and 8.4, ArH), 7.21-7.35 (5H, m, -CH2Ph), 4.96 {2H, t, J 1.6, ortho on 
(η5-C5H4)}, 4.68-4.74 (1H, m, -NHCH-), 4.45 {2H, t, J 1.6, meta on (η
5
-C5H4)}, 4.11 (2H, 
q, J 7.2, -OCH2CH3), 4.05 (5H, s, η
5
-C5H5), 3.16-3.19 (2H, m, -CH2Ph), 1.14 (3H, t, J 7.2, -
OCH2CH3); 
δC (100 MHz, DMSO-d6): 171.7 (C=O), 166.5 (C=O), 138.9 (Cq), 137.7 (Cq), 134.6 (Cq), 
130.6 (Cq), 130.1 (Cq), 129.1, 128.7, 128.2, 127.6, 127.4, 126.5, 125.9, 124.5, 122.7, 83.9 
(Cipso η
5
-C5H4), 69.5 (η
5
-C5H5), 69.4 (Cmeta η
5
-C5H4), 66.6 (Cortho η
5
-C5H4), 60.5 (-OCH2-, -
ve DEPT), 54.5 (α-C), 36.4 (-CH2Ph, -ve DEPT), 14.0 (-OCH2CH3).  
 
113 
 
N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 96 
The synthesis followed that of 80 
using the following reagents: 6-
ferrocenylnaphthalene-2-
carboxylic acid (0.29 g, 0.8 
mmol), 1-hydroxybenzotriazole 
(0.14 g, 1.0 mmol), triethylamine 
(0.5 ml), N-(3-
dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (0.19 g, 1.0 mmol) and glycine-glycine ethyl ester 
hydrochloride (0.15 g, 0.8 mmol). The product was purified by column chromatography 
(eluant 1:1 hexane:ethyl acetate) to give the title compound as an orange solid (0.33 g, 
83%), mp 179-180 
o
C;  
E
0
´/mV 47 vs. Fc/Fc
+
); 
Anal. cald. for C27H26N2O4Fe: C, 65.1; H, 5.3; N, 5.6%. Found: C, 64.7; H, 5.2; N, 5.5; 
m/z (ESI) 499.1296 [M+H]
+
. C27H27N2O4Fe requires 499.1320; 
λmax(EtOH)/nm 375 (ε/dm
3
 mol
-1
 cm
-1
 3485), 450 (1497); 
νmax(KBr)/cm
-1
 3407, 3340, 1732, 1654, 1650, 1558, 1494, 1213; 
δH (400 MHz, DMSO-d6): 8.94 (1H, t, J 5.6, -CONH-), 8.46 (1H, s, ArH), 8.38 (1H, t, J 
5.6, -CONH-), 8.06 (1H, s, ArH), 7.92-7.97 (3H, m, ArH), 7.82 (1H, dd, J 1.6 and 8.4, 
ArH), 4.96 {2H, t, J 1.6, ortho on (η5-C5H4)}, 4.45 {2H, t, J 1.6, meta on (η
5
-C5H4)}, 4.10 
(2H, q, J 7.2, -OCH2CH3), 4.05 (5H, s, η
5
-C5H5), 3.98 (2H, d, J 5.6, -NHCH2-), 3.87 (2H, d, 
J 5.6, -NHCH2-), 1.20 (3H, t, J 7.2, -OCH2CH3); 
δC (100 MHz, DMSO-d6): 169.8 (C=O), 169.6 (C=O), 166.5 (C=O), 138.8 (Cq), 134.5 (Cq), 
130.6 (Cq), 130.4 (Cq), 128.7, 127.6, 127.3, 125.9, 124.6, 122.7, 84.0 (Cipso η
5
-C5H4), 69.5 
(η5-C5H5), 69.4 (Cmeta η
5
-C5H4), 66.6 (Cortho η
5
-C5H4), 60.4 (-OCH2-, -ve DEPT), 42.5 (-
NHCH2-, -ve DEPT), 40.7 (-NHCH2-, -ve DEPT), 14.0 (-OCH2CH3). 
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N-(6-ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl ester 51 
The synthesis followed that of 80 
using the following reagents: 6-
ferrocenylnaphthalene-2-carboxylic 
acid (0.26 g, 0.7 mmol), 1-
hydroxybenzotriazole (0.14 g, 1.0 
mmol), triethylamine (0.5 ml), N-(3-
dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride 
(0.19 g, 1.0 mmol) and glycine-L-alanine ethyl ester hydrochloride (0.15 g, 0.7 mmol). The 
product was purified by column chromatography (eluant 1:1 hexane:ethyl acetate) to give 
the title compound as an orange solid (0.28 g, 79%), mp 130 
o
C;  
E
0
´/mV 56 vs. Fc/Fc
+
;  
[α] 20
D
 -78 (c 0.01 in EtOH); 
Anal. Calc. for C28H28N2O4Fe: C, 65.6; H, 5.5; N, 5.5%. Found: C, 65.4; H, 5.6; N, 5.4; 
m/z (ESI) 513.1486 [M+H]
+
. C28H29N2O4Fe requires 513.1477; 
λmax(EtOH)/nm 375 (ε/dm
3
 mol
-1
 cm
-1
 3451), 450 (1482); 
νmax(KBr)/cm
-1
 3419, 3284, 1748, 1646, 1546, 1494;  
δH (400 MHz, DMSO-d6): 8.84 (1H, t, J 5.6, -CONH-), 8.44 (1H, s, ArH), 8.41 (1H, d, J 
7.2, -CONH-), 8.06 (1H, s, ArH), 7.92-7.97 (3H, m, ArH), 7.82 (1H, dd, J 1.6 and 8.8, 
ArH), 4.95 {2H, t, J 1.6, ortho on (η5-C5H4)}, 4.44 {2H, t, J 1.6, meta on (η
5
-C5H4)}, 4.30 
(1H, qt, J 7.2, -NHCH-), 4.06-4.12 (2H, m, -OCH2CH3), 4.00-4.05 (6H, m, η
5
-C5H5, -
NHCH2-), 3.93 (1H, dd, J 5.6 and 16.4, -NHCH2-), 1.31 (3H, d, J 7.2, -CH3), 1.19 (3H, t, J 
7.2, -OCH2CH3); 
δC (100 MHz, DMSO-d6): 172.5 (C=O), 168.9 (C=O), 166.5 (C=O), 138.8 (Cq), 134.5 (Cq), 
130.6 (Cq), 130.4 (Cq), 128.7, 127.5, 127.3, 125.9, 124.5, 122.7, 84.0 (Cipso η
5
-C5H4), 69.5 
(η5-C5H5), 69.4 (Cmeta η
5
-C5H4), 66.6 (Cortho η
5
-C5H4), 60.5 (-OCH2-, -ve DEPT), 47.7 (α-
C), 42.2 (-NHCH2-, -ve DEPT), 17.0 (-CH3), 14.0 (-OCH2CH3). 
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N-(6-ferrocenyl-2-naphthoyl)-glycine-L-leucine ethyl ester 97 
The synthesis followed that of 
80 using the following 
reagents: 6-
ferrocenylnaphthalene-2-
carboxylic acid (0.36 g, 1.0 
mmol), 1-hydroxybenzotriazole 
(0.16 g, 1.2 mmol), 
triethylamine (0.5 ml), N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (0.23 g, 1.2 mmol) and glycine-
L-leucine ethyl ester hydrochloride (0.25 g, 1.0 mmol). The product was purified by 
column chromatography (eluant 1:1 hexane: ethyl acetate) to give the title compound as an 
orange solid (0.32 g, 58%), mp 160-161 
o
C;  
E
0
´/mV 60 vs. Fc/Fc
+
;  
[α] 20
D
 -12 (c 0.06 in CH3CN); 
Anal. cald. for C31H34N2O4Fe: C, 67.15; H, 6.2; N, 5.05%. Found: C, 67.2; H, 6.2; N, 5.05; 
m/z (MALDI-TOF) 554.3 [M]
+•
. C31H34N2O4Fe requires 554.5; 
λmax(CH3CN)/nm 370 (ε/dm
3
 mol
-1
 cm
-1
 3336), 445 (1422); 
νmax(neat)/cm
-1
 3298, 2955, 1744, 1682, 1644, 1624, 1512, 1184; 
δH (400 MHz, DMSO-d6): 8.82 (1H, t, J 5.6, -CONH-), 8.44 (1H, s, ArH), 8.34 (1H, d, J 
8.4, -CONH-), 8.06 (1H, s, ArH), 7.93-7.97 (3H, m, ArH), 7.82 (1H, dd, J 1.2 and 8.4, 
ArH), 4.96 {2H, t, J 2.0, ortho on (η5-C5H4)}, 4.45 {2H, t, J 2.0, meta on (η
5
-C5H4)}, 4.30-
4.35 (1H, m, -NHCH-),  4.07-4.13 (7H, m, -OCH2CH3, η
5
-C5H5), 3.93-3.99 (2H, m, -
NHCH2-), 1.48-1.72 (3H, m, -CH2CH-), 1.19 (3H, t, J 7.2, -OCH2CH3), 0.86-0.92 {6H, m, 
-CH(CH3)2}; 
δC (100 MHz, DMSO-d6): 172.5 (C=O), 169.1 (C=O), 166.5 (C=O), 138.8 (Cq), 134.5 (Cq), 
130.7 (Cq), 130.5 (Cq), 128.7, 127.5, 127.3, 125.9, 124.5, 122.7, 84.1 (Cipso η
5
-C5H4), 69.4 
(η5-C5H5, Cmeta η
5
-C5H4), 66.6 (Cortho η
5
-C5H4), 60.4 (-OCH2-, -ve DEPT), 50.3 (α-C), 42.2 
(-NHCH2-, -ve DEPT), 40.1 (-CH2-, -ve DEPT), 24.2 (-CH-), 22.7 (-CH3), 21.4 (-CH3), 
14.0 (-OCH2CH3). 
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N-(6-ferrocenyl-2-naphthoyl)-glycine-L-phenylalanine ethyl ester 98 
The synthesis followed that 
of 80 using the following 
reagents: 6-
ferrocenylnaphthalene-2-
carboxylic acid (0.16 g, 0.45 
mmol), 1-
hydroxybenzotriazole (0.07 
g, 0.5 mmol), triethylamine 
(0.1 ml), N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (0.10 g, 0.5 mmol) and glycine-
L-phenylalanine ethyl ester hydrochloride (0.13 g, 0.45 mmol). The product was purified 
by column chromatography (eluant 1:1 hexane: ethyl acetate) to give the title compound as 
an orange solid (0.15 g, 56%), mp 53-54 
o
C;  
E
0
´/mV 59 vs. Fc/Fc
+
;  
[α] 20
D
 +18 (c 0.06 in CH3CN); 
m/z (MALDI-TOF) 588.3 [M]
+•
. C34H32N2O4Fe requires 588.5; 
λmax(CH3CN)/nm 370 (ε/dm
3
 mol
-1
 cm
-1
 2894), 445 (1242); 
νmax(neat)/cm
-1
 3290, 3062, 1735, 1640, 1521, 1298, 1209; 
δH (400 MHz, DMSO-d6): 8.86 (1H, t, J 5.6, -CONH-), 8.43-8.47 (2H, m, -CONH-, ArH), 
8.10 (1H, s, ArH), 7.97-8.00 (3H, m, ArH), 7.86 (1H, dd, J 1.2 and 8.4, ArH), 7.23-7.33 
(5H, m, -CH2Ph), 5.00 {2H, t, J 1.6, ortho on (η
5
-C5H4)}, 4.49-4.56 {3H, m, -NHCH-, meta 
on (η5-C5H4)}, 3.93-4.10 (9H, m, -OCH2CH3, η
5
-C5H5, -NHCH2-), 2.98-3.13 (2H, m, -
CH2Ph), 1.15 (3H, t, J 7.2, -OCH2CH3); 
δC (100 MHz, DMSO-d6): 171.4 (C=O), 169.1 (C=O), 166.4 (C=O), 138.8 (Cq), 136.9 (Cq), 
134.5 (Cq), 130.7 (Cq), 130.4 (Cq), 129.1, 128.7, 128.2, 127.5, 127.3, 126.6, 125.9, 124.5, 
122.7, 84.1 (Cipso η
5
-C5H4), 69.4 (η
5
-C5H5, Cmeta η
5
-C5H4), 66.6 (Cortho η
5
-C5H4), 60.5 (-
OCH2-, -ve DEPT), 53.7 (α-C), 42.3 (-NHCH2-, -ve DEPT), 36.9 (-CH2Ph, -ve DEPT), 
14.1 (-OCH2CH3). 
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N-(6-ferrocenyl-2-naphthoyl)-L-alanine-glycine ethyl ester 99 
The synthesis followed that of 80 
using the following reagents: 6-
ferrocenylnaphthalene-2-carboxylic 
acid (0.24 g, 0.6 mmol), 1-
hydroxybenzotriazole (0.16 g, 1.2 
mmol), triethylamine (0.5 ml), N-(3-
dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride 
(0.19 g, 1.0 mmol) and L-alanine-glycine ethyl ester hydrochloride (0.24 g, 1.1 mmol). The 
product was purified by column chromatography (eluant 1:1 hexane:ethyl acetate) to give 
the title compound as an orange solid (0.24 g, 67%), mp 138-139 
o
C;  
E
0
´/mV 42 vs. Fc/Fc
+
;  
[α] 20
D
 -44 (c 0.01 in EtOH); 
m/z (ESI) 513.1486 [M+H]
+
. C28H29N2O4Fe requires 513.1477; 
λmax(EtOH)/nm 375 (ε/dm
3
 mol
-1
 cm
-1
 2990), 450  (1266); 
νmax(KBr)/cm
-1
 3415, 3284, 1751, 1637, 1546, 1494, 1262; 
δH (400 MHz, DMSO-d6): 8.67 (1H, d, J 7.2, -CONH-), 8.48 (1H, s, ArH), 8.38 (1H, t, J 
5.6, -CONH-), 8.06 (1H, s, ArH), 7.94 (3H, m, ArH), 7.82 (1H, dd, J 1.6 and 8.4, ArH), 
4.96 {2H, t, J 1.6, ortho on (η5-C5H4)}, 4.60 (1H, qt, J 7.2, -NHCH-), 4.45 {2H, t, J 1.6, 
meta on (η5-C5H4)}, 4.12 (2H, q, J 7.2, -OCH2CH3), 4.05 (5H, s, η
5
-C5H5), 3.89 (1H, dd, J 
5.6 and 17.6, -NHCH2-), 3.82 (1H, dd, J 5.6 and 17.6, -NHCH2-), 1.41 (3H, d, J 7.2, -CH3), 
1.19 (3H, t, J 7.2, -OCH2CH3); 
δC (100 MHz, DMSO-d6): 173.0 (C=O), 169.7 (C=O), 166.1 (C=O), 138.8 (Cq), 134.5 (Cq), 
130.6 (Cq), 130.4 (Cq), 128.7, 127.7, 127.2, 125.9, 124.8, 122.7, 84.1 (Cipso η
5
-C5H4), 69.5 
(η5-C5H5), 69.4 (Cmeta η
5
-C5H4), 66.6 (Cortho η
5
-C5H4), 60.3 (-OCH2-, -ve DEPT), 48.8 (α-
C), 40.7 (-NHCH2-, -ve DEPT), 17.9 (-CH3), 14.0 (-OCH2CH3). 
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N-(6-ferrocenyl-2-naphthoyl)-L-alanine-L-alanine ethyl ester 100 
The synthesis followed that of 80 
using the following reagents: 6-
ferrocenylnaphthalene-2-
carboxylic acid (0.29 g, 0.8 
mmol), 1-hydroxybenzotriazole 
(0.14 g, 1.0 mmol), triethylamine 
(0.9 ml), N-(3-
dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (0.19 g, 1.0 mmol) and L-alanine-L-alanine ethyl ester 
hydrochloride (0.15 g, 0.8 mmol). The product was purified by column chromatography 
(eluant 1:1 hexane:ethyl acetate) to give the title compound as an orange solid (0.12 g, 
29%), mp 80-81 
o
C;  
E
0
´/mV 42 vs. Fc/Fc
+
;  
[α] 20
D
 +58 (c 0.01 in EtOH); 
m/z (ESI) 527.1616 [M+H]
+
. C29H31N2O4Fe requires 527.1633; 
λmax(EtOH)/nm 375 (ε/dm
3
 mol
-1
 cm
-1
 3233), 450 (1349); 
νmax(KBr)/cm
-1
 3448, 3288, 1735, 1636, 1546, 1495, 1204;  
δH (400 MHz, DMSO-d6): 8.59 (1H, d, J 7.2, -CONH-), 8.46 (1H, s, ArH), 8.40 (1H, d, J 
7.2, -CONH-), 8.05 (1H, s, ArH), 7.92-7.97 (3H, m, ArH), 7.82 (1H, dd, J 1.6 and 8.8, 
ArH), 4.96 {2H, t, J 1.6, ortho on (η5-C5H4)}, 4.59 (1H, qt, J 7.2, -NHCH-), 4.45 {2H, t, J 
1.6, meta on (η5-C5H4)}, 4.27 (1H, qt, J 7.2, -NHCH-), 4.04-4.11 (7H, m, -OCH2CH3, η
5
-
C5H5), 1.40 (3H, d, J 7.2, -CH3), 1.32 (3H, d, J 7.2, -CH3), 1.18 (3H, t, J 7.2, -OCH2CH3); 
δC (100 MHz, DMSO-d6): 172.5 (C=O), 169.4 (C=O), 166.0 (C=O), 138.7 (Cq), 134.5 (Cq), 
130.6 (Cq), 130.5 (Cq), 128.7, 127.6, 127.2, 125.9, 124.7, 122.8, 84.1 (Cipso η
5
-C5H4), 69.5 
(η5-C5H5), 69.4 (Cmeta η
5
-C5H4), 66.6 (Cortho η
5
-C5H4), 60.4 (-OCH2-, -ve DEPT), 48.5 (α-
C), 47.7 (α-C), 17.9 (-CH3), 16.8 (-CH3), 14.0 (-OCH2CH3). 
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N-(6-ferrocenyl-2-naphthoyl)-L-alanine-L-leucine ethyl ester 101 
The synthesis followed that 
of 80 using the following 
reagents: 6-
ferrocenylnaphthalene-2-
carboxylic acid (0.29 g, 0.8 
mmol), 1-
hydroxybenzotriazole (0.14 
g, 1.0 mmol), triethylamine 
(0.9 ml), N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (0.19 g, 1.0 
mmol) and L-alanine-L-leucine ethyl ester hydrochloride (0.18 g, 0.8 mmol). The product 
was purified by column chromatography (eluant 1:1 hexane: ethyl acetate) to give the title 
compound as an orange solid (0.10 g, 23 %), mp 73-74 
o
C;  
E
0
´/mV 60 vs. Fc/Fc
+
;  
[α] 20
D
 +29 (c 0.06 in CH3CN);  
Anal. cald. for C32H36N2O4Fe: C, 67.6; H, 6.4; N, 4.9%. Found: C, 67.55; H, 6.4; N, 4.7;  
m/z (ESI) 568.0 [M]
+•
. C32H36N2O4Fe requires 568.5; 
λmax(CH3CN)/nm 370 (ε/dm
3
 mol
-1
 cm
-1
 3064), 445 (1298); 
νmax(neat)/cm
-1
 3282, 3089, 1734, 1633, 1530, 1187; 
δH (400 MHz, DMSO-d6): 8.58 (1H, d, J 7.2, -CONH-), 8.46 (1H, s, ArH), 8.29 (1H, d, J 
7.2, -CONH-), 8.05 (1H, s, ArH), 7.90-7.97 (3H, m, ArH), 7.79-7.86 (1H, m, ArH), 4.95 
{2H, t, J 1.6, ortho on (η5-C5H4)}, 4.60 (1H, qt, J 7.2, -NHCH-), 4.44 {2H, t, J 1.6, meta on 
(η5-C5H4)}, 4.26-4.32 (1H, m, -NHCH-), 4.00-4.14 (7H, m, -OCH2CH3,  η
5
-C5H5), 1.48-
1.73 (3H, m, -CH2CH-), 1.39 (3H, d, J 7.2, -CH3), 1.17 (3H, t, J 7.2, -OCH2CH3), 0.86-0.93 
{6H, m, -CH(CH3)2}; 
δC (100 MHz, DMSO-d6): 172.7 (C=O), 172.4 (C=O), 166.0 (C=O), 138.7 (Cq), 134.5 (Cq), 
130.6 (Cq), 130.5 (Cq), 128.7, 127.6, 127.2, 125.9, 124.7, 122.7, 84.1 (Cipso η
5
-C5H4), 69.4 
(η5-C5H5, Cmeta η
5
-C5H4), 66.6 (Cortho η
5
-C5H4), 60.4 (-OCH2-, -ve DEPT), 50.4 (α-C), 48.6 
(α-C), 39.7 (-CH2-, -ve DEPT), 24.2 (-CH-), 22.7 (-CH3), 21.4 (-CH3), 17.9 (-CH3), 14.0 (-
OCH2CH3). 
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N-(6-ferrocenyl-2-naphthoyl)-L-alanine-L-phenylalanine ethyl ester 102 
The synthesis followed 
that of 80 using the 
following reagents: 6-
ferrocenylnaphthalene-2-
carboxylic acid (0.36 g, 
1.0 mmol), 1-
hydroxybenzotriazole 
(0.18 g, 1.3 mmol), 
triethylamine (0.5 ml), N-
(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (0.25 g, 1.3 mmol) and L-
alanine-L-phenylalanine ethyl ester (0.26 g, 1.0 mmol). The product was purified by 
column chromatography (eluant 1:1 hexane: ethyl acetate) to give the title compound as an 
orange solid (0.12 g, 23%), mp 75 
o
C;  
E
0
´/mV 59 vs. Fc/Fc
+
;  
[α] 20
D
 +36 (c 0.06 in CH3CN); 
m/z (MALDI-TOF) 602.3 [M]
+•
. C35H34N2O4Fe requires 602.5; 
λmax(CH3CN)/nm 370 (ε/dm
3
 mol
-1
 cm
-1
 2774), 445 (1188); 
νmax(neat)/cm
-1
 3282, 2963, 1736, 1634, 1526, 1260, 1187; 
δH (400 MHz, DMSO-d6): 8.58 (1H, d, J 7.2, -CONH-), 8.45 (1H, s, ArH), 8.36 (1H, d, J 
7.2, -CONH-), 8.06 (1H, s, ArH), 7.93-7.97 (3H, m, ArH), 7.82 (1H, dd, J 1.6 and 8.4, 
ArH), 7.17-7.25 (5H, m, -CH2Ph), 4.96 {2H, t, J 2.0, ortho on (η
5
-C5H4)}, 4.60 (1H, qt, J 
7.2, -NHCH-), 4.43-4.50 {3H, m, -NHCH-, meta on (η5-C5H4)}, 4.00-4.08 (7H, m, -
OCH2CH3, η
5
-C5H5), 2.96-3.07 (2H, m, -CH2Ph),  1.36 (3H, d, J 7.2, -CH3), 1.10 (3H, t, J 
7.2, -OCH2CH3); 
δC (100 MHz, DMSO-d6): 172.6 (C=O), 171.3 (C=O), 166.0 (C=O), 138.8 (Cq), 137.0 (Cq), 
134.5 (Cq), 130.6 (Cq), 130.4 (Cq), 129.1, 128.7, 128.2, 127.6, 127.2, 126.5, 125.9, 124.7, 
122.7, 84.1 (Cipso η
5
-C5H4), 69.4 (η
5
-C5H5, Cmeta η
5
-C5H4), 66.6 (Cortho η
5
-C5H4), 60.4 (-
OCH2-, -ve DEPT), 53.7 (α-C), 48.6 (α-C), 36.6 (-CH2Ph, -ve DEPT), 17.8 (-CH3), 14.1 (-
OCH2CH3). 
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Chapter 3  
Biological Evaluation of N-(ferrocenyl)naphthoyl amino acid and dipeptide 
derivatives which contain α-amino acids 
3.1. Introduction 
The introduction and development of animal cell culture during in the 1940s and 1950s 
revolutionised the field of cancer drug discovery. Prior to this period of time, the toxicity of 
synthetic and natural compounds could only be evaluated in whole animal studies. Aside 
from the obvious ethical problems associated with animal studies, high costs and lack of 
reproducibility were among the disadvantages associated with this method of evaluation. In 
vitro toxicity testing has been proven to be less costly and time-consuming than in vivo 
methods, as well as being easier to carry out, thereby permitting a larger number of assays 
to be performed. Also, there is a good reproducibility of results associated with in vitro 
toxicity tests and the quantities of test compounds required for the assays are much lower.
1
 
Nowadays, the first step in the biological evaluation of synthetic and natural compounds is 
to perform an in vitro study. Where large libraries of compounds are concerned, in vitro 
studies enable the identification of the most active compounds in an efficient manner.  
 
3.1.1. Miniaturised in vitro methods  
In vitro miniaturised colorimetric end-point assays are used extensively to ascertain 
whether a substance has the ability to either enhance cell growth or promote cell death. 
These in vitro assays involve the determination of cell number (the most common measure 
of cell growth) after the cells have been treated with the test substance for a specific period 
of time.
1
 The test substance is considered to have an anti-proliferative effect on treated 
cells, if a reduction in cell number is evident when compared to untreated controls.  
Unfortunately, there is one considerable limitation to the use of in vitro colorimetric end-
point assays; it is not possible to establish whether the test substance is cytotoxic or 
cytostatic.
2
 Cytostatic agents only affect the growth rate of cells temporarily, in a reversible 
manner. The anti-proliferative effect of such drugs is lost once the cytostatic agent is 
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removed. Cytotoxic agents, on the other hand, cause irreversible cell damage, which leads 
to cell death by either an apoptotic or necrotic pathway. In either case, cell growth is 
impaired. Thus, it is not possible to distinguish between these two agents. 
There are several different colorimetric assays which can be employed for the end-point 
determination of cell number. When selecting the appropriate colorimetric end-point, a 
number of factors must be considered. These include the sensitivity and linear range of the 
colorimetric assay, which can vary depending on both the cell line being analysed and the 
end-point being employed.
2
 The range of linearity of optical density (OD) to cell number is 
offset by the sensitivity of the end-point assay. In general, end-points with high sensitivity 
give a low range of linearity of OD with cell number.  
 
3.1.1.1. MTT assay 
In the MTT assay, a solution of the soluble yellow dye known as 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT), is added to the cells at the end-point of the 
assay. MTT is reduced by the succinate dehydrogenase enzyme in the mitochondria of 
metabolically active cells to form a dark blue, insoluble formazan product (Figure 3.1). The 
formazan crystals produced are then solubilised in DMSO to give a coloured solution, the 
absorbance of which is then quantified at 570 nm.  
 
Figure 3.1 The succinate dehydrogenase catalysed conversion of the MTT dye to the 
insoluble formazan product.  
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The MTT end-point determination of cell number exhibits a good linear relationship of OD 
to cell number, however, the sensitivity of the assay is quite poor. It has also been shown 
that cells which are actively growing reduce MTT to a greater extent than cells which are 
not, which may lead to differences in assay sensitivity in various cell lines.
2
 In addition, 
MTT is a mutagenic agent, and therefore requires care in its handling and disposal. 
 
3.1.1.2. Neutral red assay 
The neutral red assay is based on the accumulation of the neutral red dye (Figure 3.2) in the 
lysosomes of viable cells. At the end-point, a neutral red solution is added to the cells and 
incubated to allow accumulation. Following washing, an acetic acid/ethanol mixture is 
added to elute the bound dye and the absorbance of the coloured solution is measured at 
570 nm.
2
 This assay is generally more sensitive than the MTT assay.  
 
Figure 3.2 Neutral red dye used to determine cell number at the end-point of the assay. 
 
3.1.1.3. Protein staining assays 
The crystal violet dye elution assay is a protein staining assay in which the cells are fixed 
with formalin and stained with crystal violet. The sulforhodamine B assay is also a protein 
binding assay in which cells are fixed with trichloroacetic acid before staining with the dye. 
Both these methods are very sensitive but they exhibit a loss of linearity of OD vs. cell 
number at higher densities.
1
  
The sulforhodamine B assay was developed by Skehan et al in the National Cancer Institute 
(NCI) for use in their NCI60 cell line drug screen. This assay was shown to overcome some 
of the problems associated with the MTT assay and proved to be robust and feasible for 
large-scale screening.
3
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Figure 3.3 Structures of the dyes employed in the protein binding dye assays. 
 
3.1.1.4. Acid phosphatase assay 
In the acid phosphatase assay, a solution of the p-nitrophenyl phosphate substrate is added 
at the end-point of the assay. This substrate is dephosphorylated by the acid phosphatase 
enzyme, which is located in the lysosomes of cells, to yield p-nitrophenol. In the presence 
of strong alkali, the p-nitrophenol chromophore can be quantified by measuring the 
absorbance at 405 nm (Figure 3.4). 
 
Figure 3.4 Acid phosphatase end-point assay: (i) Phosphatase catalysed reaction (in water); 
(ii) Colour reaction in strong base (NaOH). 
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The acid phosphatase assay is highly sensitive but, as a consequence, it also has a low range 
of linearity between OD and cell number. This assay is easier to perform than the neutral 
red assay, as it involves fewer steps and use of fewer reagents. It is also more convenient 
than the MTT assay because of the inherent problem of removal of the medium from the 
insoluble crystals. The reproducibility between replicate wells is excellent in the acid 
phosphatase assay and in many cases it has been shown to be better than the neutral red 
assay and the MTT assay.
4
 For these reasons, the acid phosphatase assay was the chosen 
colorimetric end-point assay for the in vitro biological evaluation of N-
(ferrocenyl)naphthoyl amino acid and dipeptide derivatives.  
 
3.2. Preliminary in vitro study of selected N-(ferrocenyl)naphthoyl dipeptide 
derivatives 
Previous studies carried out to evaluate the in vitro anti-cancer activity of the N-
(ferrocenyl)benzoyl peptide derivatives were performed in the H1299 cell line, which is a 
non-small cell lung cancer (NSCLC) derived cell line. The effect of these compounds on 
H1299 cell growth was expressed as an IC50 value, which corresponds to the concentration 
of the drug required for 50% inhibition of cell growth. The N-(ferrocenyl)benzoyl dipeptide 
derivatives were shown to exert a strong inhibitory effect on cancer cell proliferation. N-
(ferrocenyl)benzoyl dipeptide derivatives, such as N-{meta-(ferrocenyl)-benzoyl}-glycine-
L-alanine ethyl ester 103 (IC50 = 4.0 μM), demonstrated the strongest anti-proliferative 
effect.
5
 Thus, a preliminary investigation into the in vitro anti-cancer activity of the N-
(ferrocenyl)naphthoyl amino acid and dipeptide derivatives was conducted with six 
dipeptide derivatives in the H1299 cell line.  
To determine the IC50 values of these six compounds, individual 96-well plates containing 
H1299 cells were treated with the test compound at concentrations ranging from 0.1 μM to 
100 μM. The cells were then incubated for 5-6 days, until cell confluency was reached. Cell 
survival was determined by performing the acid phosphatase assay. The data obtained for 
each compound is shown in Figure 3.5. The IC50 value for each compound was calculated 
using data obtained from three independent experiments (Table 3.1). The IC50 values of the 
platinum anti-cancer drugs cisplatin and carboplatin in this cell line
6
 are also included 
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since, both drugs are frequently used in combination with a second agent (such as 
gemcitabine, paclitaxel, vinorelbine, and docetaxel) as the standard therapy for NSCLC.
7
 
This is despite the fact that NSCLC is known to be inherently resistant to platinum 
therapy.
8
 
 
Figure 3.5 IC50 plot for compounds 51, 85, 88, 89, 99 and100 in the H1299 cell line. 
 
Table 3.1 IC50 values in the H1299 cell line.  
Compound Number IC50 value (µM) 
Cisplatin 1 1.4 ± 0.1 
Carboplatin 2 9.9 ± 1.6 
N-(3-ferrocenyl-2-naphthoyl)-Gly-L-Ala-OEt 85 3.7 ± 0.7 
N-(3-ferrocenyl-2-naphthoyl)-L-Ala-Gly-OEt 88 6.9 ± 1.5 
N-(3-ferrocenyl-2-naphthoyl)-L-Ala-L-Ala-OEt 89 7.8 ± 0.2 
N-(6-ferrocenyl-2-naphthoyl)-Gly-L-Ala-OEt 51 1.3 ± 0.1 
N-(6-ferrocenyl-2-naphthoyl)-L-Ala-Gly-OEt 99 7.8 ± 0.2 
N-(6-ferrocenyl-2-naphthoyl)-L-Ala-L-Ala-OEt 100 3.7 ± 0.6 
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The six N-(ferrocenyl)naphthoyl dipeptide derivatives were shown to exert a strong anti-
proliferative effect in the H1299 cell line; the IC50 value of each compound is below 10 
µM. Thus, the N-(ferrocenyl)naphthoyl dipeptide derivatives are significantly more active 
than carboplatin in this cell line (Table 3.1). Furthermore, the N-(ferrocenyl)naphthoyl 
dipeptide derivatives are more potent than the corresponding N-(ferrocenyl)benzoyl 
analogues e.g. the IC50 value of N-(3-ferrocenyl-2-naphthoyl)-L-alanine-glycine ethyl ester 
88 is three times lower than that of N-{ortho-(ferrocenyl)-benzoyl}-L-alanine-glycine ethyl 
ester 104 (IC50 = 21 µM). Finally, the in vitro anti-proliferative effect of the most active 
compound, N-(6-ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl ester 51, exceeds that of 
the well-known platinum-based anti-cancer drug cisplatin. The results obtained from this 
preliminary study demonstrate the effectiveness of the N-(ferrocenyl)naphthoyl dipeptide 
derivatives as anti-cancer agents. In addition, these findings emphasise the need to assess 
the in vitro anti-cancer activity of all the N-(ferrocenyl)naphthoyl amino acid and dipeptide 
derivative that have been prepared to date. 
 
3.3. In vitro evaluation in the H1299 cell line and the Sk-Mel-28 cell line 
The panel of N-(ferrocenyl)naphthoyl amino acid and dipeptide derivatives were evaluated 
in vitro by performing a comprehensive screen of every compound at a single dose (10 µM) 
in the H1299 cell line. This approach follows that adopted by the NCI for the NCI60 cell 
line drug screen. Screening of the compounds was also performed in the metastatic 
melanoma cell line, Sk-Mel-28, in collaboration with Dr. Norma O’Donovan and Dr. 
Thamir Maghoub of the National Institute for Cellular Biotechnology (NICB), DCU. Only 
the compounds that are shown to inhibit both H1299 and Sk-Mel-28 cell growth by 50% or 
more (in comparison to the controls) will progress to further studies, whereby an IC50 value 
can be determined. The six N-(ferrocenyl)naphthoyl dipeptide derivatives selected for the 
preliminary study were included in these comprehensive screens, since they have not been 
tested previously in the Sk-Mel-28 cell line.  
The comprehensive screen was performed by treating individual wells of a 96-well plate 
containing either H1299 or Sk-Mel-28 cells with a 10 µM solution of each test compound. 
This was achieved by preparing 1 mM stock solutions of the test compounds in DMSO and 
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the required dilute solutions of each test sample were then prepared by spiking the cell 
culture medium with a calculated amount of the stock solution. Since DMSO can have an 
adverse effect on cells, a DMSO control was included in the assay, along with controls for 
normal (untreated) cell growth. In this case, the DMSO control wells contained a 2% 
DMSO solution. The cells were incubated for 5 days, until cell confluency was reached. At 
this point, cell survival was determined by the acid phosphatase assay. The H1299 cells 
treated with the 2% DMSO solution showed a significant decrease in cell growth compared 
to the untreated controls, with only 36% cell growth, on average.  Clearly, the effect of 
DMSO on H1299 cell proliferation is too strong, making any results obtained from this 
assay inaccurate. As a consequence, the compound screen was repeated, this time using 10 
mM stock solutions, to reduce the DMSO level to 0.2%. At this level, the cells treated with 
the DMSO solution exhibited normal cell growth. The Sk-Mel-28 cells appear to be more 
robust, since cell growth was unaffected when treated with the 2% DMSO solution.  
In the H1299 cell line, almost every N-(ferrocenyl)naphthoyl amino acid and dipeptide 
derivative was shown to inhibit cell growth by 50% or more. This is not that surprising, 
since in the preliminary study, an IC50 value below 10 µM was found for each N-
(ferrocenyl)naphthoyl dipeptide derivative. Hence, it was necessary to repeat the 
comprehensive screen in this cell line, this time testing each derivative at a concentration of 
1 µM (using 1 mM stock solution to give a 0.2% DMSO solution). The Sk-Mel-28 cells 
showed a greater resistance than the H1299 cells to the test compounds. Thus, it was not 
necessary to perform the compound screen at 1 µM in this cell line. The results of the 
comprehensive screens are expressed as the percentage cell growth ± standard deviation 
(relative to the DMSO controls). Standard deviations have been calculated using data 
obtained from three independent experiments. 
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3.3.1. Methyl ferrocenylnaphthalene-2-carboxylate 
The intermediate compounds, methyl 3-ferrocenylnaphthalene-2-carboxylate 71 and methyl 
6-ferrocenylnaphthalene-2-carboxylate 74 were shown to have a weak anti-proliferative 
effect in the H1299 cell line at the higher concentration of 10 μM. However, cell growth 
inhibition did not reach above 20% and therefore, this effect was not deemed to be 
significant. At the lower concentration of 1 μM, these two intermediates did not inhibit cell 
growth. Likewise, growth in the Sk-Mel-28 cell line was unaffected by these two 
intermediates.  
 
Table 3.2 Percentage cell growth in the presence of methyl ferrocenylnaphthalene-2-
carboxylate. 
Compound No. 10 μM  
H1299 
1 μM  
H1299 
10 μM  
Sk-Mel-28 
Methyl 3-ferrocenylnaphthalene-2-
carboxylate 
71 72.9 ± 8.7 102.1 ± 13.3 103.4 ± 0.6 
Methyl 6-ferrocenylnaphthalene-2-
carboxylate 
74 82.6 ± 3.2 117.5± 12.2 89.8 ± 10.4 
 
3.3.2. N-(ferrocenyl)naphthoyl amino acid derivatives 
The N-(3-ferrocenyl-2-naphthoyl) amino acid derivatives were shown to inhibit cell growth 
in the H1299 cell line by 50% or more, when tested at the higher concentration of 10 µM 
(Table 3.3). The effect of these compounds on cell proliferation follows a distinct pattern 
that correlates with the structure of these derivatives. As the side chain of the α-amino acid 
side chain is enlarged, adding steric bulk, the anti-proliferative effect increases. Thus, N-(3-
ferrocenyl-2-naphthoyl)-L-phenylalanine ethyl ester 83 shows the greatest anti-proliferative 
effect, with approximately 96% cell growth inhibition.  
In contrast, the anti-proliferative effect of the N-(6-ferrocenyl-2-naphthoyl) amino acid 
derivatives in the H1299 cell line declines as the side chain of the α-amino acid is extended. 
N-(6-ferrocenyl-2-naphthoyl)-glycine ethyl ester 92 displayed a stronger anti-proliferative 
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effect than the other N-(6-ferrocenyl-2-naphthoyl) amino acid derivatives. This compound 
inhibited cell growth by approximately 94%. A very high percentage of cell survival was 
seen when the H1299 cell line was treated with 1 μM solutions of the N-
(ferrocenyl)naphthoyl amino acid derivatives, indicating that cell growth is unaffected by 
these compounds at lower concentrations.  
 
Table 3.3 Percentage cell growth of H1299 cells in the presence of N-
(ferrocenyl)naphthoyl amino acid derivatives. 
Compound No. 10 μM 1 μM 
N-(3-ferrocenyl-2-naphthoyl)-Gly-OEt 80 43.7 ± 8.1 112.9 ± 14.6 
N-(3-ferrocenyl-2-naphthoyl)-L-Ala-OEt 81 27.8 ± 3.4 98.8 ± 1.5 
N-(3-ferrocenyl-2-naphthoyl)-L-Leu-OEt 82 22.4 ± 6.4 103.4 ± 4.5 
N-(3-ferrocenyl-2-naphthoyl)-L-Phe-OEt 83 3.5 ± 0.6 85.8 ± 11.8 
N-(6-ferrocenyl-2-naphthoyl)-Gly-OEt 92 6.0 ± 3.0 101.1 ± 8.9 
N-(6-ferrocenyl-2-naphthoyl)-L-Ala-OEt 93 44.4 ± 6.9 91.4 ± 14.4 
N-(6-ferrocenyl-2-naphthoyl)-L-Leu-OEt 94 57.3 ± 2.3 101.4 ± 2.2 
N-(6-ferrocenyl-2-naphthoyl)-L-Phe-OEt 95 40.9 ± 4.2 102.3 ± 5.3 
 
The Sk-Mel-28 cell line was found to be more resistant to the N-(ferrocenyl)naphthoyl 
amino acid derivatives (Table 3.4). The N-(3-ferrocenyl-2-naphthoyl) amino acid 
derivatives did not have any noticeable effect on cell proliferation. Similarly, the majority 
of the N-(6-ferrocenyl-2-naphthoyl) amino acid derivatives were ineffective at inhibiting 
cell growth. N-(6-ferrocenyl-2-naphthoyl)-glycine ethyl ester 92 was the only compound 
capable of producing a significant anti-proliferative effect (~70% inhibition). 
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Table 3.4 Percentage cell growth of Sk-Mel-28 cells in the presence of N-
(ferrocenyl)naphthoyl amino acid derivatives. 
Compound No. 10 μM 
N-(3-ferrocenyl-2-naphthoyl)-Gly-OEt 80 97.1 ± 8.1 
N-(3-ferrocenyl-2-naphthoyl)-L-Ala-OEt 81 99.5 ± 3.2 
N-(3-ferrocenyl-2-naphthoyl)-L-Leu-OEt 82 103.1 ± 1.7 
N-(3-ferrocenyl-2-naphthoyl)-L-Phe-OEt 83 82.9 ± 16.7 
N-(6-ferrocenyl-2-naphthoyl)-Gly-OEt 92 31.4 ± 10.1 
N-(6-ferrocenyl-2-naphthoyl)-L-Ala-OEt 93 89.6 ± 21.4 
N-(6-ferrocenyl-2-naphthoyl)-L-Leu-OEt  94 95.7 ± 9.5 
N-(6-ferrocenyl-2-naphthoyl)-L-Phe-OEt 95 95.6 ± 7.6 
 
3.3.3.  N-(ferrocenyl)naphthoyl dipeptide derivatives 
At the higher concentration of 10 µM, the N-(ferrocenyl)naphthoyl dipeptide derivatives 
were found to strongly inhibit cell proliferation in the H1299 cell line (Table 3.5). The 
weakest anti-proliferative effect was observed for the N-(6-ferrocenyl-2-naphthoyl)-L-
alanine-L-phenylalanine ethyl ester 102, however, this compound still achieved an 
appreciable level of cell inhibition (>50%). Six compounds in particular were shown to 
inhibit cell growth by almost 99%. Interestingly, none of these compounds contained either 
L-leucine or L-phenylalanine in the peptide chain. This indicates that although 
incorporation of bulkier amino acids is not completely detrimental to the anti-proliferative 
effect, the presence of the small, neutral α-amino acids glycine and L-alanine within the 
peptide chain is more favourable for biological activity. 
The screen performed at the lower concentration of 1 µM in the H1299 cell line identified 
two compounds that inhibited cell growth by more than 50%. N-(6-ferrocenyl-2-
naphthoyl)-glycine-L-alanine ethyl ester 51 showed a strong anti-proliferative effect (~70% 
growth inhibition), whilst N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 96 
demonstrated a remarkable anti-proliferative effect (~95% growth inhibition). In the 
preliminary in vitro study, N-(6-ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl ester 51 
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was identified as the most active compound out of the six derivatives that were tested in the 
H1299 cell line. Thus, the results of this screen correlate well with the data obtained in the 
preliminary in vitro study. 
 
 Table 3.5 Percentage cell growth of H1299 cells in the presence of N-
(ferrocenyl)naphthoyl dipeptide derivatives. 
Compound No. 10 μM 1 μM 
N-(3-ferrocenyl-2-naphthoyl)-Gly-Gly-OEt 84 16.8 ± 4.0 115.2 ± 13.3 
N-(3-ferrocenyl-2-naphthoyl)-Gly-L-Ala-OEt 85 0.4 ± 0.8 74.6 ± 15.2 
N-(3-ferrocenyl-2-naphthoyl)-Gly-L-Leu-OEt 86 13.8 ± 5.1 103.7 ± 5.2 
N-(3-ferrocenyl-2-naphthoyl)-Gly-L-Phe-OEt 87 4.7 ± 2.8 101.3 ± 11.3 
N-(3-ferrocenyl-2-naphthoyl)-L-Ala-Gly-OEt 88 10.5 ± 3.3 102.6 ± 4.9 
N-(3-ferrocenyl-2-naphthoyl)-L-Ala-L-Ala-OEt 89 0.9 ± 0.8 86.5 ± 14.3 
N-(3-ferrocenyl-2-naphthoyl)-L-Ala-L-Leu-OEt 90 25.2 ± 9.8 109 ± 14.0 
N-(3-ferrocenyl-2-naphthoyl)-L-Ala-L-Phe-OEt 91 11.3 ± 2.8 97.6 ±12.2 
N-(6-ferrocenyl-2-naphthoyl)-Gly-Gly-OEt 96 0.5 ± 0.8 4.4 ± 0.9 
N-(6-ferrocenyl-2-naphthoyl)-Gly-L-Ala-OEt 51 0.4 ± 0.7 31.3 ± 12.1 
N-(6-ferrocenyl-2-naphthoyl)-Gly-L-Leu-OEt 97 4.9 ± 0.9 103.2 ± 11.0 
N-(6-ferrocenyl-2-naphthoyl)-Gly-L-Phe-OEt 98 16.2 ± 5.3 102.9 ± 22.2 
N-(6-ferrocenyl-2-naphthoyl)-L-Ala-Gly-OEt 99 0.4 ± 0.7 118.0 ± 9.1 
N-(6-ferrocenyl-2-naphthoyl)-L-Ala-L-Ala-OEt 100 0.1 ± 0.6 85.8 ± 5.7 
N-(6-ferrocenyl-2-naphthoyl)-L-Ala-L-Leu-OEt 101 13.0 ± 3.5 107.4 ± 16.1 
N-(6-ferrocenyl-2-naphthoyl)-L-Ala-L-Phe-OEt 102 40.7 ± 8.0 98.8 ± 10.9 
 
As noted for the N-(ferrocenyl)naphthoyl amino acid derivatives, the Sk-Mel-28 cell line 
was more resistant than the H1299 cell line to treatment with the N-(ferrocenyl)naphthoyl 
dipeptide derivatives (Table 3.6). Only two N-(ferrocenyl)naphthoyl dipeptide derivatives 
were found to inhibit cell growth by more than 50% in the Sk-Mel-28 cell line. N-(6-
ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl ester 51 showed the strongest anti-
proliferative effect, with approximately 99% growth inhibition, whilst N-(6-ferrocenyl-2-
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naphthoyl)-glycine-glycine ethyl ester 96 inhibited cell growth by approximately 80%. 
Thus, these two compounds display a remarkable anti-proliferative effect in both cell lines, 
and are clearly the most active compounds belonging to this series of N-
(ferrocenyl)naphthoyl amino acid and dipeptide derivatives. 
 
Table 3.6 Percentage cell growth of Sk-Mel-28 cells in the presence of N-
(ferrocenyl)naphthoyl dipeptide derivatives. 
Compound No. 10 μM 
N-(3-ferrocenyl-2-naphthoyl)-Gly-Gly-OEt 84 94.8 ± 6.4 
N-(3-ferrocenyl-2-naphthoyl)-Gly-L-Ala-OEt 85 42.0 ± 21.8 
N-(3-ferrocenyl-2-naphthoyl)-Gly-L-Leu-OEt 86 89.8 ± 14.6 
N-(3-ferrocenyl-2-naphthoyl)-Gly-L-Phe-OEt 87 87.3 ± 18.3 
N-(3-ferrocenyl-2-naphthoyl)-L-Ala-Gly-OEt 88 58.0 ± 23.8 
N-(3-ferrocenyl-2-naphthoyl)-L-Ala-L-Ala-OEt 89 62.3 ± 29.4 
N-(3-ferrocenyl-2-naphthoyl)-L-Ala-L-Leu-OEt 90 93.1 ± 9.2 
N-(3-ferrocenyl-2-naphthoyl)-L-Ala-L-Phe-OEt 91 97.4 ± 8.8 
N-(6-ferrocenyl-2-naphthoyl)-Gly-Gly-OEt 96 19.0 ± 5.6 
N-(6-ferrocenyl-2-naphthoyl)-Gly-L-Ala-OEt 51 0.7 ± 0.8 
N-(6-ferrocenyl-2-naphthoyl)-Gly-L-Leu-OEt 97 79.0 ± 18.2 
N-(6-ferrocenyl-2-naphthoyl)-Gly-L-Phe-OEt 98 95.4 ± 10.7 
N-(6-ferrocenyl-2-naphthoyl)-L-Ala-Gly-OEt 99 74.7 ± 23.8 
N-(6-ferrocenyl-2-naphthoyl)-L-Ala-L-Ala-OEt 100 55.9 ± 34 
N-(6-ferrocenyl-2-naphthoyl)-L-Ala-L-Leu-OEt 101 86.3 ± 15.8 
N-(6-ferrocenyl-2-naphthoyl)-L-Ala-L-Phe-OEt 102 102.6 ± 3.9 
 
3.3.4. IC50 value determination 
In the case of N-(6-ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl ester 51, an IC50 value 
of 1.3 ± 0.1 μM had been determined during the preliminary study in the H1299 cell line. 
Hence, further studies were conducted to determine the IC50 value for N-(6-ferrocenyl-2-
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naphthoyl)-glycine-glycine ethyl ester 96 in the H1299 cell line, and the IC50 values for 
both compounds in the Sk-Mel-28 cell line. Thus, individual 96-well plates containing the 
appropriate cell line were treated with the test compound at appropriate concentration 
ranges. The cells were then incubated for 5-6 days, until cell confluency was reached. Cell 
survival was determined by performing the acid phosphatase assay. The IC50 value for each 
compound was calculated using Calcusyn software, and standard deviations have been 
calculated using data obtained from three independent experiments (Table 3.7). 
An exceptional IC50 value of 0.13 ± 0.02 μM was calculated for N-(6-ferrocenyl-2-
naphthoyl)-glycine-glycine ethyl ester 96 in the H1299 cell line. Thus, the anti-proliferative 
effect of this compound is an order of magnitude greater than that of both N-(6-ferrocenyl-
2-naphthoyl)-glycine-L-alanine ethyl ester 51 (1.3 ± 0.1 μM) and the platinum-based anti-
cancer drug cisplatin 1 (1.4 ± 0.1 μM). Previous studies carried out in our laboratories 
determined an IC50 value of 20 μM for N-{ortho-(ferrocenyl)-benzoyl}-glycine-glycine 
ethyl ester 105 in this cell line.
9
 Thus, in this instance, over a 150-fold improvement in 
biological activity has been achieved by replacing the benzoyl linker with the naphthoyl 
linker. This is an extremely encouraging finding; there is only one other ferrocenyl 
compound that has been reported recently in the literature to have a comparable IC50 value 
(0.09 ± 0.01 μM) and this value was determined in the MDA-MB-231 breast cancer cell 
line.
10
  
In the Sk-Mel-28 cell line, IC50 values of 3.74 ± 0.37 μM and 1.10 ± 0.13 μM were 
calculated for N-(6-ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl ester 51 and N-(6-
ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 96, respectively. Although the anti-
proliferative effect of these compounds is not as strong in the Sk-Mel-28 cell line as in the 
H1299 cell line, these results are promising nonetheless, since metastatic melanoma is 
notoriously resistant to chemotherapeutic drugs.
11
  
 
Table 3.7 IC50 values in the H1299 and Sk-Mel-28 cell lines. 
Compound No. H1299 (μM) Sk-Mel-28 (μM) 
N-(6-ferrocenyl-2-naphthoyl)-Gly-Gly-OEt 96 0.13 ± 0.02 1.10 ± 0.13 
N-(6-ferrocenyl-2-naphthoyl)-Gly-L-Ala-OEt 51 1.3 ± 0.1 3.74 ± 0.37 
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3.4. Structure-activity relationship of N-(ferrocenyl)naphthoyl amino acid and 
dipeptide derivatives  
The in vitro biological data obtained for the N-(ferrocenyl)naphthoyl amino acid and 
dipeptide derivatives is fundamental in aiding the establishment of a SAR for these 
ferrocenyl-peptide bioconjugates. These in vitro studies have shown that the N-
(ferrocenyl)naphthoyl amino acid and dipeptide derivatives exert a moderate to strong anti-
proliferative effect in the H1299 and Sk-Mel-28 cell lines. In the H1299 cell line, these 
derivatives are more effective at inhibiting cell proliferation than the corresponding N-
(ferrocenyl)benzoyl analogues. Thus, employing a naphthalene ring as the conjugated 
linker between the redox active ferrocene unit and the peptide chain enhances the anti-
proliferative effect of the ferrocenyl-peptide bioconjugates. This improvement in biological 
activity may be due to an improvement in conjugation with the redox active ferrocene unit 
or the increase in lipophilicity associated with the introduction of the naphthalene ring.  
The intermediate compounds methyl 3-ferrocenylnaphthalene-2-carboxylate 71 and methyl 
6-ferrocenylnaphthalene-2-carboxylate 74, showed almost no anti-proliferative effect in 
either cell line. The same observations have been made for the N-(ferrocenyl)benzoyl 
dipeptide esters in the H1299 cell line.
5
 Thus, the peptide chain of these novel ferrocenyl-
peptide bioconjugates is essential for biological activity. 
N-(6-ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl ester 51 and N-(6-ferrocenyl-2-
naphthoyl)-glycine-glycine ethyl ester 96 have been identified as the most potent 
ferrocenyl-peptide bioconjugates, in both the H1299 and Sk-Mel-28 cell lines. Evidently, 
these two N-(6-ferrocenyl-2-naphthoyl) dipeptide derivatives are more effective than the 
corresponding N-(3-ferrocenyl-2-naphthoyl) dipeptide analogues at inhibiting cell 
proliferation. The superior biological effect of the N-(6-ferrocenyl-2-naphthoyl) dipeptide 
derivatives may be a consequence, at least in part, of the presence of more effective 
conjugation between the ferrocene and naphthalene units, compared to the N-(3-ferrocenyl-
2-naphthoyl) dipeptide derivatives. In relation to the dipeptide chain, the incorporation of 
the α-amino acids L-leucine and L-phenylalanine was not detrimental to the anti-
proliferative effect. However, as illustrated by the two most potent members of this series, 
compounds that contained only the small neutral α-amino acids glycine and L-alanine 
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within the dipeptide chain produced a stronger anti-proliferative effect. This anti-
proliferative effect is strongest when glycine is the N-terminal α-amino acid.  
In the case of the N-(ferrocenyl)naphthoyl amino acid derivatives, the situation is not so 
clear cut. Substitution at the α-carbon of the amino acid is not beneficial to the activity of 
the N-(6-ferrocenyl-2-naphthoyl) amino acid derivatives. For the N-(3-ferrocenyl-2-
naphthoyl) amino acid derivatives, the anti-proliferative effect is greatest when chiral α-
amino acids with bulky side chains are employed. Also, N-(3-ferrocenyl-2-naphthoyl)-L-
phenylalanine ethyl ester 83 inhibits cell growth in the H1299 cell line to a greater extent 
than some of the N-(3-ferrocenyl-2-naphthoyl) dipeptide derivatives. This is not the case 
for the N-(6-ferrocenyl-2-naphthoyl) amino acid derivatives; N-(6-ferrocenyl-2-naphthoyl)-
glycine-L-alanine ethyl ester 51 and N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl 
ester 96 clearly exert a stronger anti-proliferative effect than the N-(6-ferrocenyl-2-
naphthoyl)-glycine ethyl ester 92. This improvement in biological activity for N-(3-
ferrocenyl-2-naphthoyl)-L-leucine ethyl ester 82 and N-(3-ferrocenyl-2-naphthoyl)-L-
phenylalanine ethyl ester 83 is not yet fully understood however, it is possible that 
conformation adopted by these compounds as a result of steric hindrance, alters the 
molecular properties in a way that is beneficial to the activity. 
In summary, for these ferrocenyl-peptide bioconjugates, the greatest anti-proliferative 
effect is achieved when:   
(i) A naphthalene unit is employed as the conjugated linker. 
(ii) The ferrocene unit is substituted in the 6-position of the naphthalene linker. 
(iii) A dipeptide chain is present. 
(iv) Glycine is the N-terminal amino acid in the dipeptide chain. 
(v) Either glycine or L-alanine is the C-terminal amino acid in the dipeptide chain. 
Figure 3.6 illustrates the main features of the SAR for the N-(ferrocenyl)naphthoyl amino 
acid and dipeptide derivatives. 
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Figure 3.6 Structure-activity relationship (SAR) for the N-(ferrocenyl)naphthoyl amino 
acid and dipeptide derivatives. 
 
3.5. Conclusions 
As part of a primary SAR study of ferrocenyl-peptide bioconjugates, a series of N-
(ferrocenyl)naphthoyl amino acid and dipeptide derivatives were evaluated for in vitro anti-
proliferative effect in lung cancer (H1299) and melanoma (Sk-Mel-28) cell lines. These 
novel ferrocenyl-peptide bioconjugates exhibited a strong anti-proliferative effect in the 
H1299 cell line, whilst the Sk-Mel-28 cells were slightly more resistant to these 
compounds. N-(6-ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl ester 51 and N-(6-
ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 96 have been identified as the most 
potent ferrocenyl-peptide bioconjugates. In particular, a remarkable inhibitory effect on cell 
proliferation was observed for N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 96 
in the H1299 cell line; the IC50 value of this compound lies in the nanomolar range. Thus, 
these two compounds show great promise as potential lead compounds in the development 
of novel bioorganometallic anti-cancer agents. 
It has been clearly demonstrated in this primary SAR study that employing a naphthalene 
ring as the conjugated linker between the redox active ferrocene unit and the peptide chain 
enhances the anti-proliferative effect of the ferrocenyl-peptide bioconjugates relative to the 
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N-(ferrocenyl)benzoyl peptide derivatives. In addition, the incorporation of the α-amino 
acids L-leucine and L-phenylalanine, into the peptide chain was shown in some cases to be 
beneficial to the in vitro biological activity. However, as illustrated by the two most potent 
ferrocenyl-peptide bioconjugates, the presence of only the small, neutral α-amino acids 
glycine and L-alanine within the peptide chain produces the strongest anti-proliferative 
effect. 
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Materials and Methods 
 
Cells and cell culture 
Cell culture media, supplements and related solutions were purchased from Sigma-Aldrich 
(Dublin, Ireland) unless otherwise stated. The H1299 cell line was obtained from the 
American Type Culture Collection (ATCC) and the Sk-Mel-28 cell line was obtained from 
the Department of Developmental Therapeutics, National Cancer Institute (NCI). Cell lines 
were grown as a monolayer culture at 37°C, under a humidified atmosphere of 95% O2 and 
5% CO2 in 75 cm
2
 flasks. Both cell lines were grown in RPMI-1640 medium supplemented 
with 10% foetal calf serum (FCS). Stock solutions of the ferrocenyl compounds (10 mM) 
were prepared in dimethyl sulfoxide (Sigma-Aldrich). 
All cell culture work was carried out in a class II laminar airflow cabinet (Holten 
LaminAir). All experiments involving cytotoxic compounds were conducted in a cytoguard 
laminar airflow cabinet (Holten LaminAir Maxisafe). Before and after use the laminar 
airflow cabinet was cleaned with 70% industrial methylated spirits (IMS). Any items 
brought into the cabinet were also swabbed with IMS. Only one cell line was used in the 
laminar airflow cabinet at a time and upon completion of work with any given cell line the 
laminar airflow cabinet was allowed to clear for at least 15 minutes before use. This was to 
eliminate any possibility of cross-contamination between cell lines. The cabinets were 
cleaned weekly with industrial disinfectants (Virkon or TEGO). These disinfectants were 
alternated fortnightly. Cells were fed with fresh media or subcultured every 2-3 days in 
order to maintain active cell growth. 
 
Sub-culturing of cell lines 
Media and trypsin/EDTA solution (0.25% trypsin (Gibco), 0.01% EDTA (Sigma-Aldrich) 
solution in PBS) were incubated at 37 
o
C for 20 min in a water bath. The cell culture 
medium was removed from the tissue culture flask and discarded into a sterile bottle. The 
flask was then rinsed out with trypsin/EDTA solution (2 ml) to ensure the removal of any 
residual media. Fresh trypsin/EDTA solution (3 ml) was then added to the flask and the 
flask was incubated at 37 
o
C for the required period of time (dependant of each cell line) 
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until all cells were detached from the inside surface of the tissue culture flask. The trypsin 
was deactivated by adding an equal volume of complete media to the flask. The cell 
suspension was removed from the flask and placed in a sterile universal container (Sterilin, 
128a) and centrifuged at 1000 rpm for 5 minutes. The supernatant was then discarded from 
the universal container and the pellet was suspended in complete medium. A cell count was 
performed. An aliquot of cells was then used to re-seed a flask at the required density, 
topping the flask up with fresh medium. 
 
Assessment of cell number 
Cells were trypsinised, pelleted and resuspended in media. A 10μl aliquot of the cell 
suspension was then applied to the chamber of a glass coverslip enclosed haemocytometer. 
Cells in the 16 squares of the four grids of the chamber were counted. The average cell 
number, per 16 squares, was multiplied by a factor of 10
4
 and the relevant dilution factor to 
determine the number of cells per ml in the original cell suspension.  
 
Cryopreservation of cells 
Cells for cryopreservation were harvested in the log phase of growth and counted as 
described above. Cell pellets were resuspended in a suitable volume of warm FCS. An 
equal volume of a 10% DMSO solution in FCS was added dropwise to the cell suspension. 
A total volume of 1 ml of this suspension was then placed in a cryovial (Greiner). These 
vials were then placed in the -20 
o
C freezer for 20 minutes and then in the -80 
o
C freezer 
overnight. Following this period the vials were removed from the -80 
o
C freezer and 
transferred to the liquid nitrogen tanks for storage (-196 
o
C).   
 
Thawing of cryopreserved cells 
A volume of 10 ml of fresh warmed growth media and 1 ml of warm FCS were added to a 
sterile T75 cm
2
 tissue culture flask. The cryopreserved cells were removed from the liquid 
nitrogen tank and thawed rapidly at 37 
o
C. The cells were removed from the vials and 
transferred to the aliquoted media. Following incubation at 37 
o
C for several hours, the 
thawed cells were fed with a suitable volume of fresh growth media.  
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In vitro proliferation assays 
Adherent cells in the exponential phase of growth were harvested by trypsinisation and a 
cell suspension of 1 x 10
4
 cells/ml was prepared in fresh culture medium. The cell 
suspension (100 µl) was added to a flat bottom 96-well plate (Costar, 3599), the plate was 
agitated gently in order to ensure even dispersion of cells over the surface of the wells, and 
then cells were incubated for an initial 24 hours in a 37 
o
C, 5% CO2 incubator, to allow cell 
attachment to the wells. A 10 μM stock solution of the test sample was prepared in 
dimethyl sulfoxide; dilute solutions of the test sample were prepared at 2X final 
concentration by spiking the cell culture medium with a calculated amount of the stock 
solution. 100 µl aliquot of each dilute solution was added to each well of the plate, the plate 
was gently agitated, and then incubated at 37 
o
C, 5% CO2 for 5-6 days, until cell 
confluency reached 80-90%. Assessment of cell survival in the presence of the test sample 
was determined by the acid phosphatase assay. For the comprehensive screen, cell growth 
% in the presence of each test sample was calculated relative to the DMSO control cells. 
For the preliminary study, the concentration of drug that causes 50% growth inhibition (the 
IC50 value) was determined by plotting % survival of cells (relative to the control cells) 
against concentration of the test sample. In subsequent studies, the IC50 value was 
determined using Calcusyn (Biosoft, UK). 
 
Acid phosphatase assay 
Following an incubation period of 5-6 days, drug media was removed from the 96-well 
plate and each well was washed with PBS (100 μl). This was then removed and 100 μl of 
freshly prepared phosphatase substrate (10 mM p-nitrophenol phosphate in 0.1 M sodium 
acetate, 0.1% triton X-100, pH 5.5) was added to each well. The plate was wrapped in 
tinfoil and incubated in the dark at 37 
o
C for 2 h. The enzymatic reaction was stopped by 
the addition of 1 M NaOH (50 μl) to each well. The absorbance of each well was read in a 
dual beam plate reader (Synergy HT, Bio-Tek, USA) at 405 nm with a reference 
wavelength of 620 nm. 
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Chapter 4  
Synthesis and structural characterisation of N-naphthoyl dipeptide derivatives and N-
(ferrocenyl)naphthoyl amino acid and dipeptide derivatives which contain unusual 
amino acids 
4.1. Introduction 
A preliminary structure-activity relationship (SAR) study of novel ferrocenyl-peptide 
bioconjugates has demonstrated that N-(ferrocenyl)naphthoyl amino acid and dipeptide 
derivatives are effective at inhibiting the in vitro proliferation of lung cancer (H1299) and 
melanoma (Sk-Mel-28) cell lines. In particular, two ferrocenyl-peptide bioconjugates were 
identified as having an exceptional inhibitory effect in both cell lines: N-(6-ferrocenyl-2-
naphthoyl)-glycine-L-alanine ethyl ester 51 and N-(6-ferrocenyl-2-naphthoyl)-glycine-
glycine ethyl ester 96. Since the introduction of a naphthoyl linker between the redox active 
ferrocene unit and the peptide chain has been shown to dramatically enhance the anti-
proliferative effect of the ferrocenyl-peptide bioconjugates it was decided to retain this unit 
for further studies. Thus, a secondary SAR study was undertaken, this time focussing on 
varying the peptide chain in the hope that the biological activity of the two potential lead 
compounds could be optimised. Since N-benzoyl peptides have been shown to have 
biological activity,
1
 the synthesis of N-naphthoyl analogues of the two most active 
derivatives was also undertaken to determine whether the redox active ferrocenyl unit of 
these derivatives contributes toward the observed biological effect.  
Isosterism is a strategy commonly employed in lead optimisation, whereby specific 
functional groups within a molecule are replaced by another group that presents a 
comparable electronic and steric arrangement. Figure 4.1 illustrates the known isosteric 
replacements for the amide bond.
2
 Perhaps the most well-established modification is N-
methylation. This is a strategy widely used by scientists to alter pharmacological properties 
of peptides, such as metabolic stability, selectivity, potency and bioavailability.
3
 There are 
also prominent examples of naturally occurring N-methylated cyclic peptides that are 
biologically active, of which the immunosuppressant drug cyclosporin A is perhaps the 
most well known.
4
 The N-methylated derivatives can be readily prepared by incorporating 
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sarcosine (N-methyl-glycine) and N-methyl-L-alanine into the peptide chain of the N-
(ferrocenyl)naphthoyl dipeptide derivatives. The inclusion of N-methyl amino acids within 
the dipeptide chain may also yield information concerning the importance of hydrogen 
bond formation for biological activity, since the presence of an N-methyl group blocks the 
ability of the nitrogen atom to act as a hydrogen bond donor.  
 
Figure 4.1 Established isosteric replacements for amide bonds.
2
 
 
Another frequently used modification is to invert the stereochemistry of the α-carbon of the 
chiral α-amino acids. This is easily achieved by incorporating D-α-amino acids into the 
peptide chain, in place of the naturally occurring L-α-amino acids. Previous studies of the 
N-(ferrocenyl)benzoyl peptide derivatives have indicated that the amino acids β-alanine and 
γ-aminobutyric acid could be of use as a potential isosteric replacement for glycine in the 
peptide chain.
5
 Thus, the synthesis of a series of analogues of N-(6-ferrocenyl-2-
naphthoyl)-glycine-glycine ethyl ester 96, which incorporate these two amino acids in the 
peptide chain, was undertaken to investigate this option further. 
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In relation to the N-(ferrocenyl)naphthoyl amino acid derivatives, it was noted that N-(6-
ferrocenyl)-glycine ethyl ester 92 exhibited a significant anti-proliferative effect in the Sk-
Mel-28 cell line but did not inhibit cell proliferation in the H1299 cell line, at the lower 
concentration of 1 μM. The inclusion of an additional glycine moiety to give N-(6-
ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 96 resulted in a dramatic increase in 
anti-proliferative effect. This striking difference in biological activity indicates that the 
length of the “peptide” chain has some influence on the anti-proliferative effect of these 
compounds. In order to investigate this effect further, the preparation of a homologous 
series of N-(ferrocenyl)naphthoyl amino acid derivatives was undertaken using the achiral 
amino acids β-alanine, γ-aminobutyric acid and δ-amino-n-valeric acid. These non-essential 
amino acids contain a varying number of methylene units between the N-terminal amine 
and the C-terminal carboxyl functional groups. The glycine ethyl ester chain represents the 
shortest chain in this homologous series, whilst the δ-amino-n-valeric acid ethyl ester chain 
is the longest. The β-alanine ethyl ester and γ-aminobutyric acid ethyl ester derivatives 
have an intermediate chain length.  
 
4.2. Protection of the amino terminus of an amino acid 
The synthesis of dipeptide molecules requires the protection of the N-terminus of one 
amino acid and protection of the C-terminus of another prior to a coupling reaction between 
the two. Therefore, when both the amino and carboxyl amino acids are coupled, only the 
required dipeptide is isolated.  
Since the amino group is both basic and nucleophilic, it is important to suppress these 
characteristics. This can be achieved by draining the electron density away and/or by 
concealing it by using bulky groups as a barrier of steric hindrance. It must also be possible 
to remove the protecting group easily under mild conditions so as not to damage other 
potentially vulnerable parts of the molecule.
6
    
A variety of protecting groups have been employed for the protection of the N-terminal and 
are usually selected so as they are orthogonal to the rest of the molecule (i.e. can be added 
or removed without affecting the other susceptible functional groups). 
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4.2.1. t-Butoxycarbonyl (Boc) protecting group 
The tert-butoxycarbonyl group is probably the most universally used amino protecting 
group. This can be explained by the fact that it is easy to use, gives good yields and does 
not cause racemisation. The standard method by which the Boc group is introduced onto 
the peptide is via its anhydride (Figure 4.2).  
 
Figure 4.2 The introduction of the Boc protecting group via the di-t-butyl dicarbonate 
derivative. 
 
The Boc group is stable towards catalytic hydrogenolysis, basic and nucleophilic reagents 
but is acid labile. Boc removal is conveniently carried out by dissolution in TFA at ambient 
temperature and proceeds by unimolecular fission, facilitated by the stability of the 
carbonium ion produced (Figure 4.3).
6
 
 
Figure 4.3 The removal of the Boc protecting group using TFA. 
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4.3. The synthesis of N-naphthoyl dipeptide derivatives and N-(ferrocenyl)naphthoyl 
amino acid and dipeptide derivatives which contain unusual amino acids 
4.3.1. N-(ferrocenyl)naphthoyl dipeptide derivatives 
The dipeptide moieties required for this study are not commercially available and thus they 
were prepared by conventional peptide chemistry. Equimolar amounts of the Boc protected 
amino acids were reacted with amino acid ethyl ester hydrochloride salts, via the 
EDC/HOBt peptide coupling protocol (Scheme 4.1). Upon completion of this reaction, the 
dipeptide was washed with water and purified by column chromatography. In each case the 
eluant was a 1:1 hexane:ethyl acetate mixture. Yields following purification were moderate 
to good and ranged from 38-73% (Table 4.1). Subsequent removal of the Boc protecting 
group using trifluoroacetic acid (TFA, Scheme 4.1) allowed for reaction at the N-terminus 
with 3-ferrocenylnaphthalene-2-carboxylic acid and 6-ferrocenylnaphthalene-2-carboxylic 
acid to yield the required N-(ferrocenyl)naphthoyl dipeptide derivatives. 
 
 
Scheme 4.1 The synthesis and deprotection of Boc protected dipeptide ethyl esters: (i) 
EDC, HOBt, Et3N; (ii) TFA, DCM. 
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Table 4.1 Percentage yields for Boc protected dipeptide ethyl esters. 
Compound Number % Yield 
Boc-glycine-sarcosine-OEt 106 70 
Boc-sarcosine-glycine-OEt 107 56 
Boc-sarcosine-sarcosine-OEt 108 54 
Boc-glycine-N-Methyl-L-alanine-OEt 109 38 
Boc-glycine-D-alanine-OEt 110 73 
Boc-glycine-β-alanine-OEt 111 71 
Boc-β-alanine-glycine-OEt 112 70 
Boc-glycine-γ-aminobutyric acid-OEt 113 46 
Boc-γ-aminobutyric acid-glycine-OEt 114 68 
 
The crude N-(ferrocenyl)naphthoyl dipeptide derivatives were purified in the usual manner 
by column chromatography employing a mixture of hexane and ethyl acetate as eluant. All 
compounds gave spectroscopic and analytical data in accordance with their proposed 
structures. Yields were found to vary according to the nature of the N-terminal of the 
reacting amino acid. In particular, yields for reactions that involved the coupling of 
secondary amino acids to ferrocenylnaphthalene-2-carboxylic acid were much lower 
compared to those that involved the coupling of primary amino acids e.g. the yield of N-(6-
ferrocenyl-2-naphthoyl)-sarcosine-sarcosine ethyl ester 121 was 12%, compared to 43% for 
N-(6-ferrocenyl-2-naphthoyl)-glycine-sarcosine ethyl ester 119. Such low yields may be 
due to the spontaneous formation of diketopiperazine upon removal of the Boc protecting 
group from the N-terminal amino acid (Figure 4.4).
7
 Table 4.2 summarises the yields of the 
N-(ferrocenyl)naphthoyl dipeptide derivatives that have been prepared.  
 
Figure 4.4 Spontaneous diketopiperazine cyclisation of sarcosine-sarcosine ethyl ester. 
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Table 4.2 Percentage yields for N-(ferrocenyl)naphthoyl dipeptide derivatives. 
Compound Number % Yield 
N-(3-ferrocenyl-2-naphthoyl)-Gly-Sar-OEt 115 33 
N-(3-ferrocenyl-2-naphthoyl)-Sar-Gly-OEt 116 20 
N-(3-ferrocenyl-2-naphthoyl)-Sar-Sar-OEt 117 31 
N-(3-ferrocenyl-2-naphthoyl)-Gly-N-Me-L-Ala-OEt 118 38 
N-(6-ferrocenyl-2-naphthoyl)-Gly-Sar-OEt 119 43 
N-(6-ferrocenyl-2-naphthoyl)-Sar-Gly-OEt 120 35 
N-(6-ferrocenyl-2-naphthoyl)-Sar-Sar-OEt 121 12 
N-(6-ferrocenyl-2-naphthoyl)-Gly-N-Me-L-Ala-OEt 122 9 
N-(3-ferrocenyl-2-naphthoyl)-Gly-D-Ala-OEt 123 41 
N-(6-ferrocenyl-2-naphthoyl)-Gly-D-Ala-OEt 124 41 
N-(3-ferrocenyl-2-naphthoyl)-Gly-β-Ala-OEt 125 30 
N-(3-ferrocenyl-2-naphthoyl)-β-Ala-Gly-OEt 126 59 
N-(3-ferrocenyl-2-naphthoyl)-Gly-GABA-OEt 127 40 
N-(3-ferrocenyl-2-naphthoyl)-GABA-Gly-OEt 128 53 
N-(6-ferrocenyl-2-naphthoyl)-Gly-β-Ala-OEt 129 43 
N-(6-ferrocenyl-2-naphthoyl)-β-Ala-Gly-OEt 130 34 
N-(6-ferrocenyl-2-naphthoyl)-Gly-GABA-OEt 131 38 
N-(6-ferrocenyl-2-naphthoyl)-GABA-Gly-OEt 132 27 
 
4.3.2. N-naphthoyl dipeptide derivatives and N-(ferrocenyl)naphthoyl amino acid 
derivatives 
The N-naphthoyl dipeptide derivatives were synthesised by the condensation of 2-naphthoic 
acid with glycine-glycine ethyl ester and glycine-L-alanine ethyl ester using the EDC/HOBt 
peptide coupling protocol. The N-(ferrocenyl)naphthoyl amino acid derivatives were 
similarly prepared by the condensation of 3-ferrocenylnaphthalene-2-carboxylic acid and 6-
ferrocenylnaphthalene-2-carboxylic acid with the amino acid ethyl esters of β-alanine, γ-
aminobutyric acid and δ-amino-n-valeric acid. Crude N-naphthoyl dipeptide derivatives and 
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N-(ferrocenyl)naphthoyl amino acid derivatives were purified by column chromatography, 
using a mixture of hexane and ethyl acetate as the eluant. All compounds gave 
spectroscopic and analytical data in accordance with their proposed structures. Yields were 
found to vary according to the substitution pattern around the naphthoyl linker, e.g. the 
yields were higher for the N-(6-ferrocenyl-2-naphthoyl) amino acid derivatives (46-81%) 
compared to the N-(3-ferrocenyl-2-naphthoyl) amino acid derivatives (35-40%). This 
disparity is due to steric hindrance around the carboxylic acid functionality in the N-(3-
ferrocenyl-2-naphthoyl) series, due to the presence of the bulky ferrocenyl group in the 
ortho-position. Table 4.3 summarises the yields of the N-naphthoyl dipeptide derivatives 
and N-(ferrocenyl)naphthoyl amino acid derivatives. 
 
Table 4.3 Percentage yields for N-naphthoyl dipeptide derivatives and N-
(ferrocenyl)naphthoyl amino acid derivatives. 
Compound Number % Yield 
N-(2-naphthoyl)-Gly-Gly-OEt 133 89 
N-(2-naphthoyl)-Gly-L-Ala-OEt 134 52 
N-(3-ferrocenyl-2-naphthoyl)-β-Ala-OEt 135 40 
N-(3-ferrocenyl-2-naphthoyl)-GABA-OEt 136 36 
N-(3-ferrocenyl-2-naphthoyl)-δ-Ava-OEt 137 35 
N-(6-ferrocenyl-2-naphthoyl)-β-Ala-OEt 138 64 
N-(6-ferrocenyl-2-naphthoyl)-GABA-OEt 139 81 
N-(6-ferrocenyl-2-naphthoyl)-δ-Ava-OEt 140 46 
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4.4. 
1
H and 
13
C NMR studies of N-(ferrocenyl)naphthoyl dipeptide derivatives which 
contain N-methyl amino acids 
1
H and 
13
C NMR spectra were obtained for the N-(ferrocenyl)naphthoyl dipeptide 
derivatives which contain N-methyl amino acids in DMSO-d6. The presence of either one 
or two N-methyl amino acids within the peptide chain of these compounds was found to 
have a strong influence on the appearance of these spectra. Signal multiplicities and/or 
broad signals were observed in the 
1
H and 
13
C NMR spectra for either some or all 
resonating nuclei, depending on the particular compound in question. These observations 
have been attributed to the presence of rotamers in solution, which arise from cis/trans 
isomerisation about the tertiary amide bond. 
The amide bond is characterised by short C-N bond lengths, co-planarity and restricted 
rotation about the C-N bond (Figure 4.5).
8
 The partial double-bond character of the C-N 
bond causes restrictions in the number of energy minima in amide bond torsion (dihedral 
angle ω). The amide bond possesses just two minimum-energy structures: the geometric 
isomers at the angle ω ≈ 0o (cis) and ω ≈ 180o (trans).9 
 
Figure 4.5 Canonical structures of the amide bond. 
 
In terms of thermodynamics, the trans-isomer of a secondary amide bond is more stable 
than the cis-isomer, due to the absence of steric hindrance of the groups flanking the C-N 
bond when the trans configuration is adopted. For this reason, the cis-isomer of secondary 
amides is present in solution only at very low concentrations (~1%).
8
 In contrast, tertiary 
amides isomerise far more readily between cis and trans conformations, since both 
conformers have similar steric strain.  
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Figure 4.6 Inter-conversion between the trans (ω ≈ 180o) and cis (ω ≈ 0o) configurations of 
a tertiary amide bond. 
 
The effect of the presence of cis and trans isomers on NMR spectra depends on the lifetime 
of each rotameric state. Using the uncertainty principle, the lower limit for the lifetime (t) is 
tδν≈1/2π, where δν is the difference in frequency between the two signals in Hz. If t shows 
a slow interconversion rate between the two states, two sets of distinguishable signals will 
be observed. A rapid exchange between the two states gives a low t value and only a single 
peak appears. At an intermediate value for t, the two peaks are indistinguishable leading to 
the observation of broad peaks. 
 
4.4.1.
 1
H NMR studies of N-(ferrocenyl)naphthoyl dipeptide derivatives which contain 
N-methyl amino acids 
The interpretation of the 
1
H NMR spectra obtained for the N-(ferrocenyl)naphthoyl 
dipeptide derivatives which contain N-methyl amino acids was significantly hampered by 
the presence of different rotamers in solution. In cases where both amino acids in the 
dipeptide chain are N-methylated, cis/trans isomerisation can result in the presence of up to 
four different rotameric species. Signal multiplicity in the 
1
H NMR spectra of these N-
(ferrocenyl)naphthoyl dipeptide derivatives varies according to the naphthoyl linker 
employed and the location of the N-methyl amino acid in the dipeptide chain. In the case of 
N-(6-ferrocenyl-2-naphthoyl)-sarcosine-glycine ethyl ester 120, the only indications of 
isomerisation are the distortion of peaks appearing between δ 3.96 and δ 4.26 and the 
appearance of two broad singlets at δ 8.53 and δ 8.61, which together integrate for one 
proton and correspond to the amide N-H of the glycine residue. These observations suggest 
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that any alteration in chemical shift due to isomerisation is restricted to the dipeptide chain; 
the remainder of the molecule is unaffected. In contrast, signal multiplicities are observed 
for every signal within the 
1
H NMR spectrum of N-(3-ferrocenyl-2-naphthoyl)-sarcosine-
glycine ethyl ester 116. 
The most informative region of the 
1
H NMR spectra of these N-(ferrocenyl)naphthoyl 
dipeptide derivatives is from δ 2.60-3.15, where the N-methyl protons are the only nuclei to 
come into resonance. Thus, the number and type of signals appearing in this region are 
indicative of the number of rotamers present in solution. For example, the 
1
H NMR 
spectrum of N-(3-ferrocenyl-2-naphthoyl)-glycine-sarcosine ethyl ester 115 shows two 
sharp signals at δ 2.90 and δ 3.11, which together integrate for 3 protons and indicate the 
presence of two rotamers. In the case of N-(6-ferrocenyl-2-naphthoyl)-glycine-sarcosine 
ethyl ester 119, two sharp signals appear at δ 2.88 and δ 3.12, together with a broad signal 
at δ 3.01. This extra broad signal indicates that there are more than two rotamers present in 
solution. It is evident that cis/trans isomerisation is also occurring about the glycine amide 
bond, except in this case inter-conversion between the two states occurs at an intermediate 
rate. 
 
Table 4.4 Selected 
1
H NMR spectral data (δ, DMSO-d6) for N-(ferrocenyl)naphthoyl 
dipeptide derivatives which contain N-methyl amino acids. 
Compound 
No. 
-NH- -N(CH3)- ortho (η
5
-C5H4) meta (η
5
-C5H4) 
115 8.63 & 8.59 3.11 & 2.90 4.84 4.31 
116 8.49 & 8.41 3.05 & 2.76 4.91 & 4.81 &  
4.78 & 4.74 
4.44 & 4.42 & 
4.41 & 4.40 
118 8.57-8.63 2.99 & 2.77 4.83-4.85 4.30-4.32 
119 8.72 & 7.45-
7.51 
3.12 & 3.01 & 
2.88 
4.95-4.97 4.44-4.46 
120 8.61 & 8.53 3.08 5.01 4.49-4.52 
122 8.75-8.78 3.06 & 2.80 5.02 4.51 
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4.4.2.
 13
C NMR and DEPT 135 studies of N-(ferrocenyl)naphthoyl dipeptide 
derivatives which contain N-methyl amino acids  
The resolved and decoupled nature of 
13
C NMR and DEPT 135 spectra, make it relatively 
easier to interpret and assign the 
13
C NMR and DEPT 135 spectra of the N-
(ferrocenyl)naphthoyl dipeptide derivatives which contain N-methyl amino acids. In most 
cases, signal multiplicities in these spectra only occur for the carbon atoms of the dipeptide 
chain, suggesting that the chemical shift of the other carbon atoms of the molecule are 
unaltered upon isomerisation. N-(3-ferrocenyl-2-naphthoyl)-sarcosine-glycine ethyl ester 
116 is the exception; the number of resonance signals observed in both the 
13
C NMR and 
DEPT 135 spectra of this compound was double the number anticipated.  
Aside from signal multiplicities, the 
13
C NMR and DEPT 135 spectra of these N-
(ferrocenyl)naphthoyl dipeptide derivatives resemble those of the other N-
(ferrocenyl)naphthoyl amino acid and peptide derivatives. The amide and ester carbonyl 
carbons of these N-(ferrocenyl)naphthoyl dipeptide derivatives appear at downfield 
positions in the range of δ 166.4-171.3. The ten non-equivalent carbon atoms of the 
naphthalene ring system appear from δ 122.7-138.8. DEPT 135 spectra were utilised to 
identify the four aromatic quaternary carbons occurring in this range. Signals due to the 
ferrocenyl carbons occur in the range of δ 66.6-84.3 in the 13C NMR spectra.  
The methylene group of the ethyl ester more often than not appears as two signals, in the 
narrow range of δ 58.9-61.1, which are easily identifiable due to the negative resonance in 
the DEPT 135 spectrum. The methyl carbon comes into resonance at approximately δ 14 
and can in some cases be observed as two signals. The carbon of the N-methyl group comes 
into resonance from δ 30.0-40.0 and the signal multiplicity varies according to the number 
of rotamers present in solution.  
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Table 4.5 Selected 
13
C NMR spectral data (δ, DMSO-d6) for N-(ferrocenyl)naphthoyl 
dipeptide derivatives which contain N-methyl amino acids. 
Compound No. -N(CH3)- ipso (η
5
-C5H4) (η
5
-C5H5) -OCH2CH3 
115 33.5 & 32.9 82.6 67.9 59.3 & 58.9, 14.1 
116 37.32 & 33.25 83.3 69.65 & 69.64 60.48 & 60.43,  
14.06  & 13.98 
117 37.4 & 35.2 & 
34.5 & 33.4 
83.2 69.6 60.9 & 60.5,  
14.1 & 13.9 
119 35.2 & 34.5 & 
30.7 
84.1 69.4 60.9 & 60.5,  
14.0 
120 39.3 & 34.1 84.1 69.41 60.5 & 59.7, 14.1 
122 30.9 84.1 69.5 60.6, 14.1 & 14.0 
 
4.4.3. 
1
H and 
13
C NMR study of N-(3-ferrocenyl-2-naphthoyl)-sarcosine-glycine ethyl 
ester (116) 
 
Figure 4.7 N-(3-ferrocenyl-2-naphthoyl)-sarcosine-glycine ethyl ester 116. 
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N-(3-ferrocenyl-2-naphthoyl)-sarcosine-glycine ethyl ester 116 is the only compound 
belonging to this series for which every resonance (except one) was doubled in both the 
1
H 
and 
13
C NMR spectra. This doubling effect indicates that there are two different rotameric 
species present in solution and more importantly, that each particular atom in one of the 
rotamers has a different chemical shift to the corresponding atom in the other rotamer. 
Hence, N-(3-ferrocenyl-2-naphthoyl)-sarcosine-glycine ethyl ester 116 was selected for 
further NMR experiments to allow for the full assignment of the 
1
H and 
13
C NMR spectra. 
These experiments were undertaken in collaboration with Dr. John O’Brien of the School 
of Chemistry, TCD. The NMR experiments performed included a number of selective ROE 
and TOCSY experiments, as well as a number of 2D-NMR experiments including HH-
COSY, NH-COSY, HSQC, HMBC, and ROESY.  
Figure 4.7 illustrates the structure of N-(3-ferrocenyl-2-naphthoyl)-sarcosine-glycine ethyl 
ester 116 and the numbering system employed in the NMR assignment. The 
1
H and 
13
C 
NMR spectra of N-(3-ferrocenyl-2-naphthoyl)-sarcosine-glycine ethyl ester 116 are shown 
in Figure 4.8 and 4.9, respectively. Table 4.6 summarises the 
1
H and 
13
C resonances of both 
rotamers. Unfortunately, it was not possible to assign the geometry of the tertiary amide 
bond in either rotamer. 
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Figure 4.8 
1
H NMR spectrum of N-(3-ferrocenyl-2-naphthoyl)-sarcosine-glycine ethyl 
ester 116. 
 
 
Figure 4.9 
13
C NMR spectrum of N-(3-ferrocenyl-2-naphthoyl)-sarcosine-glycine ethyl 
ester 116. 
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Table 4.6 
1
H and 
13
C NMR data (δ, DMSO-d6) obtained for N-(3-ferrocenyl-2-naphthoyl)-
sarcosine-glycine ethyl ester 116. 
 
Site 
 
1
H NMR 
rotamer A
 
13
C NMR 
rotamer A 
1
H NMR 
rotamer B 
13
C NMR 
rotamer B 
1 - 83.3 - 83.3 
2 4.81 68.75 4.74 68.51 
3 4.42 68.33 4.44 68.36 
4 4.40 68.18 4.41 68.22 
5 4.91 68.77 4.78 68.71 
6 to 10 4.21 69.65 4.22 69.64 
11 - 133.48 - 133.45 
12 8.44 127.61 8.43 127.75 
13 - 132.84 - 132.82 
14 8.08 127.50 8.06 127.44 
15 7.61 126.89 7.60 126.89 
16 7.57 126.06 7.55 126.00 
17 7.90 127.56 7.96 127.70 
18 - 130.79 - 130.66 
19 7.78 125.57 7.75 125.49 
20 - 133.52 - 133.06 
21 - 170.84 - 170.68 
22 2.76 37.32 3.05 33.25 
23 3.97, 4.46 48.90 3.81, 3.76 52.87 
24 - 168.47 - 168.19 
25 8.49  8.41  
26 3.96, 4.00 40.66 3.79, 3.86 40.59 
27 - 169.75 - 169.49 
28 4.18 60.48 4.11 60.43 
29 1.27 13.98 1.19 14.06 
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4.4.4. Variable temperature 
1
H NMR study of N-(3-ferrocenyl-2-naphthoyl)-sarcosine-
sarcosine ethyl ester (117) 
 
Figure 4.10 N-(3-ferrocenyl-2-naphthoyl)-sarcosine-sarcosine ethyl ester 117. 
 
The 
1
H NMR spectrum of N-(3-ferrocenyl-2-naphthoyl)-sarcosine-sarcosine ethyl ester 117 
obtained at room temperature is highly complex due to the presence of four rotamers in 
solution for which the rate of interconversion is slow on the NMR time scale. One possible 
way to overcome this problem is to perform the 
1
H NMR experiment at a higher 
temperature so that the rate of interconversion increases. Once a particular temperature, 
known as the coalescence temperature (Tc), is reached, the rate of interconversion will be 
such that separate signals due to rotamers will coalesce to form one broad signal. At 
temperatures above the Tc, this broad signal will sharpen to give a single line. This is due to 
the fact that the rate of interconversion has increased to the point where a rapid exchange 
between rotamers has been established. Thus, a variable temperature study of the 
1
H NMR 
spectrum of N-(3-ferrocenyl-2-naphthoyl)-sarcosine-sarcosine ethyl ester 117 was 
performed at 25, 40, 60, 80 and 100 
o
C in DMSO-d6 (Figure 4.11 to Figure 4.14).  
The aromatic region of the 
1
H NMR spectrum (Figure 4.11) of N-(3-ferrocenyl-2-
naphthoyl)-sarcosine-sarcosine ethyl ester 117 does not alter significantly upon heating. In 
contrast, the signals present in the ferrocenyl region of the spectrum appear less defined as 
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the sample is heated indicating that at the upper limit of the temperature range, the point of 
the coalescence is being approached. This is clearly illustrated in Figure 4.12.  
The N-methyl region (δ 2.2-3.5) of the 1H NMR spectrum is more informative (Figure 
4.13). At room temperature (25 
o
C), the signals due to the two N-methyl groups appear as 
complex multiplets from δ 2.91-3.10 and δ 2.64-2.78. As the sample is heated, these signals 
start to appear slightly broadened at 60 
o
C. In the 
1
H NMR spectrum obtained at 80 
o
C, this 
broadening effect is more apparent. At 100 
o
C, these signals appear even sharper; the N-
methyl group that appeared as a multiplet at δ 2.64-2.78 at 25 oC is now present as a sharp 
singlet at approximately δ 2.75. The other signal due to the second N-methyl group is 
masked by the large signal due to H2O contained in the DMSO-d6 solvent. This signal is 
shifted gradually upfield upon heating due to weakening of hydrogen bonds present in 
solution. The complex signal due to the methyl group of the ethyl ester is also shown to 
coalesce upon heating (Figure 4.14). Thus, this variable temperature NMR study indicates 
that the coalescence temperature (Tc) of N-(3-ferrocenyl-2-naphthoyl)-sarcosine-sarcosine 
ethyl ester lies close to the upper limit of the temperature range.  
 
Figure 4.11 Variable temperature NMR study of N-(3-ferrocenyl-2-naphthoyl)-sarcosine-
sarcosine ethyl ester 117: the aromatic region (7.3-8.6 ppm) of the 
1
H NMR spectrum.  
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Figure 4.12 Variable temperature NMR study of N-(3-ferrocenyl-2-naphthoyl)-sarcosine-
sarcosine ethyl ester 117: the ferrocenyl region (3.8-5.1 ppm) of the 
1
H NMR spectrum.  
 
 
Figure 4.13 Variable temperature NMR study of N-(3-ferrocenyl-2-naphthoyl)-sarcosine-
sarcosine ethyl ester 117: the N-methyl region (2.2-3.5 ppm) of the 
1
H NMR spectrum. 
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Figure 4.14 Variable temperature NMR study of N-(3-ferrocenyl-2-naphthoyl)-sarcosine-
sarcosine ethyl ester 117: the alkyl region (0.7-1.4 ppm) of the 
1
H NMR spectrum. 
 
4.5.
 1
H NMR studies of N-naphthoyl dipeptide derivatives and N-
(ferrocenyl)naphthoyl amino acid and dipeptide derivatives 
The 
1
H NMR studies of N-naphthoyl dipeptide derivatives and N-(ferrocenyl)naphthoyl 
amino acid and dipeptide derivatives were performed in DMSO-d6, except in cases where 
signals were masked by the solvent peaks in the region δ 2.0 to δ 3.5, in which case, 
acetone-d6 was employed. In the 
1
H NMR spectra of the N-naphthoyl dipeptide derivatives, 
the aromatic region shows a singlet, multiplet, and multiplet splitting pattern, integrating 
for one, four and two protons, respectively. The aromatic peak patterns for the N-
(ferrocenyl)naphthoyl amino acid and dipeptide derivatives are similar to those described in 
Chapter 2, Section 2.5. 
The chemical shifts at which the amide protons of the N-(ferrocenyl)naphthoyl amino acid 
and dipeptide derivatives appear depends on the solvent that is employed. The amide proton 
peaks appear slightly further downfield from δ 8.36-8.83 in the cases were DMSO-d6 was 
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employed, compared to the range of δ 6.95-8.01 in acetone-d6. For the samples obtained in 
acetone-d6, a slight downfield shift is discernable for the amide protons of the N-(6-
ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives (δ 7.33-8.01) relative to the 
amide protons of the N-(3-ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives (δ 
6.95-7.46). In the case of the N-naphthoyl dipeptide derivatives, the amide protons appear 
in the range of δ 8.40-9.05. 
The 
1
H NMR spectra of the N-(ferrocenyl)naphthoyl amino acid and dipeptide derivatives 
showed peaks in the range of δ 3.91-5.02 that are representative of a monosubstituted 
ferrocene derivative. A singlet due to the unsubstituted cyclopentadienyl ring (η5-C5H5) 
typically appears from δ 3.91-4.17, with an integration of five protons. The ortho 
hydrogens on the cyclopentadienyl (η5-C5H4) ring appear in the range δ 4.64-5.02 as a fine 
triplet or a singlet, each integrating for two protons. The meta hydrogens of the (η5-C5H4) 
ring appear from δ 4.18-4.50, also as a fine triplet or a singlet that integrates for two 
protons. These signals are absent from the 
1
H NMR spectra of the N-naphthoyl dipeptide 
derivatives. 
 
Table 4.7 Selected 
1
H NMR spectral data (δ) for N-naphthoyl dipeptide derivatives and N-
(ferrocenyl)naphthoyl amino acid and dipeptide derivatives. 
Compound No. NH’s (η5-C5H5) ortho (η
5
-C5H4) meta (η
5
-C5H4) 
124 8.83, 8.39 3.91-4.14 4.97 4.46 
125* 7.36-7.44, 7.09 3.96-4.01 4.66 4.20 
129* 7.34, 8.01 3.91-3.97 4.79 4.30 
132 8.67, 8.38 4.08-4.17 5.02 4.50 
134 8.88, 8.40 - - - 
135 8.50 4.09-4.13 4.72 4.33 
* 
1
H NMR spectra obtained in acetone-d6. 
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4.5.1.
 1
H NMR study of N-(3-ferrocenyl-2-naphthoyl)-γ-aminobutyric acid ethyl ester 
(136) 
 
Figure 4.15 N-(3-ferrocenyl-2-naphthoyl)-γ-aminobutyric acid ethyl ester 136. 
 
The 
1
H NMR spectrum of N-(3-ferrocenyl-2-naphthoyl)-γ-aminobutyric acid ethyl ester 
136 was obtained in DMSO-d6 and hence, the amide proton peak is positioned downfield at 
δ 8.40. This signal integrates for one proton and appears as a triplet due to the adjacent 
methylene group. The signals in the aromatic region confirm the presence of six protons, 
which appear from δ 7.48- 8.33.  
The characteristic monosubstituted ferrocenyl splitting pattern is observed from δ 4.06-
4.73. The peak due to the ortho protons of the substituted (η5-C5H4) ring appears as the 
furthest downfield ferrocenyl signal at δ 4.73, and is observed as a fine triplet with a 
coupling constant of 2 Hz. Similarly, the signal due to the meta (η5-C5H4) protons also 
appears as a fine triplet at δ 4.32. Both the ortho and meta peaks integrate for two protons 
each. The singlet due to the unsubstituted (η5-C5H5) ring appears in a multiplet with a 
quartet representing the methylene protons of the ethyl ester. This multiplet occurs from δ 
4.06-4.11 and integrates for seven protons.  
From δ 1.76-3.23, there are three signals that integrate for two protons each, representing 
the three methylene groups of the γ-aminobutyric acid chain. The furthest downfield of 
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these signals appears as a quartet at δ 3.23 and represents the methylene group adjacent to 
the amide group. The coupling constant observed is 5.6 Hz. The central methylene group of 
the γ-aminobutyric acid chain appears as a quintet at δ 1.76, with a coupling constant of 7.2 
Hz. The remaining signal at δ 2.35 appears as a triplet, and is due to the methylene group 
adjacent to the ester carboxyl group. The methyl group of the ethyl ester appears as a triplet 
at δ 1.20, with a coupling constant of 7.2 Hz. 
 
Figure 4.16 
1
H NMR spectrum of N-(3-ferrocenyl-2-naphthoyl)-γ-aminobutyric acid ethyl 
ester 136. 
 
4.6.
 13
C NMR and DEPT 135 studies of N-naphthoyl dipeptide derivatives and N-
(ferrocenyl)naphthoyl amino acid and dipeptide derivatives 
13
C NMR and DEPT 135 spectra were obtained for all of the N-naphthoyl dipeptide 
derivatives and N-(ferrocenyl)naphthoyl amino acid and dipeptide derivatives. In the 
13
C 
spectra of the N-(ferrocenyl)naphthoyl amino acid and dipeptide derivatives and N-
naphthoyl dipeptide derivatives, the amide and ester carbonyl carbons appear at downfield 
positions usually in the range of δ 166.2-173.5. In the aromatic region, ten carbon peaks are 
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observed, which correspond to the ten non-equivalent carbon atoms of the naphthalene ring 
system. The four aromatic quaternary carbons of the N-(ferrocenyl)naphthoyl amino acid 
and dipeptide derivatives, and the three aromatic quaternary carbons of the N-naphthoyl 
dipeptide derivatives were easily identified with the aid of DEPT 135 spectra.  
The ferrocenyl carbon atoms of the N-(ferrocenyl)naphthoyl amino acid and dipeptide 
derivatives are present from δ 86.2-66.6. In cases where the 13C and DEPT 135 spectra 
were obtained in acetone-d6, a slight downfield shift is discernable for the ferrocenyl carbon 
atoms. The ipso carbon on the substituted cyclopentadienyl (η5-C5H4) ring appears in the 
range of δ 84.0-84.5 in DMSO-d6 and from δ 85.4-86.2 in acetone-d6. Similarly, the 
unsubstituted cyclopentadienyl ring (η5-C5H5) appears as an intense peak at approximately 
δ 70.5 in acetone-d6 and δ 69.5 in DMSO-d6. For the N-(6-ferrocenyl-2-naphthoyl) amino 
acid and dipeptide derivatives, the signal due to the meta (η5-C5H4) carbon atoms generally 
overlaps with this peak or appears in close proximity, whilst the ortho (η5-C5H4) carbon 
peak appears slightly upfield at δ 67.6 in acetone-d6 and δ 66.6 in DMSO-d6. In the case of 
the N-(3-ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives, the signal due to the 
ortho (η5-C5H4) carbon atoms is shifted downfield to δ 70.3 in acetone-d6 and δ 68.8 in 
DMSO-d6. The meta (η
5
-C5H4) carbon atoms come into resonance at approximately δ 69 in 
acetone-d6 and δ 68 in DMSO-d6. These signals are absent from the 
13
C NMR spectra of the 
N-naphthoyl dipeptide derivatives. 
The methylene group of the ethyl ester appears in the narrow range of δ 59.7-61.4. This 
peak and the methylene peaks of the peptide chain are easily identified by their negative 
resonances in DEPT 135 spectra. The methylene carbons of the amino acids and dipeptide 
chains appear from δ 22.0-44.1. The methyl group of the ethyl ester is at approximately δ 
14.1 in all spectra obtained in DMSO-d6 and at δ 14.5 in all spectra obtained in acetone-d6. 
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Table 4.8 Selected 
13
C NMR data (δ) for N-naphthoyl dipeptide derivatives and N-
(ferrocenyl)naphthoyl amino acid and dipeptide derivatives. 
Compound 
No. 
C=O Ipso (η5-
C5H4) 
(η5-C5H5) -OCH2CH3 Peptide CH2 
123 168.6-172.5 84.3 69.5 60.5, 14.0 41.8 
126* 169.5-172.0 86.1 70.5 61.4, 14.5 35.9-41.7 
130* 167.3-172.4 85.5 70.4 61.4, 14.5 36.3-41.7 
133 166.5-169.8 - - 60.4, 14.0 40.7-42.5 
136 169.7-172.6 84.5 69.5 59.7, 14.1 24.2-38.3 
138 166.4-171.3 84.0 69.4 59.9, 14.1 33.8-35.6 
* 
13
C and DEPT 135 NMR spectra obtained in acetone-d6. 
 
4.6.1.
 13
C and DEPT 135 NMR study of N-(6-ferrocenyl-2-naphthoyl)-δ-amino-n-
valeric acid ethyl ester (140) 
 
Figure 4.17 N-(6-ferrocenyl-2-naphthoyl)-δ-amino-n-valeric acid ethyl ester 140. 
 
The 
13
C NMR spectrum of N-(6-ferrocenyl-2-naphthoyl)-δ-amino-n-valeric acid ethyl ester 
140 displays two carbonyl carbon atoms at δ 172.8 and δ 166.2. Both signals are absent 
from the DEPT 135 spectrum. The aromatic region shows ten individual signals, 
representing the ten non-equivalent carbons of the 2,6-disubstituted naphthalene group. The 
absence of the carbons at δ 138.6, δ 134.4, δ 131.1 and δ 130.7 in the DEPT 135 spectrum 
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indicates their quaternary nature. The six remaining carbons appear at δ 128.7, δ 127.3, δ 
127.1, δ 125.9, δ 124.5 and δ 122.7, respectively.  
The signal at δ 84.1 in the ferrocenyl region represents the ipso carbon of the (η5-C5H4) as 
this does not appear in the DEPT 135 spectrum. The unsubstituted ring appears as an 
intense signal at δ 69.4 together with the meta (η5-C5H4) carbon atoms. The ortho (η
5
-C5H4) 
carbon atoms appear at δ 66.6. The methylene groups of the ethyl ester and δ-amino-n-
valeric acid moiety are easily assigned as they show negative resonance peaks in the DEPT 
135 spectrum at δ 59.7, δ 38.8, δ 33.2, δ 28.6 and δ 22.0. The methyl carbon of the ester 
group is observed in the most upfield position at δ 14.1. 
 
 
Figure 4.18 
13
C NMR spectrum of N-(6-ferrocenyl-2-naphthoyl)-δ-amino-n-valeric acid 
ethyl ester 140. 
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Figure 4.19 DEPT 135 spectrum of N-(6-ferrocenyl-2-naphthoyl)-δ-amino-n-valeric acid 
ethyl ester 140.  
 
4.7. COSY study of N-(6-ferrocenyl-2-naphthoyl)-glycine-γ-aminobutyric acid ethyl 
ester (131) 
COSY (Correlation Spectroscopy) is a 2D-NMR technique that indicates all of the spin-
spin coupled protons in one spectrum. In a COSY spectrum, two identical chemical shift 
axes are plotted orthogonally and the one-dimensional spectrum appears on the diagonal 
from the bottom left to the top right of the resulting square. All peaks that are mutually 
spin-spin coupled are shown by cross-peaks in the third dimension, which are placed 
symmetrically about the diagonal.
10
 In the COSY spectrum of N-(6-ferrocenyl-2-
naphthoyl)-glycine-γ-aminobutyric acid ethyl ester 131 the proton spectrum is plotted along 
each axis. It is clear that the amide proton of the glycine a (δ 8.01) correlates with the 
methylene group b of the glycine residue (δ 3.90-3.96), while the amide proton of the γ-
aminobutyric acid c (δ 7.33) couples with the methylene group d (δ 3.15)  of the γ-
aminobutyric acid chain. The central methylene group of the γ-aminobutyric acid chain e (δ 
1.66) is easily identified due to its coupling with the methylene protons d and f (δ 2.22) 
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positioned on either side. Correlation is also present between the ortho and meta protons of 
the substituted (η5-C5H4) ring, i and j.  The methylene g (δ 3.90-3.96) and methyl protons h 
(δ 1.06) of the ethyl ester only show coupling with each other, as do the aromatic protons of 
the naphthoyl group k-p.  
 
Figure 4.20 N-(6-ferrocenyl-2-naphthoyl)-glycine-γ-aminobutyric acid ethyl ester 131. 
 
Figure 4.21 COSY spectrum of N-(6-ferrocenyl-2-naphthoyl)-glycine-γ-aminobutyric acid 
ethyl ester 131. 
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4.8. Infra red studies of N-naphthoyl dipeptide derivatives and N-
(ferrocenyl)naphthoyl amino acid and dipeptide derivatives 
The IR spectra of the N-(naphthoyl) dipeptide derivatives and the N-(ferrocenyl)naphthoyl 
amino acid and dipeptide derivatives were obtained from the pure solid and all show 
characteristic peaks, as described in Chapter 2 (Section 2.8). Table 4.9 summarises the 
main absorptions for a representative selection of compounds. In the case of the N-
(ferrocenyl)naphthoyl dipeptide derivatives which contain tertiary amide bonds, the amide 
II band which is normally found between 1570 and 1515 cm
-1
 is absent from the IR 
spectrum (Figure 4.22). However, the stretching vibration of the C=O bond is still observed 
between 1680 and 1630 cm
-1
. The ester carbonyl band appears at higher frequency, 
between 1750 and 1735 cm
-1
. Bands due to aryl rings are present in the 1225-950 cm
-1
 
region but are of little diagnostic value, as are a group of weak overtone and combination 
bands in the 2000-1600 cm
-1
 region. 
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Figure 4.22 IR spectrum of N-(3-ferrocenyl-2-naphthoyl)-glycine-N-methyl-L-alanine 
ethyl ester 118. 
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Table 4.9 Selected IR data for N-naphthoyl dipeptide derivatives and N-
(ferrocenyl)naphthoyl amino acid and dipeptide derivatives. The values quoted are in cm
-1
. 
Compound No. N-H C=O amide I C=O amide II C=O ester 
117 - 1635 - 1741 
119 3300 1626 1507 1739 
123 3285 1643 1516 1733 
127 3281 1640 1521 1727 
130 3357, 3282 1678, 1633 1540 1735 
134 3364, 3319 1672, 1644 1532 1750 
 
4.9. UV-Vis studies of N-(ferrocenyl)naphthoyl amino acid and dipeptide derivatives 
The UV-Vis spectra obtained for N-(ferrocenyl)naphthoyl amino acid and dipeptide 
derivatives are comparable to those obtained for the compounds prepared in Chapter 2 
(Section 2.9). The N-(3-ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives have 
much weaker absorbances at around 450 nm than the N-(6-ferrocenyl-2-naphthoyl) amino 
acid and dipeptide derivatives, so for this reason the UV-Vis spectra of the first set of 
compounds were obtained at a concentration of 1 x 10
-3
 M, whilst the latter set were 
analysed at a concentration of 5 x 10
-4
 M. The difference in the intensity of these 
absorbances is indicative of the degree of conjugation that exists between the substituted 
(η5-C5H4) ring and the naphthoyl ring. Extinction coefficients (ε) were calculated for each 
local maxima from the Beer-Lambert Law i.e. A=εCl, where A is absorbance, C is 
concentration, l is the path length of the cell. Table 4.10 summarises the main features of 
the UV-Vis spectra obtained for a representative selection of compounds. 
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Table 4.10 Selected UV-Vis data (nm) for N-(ferrocenyl)naphthoyl amino acid and 
dipeptide derivatives. 
Compound No. λmax1 (nm) ε1 λmax2 (nm) ε2 
115 - - 450 537 
122 370 2450 450 1016 
124 370 3048 445 1288 
129 370 3006 450 1288 
137 - - 450 508 
 
4.10. Cyclic voltammetry studies of N-(ferrocenyl)naphthoyl amino acid and dipeptide 
derivatives 
The cyclic voltammograms obtained for the N-(ferrocenyl)naphthoyl amino acid and 
dipeptide derivatives are comparable to those obtained for the compounds prepared in 
Chapter 2 (Section 2.10). Thus, the N-(ferrocenyl)naphthoyl amino acid and dipeptide 
derivatives exhibit one electron, reversible, redox waves similar to ferrocene, under the 
same conditions. The E
0
´ (oxidation potential) values for the N-(3-ferrocenyl-2-naphthoyl) 
amino acid and dipeptide derivatives were in the range of 24-38 mV, whilst the N-(6-
ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives showed values in the 55-65 
mV range versus the ferrocene/ferricenium redox couple (Fc/Fc
+
). Figure 4.23 illustrates 
the difference in potential of the CVs obtained for N-(3-ferrocenyl-2-naphthoyl)-β-alanine-
glycine ethyl ester 126 and N-(6-ferrocenyl-2-naphthoyl)-β-alanine-glycine ethyl ester 130.  
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Figure 4.23 Cyclic voltammograms of N-(3-ferrocenyl-2-naphthoyl)-β-alanine-glycine 
ethyl ester 126 and N-(6-ferrocenyl-2-naphthoyl)-β-alanine-glycine ethyl ester 130 (0.1 M 
TBAP in ACN, Ag|AgCl, 0.1 V s
-1
). 
 
4.11. Conclusions 
N-(6-ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl ester 51 and N-(6-ferrocenyl-2-
naphthoyl)-glycine-glycine ethyl ester 96 have been identified as potential lead compounds 
in the development of bioorganometallic anti-cancer agents, following a primary SAR 
study. This project sought to optimise the biological activity of these novel ferrocenyl-
peptide bioconjugates by conducting a secondary SAR study. The focus of this study was 
directed to the peptide chain, whereby isosteric replacements for the amide bond were 
employed to generate an additional series of novel N-(ferrocenyl)naphthoyl dipeptide 
derivatives. In addition, N-naphthoyl analogues of the two potential lead compounds were 
prepared to determine whether the redox active ferrocenyl unit of these derivatives 
contributes toward the observed biological effect. A homologous series of novel N-
(ferrocenyl)naphthoyl amino acid derivatives were also prepared to investigate the 
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significance of peptide chain length in relation to the anti-proliferative effect. These novel 
compounds were isolated in moderately good yields and have been characterised by a range 
of spectroscopic techniques including 
1
H NMR, 
13
C NMR, DEPT 135, COSY, IR, UV-Vis 
and CV. Each compound gave spectroscopic data in accordance with their proposed 
structures. 
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Experimental Procedures 
 
Experimental Note 
All chemicals were purchased from Sigma-Aldrich, Lennox Chemicals, Fluorochem 
Limited or Tokyo Chemical Industry UK Limited; and used as received. Commercial grade 
reagents were used without further purification. When necessary, all solvents were purified 
and dried prior to use. Riedel-Haën silica gel was used for thin layer and column 
chromatography. Melting points were determined using either a Stuart melting point 
(SMP3) apparatus and are uncorrected. Optical rotation measurements were made on a 
Perkin Elmer 343 Polarimeter and are quoted in units of 10
-1
 deg cm
2
 g
-1
. Infrared spectra 
were recorded on either a Perkin Elmer Spectrum 100 FT-IR with ATR. UV-Vis spectra 
were recorded on a Hewlett Packard 8452 A diode array UV-Vis spectrophotometer. 
1
H 
and 
13
C NMR spectra were recorded in deuterated solvents on either a Bruker Avance 400 
NMR or a Bruker Avance Ultrashield 600 NMR. The 
1
H and 
13
C NMR chemical shifts are 
reported in ppm (parts per million). Tetramethylsilane (TMS) or the residual solvent peaks 
have been used as an internal reference. All coupling constants (J) are in Hertz. The 
abbreviations for the peak multiplicities are as follows: s (singlet), d (doublet), dd (doublet 
of doublets), t (triplet), q (quartet), qt (quintet), m (multiplet) and br (broad). Elemental 
analysis was carried out by the microanalytical laboratory at University College Dublin. 
Cyclic voltammograms were recorded in anhydrous acetonitrile (Sigma-Aldrich), with 
0.1 M tetrabutylammonium perchlorate (TBAP) as a supporting electrolyte, using a CH 
Instruments 600a electrochemical analyzer (Pico-Amp Booster and Faraday Cage). The 
experiments were carried out at room temperature. A three-electrode cell consisting of a 
glassy carbon working-electrode, a platinum wire counter-electrode and an Ag|AgCl 
reference electrode was used. The glassy carbon electrode was polished with 0.3 μm 
alumina followed by 0.05 μm alumina, between each experiment to remove any surface 
contaminants. The scan rate was 0.1 V s
-1
. The concentration range of the ferrocene 
compounds was 1.0 mM in acetonitrile. The E
0
´ values obtained for the test samples were 
referenced relative to the ferrocene/ferricenium redox couple. 
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General procedure for the preparation of Boc protected dipeptide ethyl esters. 
Boc-glycine-sarcosine ethyl ester 106 
Sarcosine ethyl ester hydrochloride (0.80 g, 5 mmol) 
was added to a solution of N-Boc-glycine (0.88 g, 5 
mmol), 1-hydroxybenzotriazole (0.70 g, 5.2 mmol), 
triethylamine (0.9 ml) and N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.99 g, 5.2 mmol) in 50 ml of 
dichloromethane at 0 
o
C. After 30 min the solution was raised to room temperature and the 
reaction was allowed to proceed for 48 h. The reaction mixture was then washed with 
water. The dichloromethane layer was dried over MgSO4 and the solvent was removed in 
vacuo. The product was purified by column chromatography (eluant 1:1 hexane:ethyl 
acetate) to give the title compound as an white solid (0.95 g, 70%), mp 54-56 
o
C; 
δH (400 MHz, CDCl3): 5.46 (1H, br. s, -CONH-), 3.89-4.24 {6H, m, -OCH2CH3, -NHCH2-, 
-N(CH3)CH2-}, 3.04 & 3.01 {3H, s, s, -N(CH3)-}, 1.45 {9H, s, (CH3)3CO2CNH-}, 1.28 
(3H, t, J 7.2, -OCH2CH3). 
δC (100 MHz, CDCl3): 169.3 (C=O), 168.9 (C=O), 155.8 (C=O), 79.7 (Cq), 61.9 & 61.4 (-
OCH2-, -ve DEPT), 50.4 & 49.6 {-N(CH3)CH2-, -ve DEPT}, 42.3 (-NHCH2-, -ve DEPT), 
35.2 & 35.1 {-N(CH3)-}, 28.4 & 28.3 {(CH3)3}, 14.2 (-OCH2CH3). 
 
Boc-sarcosine-glycine ethyl ester 107 
The synthesis followed that of 106 using the 
following reagents: Boc-sarcosine (0.95 g, 5.0 mmol), 
1-hydroxybenzotriazole (0.70 g, 5.2 mmol), 
triethylamine (0.9 ml), N-(3-dimethylaminopropyl)-
N’-ethylcarbodiimide hydrochloride (0.99 g, 5.2 
mmol) and glycine ethyl ester hydrochloride (0.7 g, 
5.0 mmol). The product was purified by column chromatography (eluant 1:1 hexane:ethyl 
acetate) to give the title compound as a white solid (0.78 g, 56%), mp 56-57 
o
C; 
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δH (400 MHz, CDCl3): 6.39-6.56 (1H, m, -CONH-), 4.14 (2H, q, J 7.2, -OCH2CH3), 3.98 
(2H, d, J 5.6, -NHCH2-), 3.85 {2H, s, -N(CH3)CH2-}, 2.89 {3H, s, -N(CH3)-}, 1.41{9H, s, 
(CH3)3CO2CN-}, 1.20 (3H, t, J 7.2, -OCH2CH3); 
δC (100 MHz, CDCl3): 169.6 (C=O), 168.9 (C=O), 155.9 (C=O), 80.8 (Cq), 61.6 (-OCH2-, -
ve DEPT), 52.9 {-N(CH3)CH2-, -ve DEPT}, 41.1 (-NHCH2-, -ve DEPT), 35.7 {-N(CH3)-}, 
28.3 {(CH3)3}, 14.1 (-OCH2CH3). 
  
Boc-sarcosine-sarcosine ethyl ester 108 
The synthesis followed that of 106 using the 
following reagents: Boc-sarcosine (0.80 g, 5.0 mmol), 
1-hydroxybenzotriazole (0.70 g, 5.2 mmol), 
triethylamine (0.9 ml), N-(3-dimethylaminopropyl)-
N’-ethylcarbodiimide hydrochloride (0.99 g, 5.2 
mmol) and sarcosine ethyl ester hydrochloride (0.80 
g, 5.0 mmol). The product was purified by column chromatography (eluant 1:1 
hexane:ethyl acetate) to give the title compound as a transparent oil (0.77 g, 54%). 
δH (400 MHz, CDCl3): 4.01-4.25 {6H, m, -OCH2CH3, -N(CH3)CH2-, -N(CH3)CH2-}, 2.91-
3.05 {6H, m, -N(CH3)-, -N(CH3)-}, 1.47 & 1.44 {9H, s, s, (CH3)3CO2CN-}, 1.25-1.30 (3H, 
m, -OCH2CH3); 
δC (100 MHz, CDCl3): 169.3 (C=O), 168.9 (C=O), 156.3 (C=O), 80.0 (Cq), 61.2 (-OCH2-, -
ve DEPT), 50.0 {-N(CH3)CH2-, -ve DEPT}, 49.6 {-N(CH3)CH2-, -ve DEPT}, 35.6 {-
N(CH3)-}, 35.4 {-N(CH3)-}, 28.4 {(CH3)3}, 14.2 (-OCH2CH3).  
 
Boc-glycine-N-methyl-L-alanine ethyl ester 109 
The synthesis followed that of 106 using the 
following reagents: Boc-glycine (0.88 g, 5.0 mmol), 
1-hydroxybenzotriazole (0.70 g, 5.2 mmol), 
triethylamine (0.9 ml), N-(3-dimethylaminopropyl)-
N’-ethylcarbodiimide hydrochloride (0.99 g, 5.2 
mmol) and N-methyl-L-alanine ethyl ester 
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hydrochloride (0.74 g, 5.0 mmol). The product was purified by column chromatography 
(eluant 1:1 hexane:ethyl acetate) to give the title compound as a transparent oil (0.52 g, 
38%). 
δH (400 MHz, CDCl3): 5.43 {1H, br. s, (CH3)3CO2CNH-}, 5.14 {1H, q, J 7.2, -N(CH3)CH-
}, 4.06-4.16 (2H, m, -OCH2CH3), 3.93 (2H, br. s, -NHCH2-), 2.84 & 2.80 {3H, s, s, -
N(CH3)-}, 1.38 {9H, s, (CH3)3CO2CNH-}, 1.34 (3H, d, J 7.2, -CH3), 1.19 (3H, t, J 7.2, -
OCH2CH3); 
δC (100 MHz, CDCl3): 171.4 (C=O), 168.9 (C=O), 155.8 (C=O), 79.6 (Cq), 61.4 (-OCH2-, -
ve DEPT), 52.5 (α-C), 42.6 (-NHCH2-, -ve DEPT), 30.2 {-N(CH3)-}, 28.4 {(CH3)3}, 14.4 
(-CH3), 14.2 (-OCH2CH3). 
 
Boc-Glycine-D-Alanine ethyl ester 110 
The synthesis followed that of 106 using the 
following reagents: Boc-glycine (0.88 g, 5.0 mmol), 
1-hydroxybenzotriazole (0.70 g, 5.2 mmol), 
triethylamine (0.9 ml), N-(3-dimethylaminopropyl)-
N’-ethylcarbodiimide hydrochloride (0.99 g, 5.2 
mmol) and D-alanine ethyl ester hydrochloride (0.77 
g, 5.0 mmol). The product was purified by column 
chromatography (eluant 1:1 hexane:ethyl acetate) to give the title compound as a 
transparent oil (1.0g, 73%). 
δH (400 MHz, CDCl3): 6.54 (1H, br. s, -CONH-), 5.05 (1H, br. s, -CONH-), 4.51 (1H, qt, J 
7.2, -NHCH-), 4.14 (2H, q, J 7.2, -OCH2CH3), 3.69-3.80 (2H, m, -NHCH2-), 1.39 {9H, s, 
(CH3)3CO2CNH-}, 1.34 (H, d, J 7.2, -CH3), 1.22 (3H, t, J 7.2, -OCH2CH3); 
δC (100 MHz, CDCl3): 172.3 (C=O), 168.9 (C=O), 155.9 (C=O), 80.4 (Cq), 61.6 (-OCH2-, -
ve DEPT), 48.1 (α-C), 44.3 (-NHCH2-, -ve DEPT), 28.3 {(CH3)3}, 18.5 (-CH3), 14.1 (-
OCH2CH3). 
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Boc-glycine-β-alanine ethyl ester 111 
The synthesis followed that of 106 using the following 
reagents: Boc-glycine (0.72 g, 4.1 mmol), 1-
hydroxybenzotriazole (0.70 g, 5.2 mmol), triethylamine 
(0.9 ml), N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (0.99 g, 5.2 mmol) and 
β-Alanine ethyl ester hydrochloride (0.63 g, 4.1 mmol). 
The product was purified by column chromatography 
(eluant 1:1 hexane:ethyl acetate) to give the title 
compound as a transparent oil (0.80 g, 71%); 
δH (400 MHz, CDCl3): 6.78 (1H, br. s, -CONH-), 5.28 {1H, br. s, (CH3)3CO2CNH-}, 4.14 
(2H, q, J 7.2, -OCH2CH3), 3.77 (2H, d, J 5.6, -NHCH2-), 3.54 (2H, q, J 6.0, -CH2CH2-), 
2.54 (2H, t, J 6.0, -CH2CH2-), 1.46 {9H, s, (CH3)3CO2CNH-}, 1.28 (3H, t, J 7.2, -
OCH2CH3); 
δC (100 MHz, CDCl3): 172. 5 (C=O), 169.5 (C=O), 156.0 (C=O), 80.2 (Cq), 60.8 (-OCH2-, 
-ve DEPT), 44.3 (-NHCH2-, -ve DEPT), 34.8 (-CH2CH2-, -ve DEPT), 33.9 (-CH2CH2-, -ve 
DEPT), 28.3 {(CH3)3}, 14.2 (-OCH2CH3). 
 
Boc-β-alanine-glycine ethyl ester 112 
The synthesis followed that of 106 using the following 
reagents: Boc-β-alanine (0.95 g, 5.0 mmol), 1-
hydroxybenzotriazole (0.70 g, 5.2 mmol), triethylamine 
(0.9 ml), N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (0.99 g, 5.2 mmol) and 
glycine ethyl ester hydrochloride (0.70 g, 5.0 mmol). 
The product was purified by column chromatography 
(eluant 1:1 hexane:ethyl acetate) to give the title 
compound as a white solid (0.95 g, 70%), mp 62-63 
o
C; 
δH (400 MHz, CDCl3): 6.31 (1H, br. s, -CONH-), 5.24 {1H, br. s, (CH3)3CO2CNH-}, 4.20-
4.26 (2H, m, -OCH2CH3), 4.03 (2H, d, J 5.6, -NHCH2-), 3.43 (2H, q, J 6.0, -CH2CH2-), 
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2.48 (2H, t, J 6.0, -CH2CH2-), 1.43 {9H, s, (CH3)3CO2CNH-}, 1.31 (3H, t, J 7.2, -
OCH2CH3); 
δC (100 MHz, CDCl3): 171.8 (C=O), 169.9 (C=O), 156.1 (C=O), 79.4 (Cq), 61.6 (-OCH2-, -
ve DEPT), 41.4 (-NHCH2-, -ve DEPT), 36.6 (-CH2CH2-, -ve DEPT), 36.0 (-CH2CH2-, -ve 
DEPT), 28.4 {(CH3)3}, 14.2 (-OCH2CH3). 
 
Boc-glycine-γ-aminobutyric acid ethyl ester 113 
The synthesis followed that of 106 using the following 
reagents: Boc-glycine (0.88 g, 5.0 mmol), 1-
hydroxybenzotriazole (0.70 g, 5.2 mmol), triethylamine 
(0.9 ml), N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (0.99 g, 5.2 mmol) and 
γ-aminobutyric acid ethyl ester hydrochloride (0.84 g, 5.0 
mmol). The product was purified by column chromatography (eluant 1:1 hexane:ethyl 
acetate) to give the title compound as a transparent oil (0.65 g, 46%). 
δH (400 MHz, CDCl3): 6.33 (1H, br. s, -CONH-), 5.09 (1H, br. s, -CONH-), 4.06 (2H, q, J 
7.2, -OCH2CH3), 3.70 (2H, d, J 5.6, -NHCH2-), 3.25 (2H, q, J 6.0, -CH2CH2CH2-), 2.29 
(2H, t, J 7.2, -CH2CH2CH2-), 1.78 (2H, qt, J 7.2, -CH2CH2CH2-), 1.39 {9H, s, 
(CH3)3CO2CN-}, 1.19 (3H, t, J 7.2, -OCH2CH3); 
δC (100 MHz, CDCl3): 173.4 (C=O), 169.5 (C=O), 156.2 (C=O), 80.4 (Cq), 60.6 (-OCH2-, -
ve DEPT), 44.4 (-NHCH2-, -ve DEPT), 38.9 (-CH2CH2CH2-, -ve DEPT), 31.7 (-
CH2CH2CH2-, -ve DEPT), 28.3 {(CH3)3}, 24.6 (-CH2CH2CH2-, -ve DEPT), 14.2 (-
OCH2CH3). 
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Boc-γ-aminobutyric acid-glycine ethyl ester 114 
The synthesis followed that of 106 using the 
following reagents: Boc-γ-aminobutyric acid (1.02 g, 
5.0 mmol), 1-hydroxybenzotriazole (0.70 g, 5.2 
mmol), triethylamine (0.9 ml), N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.99 g, 5.2 mmol) and glycine ethyl 
ester hydrochloride (0.70 g, 5.0 mmol). The product was purified by column 
chromatography (eluant 1:1 hexane:ethyl acetate) to give the title compound as a white 
solid (1.11g, 68%), mp 67-68 
o
C; 
δH (400 MHz, CDCl3): 6.58 (1H, br. s, -CONH-), 4.78 {1H, br. s, (CH3)3CO2CNH-}, 4.14 
(2H, q, J 7.2, -OCH2CH3), 3.96 (2H, d, J 5.6, -NHCH2-), 3.14 (2H, br. s, -CH2CH2CH2-), 
2.22 (2H, t, J 7.2, -CH2CH2CH2-), 1.76 (2H, qt, J 7.2, -CH2CH2CH2-), 1.37 {9H, s, 
(CH3)3CO2CNH-}, 1.22 (3H, t, J 7.2, -OCH2CH3); 
δC (100 MHz, CDCl3): 172.9 (C=O), 170.1 (C=O), 156.5 (C=O), 79.4 (Cq), 61.5 (-OCH2-, -
ve DEPT), 41.4 (-NHCH2-, -ve DEPT), 39.6 (-CH2CH2CH2-, -ve DEPT), 33.3 (-
CH2CH2CH2-, -ve DEPT), 28.4 {(CH3)3}, 26.4 (-CH2CH2CH2-, -ve DEPT), 14.1 (-
OCH2CH3). 
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General procedure for the preparation of N-(ferrocenyl)naphthoyl dipeptide derivatives. 
N-(3-ferrocenyl-2-naphthoyl)-glycine-sarcosine ethyl ester 115 
Glycine-sarcosine ethyl ester trifluoroacetate salt 
(0.29 g, 1.0 mmol) was added to a solution of 3-
ferrocenylnaphthalene-2-carboxylic acid (0.36 g, 
1.0 mmol), 1-hydroxybenzotriazole (0.18 g, 1.3 
mmol), triethylamine (5.0 ml) and N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.25 g, 1 mmol) in 50 ml of 
dichloromethane at 0 
o
C. After 30 min the 
solution was raised to room temperature and the 
reaction was allowed to proceed for 48 h. The 
reaction mixture was then washed with water. 
The dichloromethane layer was dried over MgSO4 and the solvent was removed in vacuo. 
The product was purified by column chromatography (eluant 1:1 hexane: ethyl acetate) to 
give the title compound as an orange solid (0.12 g, 33%), mp 65-66 
o
C;  
E
0
´/mV 24 vs. Fc/Fc
+
; 
m/z (ESI) 512.1385 [M]
+•
. C28H28N2O4Fe requires 512.1398; 
λmax(CH3CN)/nm 450 (ε/dm
3
 mol
-1
 cm
-1
 537); 
νmax(neat)/cm
-1
 3298, 1743, 1645, 1486, 1194; 
δH (400 MHz, DMSO-d6): 8.63 & 8.59 (1H, t, J 5.6, t, J 5.6, -CONH-), 8.32 (1H, s, ArH), 
7.99 (1H, d, J 8.0, ArH), 7.91 (1H, d, J 8.0, ArH), 7.85 (1H, s, ArH), 7.50-7.58 (2H, m, 
ArH), 4.84 {2H, t, J 1.6, ortho on (η5-C5H4)}, 4.31 {2H, t, J 1.6, meta on (η
5
-C5H4)}, 4.35 
& 4.07-4.22 {11H, m, -OCH2CH3,  η
5
-C5H5, -NHCH2-, -N(CH3)CH2-}, 3.11 & 2.90 {3H, s, 
s, -N(CH3)-}, 1.19-1.30 (3H, m -OCH2CH3);   
δC (100 MHz, DMSO-d6): 168.2 (C=O), 167.6 (C=O), 167.5 (C=O), 133.5 (Cq), 132.6 (Cq), 
131.3 (Cq), 128.8 (Cq), 126.3, 125.9, 125.7, 125.3, 125.1, 124.4, 82.6 (Cipso η
5
-C5H4), 67.9 
(η5-C5H5), 67.3 (Cortho η
5
-C5H4), 66.6 (Cmeta η
5
-C5H4), 59.3 & 58.9 (-OCH2-, -ve DEPT), 
47.6 {-N(CH3)CH2-, -ve DEPT}, 38.9 (-NHCH2-, -ve DEPT), 33.5 & 32.9 {-N(CH3)-}, 
14.1 (-OCH2CH3). 
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N-(3-ferrocenyl-2-naphthoyl)-sarcosine-glycine ethyl ester 116 
The synthesis followed that of 115 using the 
following reagents: 3-ferrocenylnaphthalene-2-
carboxylic acid (0.36 g, 1.0 mmol), 1-
hydroxybenzotriazole (0.18 g, 1.3 mmol), 
triethylamine (5 ml), N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.25 g, 1.3 mmol) and sarcosine-
glycine ethyl ester trifluoroacetate salt (0.29 g, 
1.0 mmol). The product was purified by column 
chromatography (eluant 1:1 hexane: ethyl 
acetate) to give the title compound as an orange 
solid (0.1 g, 20%), mp 67-68 
o
C; E
0
´/mV 26 vs. Fc/Fc
+
;  
m/z (ESI) 512.1389 [M]
+•
. C28H28N2O4Fe requires 512.1398; 
λmax(CH3CN)/nm 450 (ε/dm
3
 mol
-1
 cm
-1
 470); 
νmax(neat)/cm
-1
 3291, 3082, 1748, 1684, 1622, 1485, 1192; 
δH (600 MHz, DMSO-d6): 8.49 & 8.41 (1H, t, J 5.8, t, J 5.8, -CONH-), 8.44 & 8.43 (1H, s, 
s, ArH),  8.07 (1H, m, ArH), 7.97 & 7.89 (1H, d, J 8.0, d, J 8.0, ArH), 7.75 & 7.78 (1H, s, 
s, ArH), 7.55-7.63 (2H, m, ArH), 4.91, 4.81, 4.78-4.79 & 4.73-4.74 {2H, s, s, m, m, ortho 
on (η5-C5H4)}, 3.76-4.46 {13H, m, meta on (η
5
-C5H4), η
5
-C5H5, -OCH2CH3, -N(CH3)CH2-, 
-NHCH2-}, 3.05 & 2.76 {3H, s, s, -N(CH3)-}, 1.19 & 1.27 (3H, t, J 7.2, t, J 7.2, -
OCH2CH3);  
δC (150 MHz, DMSO-d6): 170.84 & 170.68 (C=O), 169.75 & 169.49 (C=O), 168.47 & 
168.19 (C=O), 133.52 & 133.06 (Cq), 133.48 & 133.45 (Cq), 132.84 & 132.82 (Cq), 130.79 
& 130.66 (Cq), 127.75 & 127.61, 127.70 & 127.56, 127.50 & 127.44, 126.89, 126.06 & 
126.00, 125.57 & 125.49, 83.3 (Cipso η
5
-C5H4), 69.65 & 69.64 (η
5
-C5H5), 68.77 & 68.71 
(Cortho η
5
-C5H4), 68.75 & 68.51 (Cortho η
5
-C5H4), 68.36 & 68.33 (Cmeta η
5
-C5H4), 68.22 & 
68.18 (Cmeta η
5
-C5H4), 60.48 & 60.43 (-OCH2-, -ve DEPT), 52.87 & 48.90 {-N(CH3)CH2-, -
ve DEPT}, 40.66 & 40.59 (-NHCH2-, -ve DEPT), 37.32 & 33.25 {-N(CH3)-}, 14.06  & 
13.98 (-OCH2CH3). 
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N-(3-ferrocenyl-2-naphthoyl)-sarcosine-sarcosine ethyl ester 117 
The synthesis followed that of 115 using the 
following reagents: 3-ferrocenylnaphthalene-2-
carboxylic acid (0.32 g, 0.9 mmol), 1-
hydroxybenzotriazole (0.12 g, 0.9 mmol), 
triethylamine (5 ml), N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.17 g, 0.9 mmol) and sarcosine-
sarcosine ethyl ester trifluoroacetate salt (0.27 g, 
0.9 mmol). The product was purified by column 
chromatography (eluant 1:1 hexane: ethyl 
acetate) to give the title compound as an orange 
solid (0.15 g, 31.1%), mp 74-75 
o
C;  
E
0
´/mV 32 vs. Fc/Fc
+
; 
m/z (ESI) 526.2 [M]+. C29H30N2O4Fe requires 526.4; 
m/z (ESI) 526.1547 [M]
+•
. C29H30N2O4Fe requires 526.1555; 
λmax(CH3CN)/nm 450 (ε/dm
3
 mol
-1
 cm
-1
 568); 
νmax(neat)/cm
-1
 2928, 1741, 1635, 1483, 1394, 1196; 
δH (400 MHz, DMSO-d6): 8.35-8.39 (1H, m, ArH), 7.99-8.03 (1H, m, ArH), 7.93 & 7.81 
(1H, d, J 8.8, d J 8.8, ArH), 7.46-7.68 (3H, m, ArH), 3.79-4.91 {15H, η5-C5H4, η
5
-C5H5, -
OCH2CH3, -N(CH3)CH2-, -N(CH3)CH2-}, 2.91-3.10 {3H, m, -N(CH3)-}, 2.64-2.78 {3H, m, 
-N(CH3)-}, 0.81-1.27 (3H, m, -OCH2CH3); 
δC (100 MHz, DMSO-d6): 170.8 (C=O), 169.2 (C=O), 168.2 (C=O), 133.7 (Cq), 133.4 (Cq), 
132.8 (Cq), 130.8 (Cq), 127.6, 127.5, 126.9, 126.0, 125.9, 125.5, 83.2 (Cipso η
5
-C5H4), 69.6 
(η5-C5H5), 68.8 (C η
5
-C5H4), 68.7 (C η
5
-C5H4), 68.4 (C η
5
-C5H4), 68.3 (C η
5
-C5H4), 60.9 & 
60.5 (-OCH2-, -ve DEPT), 49.2 (-CH2-, -ve DEPT), 47.7 (-CH2, -ve DEPT), 37.4 & 35.2 & 
34.5 & 33.4 {-N(CH3)-}, 14.1 & 13.9 (-OCH2CH3). 
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N-(3-ferrocenyl-2-naphthoyl)-glycine-N-methyl-L-alanine ethyl ester 118 
The synthesis followed that of 115 using the 
following reagents: 3-ferrocenylnaphthalene-2-
carboxylic acid (0.32 g, 0.9 mmol), 1-
hydroxybenzotriazole (0.12 g, 0.9 mmol), 
triethylamine (5 ml), N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.17 g, 0.9 mmol) and glycine-N-
methyl-L-alanine ethyl ester trifluoroacetate salt 
(0.27 g, 0.9 mmol). The product was purified by 
column chromatography (eluant 1:1 hexane: 
ethyl acetate) to give the title compound as an 
orange solid (0.18 g, 38%), mp 62-63 
o
C;  
E
0
´/mV 25 vs. Fc/Fc
+
;  
[α] 20
D
 -25 (c 0.05 in CH3CN); 
m/z (ESI) 526.4 [M]
+•
. C29H30N2O4Fe requires 526.4; 
m/z (ESI) 526.1534 [M]
+•
. C29H30N2O4Fe requires 526.1555; 
λmax(CH3CN)/nm 445 (ε/dm
3
 mol
-1
 cm
-1
 574); 
νmax(neat)/cm
-1
 3303, 2937, 1734, 1640, 1484, 1199; 
δH (400 MHz, DMSO-d6): 8.57-8.63 (1H, m, -CONH-), 8.32 (1H, s, ArH), 7.99 (1H, d, J 
8.0, ArH), 7.91 (1H, d, J 8.0, ArH), 7.86-7.87 (1H, m, ArH), 7.47-7.58 (2H, m, ArH), 4.88-
4.99 {1H, m, -N(CH3)CH-}, 4.83-4.85 {2H, m, ortho on (η
5
-C5H4)}, 4.30-4.32 {2H, m, 
meta on (η5-C5H4)}, 4.03-4.24 (9H, m, -OCH2CH3,  η
5
-C5H5, -NHCH2-), 2.99 & 2.77 {3H, 
s, s, -N(CH3)-}, 1.43 & 1.35 (3H, d, J 7.2, d, J 7.2, -CH3), 1.18-1.26 (3H, m, -OCH2CH3); 
δC (100 MHz, DMSO-d6): 171.3 (C=O), 169.8 (C=O), 168.7 (C=O), 135.2 (Cq), 134.3 (Cq), 
132.9 (Cq), 130.5 (Cq), 128.0, 127.6, 127.4, 126.9, 126.8, 126.0, 84.3 (Cipso η
5
-C5H4), 69.5 
(η5-C5H5), 69.0 (Cortho η
5
-C5H4), 68.9 (Cortho η
5
-C5H4), 68.3 (Cmeta η
5
-C5H4), 61.1 & 60.6 (-
OCH2-, -ve DEPT), 53.6 & 52.7 (α-C), 40.8 (-NHCH2-, -ve DEPT), 30.9 & 28.7 {-N(CH3)-
}, 15.4 & 15.2 (-CH3), 14.2 & 14.1 (-OCH2CH3).  
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N-(6-ferrocenyl-2-naphthoyl)-glycine-sarcosine ethyl ester 119 
The synthesis followed that of 115 
using the following reagents: 6-
ferrocenylnaphthalene-2-
carboxylic acid (0.32 g, 0.9 
mmol), 1-hydroxybenzotriazole 
(0.16 g, 1.2 mmol), triethylamine 
(5 ml), N-(3-
dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (0.23 g, 1.2 mmol) and glycine-sarcosine ethyl ester 
trifluoroacetate salt (0.26 g, 0.9 mmol). The product was purified by column 
chromatography (eluant 1:1 hexane: ethyl acetate) to give the title compound as an orange 
solid (0.20 g, 43%), mp 64-65 
o
C;  
E
0
´/mV 63 vs. Fc/Fc
+
; 
Anal. Calc. for C28H28N2O4Fe: C, 65.6; H, 5.5; N, 5.5%. Found: C, 65.3; H, 5.7; N, 5.3; 
m/z (ESI) 512.1398 [M]
+•
. C28H28N2O4Fe requires 512.1398; 
λmax(CH3CN)/nm 370 (ε/dm
3
 mol
-1
 cm
-1
 2670), 450 (1098); 
νmax(neat)/cm
-1
 3300, 2928, 1739, 1626, 1507, 1480, 1200; 
δH (400 MHz, DMSO-d6): 8.72 & 7.45-7.51 (1H, t, J 5.6, m, -CONH-), 8.44-8.48 (1H, m, 
ArH), 8.05-8.07 (1H, m, ArH), 7.81-7.98 (4H, m, ArH), 4.95-4.97 {2H, m, ortho on (η5-
C5H4)}, 4.44-4.46 {2H, m, meta on (η
5
-C5H4)}, 3.96-4.36 {11H, m, -OCH2CH3, η
5
-C5H5, -
NHCH2-, -N(CH3)CH2-}, 3.12 & 3.01 & 2.88 {3H, s, br. s, s, -N(CH3)-}, 1.18-1.26 (3H, m, 
-OCH2CH3); 
δC (100 MHz, DMSO-d6): 171.2 (C=O), 169.2 (C=O), 166.4 (C=O), 138.8 (Cq), 134.5 (Cq), 
133.4 (Cq), 130.7 (Cq), 128.7, 128.2, 127.4, 125.9, 124.4, 122.7, 84.1 (Cipso η
5
-C5H4), 69.4 
(η5-C5H5, Cmeta η
5
-C5H4), 66.6 (Cortho η
5
-C5H4), 60.9 & 60.5 (-OCH2-, -ve DEPT), 49.3 {-
N(CH3)CH2-, -ve DEPT}, 40.8 (-NHCH2-, -ve DEPT), 35.2 & 34.5 & 30.7 {-N(CH3)-}, 
14.0 (-OCH2CH3). 
 
 
190 
 
N-(6-ferrocenyl-2-naphthoyl)-sarcosine-glycine ethyl ester 120 
The synthesis followed that of 115 
using the following reagents: 6-
ferrocenylnaphthalene-2-
carboxylic acid (0.36 g, 1.0 
mmol), 1-hydroxybenzotriazole 
(0.18 g, 1.3 mmol), triethylamine 
(5 ml), N-(3-
dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (0.25 g, 1.3 mmol) and sarcosine-glycine ethyl ester 
trifluoroacetate salt (0.38 g, 1.3 mmol). The product was purified by column 
chromatography (eluant 1:1 hexane: ethyl acetate) to give the title compound as a red solid 
(0.18 g, 35%), mp 66-67 
o
C;  
E
0
´/mV 55 vs. Fc/Fc
+
; 
m/z (ESI) 512.2 [M]
+•
. C28H28N2O4Fe requires 512.4; 
m/z (ESI) 512.1399 [M]
+•
. C28H28N2O4Fe requires 512.1398; 
λmax(CH3CN)/nm 370 (ε/dm
3
 mol
-1
 cm
-1
 2492), 450 (988); 
νmax(neat)/cm
-1
 3291, 2930, 1745, 1677, 1623, 1507, 1396, 1196; 
δH (600 MHz, DMSO-d6): 8.61 & 8.53 (1H, br. s, br. s, -CONH-), 8.11 (1H, s, ArH), 7.95-
8.03 (3H, m, ArH), 7.87 (1H, d, J 8.4, ArH), 7.54-7.58 (1H, m, ArH), 5.01 {2H, t, J 1.8, 
ortho on (η5-C5H4)}, 4.49-4.52 {2H, m, meta on (η
5
-C5H4)}, 3.96-4.26 {11H, m, -
OCH2CH3, η
5
-C5H5, -NHCH2-, -N(CH3)CH2-}, 3.08 {3H, s, -N(CH3)-}, 1.27 (3H, t, J 7.2, -
OCH2CH3); 
δC (150 MHz, DMSO-d6): 171.1 (C=O), 169.7 (C=O), 168.6 (C=O), 138.2 (Cq), 133.4 (Cq), 
132.4 (Cq), 130.7 (Cq), 128.3, 126.5, 125.9, 125.0, 124.8, 122.8, 84.1 (Cipso η
5
-C5H4), 69.41 
(η5-C5H5), 69.38 (Cmeta η
5
-C5H4), 66.6 (Cortho η
5
-C5H4), 60.5 & 59.7 (-OCH2-, -ve DEPT), 
53.9 & 49.7 {-N(CH3)CH2-, -ve DEPT}, 40.7 (-NHCH2-, -ve DEPT), 39.3 & 34.1 {-
N(CH3)-}, 14.1 (-OCH2CH3). 
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N-(6-ferrocenyl-2-naphthoyl)-sarcosine-sarcosine ethyl ester 121 
The synthesis followed that of 115 
using the following reagents: 6-
ferrocenylnaphthalene-2-
carboxylic acid (0.27 g, 0.8 
mmol), 1-hydroxybenzotriazole 
(0.14 g, 1.0 mmol), triethylamine 
(5 ml), N-(3-
dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (0.20 g, 1.0 mmol) and sarcosine-sarcosine ethyl ester 
trifluoroacetate salt (0.23 g, 0.8 mmol). The product was purified by column 
chromatography (eluant 1:1 hexane: ethyl acetate) to give the title compound as an orange 
solid (0.05 g, 12%), mp 68-69 
o
C;  
E
0
´/mV 58 vs. Fc/Fc
+
; 
m/z (ESI) 526.2 [M]
+•
. C29H30N2O4Fe requires 526.4; 
m/z (ESI) 526.1536 [M]
+•
. C29H30N2O4Fe requires 526.1555; 
λmax(CH3CN)/nm 370 (ε/dm
3
 mol
-1
 cm
-1
 2106), 450 (836); 
νmax(neat)/cm
-1
 2926, 1739, 1663, 1626, 1479, 1394, 1198; 
δH (600 MHz, DMSO-d6): 8.08-8.11 (1H, m, ArH), 7.86-8.02 (4H, m, ArH), 7.54 & 7.42-
7.46 (1H, d, J 8.4, m, ArH), 5.01 {2H, s, ortho on (η5-C5H4)}, 3.87-4.51 {13H, meta on (η
5
-
C5H4), -OCH2CH3, η
5
-C5H5, -N(CH3)CH2-, -N(CH3)CH2-}, 3.03-3.16 {3H, m, -N(CH3)-},  
2.88-3.01 {3H, m, -N(CH3)-},  1.24-1.32 & 1.00 (3H, m, s, J 7.2, -OCH2CH3); 
δC (150 MHz, DMSO-d6): 171.0 (C=O), 169.1 (C=O), 168.1 (C=O), 138.1 (Cq), 133.4 (Cq), 
132.5 (Cq), 130.7 (Cq), 128.2, 127.5, 126.3, 125.9, 124.7, 122.8, 84.2 (Cipso η
5
-C5H4), 69.40 
(η5-C5H5), 69.38 (Cmeta η
5
-C5H4), 66.6 (Cortho η
5
-C5H4), 60.58 & 60.54 (-OCH2-, -ve 
DEPT), 52.48 & 49.60 & 49.23 & 48.36 {-N(CH3)CH2-, -ve DEPT}, 38.34 & 35.19 & 
34.47 & 34.35 {-N(CH3)-}, 14.1 (-OCH2CH3). 
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N-(6-ferrocenyl-2-naphthoyl)-glycine-N-methyl-L-alanine ethyl ester 122 
The synthesis followed that of 115 
using the following reagents: 6-
ferrocenylnaphthalene-2-
carboxylic acid (0.32 g, 0.9 
mmol), 1-hydroxybenzotriazole 
(0.12 g, 0.9 mmol), triethylamine 
(5 ml), N-(3-
dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (0.17 g, 0.9 mmol) and glycine-N-methyl-L-alanine ethyl 
ester trifluoroacetate salt (0.27 g, 0.9 mmol). The product was purified by column 
chromatography (eluant 1:1 hexane: ethyl acetate) to give the title compound as an orange 
solid (0.04 g, 9%), mp 63-64 
o
C;  
E
0
´/mV 63 vs. Fc/Fc
+
;  
[α] 20
D
 -9 (c 0.05 in CH3CN); 
m/z (ESI) 526.2 [M]
+•
. C29H30N2O4Fe requires 526.4; 
m/z (ESI) 526.1561 [M]
+•
. C29H30N2O4Fe requires 526.1555; 
λmax(CH3CN)/nm 370 (ε/dm
3
 mol
-1
 cm
-1
 2450), 450 (1016); 
νmax(neat)/cm
-1
 3332, 2928, 1733, 1639, 1512, 1480, 1203; 
δH (600 MHz, DMSO-d6): 8.75-8.78 (1H, m, -CONH-), 8.46-8.55 (1H, m, ArH), 8.12 (1H, 
s, ArH), 7.96-8.03 (3H, m, ArH), 7.89 (1H, dd, J 1.8 and 8.4, ArH), 5.02 {2H, t, J 1.8, 
ortho on (η5-C5H4)}, 4.95-4.99 {1H, m, -N(CH3)CH-}, 4.51 {2H, t, J 1.8, meta on (η
5
-
C5H4)}, 4.13-4.39 (9H, m, -OCH2CH3, η
5
-C5H5, -NHCH2-), 3.06 & 2.80 {3H, s, s, -
N(CH3)-}, 1.49 & 1.39 (3H, d, J 7.2, d, J 7.2, -CH3), 1.24-1.29 (3H, m, -OCH2CH3);  
δC (150 MHz, DMSO-d6): 171.2 (C=O), 168.8 (C=O), 166.4 (C=O), 138.8 (Cq), 134.5 (Cq), 
130.7 (Cq), 130.5 (Cq), 128.8, 127.4, 127.3, 126.0, 124.4, 122.8, 84.1 (Cipso η
5
-C5H4), 69.5 
(η5-C5H5), 69.4 (Cmeta η
5
-C5H4), 66.7 (Cortho η
5
-C5H4), 60.6 (-OCH2-, -ve DEPT), 52.8 (α-
C), 41.2 (-NHCH2-, -ve DEPT), 30.9 {-N(CH3)-}, 15.2  (-CH3), 14.1 & 14.0 (-OCH2CH3). 
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N-(3-ferrocenyl-2-naphthoyl)-glycine-D-alanine ethyl ester 123 
The synthesis followed that of 115 using the 
following reagents: 3-ferrocenylnaphthalene-2-
carboxylic acid (0.32 g, 0.9 mmol), 1-
hydroxybenzotriazole (0.16 g, 1.2 mmol), 
triethylamine (5 ml), N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.23 g, 1.2 mmol) and glycine-D-
alanine ethyl ester trifluoroacetate salt (0.26 g, 
0.9 mmol). The product was purified by column 
chromatography (eluant 1:1 hexane: ethyl 
acetate) to give the title compound as an orange 
solid (0.19 g, 41%), mp 63-64 
o
C;  
E
0
´/mV 24 vs. Fc/Fc
+
;  
[α] 20
D
 +2 (c 0.05 in CH3CN); 
Anal. cald. for C28H28N2O4Fe requires: C, 65.6; H, 5.5; N, 5.5%. Found: C, 64.85; H, 5.4 
N, 5.2; 
λmax(CH3CN)/nm 435 (ε/dm
3
 mol
-1
 cm
-1
 395);  
νmax(neat)/cm
-1
 3285, 3081, 1733, 1643, 1516, 1450, 1203; 
δH (400 MHz, DMSO-d6): 8.69 (1H, t, J 5.6, -CONH-), 8.36 (1H, d, J 7.2, -CONH-), 8.32 
(1H, s, ArH), 7.99 (1H, d, J 8.0, ArH), 7.90 (1H, d, J 8.0, ArH), 7.84 (1H, s, ArH), 7.49-
7.58 (2H, m, ArH), 4.81-4.82 {2H, m, ortho on (η5-C5H4)}, 4.31-4.37 {3H, m, -NHCH-, 
meta on (η5-C5H4)}, 4.08-4.16 (7H, m, -OCH2CH3, η
5
-C5H5), 3.97 (1H, dd, J 5.6 and 16.4, 
-NHCH2-), 3.88 (1H, dd, J 5.6 and 16.4, -NHCH2-), 1.33 (H, d, J 7.2, -CH3), 1.22 (3H, t, J 
7.2, -OCH2CH3); 
δC (100 MHz, DMSO-d6): 172.5 (C=O), 169.8 (C=O), 168.6 (C=O), 135.0 (Cq), 134.3 (Cq), 
132.9 (Cq), 130.5 (Cq), 128.1, 127.6, 127.4, 127.0, 126.7, 126.0, 84.3 (Cipso η
5
-C5H4), 69.5 
(η5-C5H5), 69.0 (Cortho η
5
-C5H4), 68.3 (Cmeta η
5
-C5H4), 60.5 (-OCH2-, -ve DEPT), 47.7 (α-
C), 41.8 (-NHCH2-, -ve DEPT), 17.1 (-CH3), 14.0 (-OCH2CH3). 
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N-(6-ferrocenyl-2-naphthoyl)-glycine-D-alanine ethyl ester 124 
The synthesis followed that of 115 
using the following reagents: 6-
ferrocenylnaphthalene-2-
carboxylic acid (0.32 g, 0.9 
mmol), 1-hydroxybenzotriazole 
(0.16 g, 1.2 mmol), triethylamine 
(5 ml), N-(3-
dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (0.23 g, 1.2 mmol) and glycine-D-alanine ethyl ester 
trifluoroacetate salt (0.26 g, 0.9 mmol). The product was purified by column 
chromatography (eluant 1:1 hexane: ethyl acetate) to give the title compound as an orange 
solid (0.19 g, 41%), mp 73-74 
o
C;  
E
0
´/mV 63 vs. Fc/Fc
+
;  
[α] 20
D
 +5 (c 0.05 in CH3CN);  
m/z (ESI) 512.2 [M]
+•
. C28H28N2O4Fe requires 512.4; 
m/z (ESI) 512.1397 [M]
+•
. C28H28N2O4Fe requires 512.1398; 
λmax(CH3CN)/nm 370 (ε/dm
3
 mol
-1
 cm
-1
 3048), 445 (1288);  
νmax(neat)/cm
-1
 3290, 3084, 1733, 1640, 1529, 1450, 1206; 
δH (400 MHz, DMSO-d6): 8.83 (1H, t, J 5.6, -CONH-), 8.44 (1H, s, ArH), 8.39 (1H, d, J 
7.2, -CONH-), 8.06 (1H, s, ArH), 7.94-7.97 (3H, m, ArH), 7.83 (1H, dd, J 1.6 and 8.4, 
ArH), 4.97 {2H, t, J 2.0, ortho on (η5-C5H4)}, 4.46 {2H, m, J 2.0, meta on (η
5
-C5H4)}, 4.31 
(1H, qt, J 7.2, -NHCH-), 3.91-4.14 (9H, m, -OCH2CH3, η
5
-C5H5, -NHCH2-), 1.31 (3H, d, J 
7.2, -CH3), 1.20 (3H, t, J 7.2, -OCH2CH3);  
δC (100 MHz, DMSO-d6): 172.5 (C=O), 168.9 (C=O), 166.4 (C=O), 138.8 (Cq), 134.5 (Cq), 
130.7 (Cq), 130.5 (Cq), 128.7, 127.5, 127.3, 125.9, 124.5, 122.7, 84.1 (Cipso η
5
-C5H4), 69.4 
(η5-C5H5, Cmeta η
5
-C5H4), 66.6 (Cortho η
5
-C5H4), 60.4 (-OCH2-, -ve DEPT), 47.7 (α-C), 42.2 
(-NHCH2-, -ve DEPT), 17.1 (-CH3), 14.0 (-OCH2CH3). 
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N-(3-ferrocenyl-2-naphthoyl)-glycine-β-alanine ethyl ester 125 
The synthesis followed that of 115 using 
the following reagents: 3-
ferrocenylnaphthalene-2-carboxylic acid 
(0.32 g, 0.9 mmol), 1-hydroxybenzotriazole 
(0.16 g, 1.2 mmol), triethylamine (5 ml), N-
(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (0.23 g, 
1.2 mmol) and glycine-β-alanine ethyl ester 
trifluoroacetate salt (0.26 g, 0.9 mmol). The 
product was purified by column 
chromatography (eluant 1:1 hexane: ethyl 
acetate) to give the title compound as an 
orange solid (0.14 g, 30%), mp 49-50 
o
C;  
E
0
´/mV 27 vs. Fc/Fc
+
; 
Anal. Calc. for C28H28N2O4Fe: C, 65.6; H, 5.5; N, 5.5%. Found: C, 65.6; H, 5.65; N, 5.25; 
λmax(CH3CN)/nm 450 (ε/dm
3
 mol
-1
 cm
-1
 533); 
νmax(neat)/cm
-1
 3285, 3085, 1728, 1644, 1519, 1183; 
δH (400 MHz, acetone-d6): 8.26 (1H, s, ArH), 7.85 (1H, d, J 8.0, ArH), 7.77-7.78 (2H, m, 
ArH), 7.36-7.44 (3H, m, -CONH-, ArH), 7.09 (1H, br. s, -CONH-), 4.66 {2H, t, J 2.0, 
ortho on (η5-C5H4)}, 4.20 {2H, t, J 2.0, meta on (η
5
-C5H4)}, 3.96-4.01 (7H, m, -OCH2CH3, 
η5-C5H5), 3.84 (2H, d, J 5.6, -NHCH2-), 3.34 (2H, q, J 5.6, -CH2CH2-), 2.40 (2H, t, J 6.8, -
CH2CH2-), 1.09 (3H, t, J 7.2, -OCH2CH3); 
δC (100 MHz, acetone-d6): 172.3 (C=O), 171.1 (C=O), 169.5 (C=O), 136.3 (Cq), 135.3 (Cq), 
134.5 (Cq), 132.1 (Cq), 129.6, 128.7, 128.4, 127.9, 127.8, 126.9, 86.1 (Cipso η
5
-C5H4), 70.5 
(η5-C5H5), 70.2 (Cortho η
5
-C5H4), 69.3 (Cmeta η
5
-C5H4), 60.9 (-OCH2-, -ve DEPT), 43.9 (-
NHCH2-, -ve DEPT), 35.8 (-CH2CH2-, -ve DEPT), 34.8 (-CH2CH2-, -ve DEPT), 14.5 (-
OCH2CH3). 
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N-(3-ferrocenyl-2-naphthoyl)-β-alanine-glycine ethyl ester 126 
The synthesis followed that of 115 using 
the following reagents: 3-
ferrocenylnaphthalene-2-carboxylic acid 
(0.32 g, 0.9 mmol), 1-hydroxybenzotriazole 
(0.18 g, 1.3 mmol), triethylamine (5 ml), N-
(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (0.25 g, 
1.3 mmol) and β-alanine-glycine ethyl ester 
trifluoroacetate salt (0.29 g, 1.0 mmol). The 
product was purified by column 
chromatography (eluant 1:1 hexane: ethyl 
acetate) to give the title compound as an 
orange solid (0.30 g, 59%), mp 56-57 
o
C;  
E
0
´/mV 34 vs. Fc/Fc
+
; 
λmax(CH3CN)/nm 450 (ε/dm
3
 mol
-1
 cm
-1
 521); 
νmax(neat)/cm
-1
 3286, 3082, 1745, 1698, 1644, 1521, 1192; 
δH (400 MHz, acetone-d6): 8.23 (1H, s, ArH), 7.82 (1H, d, J 8.0, ArH), 7.76 (1H, d, J 8.0, 
ArH), 7.71 (1H, s, ArH), 7.33-7.45 (3H, m, -CONH-, ArH), 7.17 (1H, br. s, -CONH-), 4.64 
(2H, t, J 2.0, ortho on (η5-C5H4)}, 4.18 {2H, t, J 2.0, meta on (η
5
-C5H4)}, 3.96-4.02 (7H, m, 
-OCH2CH3, η
5
-C5H5), 3.80 (2H, d, J 5.6, -NHCH2-), 3.48 (2H, q, J 5.6, -CH2CH2-), 2.42 
(2H, t, J 6.8, -CH2CH2-), 1.07 (3H, t, J 7.2, -OCH2CH3); 
δC (100 MHz, acetone-d6): 172.0 (C=O), 170.7 (C=O), 169.5 (C=O), 136.9 (Cq), 135.3 (Cq), 
134.4 (Cq), 132.2 (Cq), 129.5, 128.7, 128.4, 127.8, 127.6, 126.8, 86.1 (Cipso η
5
-C5H4), 70.5 
(η5-C5H5), 70.2 (Cortho η
5
-C5H4), 69.2 (Cmeta η
5
-C5H4), 61.4 (-OCH2-, -ve DEPT), 41.7 (-
NHCH2-, -ve DEPT), 36.9 (-CH2CH2-, -ve DEPT), 35.9 (-CH2CH2-, -ve DEPT), 14.5 (-
OCH2CH3). 
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N-(3-ferrocenyl-2-naphthoyl)-glycine-γ-aminobutyric acid ethyl ester 127 
The synthesis followed that of 115 using 
the following reagents: 3-
ferrocenylnaphthalene-2-carboxylic acid 
(0.32 g, 0.9 mmol), 1-
hydroxybenzotriazole (0.16 g, 1.2 
mmol), triethylamine (5 ml), N-(3-
dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (0.23 g, 
1.2 mmol) and glycine-γ-aminobutyric 
acid ethyl ester trifluoroacetate salt (0.27 
g, 0.9 mmol). The product was purified 
by column chromatography (eluant 1:1 
hexane: ethyl acetate) to give the title compound as an orange solid (0.19 g, 40%), mp 47-
48 
o
C;  
E
0
´/mV 28 vs. Fc/Fc
+
; 
Anal. Calc. for C29H30N2O4Fe: C, 66.2; H, 5.7; N, 5.3%. Found: C, 65.9; H, 5.8; N, 5.1; 
λmax(CH3CN)/nm 450 (ε/dm
3
 mol
-1
 cm
-1
 451); 
νmax(neat)/cm
-1
 3281, 3086, 1727, 1640, 1521, 1176; 
δH (400 MHz, acetone-d6): 8.27 (1H, s, ArH), 7.85 (1H, d, J 8.0, ArH), 7.76-7.78 (2H, m, 
ArH), 7.36-7.44 (3H, m, -CONH-, ArH), 6.95 (1H, br. s, -CONH-), 4.66 {2H, t, J 2.0, 
ortho on (η5-C5H4)}, 4.20 {2H, t, J 2.0, meta on (η
5
-C5H4)}, 3.93-4.00 (7H, m, η
5
-C5H5, -
OCH2CH3), 3.85 (2H, d, J 5.6, -NHCH2-), 3.13 (2H, q, J 6.8, -CH2CH2CH2-), 2.21 (2H, t, J 
7.2, -CH2CH2CH2-), 1.65 (2H, qt, J 7.2, -CH2CH2CH2-), 1.08 (3H, t, J 7.2, -OCH2CH3); 
δC (100 MHz, acetone-d6): 173.4 (C=O), 171.0 (C=O), 169.5 (C=O), 136.4 (Cq), 135.3 (Cq), 
134.5 (Cq), 132.1 (Cq), 129.7, 128.7, 128.4, 127.9, 127.7, 126.9, 86.2 (Cipso η
5
-C5H4), 70.6 
(η5-C5H5), 70.3 (Cortho η
5
-C5H4), 69.3 (Cmeta η
5
-C5H4), 60.6 (-OCH2-, -ve DEPT), 43.9 (-
NHCH2-, -ve DEPT), 39.1 (-CH2CH2CH2-, -ve DEPT), 31.9 (-CH2CH2CH2-, -ve DEPT), 
25.8 (-CH2CH2CH2-, -ve DEPT), 14.6 (-OCH2CH3). 
 
198 
 
N-(3-ferrocenyl-2-naphthoyl)-γ-aminobutyric acid-glycine ethyl ester 128 
The synthesis followed that of 115 using 
the following reagents: 3-
ferrocenylnaphthalene-2-carboxylic acid 
(0.36 g, 1.0 mmol), 1-
hydroxybenzotriazole (0.18 g, 1.3 
mmol), triethylamine (5 ml), N-(3-
dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (0.25 g, 
1.3 mmol) and γ-aminobutyric acid-
glycine ethyl ester trifluoroacetate salt 
(0.39 g, 1.3 mmol). The product was 
purified by column chromatography 
(eluant 1:1 hexane: ethyl acetate) to give the title compound as an orange solid (0.28 g, 
53%), mp 64 
o
C;  
E
0
´/mV 38 vs. Fc/Fc
+
; 
λmax(CH3CN)/nm 450 (ε/dm
3
 mol
-1
 cm
-1
 509); 
νmax(neat)/cm
-1
 3280, 3083, 1746, 1698, 1641, 1522, 1194; 
δH (400 MHz, acetone-d6): 8.24 (1H, s ArH), 7.83 (1H, d, J 8.0, ArH), 7.75 (1H, d, J 7.6, 
ArH), 7.66 (1H, s, ArH), 7.34-7.46 (3H, m, -CONH-, ArH), 7.25 (1H, br. s, -CONH-), 4.64 
{2H, t, J 2.0, ortho on (η5-C5H4)}, 4.19 {2H, t, J 2.0, meta on (η
5
-C5H4)},  3.93-4.00 (7H, 
m, -OCH2CH3, η
5
-C5H5), 3.79 (2H, d, J 6.0, -NHCH2-), 3.28 (2H, q, J 5.6, -CH2CH2CH2-), 
2.17 (2H, t, J 7.2, -CH2CH2CH2-), 1.74 (2H, qt, J 7.2, -CH2CH2CH2-), 1.07 (3H, t, J 7.2, -
OCH2CH3); 
δC (100 MHz, acetone-d6): 173.3 (C=O), 170.9 (C=O), 170.8 (C=O), 137.2 (Cq), 135.3 (Cq), 
134.4 (Cq), 132.2 (Cq), 129.4, 128.7, 128.3, 127.7, 127.5, 126.8, 86.1 (Cipso η
5
-C5H4), 70.5 
(η5-C5H5), 70.2 (Cortho η
5
-C5H4), 69.3 (Cmeta η
5
-C5H4), 61.3 (-OCH2-, -ve DEPT), 41.7 (-
NHCH2-, -ve DEPT), 39.9 (-CH2CH2CH2-, -ve DEPT), 34.0 (-CH2CH2CH2-, -ve DEPT), 
26.3 (-CH2CH2CH2-, -ve DEPT), 14.5 (-OCH2CH3). 
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N-(6-ferrocenyl-2-naphthoyl)-glycine-β-alanine ethyl ester 129 
The synthesis followed that of 115 
using the following reagents: 6-
ferrocenylnaphthalene-2-
carboxylic acid (0.32 g, 0.9 
mmol), 1-hydroxybenzotriazole 
(0.16 g, 1.2 mmol), triethylamine 
(5 ml), N-(3-
dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride 
(0.23 g, 1.2 mmol) and glycine-β-alanine ethyl ester trifluoroacetate salt (0.26 g, 0.9 
mmol). The product was purified by column chromatography (eluant 1:1 hexane: ethyl 
acetate) to give the title compound as an orange solid (0.20 g, 43%), mp 148-149 
o
C; 
E
0
´/mV 61 vs. Fc/Fc
+
; 
m/z (ESI) 512.2 [M]
+•
. C28H28N2O4Fe requires 512.4; 
m/z (ESI) 512.1410 [M]
+•
. C28H28N2O4Fe requires 512.1398; 
λmax(CH3CN)/nm 370 (ε/dm
3
 mol
-1
 cm
-1
 3006), 450 (1288); 
νmax(neat)/cm
-1
 3312, 3084, 1728, 1677, 1639, 1625, 1538, 1185; 
δH (400 MHz, acetone-d6): 8.32 (1H, s, ArH), 8.01 (1H, t, J 5.6, -CONH-), 7.93 (1H, s, 
ArH), 7.78-7.86 (3H, m, ArH), 7.71 (1H, dd, J 1.6 and 8.4, ArH), 7.34 (1H, br. s, -CONH-), 
4.79 {2H, t, J 2.0, ortho on (η5-C5H4)}, 4.30 {2H, t, J 2.0, meta on (η
5
-C5H4)}, 3.91-3.97 
(9H, m, -OCH2CH3, η
5
-C5H5, -NHCH2-), 3.35 (2H, q, J 6.8, -CH2CH2-), 2.40 (2H, t, J 6.8, -
CH2CH2-), 1.06 (3H, t, J 7.2, -OCH2CH3); 
δC (100 MHz, acetone-d6): 172.2 (C=O), 169.9 (C=O), 167.7 (C=O), 140.3 (Cq), 136.1 (Cq), 
132.2 (Cq), 131.7 (Cq), 129.7, 128.5, 128.4, 126.9, 125.3, 123.9, 85.4 (Cipso η
5
-C5H4), 70.4 
(η5-C5H5), 70.3 (Cmeta η
5
-C5H4), 67.6 (Cortho η
5
-C5H4), 60.8 (-OCH2-, -ve DEPT), 44.1 (-
NHCH2-, -ve DEPT), 35.9 (-CH2CH2-, -ve DEPT), 34.9 (-CH2CH2-, -ve DEPT), 14.5 (-
OCH2CH3). 
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N-(6-ferrocenyl-2-naphthoyl)-β-alanine-glycine ethyl ester 130 
The synthesis followed that of 115 
using the following reagents: 6-
ferrocenylnaphthalene-2-carboxylic 
acid (0.32 g, 0.9 mmol), 1-
hydroxybenzotriazole (0.18 g, 1.3 
mmol), triethylamine (5 ml), N-(3-
dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (0.25 
g, 1.3 mmol) and β-alanine-glycine ethyl ester trifluoroacetate salt (0.29 g, 1.0 mmol). The 
product was purified by column chromatography (eluant 1:1 hexane: ethyl acetate) to give 
the title compound as an orange solid (0.16 g, 34%), mp 171-172 
o
C; E
0
´/mV 60 vs. Fc/Fc
+
; 
λmax(CH3CN)/nm 370 (ε/dm
3
 mol
-1
 cm
-1
 2758), 450 (1154); 
νmax(neat)/cm
-1
 3357, 3282, 3073, 1735, 1678, 1633, 1600, 1540, 1214; 
δH (400 MHz, acetone-d6): 8.28 (1H, s, ArH), 7.92 (1H, s, ArH), 7.76-7.84 (4H, m, -
CONH-, ArH), 7.69 (1H, dd, J 1.6 and 8.8, ArH), 7.51 (1H, br. s, -CONH-), 4.78 {2H, t, J 
1.6, ortho on (η5-C5H4)}, 4.29 {2H, t, J 1.6, meta on (η
5
-C5H4)}, 4.02 (2H, q, J 7.2, -
OCH2CH3), 3.92 (5H, s, η
5
-C5H5), 3.84 (2H, d, J 5.6, -NHCH2-), 3.59 (2H, q, J 6.4, -
CH2CH2-), 2.47 (2H, t, J 6.4, -CH2CH2-),  1.09 (3H, t, J 7.2, -OCH2CH3); 
δC (100 MHz, acetone-d6): 172.4 (C=O), 170.8 (C=O), 167.3 (C=O), 140.0 (Cq), 135.9 (Cq), 
132.4 (Cq), 132.2 (Cq), 129.6, 128.4, 128.1, 126.9, 125.4, 123.9, 85.5 (Cipso η
5
-C5H4), 70.4 
(η5-C5H5), 70.3 (Cmeta η
5
-C5H4), 67.6 (Cortho η
5
-C5H4), 61.4 (-OCH2-, -ve DEPT), 41.7 (-
NHCH2-, -ve DEPT), 37.2 (-CH2CH2-, -ve DEPT), 36.3 (-CH2CH2-,-ve DEPT), 14.5 (-
OCH2CH3). 
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N-(6-ferrocenyl-2-naphthoyl)-glycine-γ-aminobutyric acid ethyl ester 131 
The synthesis followed that of 115 
using the following reagents: 6-
ferrocenylnaphthalene-2-
carboxylic acid (0.32 g, 0.9 
mmol), 1-hydroxybenzotriazole 
(0.16 g, 1.2 mmol), triethylamine 
(5 ml), N-(3-
dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride 
(0.23 g, 1.2 mmol) and glycine-γ-aminobutyric acid ethyl ester trifluoroacetate salt (0.27 g, 
0.9 mmol). The product was purified by column chromatography (eluant 1:1 hexane: ethyl 
acetate) to give the title compound as an orange solid (0.18 g, 38%), mp 140-142 
o
C;  
E
0
´/mV 65 vs. Fc/Fc
+
; 
Anal. Calc. for C29H30N2O4Fe: C, 66.2; H, 5.7; N, 5.3%. Found: C, 65.9; H, 5.9; N, 5.1; 
λmax(CH3CN)/nm 375 (ε/dm
3
 mol
-1
 cm
-1
 3070), 450 (1312); 
νmax(neat)/cm
-1
 3374, 3246, 3082, 1704, 1672, 1638, 1566, 1538; 
δH (400 MHz, acetone-d6): 8.32 (1H, s, ArH), 8.01 (1H, t, J 5.6, -CONH-), 7.94 (1H, s, 
ArH), 7.78-7.86 (3H, m, ArH), 7.71 (1H, dd, J 1.6 and 8.4, ArH), 7.33 (1H, br. s, -CONH-), 
4.78 {2H, t, J 2.0, ortho on (η5-C5H4)}, 4.30 {2H, t, J 2.0, meta on (η
5
-C5H4)}, 3.90-3.96 
(9H, m, -OCH2CH3, η
5
-C5H5, -NHCH2-), 3.15 (2H, q, J 6.8, -CH2CH2CH2-), 2.22 (2H, t, J 
7.2, -CH2CH2CH2-), 1.66 (2H, qt, J 7.2, -CH2CH2CH2-), 1.06 (3H, t, J 7.2, -OCH2CH3); 
δC (100 MHz, acetone-d6): 173.5 (C=O), 169.8 (C=O), 167.7 (C=O), 140.3 (Cq), 136.1 (Cq), 
132.2 (Cq), 131.8 (Cq), 129.7, 128.5, 128.4, 126.9, 125.4, 123.9, 85.4 (Cipso η
5
-C5H4), 70.4 
(η5-C5H5), 70.3 (Cmeta η
5
-C5H4), 67.6 (Cortho η
5
-C5H4), 60.6 (-OCH2-, -ve DEPT), 44.1 (-
NHCH2-, -ve DEPT), 39.1 (-CH2CH2CH2-, -ve DEPT), 32.0 (-CH2CH2CH2-, -ve DEPT), 
25.8 (-CH2CH2CH2-, -ve DEPT), 14.5 (-OCH2CH3). 
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N-(6-ferrocenyl-2-naphthoyl)-γ-aminobutyric acid-glycine ethyl ester 132 
The synthesis followed that of 115 
using the following reagents: 6-
ferrocenylnaphthalene-2-
carboxylic acid (0.36 g, 1.0 
mmol), 1-hydroxybenzotriazole 
(0.18 g, 1.3 mmol), triethylamine 
(5 ml), N-(3-
dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride 
(0.25 g, 1.3 mmol) and γ-aminobutyric acid-glycine ethyl ester trifluoroacetate salt (0.39 g, 
1.3 mmol). The product was purified by column chromatography (eluant 1:1 hexane: ethyl 
acetate) to give the title compound as an orange solid (0.14 g, 27%), mp 150-151 
o
C; 
E
0
´/mV 60 vs. Fc/Fc
+
; 
Anal. Calc. for C29H30N2O4Fe: C, 66.2; H, 5.7; N, 5.3%. Found: C, 65.9; H, 5.8; N, 5.3; 
λmax(CH3CN)/nm 370 (ε/dm
3
 mol
-1
 cm
-1
 2700), 450 (1112); 
νmax(neat)/cm
-1
 3256, 3081, 1750, 1656, 1634, 1622, 1575, 1551, 1201; 
δH (400 MHz, DMSO-d6): 8.67 (1H, t, J 5.6, -CONH-), 8.45 (1H, s, ArH), 8.38 (1H, t, J 
6.0, -CONH-), 8.11 (1H, s, ArH), 7.94-8.01 (3H, m, ArH), 7.87 (1H, dd, J 1.6 and 8.4, 
ArH), 5.02 {2H, t, J 2.0, ortho on (η5-C5H4)}, 4.50 {2H, t, J 2.0, meta on (η
5
-C5H4)}, 4.08-
4.17 (7H, m, -OCH2CH3, η
5
-C5H5), 3.88 (2H, d, J 5.6, -NHCH2-), 3.37-3.42 (2H, m, -
CH2CH2CH2-), 2.30 (2H, t, J 7.2, -CH2CH2CH2-), 1.87 (2H, qt, J 7.2, -CH2CH2CH2-), 1.25 
(3H, t, J 7.2, -OCH2CH3); 
δC (100 MHz, DMSO-d6): 172.5 (C=O), 170.0 (C=O), 166.2 (C=O), 138.6 (Cq), 134.4 (Cq), 
131.1 (Cq), 130.7 (Cq), 128.7, 127.3, 127.2, 125.9, 124.5, 122.7, 84.1 (Cipso η
5
-C5H4), 69.4 
(η5-C5H5, Cmeta η
5
-C5H4), 66.6 (Cortho η
5
-C5H4), 60.3 (-OCH2-, -ve DEPT), 40.6 (-NHCH2-, 
-ve DEPT), 39.0 (-CH2CH2CH2-, -ve DEPT), 32.7 (-CH2CH2CH2-, -ve DEPT), 25.3 (-
CH2CH2CH2-, -ve DEPT), 14.0 (-OCH2CH3). 
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General procedure for the preparation of N-naphthoyl dipeptide derivatives. 
N-(2-naphthoyl)-glycine-glycine ethyl ester 133 
Glycine-glycine ethyl ester hydrochloride (0.20 g, 
1.0 mmol) was added to a solution of 2-naphthoic 
acid (0.18 g, 1.0 mmol), 1-hydroxybenzotriazole 
(0.18 g, 1.3 mmol), triethylamine (0.5 ml) and N-
(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.25 g, 1.3 mmol) in 50 ml of 
dichloromethane at 0 
o
C. After 30 minutes the 
solution was raised to room temperature and the 
reaction was allowed to proceed for 48 h. The reaction mixture was then washed with 
water. The dichloromethane layer was dried over MgSO4 and the solvent was removed in 
vacuo. The product was purified by column chromatography (eluant 1:1 hexane: ethyl 
acetate) to give the title compound as a white solid (0.28 g, 89%), mp 128-129 
o
C; 
Anal. cald. for C17H18N2O4: C, 65.0; H, 5.8; N, 8.9%. Found: C, 65.2; H, 5.9; N, 8.6; 
νmax(neat)/cm
-1
 3264, 3056, 1738, 1646, 1633, 1619, 1546, 1203; 
δH (400 MHz, DMSO-d6): 9.05 (1H, t, J 5.6, -CONH-), 8.58 (1H, s, -ArH), 8.46 (1H, t, J 
5.6, -CONH-), 8.10-8.02 (4H, m, -ArH), 7.71-7.64 (2H, m, -ArH), 4.15 (2H, q, J 7.2, -
OCH2CH3), 4.04 (2H, d, J 5.6, -NHCH2-), 3.92 (2H, d, J 5.6, -NHCH2-), 1.25 (3H, t, J 7.2, 
-OCH2CH3); 
δC (100 MHz, DMSO-d6): 169.8 (C=O), 169.6 (C=O), 166.5 (C=O), 134.2 (Cq), 132.1 (Cq), 
131.3 (Cq), 128.8, 127.8, 127.7, 127.62, 127.59, 126.7, 124.2, 60.4 (-OCH2-, -ve DEPT), 
42.5 (-NHCH2-, -ve DEPT), 40.7 (-NHCH2-, -ve DEPT), 14.0 (-OCH2CH3). 
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N-(2-naphthoyl)-glycine-L-alanine ethyl ester 134 
The synthesis followed that of 133 using the 
following reagents: 2-naphthoic acid (0.17 g, 1.0 
mmol), 1-hydroxybenzotriazole (0.18 g, 1.3 
mmol), triethylamine (0.5 ml), N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.25 g, 1.3 mmol) and glycine-L-
alanine ethyl ester hydrochloride (0.21 g, 1.0 
mmol). The product was purified by column 
chromatography (eluant 1:1 hexane: ethyl acetate) to give the title compound as a white 
solid (0.17 g, 52%), mp 115-116 
o
C;  
[α] 20
D
 -12 (c 0.03 in CH3CN); 
Anal. cald. for C18H20N2O4: C, 65.8; H, 6.1; N, 8.5%. Found: C, 65.8; H, 6.2; N, 8.4; 
νmax(neat)/cm
-1
 3364, 3319, 3063, 1750, 1672, 1644, 1629, 1602, 1532, 1199; 
δH (400 MHz, DMSO-d6): 8.88 (1H, t, J 6.0, -CONH-), 8.50 (1H, s, ArH), 8.40 (1H, d, J 
7.2, -CONH-), 7.95-8.04 (4H, m, ArH), 7.58-7.65 (2H, m, ArH), 4.30 (1H, qt, J 7.2, -
NHCH-), 4.00-4.12 (3H, m, -OCH2CH3, -NHCH2-), 3.93 (1H, dd, J 6.0 and 16.4, -NHCH2-
), 1.31 (3H, d, J 7.2, -CH3), 1.17 (3H, t, J 7.2, -OCH2CH3);  
δC (100 MHz, DMSO-d6): 172.5 (C=O), 168.9 (C=O), 166.4 (C=O), 134.1 (Cq), 132.1 (Cq), 
131.3 (Cq), 128.8, 127.8, 127.7, 127.62, 127.59, 126.7, 124.2, 60.4 (-OCH2-, -ve DEPT), 
47.7 (α-C), 42.2 (-NHCH2-, -ve DEPT), 17.0 (-CH3), 14.0 (-OCH2CH3).  
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General procedure for the preparation of N-(ferrocenyl)naphthoyl amino acid  derivatives. 
N-(3-ferrocenyl-2-naphthoyl)-β-alanine ethyl ester 135 
β-alanine ethyl ester hydrochloride (0.15 g, 1 mmol) 
was added to a solution of 3-ferrocenylnaphthalene-2-
carboxylic acid (0.37 g, 1 mmol), 1-
hydroxybenzotriazole (0.16 g, 1.2 mmol), triethylamine 
(0.5 ml) and N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (0.23 g, 1.2 mmol) in 
50 ml of dichloromethane at 0 
o
C. After 30 min the 
solution was raised to room temperature and the 
reaction was allowed to proceed for 48 h. The reaction 
mixture was then washed with water. The 
dichloromethane layer was dried over MgSO4 and the 
solvent was removed in vacuo. The product was purified by column chromatography 
(eluant 1:1 hexane: ethyl acetate) to give the title compound as an orange solid (0.18 g, 
40%), mp 117 
o
C; E
0
´/mV 24 vs. Fc/Fc
+
; 
Anal. cald. for C26H25NO3Fe: C, 68.6; H, 5.5; N, 3.1%. Found: C, 68.1; H, 5.7; N, 3.05; 
m/z (ESI) 456.1268 [M+H]
+
. C26H26NO3Fe requires 456.1262; 
λmax(CH3CN)/nm 435 (ε/dm
3
 mol
-1
 cm
-1
 493); 
νmax(neat)/cm
-1
 3234, 3064, 1721, 1629, 1557, 1192; 
δH (400 MHz, DMSO-d6): 8.50 (1H, t, J 5.6, -CONH-), 8.32 (1H, s, ArH), 8.00 (1H, d, J 
8.0, ArH), 7.89 (1H, d, J 8.0, ArH), 7.73 (1H, s, ArH), 7.49-7.56 (2H, m, ArH), 4.72 {2H, 
s, ortho on (η5-C5H4)}, 4.33 {2H, s, meta on (η
5
-C5H4)}, 4.09-4.13 (7H, m, -OCH2CH3, η
5
-
C5H5), 3.44-3.51 (2H, m, -CH2CH2-), 2.57 (2H, t, J 6.8, -CH2CH2-),  1.23 (3H, t, J 7.2, -
OCH2CH3); 
δC (100 MHz, DMSO-d6): 171.2 (C=O), 169.7 (C=O), 135.5 (Cq), 134.0 (Cq), 132.8 (Cq), 
130.5 (Cq), 128.1, 127.6, 127.4, 126.9, 126.3, 126.0, 84.5 (Cipso η
5
-C5H4), 69.5 (η
5
-C5H5), 
68.8 (Cortho η
5
-C5H4), 68.3 (Cmeta η
5
-C5H4), 60.0 (-OCH2-, -ve DEPT), 35.3 (-CH2CH2-, -ve 
DEPT), 33.5 (-CH2CH2-, -ve DEPT), 14.1 (-OCH2CH3). 
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N-(3-ferrocenyl-2-naphthoyl)-γ-aminobutyric acid ethyl ester 136 
The synthesis followed that of 135 using the 
following reagents: 3-ferrocenylnaphthalene-2-
carboxylic acid (0.36 g, 1.0 mmol), 1-
hydroxybenzotriazole (0.18 g, 1.3 mmol), 
triethylamine (0.5 ml), N-(3-dimethylaminopropyl)-
N’-ethylcarbodiimide hydrochloride (0.25 g, 1.3 
mmol) and γ-aminobutyric acid ethyl ester 
hydrochloride (0.17 g, 1 mmol). The product was 
purified by column chromatography (eluant 1:1 
hexane: ethyl acetate) to give the title compound as 
an orange solid (0.17 g, 36%), mp 104-105 
o
C;  
E
0
´/mV 29 vs. Fc/Fc
+
;  
Anal. cald. for C27H27NO3Fe: C, 69.1; H, 5.8; N, 3.0%. Found: C, 68.8; H, 5.8; N, 2.9; 
m/z (ESI) 470.1411 [M+H]
+
. C27H28NO3Fe requires 470.1419; 
λmax(CH3CN)/nm 435 (ε/dm
3
 mol
-1
 cm
-1
 294); 
νmax(neat)/cm
-1
 3307, 3086, 1730, 1628, 1535, 1166; 
δH (400 MHz, DMSO-d6): 8.40 (1H, t, J 5.6, -CONH-), 8.33 (1H, s, ArH), 7.99 (1H, d, J 
8.0, ArH), 7.92 (1H, d, J 8.0, ArH), 7.76 (1H, s, ArH), 7.48-7.56 (2H, m, ArH), 4.73 {2H, t, 
J 2.0, ortho on (η5-C5H4)}, 4.32 {2H, t, J 2.0, meta on (η
5
-C5H4)}, 4.06-4.11 (7H, m, -
OCH2CH3, η
5
-C5H5), 3.23 (2H, q, J 5.6, -CH2CH2CH2-), 2.35 (2H, t, J 7.2, -CH2CH2CH2-), 
1.76 (2H, qt, J 7.2, -CH2CH2CH2-), 1.20 (3H, t, J 7.2, -OCH2CH3); 
δC (100 MHz, DMSO-d6): 172.6 (C=O), 169.7 (C=O), 135.8 (Cq), 133.9 (Cq), 132.8 (Cq), 
130.6 (Cq), 128.0, 127.6, 127.3, 126.9, 126.1, 126.0, 84.5 (Cipso η
5
-C5H4), 69.5 (η
5
-C5H5), 
68.8 (Cortho η
5
-C5H4), 68.2 (Cmeta η
5
-C5H4), 59.7 (-OCH2-, -ve DEPT), 38.3 (-CH2CH2CH2-, 
-ve DEPT), 31.0 (-CH2CH2CH2-, -ve DEPT), 24.2 (-CH2CH2CH2-, -ve DEPT), 14.1 (-
OCH2CH3).    
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N-(3-ferrocenyl-2-naphthoyl)-δ-amino-n-valeric acid ethyl ester 137 
The synthesis followed that of 135 using the 
following reagents: 3-ferrocenylnaphthalene-2-
carboxylic acid (0.36 g, 1.0 mmol), 1-
hydroxybenzotriazole (0.16 g, 1.2 mmol), 
triethylamine (0.5 ml), N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.23 g, 1.2 mmol) and δ-amino-
n-valeric acid ethyl ester hydrochloride (0.18 g, 
1.0 mmol). The product was purified by column 
chromatography (eluant 1:1 hexane: ethyl 
acetate) to give the title compound as an orange 
oil (0.17 g, 35%), mp 79 
o
C;  
E
0
´/mV 27 vs. Fc/Fc
+
;  
Anal. cald. for C28H29NO3Fe: C, 69.6; H, 6.05; N, 2.9%. Found: C, 69.3; H, 6.0; N, 2.9; 
m/z (ESI) 484.1566 [M+H]
+
. C28H30NO3Fe requires 484.1575; 
λmax(CH3CN)/nm 450 (ε/dm
3
 mol
-1
 cm
-1
 508); 
νmax(neat)/cm
-1
 3282, 3093, 1726, 1628, 1638, 1538; 
δH (400 MHz, DMSO-d6): 8.38 (1H, t, J 5.6, -CONH-), 8.32 (1H, s, ArH), 7.99 (1H, d, J 
8.0, ArH), 7.91 (1H, d, J 8.0, ArH), 7.74 (1H, s, ArH), 7.48-7.56 (2H, m, ArH), 4.74 {2H, t, 
J 1.6, ortho on (η5-C5H4)}, 4.33 {2H, t, J 1.6, meta on (η
5
-C5H4)}, 4.05-4.12 (7H, m, η
5
-
C5H5, -OCH2CH3), 3.22 (2H, q, J 5.6, -CH2CH2CH2CH2 -), 2.33 (2H, t, J 7.2, -
CH2CH2CH2CH2-), 1.48-1.62 (4H, m, -CH2CH2CH2CH2-), 1.20 (3H, t, J 7.2, -OCH2CH3); 
δC (100 MHz, DMSO-d6): 172.8 (C=O), 169.6 (C=O), 135.9 (Cq), 133.9 (Cq), 132.8 (Cq), 
130.6 (Cq), 127.9, 127.6, 127.3, 126.8, 126.1, 125.9, 84.5 (Cipso η
5
-C5H4), 69.5 (η
5
-C5H5), 
68.8 (Cortho η
5
-C5H4), 68.2 (Cmeta η
5
-C5H4), 59.7 (-OCH2-, -ve DEPT), 38.6 (-
CH2CH2CH2CH2-, -ve DEPT), 33.2 (-CH2CH2CH2CH2-, -ve DEPT), 28.2 (-
CH2CH2CH2CH2-, -ve DEPT), 22.0 (-CH2CH2CH2CH2-, -ve DEPT), 14.1 (-OCH2CH3). 
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N-(6-ferrocenyl-2-naphthoyl)-β-alanine ethyl ester 138 
The synthesis followed that of 135 using 
the following reagents: 6-
ferrocenylnaphthalene-2-carboxylic acid 
(0.36 g, 1.0 mmol), 1-
hydroxybenzotriazole (0.16 g, 1.2 
mmol), triethylamine (0.5 ml), N-(3-
dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (0.23 
g, 1.2 mmol) and β-alanine ethyl ester hydrochloride (0.15 g, 1.0 mmol). The product was 
purified by column chromatography (eluant 1:1 hexane: ethyl acetate) to give the title 
compound as an orange solid (0.29 g, 64%), mp 123-124 
o
C;  
E
0
´/mV 63 vs. Fc/Fc
+
; 
Anal. cald. for C26H25NO3Fe: C, 68.6; H, 5.5; N, 3.1%. Found: C, 67.8; H, 5.6; N, 3.0; 
m/z (ESI) 456.1240 [M+H]
+
. C26H26NO3Fe requires 456.1262; 
λmax(CH3CN)/nm 360 (ε/dm
3
 mol
-1
 cm
-1
 2818), 435 (1168); 
νmax(neat)/cm
-1
 3301, 3095, 1733, 1637, 1625, 1538; 
δH (400 MHz, DMSO-d6): 8.70 (1H, t, J 5.6, -CONH-), 8.38 (1H, s, ArH), 8.05 (1H, s, 
ArH), 7.88-7.96 (3H, m, ArH), 7.81 (1H, dd, J 1.6 and 8.4, ArH), 4.95 {2H, t, J 2.0, ortho 
on (η5-C5H4)}, 4.44 {2H, t, J 2.0, meta on (η
5
-C5H4)}, 4.08 (2H, q, J 7.2, -OCH2CH3), 4.04 
(5H, s, η5-C5H5), 3.56 (2H, q, J 6.8, -CH2CH2-), 2.63 (2H, t, J 6.8, -CH2CH2-),  1.19 (3H, t, 
J 7.2, -OCH2CH3);  
δC (100 MHz, DMSO-d6): 171.3 (C=O), 166.4 (C=O), 138.7 (Cq), 134.5 (Cq), 130.8 (Cq), 
130.7 (Cq), 128.7, 127.3, 127.2, 125.9, 124.4, 122.7, 84.0 (Cipso η
5
-C5H4), 69.4 (η
5
-C5H5, 
Cmeta η
5
-C5H4) 66.6 (Cortho η
5
-C5H4), 59.9 (-OCH2-, -ve DEPT), 35.6 (-CH2CH2-, -ve 
DEPT), 33.8 (-CH2CH2-, -ve DEPT), 14.1 (-OCH2CH3). 
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N-(6-ferrocenyl-2-naphthoyl)-γ-aminobutyric acid ethyl ester 139 
The synthesis followed that of 135 
using the following reagents: 6-
ferrocenylnaphthalene-2-
carboxylic acid (0.36 g, 1.0 
mmol), 1-hydroxybenzotriazole 
(0.18 g, 1.3 mmol), triethylamine 
(0.5 ml), N-(3-
dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (0.25 g, 1.3 mmol) and γ-aminobutyric acid ethyl ester 
hydrochloride (0.17 g, 1.0 mmol). The product was purified by column chromatography 
(eluant 1:1 hexane: ethyl acetate) to give the title compound as an orange solid (0.38 g, 
81%), mp 117 
o
C;  
E
0
´/mV 58 vs. Fc/Fc
+
; 
Anal. cald. for C27H27NO3Fe: C, 69.1; H, 5.8; N, 3.0%. Found: C, 68.9; H, 5.8; N, 3.0; 
m/z (ESI) 470.1417 [M+H]
+
. C27H28NO3Fe requires 470.1419; 
UV-Vis λmax(CH3CN)/nm 335 (ε/dm
3
 mol
-1
 cm
-1
 2532), 435 (1038); 
IR νmax(neat)/cm
-1
 3397, 3101, 1729, 1706, 1654, 1626, 1527, 1179; 
δH (400 MHz, DMSO-d6): 8.63 (1H, t, J 5.6, -CONH-), 8.39 (1H, s, ArH), 8.04 (1H, s, 
ArH), 7.89-7.96 (3H, m, ArH), 7.81 (1H, dd, J 1.6 and 8.4, ArH), 4.94 {2H, t, J 2.0, ortho 
on (η5-C5H4)}, 4.43 {2H, t, J 2.0, meta on (η
5
-C5H4)}, 4.03-4.08 (7H, m, -OCH2CH3, η
5
-
C5H5), 3.34 (2H, q, J 5.6, -CH2CH2CH2-), 2.39 (2H, t, J 7.2, -CH2CH2CH2-), 1.83 (2H, qt, J 
7.2, -CH2CH2CH2-), 1.18 (3H, t, J 7.2, -OCH2CH3); 
δC (100 MHz, DMSO-d6): 172.7 (C=O), 166.3 (C=O), 138.7 (Cq), 134.4 (Cq), 131.0 (Cq), 
130.7 (Cq), 128.7, 127.3, 127.2, 125.9, 124.5, 122.7, 84.1 (Cipso η
5
-C5H4), 69.4 (η
5
-C5H5, 
Cmeta η
5
-C5H4), 66.6 (Cortho η
5
-C5H4), 59.8 (-OCH2-, -ve DEPT), 38.6 (-CH2CH2CH2-, -ve 
DEPT), 31.1 (-CH2CH2CH2-, -ve DEPT), 24.5 (-CH2CH2CH2-, -ve DEPT), 14.1 (-
OCH2CH3). 
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N-(6-ferrocenyl-2-naphthoyl)-δ-amino-n-valeric acid ethyl ester 140 
The synthesis followed that of 135 using 
the following reagents: 6-
ferrocenylnaphthalene-2-carboxylic acid 
(0.36 g, 1.0 mmol), 1-
hydroxybenzotriazole (0.18 g, 1.3 
mmol), triethylamine (0.5 ml), N-(3-
dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (0.25 
g, 1.3 mmol) and γ-aminobutyric acid ethyl ester hydrochloride (0.17 g, 1.0 mmol). The 
product was purified by column chromatography (eluant 1:1 hexane: ethyl acetate) to give 
the title compound as an orange solid (0.22 g, 46%), mp 65-66 
o
C;  
E
0
´/mV 58 vs. Fc/Fc
+
;  
Anal. cald. for C28H29NO3Fe: C, 69.6; H, 6.05; N, 2.9%. Found: C, 69.7; H, 6.1; N, 2.9; 
m/z (ESI) 484.1553 [M+H]
+
. C28H30NO3Fe requires 484.1575; 
λmax(CH3CN)/nm 370 (ε/dm
3
 mol
-1
 cm
-1
 3204), 450 (1304); 
νmax(neat)/cm
-1
 3321, 3095, 1727, 1634, 1602, 1536, 1157; 
δH (400 MHz, DMSO-d6): 8.62 (1H, t, J 5.6, -CONH-), 8.38 (1H, s, -ArH), 8.05 (1H, s, -
ArH), 7.86-7.96 (3H, m, -ArH), 7.81 (1H, dd, J 1.6 and 8.0, -ArH), 4.96 {2H, t, J 1.6, ortho 
on (η5-C5H4)}, 4.45 {2H, t, J 1.6, meta on (η
5
-C5H4)}, 4.02-4.08 (7H, m, -OCH2CH3,  η
5
-
C5H5),  3.31 (2H, m, -CH2CH2CH2CH2-), 2.35 (2H, t, J 7.2, -CH2CH2CH2CH2-), 1.56-1.62 
(4H, m, -CH2CH2CH2CH2-), 1.17 (3H, t, J 7.2, -OCH2CH3); 
δC (100 MHz, DMSO-d6): 172.8 (C=O), 166.2 (C=O), 138.6 (Cq), 134.4 (Cq), 131.1 (Cq), 
130.7 (Cq), 128.7, 127.3, 127.1, 125.9, 124.5, 122.7, 84.1 (Cipso η
5
-C5H4), 69.4 (η
5
-C5H5, 
Cmeta η
5
-C5H4), 66.6 (Cortho η
5
-C5H4), 59.7 (-OCH2-, -ve DEPT), 38.8 (-CH2CH2CH2CH2-, -
ve DEPT), 33.2 (-CH2CH2CH2CH2-, -ve DEPT), 28.6 (-CH2CH2CH2CH2-, -ve DEPT), 22.0 
(-CH2CH2CH2CH2-, -ve DEPT), 14.1 (-OCH2CH3). 
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Chapter 5  
Biological Evaluation of N-naphthoyl dipeptide derivatives and N-
(ferrocenyl)naphthoyl amino acid and dipeptide derivatives which contain unusual 
amino acids 
5.1. In vitro evaluation in the H1299 cell line and the Sk-Mel-28 cell line 
The in vitro biological evaluation of N-naphthoyl dipeptide derivatives and N-
(ferrocenyl)naphthoyl amino acid and dipeptide derivatives was undertaken in order to 
enable comparisons to be drawn with the previous group of N-(ferrocenyl)naphthoyl amino 
acid and dipeptide derivatives studied in Chapter 3. This was achieved by performing a 
comprehensive screen of every compound at 10 µM and 1 µM in the H1299 cell line, and at 
10 µM in the Sk-Mel-28 cell line, as outlined in Chapter 3 (Section 3.3). The results of the 
comprehensive screens are expressed as the percentage cell growth ± standard deviation 
(relative to the DMSO controls). Standard deviations have been calculated using data 
obtained from three independent experiments. 
 
5.1.1. N-(ferrocenyl)naphthoyl dipeptide derivatives 
The N-(ferrocenyl)naphthoyl dipeptide derivatives that contain N-methyl amino acids were 
shown to inhibit cell growth in the H1299 cell line by 90% or more, when tested at the 
higher concentration of 10 μM (Table 5.1). Four compounds in particular were shown to 
inhibit cell growth by almost 99%. A higher percentage of cell survival was observed when 
the H1299 cell line was treated with 1 μM solutions of these compounds, except in the case 
of N-(6-ferrocenyl-2-naphthoyl)-sarcosine-glycine ethyl ester 120, which was shown to be 
a potent inhibitor of cell growth (~95% inhibition). N-(3-ferrocenyl-2-naphthoyl)-
sarcosine-sarcosine ethyl ester 117 and N-(3-ferrocenyl-2-naphthoyl)-glycine-N-methyl-L-
alanine ethyl ester 118, were also shown to exert a weak anti-proliferative effect (~20% 
inhibition) at this lower concentration. 
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Table 5.1 Percentage cell growth of H1299 cells in the presence of N-
(ferrocenyl)naphthoyl dipeptide derivatives which contain N-methyl amino acids (115-
122). 
Compound No. 10 μM 1 μM 
N-(3-ferrocenyl-2-naphthoyl)-Gly-Sar-OEt 115 8.8 ± 3.8 97.4 ± 4.8 
N-(3-ferrocenyl-2-naphthoyl)-Sar-Gly-OEt 116 4.7 ± 1.5 86.1 ± 15.1 
N-(3-ferrocenyl-2-naphthoyl)-Sar-Sar-OEt 117 4.9 ± 1.1 75.2 ± 5.4 
N-(3-ferrocenyl-2-naphthoyl)-Gly-N-Me-L-Ala-OEt 118 0.4 ± 0.6 66.0 ± 12.8 
N-(6-ferrocenyl-2-naphthoyl)-Gly-Sar-OEt 119 0.5 ± 0.7 98.1 ± 4.4 
N-(6-ferrocenyl-2-naphthoyl)-Sar-Gly-OEt 120 0.5 ± 0.8 4.8 ± 1.4 
N-(6-ferrocenyl-2-naphthoyl)-Sar-Sar-OEt 121 0.4 ± 0.7 102.2 ± 16.4 
N-(6-ferrocenyl-2-naphthoyl)-Gly-N-Me-L-Ala-OEt 122 4.5 ± 2.7 97.4 ± 12.1 
 
The anti-proliferative effect of these N-methylated derivatives was shown to be weaker in 
the Sk-Mel-28 cell line (Table 5.2). At a concentration of 10 μM, over half of the 
compounds did not exhibit any considerable inhibition of cell growth. However, N-(3-
ferrocenyl-2-naphthoyl)-glycine-N-methyl-L-alanine ethyl ester 118 was found to have a 
reasonable anti-proliferative effect, achieving over 50% inhibition. N-(6-ferrocenyl-2-
naphthoyl)-glycine-sarcosine ethyl ester 119 showed the strongest anti-proliferative effect, 
with approximately 95% inhibition, whilst N-(6-ferrocenyl-2-naphthoyl)-sarcosine-glycine 
ethyl ester 120 inhibited cell growth by approximately 80%. Despite the strong inhibitory 
effect of N-(6-ferrocenyl-2-naphthoyl)-glycine-sarcosine ethyl ester 119 in the Sk-Mel-28 
cell line, this compound had no effect on proliferation in the H1299 cell line, when tested at 
the lower concentration of 1 μM. N-(6-ferrocenyl-2-naphthoyl)-sarcosine-glycine ethyl 
ester 120, on the other hand,  displays a potent anti-proliferative effect in both cell lines, 
and therefore, further studies to determine the IC50 value of this compound will be carried 
out. 
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Table 5.2 Percentage cell growth of Sk-Mel-28 cells in the presence of N-
(ferrocenyl)naphthoyl dipeptide derivatives which contain N-methyl amino acids (115-
122). 
Compound No. 10 μM 
N-(3-ferrocenyl-2-naphthoyl)-Gly-Sar-OEt 115 61.7 ± 27.3 
N-(3-ferrocenyl-2-naphthoyl)-Sar-Gly-OEt 116 73.6 ± 19.6 
N-(3-ferrocenyl-2-naphthoyl)-Sar-Sar-OEt 117 64.0 ± 21.5 
N-(3-ferrocenyl-2-naphthoyl)-Gly-N-Me-L-Ala-OEt 118 29.3 ± 19.6 
N-(6-ferrocenyl-2-naphthoyl)-Gly-Sar-OEt 119 3.2 ± 3.4 
N-(6-ferrocenyl-2-naphthoyl)-Sar-Gly-OEt 120 15.7 ± 9.8 
N-(6-ferrocenyl-2-naphthoyl)-Sar-Sar-OEt 121 65.0 ± 29.8 
N-(6-ferrocenyl-2-naphthoyl)-Gly-N-Me-L-Ala-OEt 122 85.0 ± 17 
 
At the higher concentration of 10 µM, the remaining N-(ferrocenyl)naphthoyl dipeptide 
derivatives were found to inhibit cell proliferation in the H1299 cell line by approximately 
80% or more, except for N-(6-ferrocenyl-2-naphthoyl)-β-alanine-glycine ethyl ester 130, 
which had no affect on cell growth (Table 5.3). Three compounds in particular were shown 
to inhibit cell growth by more than 96%: N-(6-ferrocenyl-2-naphthoyl)-glycine-D-alanine 
ethyl ester 124, N-(6-ferrocenyl-2-naphthoyl)-glycine-β-alanine ethyl ester 129, and N-(6-
ferrocenyl-2-naphthoyl)-γ-aminobutyric acid-glycine ethyl ester 132. At the lower 
concentration of 1 μM, the majority of these derivatives had no effect on H1299 cell 
growth. N-(6-ferrocenyl-2-naphthoyl)-glycine-β-alanine ethyl ester 129 was shown to have 
a weak anti-proliferative effect (~25% inhibition), whilst N-(6-ferrocenyl-2-naphthoyl)-
glycine-D-alanine ethyl ester 124 displayed a significant anti-proliferative effect (>50% 
inhibition). 
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Table 5.3 Percentage cell growth of H1299 cells in the presence of N-
(ferrocenyl)naphthoyl dipeptide derivatives (123-132). 
Compound No. 10 μM 1 μM 
N-(3-ferrocenyl-2-naphthoyl)-Gly-D-Ala-OEt 123 18.0 ± 0.7 102.7 ± 9.6 
N-(6-ferrocenyl-2-naphthoyl)-Gly-D-Ala-OEt 124 1.9 ± 0.7 44.8 ± 3.0 
N-(3-ferrocenyl-2-naphthoyl)-Gly-β-Ala-OEt 125 21.4 ± 4.2 109.7 ± 2.6 
N-(3-ferrocenyl-2-naphthoyl)-β-Ala-Gly-OEt 126 21.5 ± 2.8 116.2 ± 11.0 
N-(3-ferrocenyl-2-naphthoyl)-Gly-GABA-OEt 127 24.6 ± 2.7 100.7 ± 21.0 
N-(3-ferrocenyl-2-naphthoyl)-GABA-Gly-OEt 128 18.9 ± 4.5 107.0 ± 5.4 
N-(6-ferrocenyl-2-naphthoyl)-Gly-β-Ala-OEt 129 3.3 ± 0.5 72.9 ± 5.2 
N-(6-ferrocenyl-2-naphthoyl)-β-Ala-Gly-OEt 130 87.9 ± 9.2 87.7 ± 8.1 
N-(6-ferrocenyl-2-naphthoyl)-Gly-GABA-OEt 131 14.7 ± 8.4 97.5 ± 14.3 
N-(6-ferrocenyl-2-naphthoyl)-GABA-Gly-OEt 132 0.2 ± 0.6 102.8 ± 4.6 
 
The Sk-Mel-28 cell line was more resistant than the H1299 cell line to treatment with the 
remaining N-(ferrocenyl)naphthoyl dipeptide derivatives (Table 5.4). Only two compounds 
from this group were found to inhibit Sk-Mel-28 cell growth by more than 50%. N-(6-
ferrocenyl-2-naphthoyl)-glycine-D-alanine ethyl ester 124 and N-(6-ferrocenyl-2-
naphthoyl)-glycine-β-alanine ethyl ester 129 both had a strong anti-proliferative effect in 
this cell line, with approximately 85% cell growth inhibition. However, since N-(6-
ferrocenyl-2-naphthoyl)-glycine-β-alanine ethyl ester 129 had only a weak anti-
proliferative effect in the H1299 cell line at the lower concentration, only N-(6-ferrocenyl-
2-naphthoyl)-glycine-D-alanine ethyl ester 124 will progress to further studies. 
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Table 5.4 Percentage cell growth of Sk-Mel-28 cells in the presence of N-
(ferrocenyl)naphthoyl dipeptide derivatives (123-132). 
Compound No. 10 μM 
N-(3-ferrocenyl-2-naphthoyl)-Gly-D-Ala-OEt 123 84.9 ± 9.6 
N-(6-ferrocenyl-2-naphthoyl)-Gly-D-Ala-OEt 124 15.6 ± 4.0 
N-(3-ferrocenyl-2-naphthoyl)-Gly-β-Ala-OEt 125 83.9 ± 11.1 
N-(3-ferrocenyl-2-naphthoyl)-β-Ala-Gly-OEt 126 91.7 ± 12.8 
N-(3-ferrocenyl-2-naphthoyl)-Gly-GABA-OEt 127 80.9 ± 14.2 
N-(3-ferrocenyl-2-naphthoyl)-GABA-Gly-OEt 128 82.3 ± 16.3 
N-(6-ferrocenyl-2-naphthoyl)-Gly-β-Ala-OEt 129 14.8 ± 3.5 
N-(6-ferrocenyl-2-naphthoyl)-β-Ala-Gly-OEt 130 98.4 ± 7.6 
N-(6-ferrocenyl-2-naphthoyl)-Gly-GABA-OEt 131 62.5 ± 30.7 
N-(6-ferrocenyl-2-naphthoyl)-GABA-Gly-OEt 132 89.1 ± 17.8 
 
5.1.2. N-naphthoyl dipeptide derivatives 
N-naphthoyl-glycine-glycine ethyl ester 133 was found to have a slight inhibitory effect 
(~20% inhibition) on cell proliferation in the H1299 cell line at the higher concentration of 
10 μM, but had no effect on cell proliferation at the lower concentration of 1 μM. At the 
higher concentration of 10 μM, N-naphthoyl-glycine-L-alanine ethyl ester 134 had a more 
marked effect on cell proliferation (~70% inhibition) in the H1299 cell line, but again, 
H1299 cell growth was unaffected at the lower concentration of 1 μM. The N-naphthoyl 
dipeptide derivatives did not affect cell growth in the Sk-Mel-28 cell line (Table 5.5). 
 
Table 5.5 Percentage cell growth in the presence of N-naphthoyl dipeptide derivatives 
(133-134). 
Compound No. 10 μM  
H1299 
1 μM  
H1299 
10 μM  
Sk-Mel-28 
N-(2-naphthoyl)-Gly-Gly-OEt 133 69.3 ± 11.6 87.6 ± 18.4 95.6 ± 10.9 
N-(2-naphthoyl)-Gly-L-Ala-OEt 134 28.6 ± 4.3 107.4 ± 9.7 96.9 ± 8.7 
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5.1.3. N-(ferrocenyl)naphthoyl amino acid derivatives 
The N-(3-ferrocenyl-2-naphthoyl) amino acid derivatives achieved an appreciable level of 
cell growth inhibition (30-60%) in the H1299 cell line, at the higher concentration of 10 
μM (Table 5.6). Of these compounds, the N-(3-ferrocenyl-2-naphthoyl)-γ-aminobutyric 
acid ethyl ester 136 showed the strongest anti-proliferative effect (~60%). Interestingly, a 
greater anti-proliferative effect was observed for the N-(3-ferrocenyl-2-naphthoyl) amino 
acid derivatives that contained α-amino acids (Chapter 3, Section 3.3.2.).  In comparison, 
the N-(6-ferrocenyl-2-naphthoyl) amino acid derivatives were found to have a stronger anti-
proliferative effect; cell growth was inhibited by at least 89%. N-(6-ferrocenyl-2-
naphthoyl)-γ-aminobutyric acid ethyl ester 139 and N-(6-ferrocenyl-2-naphthoyl)-δ-amino-
n-valeric acid ethyl ester 140 showed a similarly strong anti-proliferative effect (~97%). 
However, N-(6-ferrocenyl-2-naphthoyl)-γ-aminobutyric acid ethyl ester 139 was the only 
N-(ferrocenyl)naphthoyl amino acid derivative found to inhibit H1299 cell growth by more 
than 50% at the lower concentration of 1 μM. At this concentration, N-(6-ferrocenyl-2-
naphthoyl)-δ-amino-n-valeric acid ethyl ester 140 displayed only a weak anti-proliferative 
effect (~30% inhibition). 
 
Table 5.6 Percentage cell growth of H1299 cells in the presence of N-
(ferrocenyl)naphthoyl amino acid derivatives (135-140). 
Compound No. 10 μM 1 μM 
N-(3-ferrocenyl-2-naphthoyl)-β-Ala-OEt 135 63.8 ± 5.6 112.6 ± 16.5 
N-(3-ferrocenyl-2-naphthoyl)-GABA-OEt 136 39.0 ± 5.4 105.0 ± 24.6 
N-(3-ferrocenyl-2-naphthoyl)-δ-Ava-OEt 137 57.0 ± 9.7 110.3 ± 9.2 
N-(6-ferrocenyl-2-naphthoyl)-β-Ala-OEt 138 11.6 ± 0.5 109.6 ± 9.5 
N-(6-ferrocenyl-2-naphthoyl)-GABA-OEt 139 3.0 ± 0.6 45.7 ± 3.6 
N-(6-ferrocenyl-2-naphthoyl)-δ-Ava-OEt 140 3.0 ± 0.9 62.1 ± 6.8 
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In the Sk-Mel-28 cell line, only two N-(ferrocenyl)naphthoyl amino acid derivatives  were 
found to have an inhibitory effect on cell growth: N-(6-ferrocenyl-2-naphthoyl)-δ-amino-n-
valeric acid ethyl ester 140 had a significant anti-proliferative effect (~70% inhibition), 
whilst N-(6-ferrocenyl-2-naphthoyl)-γ-aminobutyric acid ethyl ester 139  displayed a strong 
anti-proliferative effect (~90% inhibition).  
 
Table 5.7 Percentage cell growth of Sk-Mel-28 cells in the presence of N-
(ferrocenyl)naphthoyl amino acid derivatives (135-140). 
Compound No. 10 μM 
N-(3-ferrocenyl-2-naphthoyl)-β-Ala-OEt 135 103.5 ± 2.9 
N-(3-ferrocenyl-2-naphthoyl)-GABA-OEt 136 92.3 ± 2.7 
N-(3-ferrocenyl-2-naphthoyl)-δ-Ava-OEt 137 98.9 ± 5.5 
N-(6-ferrocenyl-2-naphthoyl)-β-Ala-OEt 138 69.4 ± 24.5 
N-(6-ferrocenyl-2-naphthoyl)-GABA-OEt 139 9.6 ± 1.6 
N-(6-ferrocenyl-2-naphthoyl)-δ-Ava-OEt 140 33.1 ± 10.5 
 
5.1.4. IC50 value determination 
Further studies were conducted, as described in Chapter 3 (Section 3.3.4), to determine IC50 
values for N-(6-ferrocenyl-2-naphthoyl)-sarcosine-glycine ethyl ester 120, N-(6-ferrocenyl-
2-naphthoyl)-glycine-D-alanine ethyl ester 124, and N-(6-ferrocenyl-2-naphthoyl)-δ-
aminobutyric acid ethyl ester 139 in the H1299 cell line and the Sk-Mel-28 cell line. The 
IC50 value for each compound was calculated using Calcusyn software, and standard 
deviations have been calculated using data obtained from three independent experiments. 
The values obtained are listed in Table 5.8. 
In the H1299 cell line, a remarkable IC50 value of 0.14 ± 0.02 μM was calculated for N-(6-
ferrocenyl-2-naphthoyl)-sarcosine-glycine ethyl ester 120. This value is comparable to the 
IC50 value determined for N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 96 (0.13 
± 0.02 μM) in Chapter 3. Similarly, in the Sk-Mel-28 cell line an IC50 value of 1.06 ± 0.05 
μM was calculated for N-(6-ferrocenyl-2-naphthoyl)-sarcosine-glycine ethyl ester 120. For 
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N-(6-ferrocenyl-2-naphthoyl)-glycine-D-alanine ethyl ester 124, IC50 values of 0.33 ± 0.02 
μM and 1.83 ± 0.04 μM were calculated in the H1299 and Sk-Mel-28 cell lines, 
respectively. In comparison to N-(6-ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl ester 
51, this represents a four-fold improvement in anti-proliferative effect in the H1299 cell 
line, and a two-fold improvement in the Sk-Mel-28 cell line. N-(6-ferrocenyl-2-naphthoyl)-
γ-aminobutyric acid ethyl ester 139 was found to have an IC50 value of 0.62 ± 0.07 μM in 
the H1299 cell line and 1.41 ± 0.04 μM in the Sk-Mel-28 cell line.  
Thus, in total, the primary and secondary SAR studies of novel ferrocenyl-peptide 
bioconjugates have identified five compounds that have an equivalent or more potent anti-
proliferative effect in the H1299 cell line than the platinum-based anti-cancer drug, 
cisplatin 1 (1.4 ± 0.1 μM). Four of these compounds possess IC50 values that lie in the 
nanomolar range. These findings represent an important progression in the study of 
bioorganometallic anti-cancer agents, since reported IC50 values for other ferrocenyl 
derivatives in the A549 lung cancer cell line remain above 10 μM.1 In addition, noteworthy 
IC50 values that range from 1.06 ± 0.05 μM to 3.74 ± 0.37 μM have been determined for 
these five compounds in the Sk-Mel-28 cell line.  
 
Table 5.8 IC50 values in the H1299 and Sk-Mel-28 cell lines. 
Compound No. H1299 (μM) Sk-Mel-28 (μM) 
N-(6-ferrocenyl-2-naphthoyl)-Sar-Gly-OEt 120 0.14 ± 0.02 1.06 ± 0.05 
N-(6-ferrocenyl-2-naphthoyl)-Gly-D-Ala-OEt 124 0.33 ± 0.02 1.83 ± 0.04 
N-(6-ferrocenyl-2-naphthoyl)-GABA-OEt 139 0.62 ± 0.07 1.41 ± 0.04 
 
5.2. Structure-activity relationship of N-(ferrocenyl)naphthoyl amino acid and 
dipeptide derivatives  
The biological data obtained from these in vitro studies provides more information 
regarding the structure-activity relationship of the N-(ferrocenyl)naphthoyl amino acid and 
dipeptide derivatives, which was established in Chapter 3 (Section 3.4). First of all, in 
relation to the N-(3-ferrocenyl-2-naphthoyl) amino acid derivatives, the anti-proliferative 
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effect is greatest when chiral α-amino acids with bulky side chains are employed. 
Extending the peptide chain length by incorporating the achiral amino acids β-alanine, γ-
aminobutyric acid and δ-amino-n-valeric acid does not improve the anti-proliferative effect. 
In contrast, substitution at the α-carbon of the amino acid is not beneficial to the biological 
activity of the N-(6-ferrocenyl-2-naphthoyl) amino acid derivatives. The achiral amino acid 
derivatives (including glycine), which are devoid of steric bulk, show a greater anti-
proliferative effect. The weakest anti-proliferative effect for this homologous series is 
observed when n=2, in the case of N-(6-ferrocenyl-2-naphthoyl)-β-alanine ethyl ester 138, 
whilst the greatest anti-proliferative effect is observed when n=3, in the case of N-(6-
ferrocenyl-2-naphthoyl)-γ-aminobutyric acid ethyl ester 139. N-(6-ferrocenyl-2-naphthoyl)-
glycine ethyl ester 92 and N-(6-ferrocenyl-2-naphthoyl)-δ-amino-n-valeric acid ethyl ester 
140 both display an intermediate anti-proliferative effect. These results indicate that 
extending the length of the α-amino acid glycine by two methylene units enhances the 
biological activity of the N-(6-ferrocenyl-2-naphthoyl) amino acid derivatives. This 
improvement in anti-proliferative effect may be a consequence of an increase in 
lipophilicity or the conformational flexibility afforded by the γ-aminobutyric acid moiety. 
Secondly, the N-naphthoyl analogues of the two most potent compounds, N-naphthoyl-
glycine-glycine ethyl ester 133 and N-naphthoyl-glycine-L-alanine ethyl ester 134 were 
found to be ineffective at inhibiting cell growth in the Sk-Mel-28 cell line and in the H1299 
cell line at the lower concentration of 1 μM. This dramatic decrease in anti-proliferative 
effect demonstrates conclusively that the ferrocenyl unit is essential for in vitro biological 
activity.  
Finally, in relation to the N-(ferrocenyl)naphthoyl dipeptide derivatives, it is again evident 
that the N-(6-ferrocenyl-2-naphthoyl) dipeptide derivatives have a superior anti-
proliferative effect compared to the corresponding N-(3-ferrocenyl-2-naphthoyl) analogues. 
The results of this study demonstrate that, with regard to N-(6-ferrocenyl-2-naphthoyl)-
glycine-glycine ethyl ester 96, N-methylation of the N-terminal glycine residue is well 
tolerated; the anti-proliferative effect of N-(6-ferrocenyl-2-naphthoyl)-sarcosine-glycine 
ethyl ester 120 displays a comparable anti-proliferative effect in both cell lines. However, 
N-methylation of the C-terminal glycine residue results in a loss of potency in the H1299 
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cell line, whilst N-methylation of both residues produces a fall in activity in both cell lines. 
The isosteric replacement of the N-terminal glycine residue with β-alanine results in a 
dramatic decrease in anti-proliferative effect; N-(6-ferrocenyl-2-naphthoyl)-β-alanine-
glycine ethyl ester 130 has no effect on cell proliferation in either cell line. Similarly, 
isosteric replacement with γ-aminobutyric acid reduces the anti-proliferative effect. For the 
C-terminal glycine residue, replacement with the β-alanine and γ-aminobutyric acid 
isosteres also decreases the inhibitory effect on cell proliferation although the fall in 
activity is not as drastic as that observed for the N-terminal glycine residue.  
For N-(6-ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl ester 51, N-methylation of the C-
terminal L-alanine residue results in a loss of potency. In contrast, inverting the 
stereochemistry of C-terminal α-carbon atom enhances the anti-proliferative effect; N-(6-
ferrocenyl-2-naphthoyl)-glycine-D-alanine ethyl ester 124 is four times more potent than N-
(6-ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl ester 51 in the H1299 cell line, and two 
times more potent in the Sk-Mel-28 cell line.  
 
5.3. Cell cycle analysis of N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester (96) 
and N-(6-ferrocenyl-2-naphthoyl)-sarcosine-glycine ethyl ester (120) 
The growth and division of cells proceeds via the cell cycle, which is typically divided into 
four distinct stages: the synthesis (S), mitosis (M) and two gap (G1 and G2) phases. Most 
normal cells, unless they have received a stimulus to proliferate or differentiate, exist in a 
non-dividing, quiescent state known as G0.
2
 Cancer cells, on the other hand, are in a state 
of aberrant growth. The boundary between the G1 and S phases represents the main control 
point, or restriction point. It is at this point that the cell must decide whether to divide into 
two daughter cells or die, as the cell can only exist in subsequent phases for a short period. 
The majority of chemotherapeutic agents, e.g. paclitaxel 11, function by blocking cell cycle 
progression after this restriction point.
3
  
The cell cycle distribution of cells is typically analysed by flow cytometry or fluorescence 
activated cell sorting (FACS). Prior to analysis, the cells are stained with propidium iodide 
141, a fluorescent molecule that intercalates with the DNA present in the cell nucleus. 
Discrimination between the various stages of the cell cycle is possible due to changes in the 
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concentrations of DNA in the cells as the cycle progresses. Resting cells (G0/G1 phase) 
contain two copies of each chromosome. As the cells progress towards mitosis, they 
synthesise DNA (S phase), which allows for more intercalation and increases the 
fluorescence intensity. When all chromosomes have been replicated, the DNA content has 
doubled (G2/M phase), and thus, the cells fluoresce with twice the intensity of the G0/G1 
phase. Cells in which the DNA has become fragmented or degraded (such as apoptotic 
cells) will exhibit a decrease in fluorescence intensity, compared to the G0/G1 phase. These 
cells will appear as a broad “sub-G0/G1” peak, and can represent, in addition to apoptotic 
cells, nuclear fragments, clumps of chromosomes, micronuclei or cells undergoing 
differentiation.
4
  
 
Cell cycle analysis was performed by treating individual wells of a 24-well plate containing 
H1299 cells with either N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 96 or N-
(6-ferrocenyl-2-naphthoyl)-sarcosine-glycine ethyl ester 120 at a concentration of 0.5 µM 
and 1.0 µM. Since DMSO can have an adverse effect on cells, a DMSO control was 
included in the assay, along with controls for normal (untreated) cell growth. In this case, 
the DMSO control wells contained a 0.2% DMSO solution. Following incubation for 48 
and 72 hours, the cells were fixed in 70% ethanol, stained with propidium iodide 141 and 
analysed by flow cytometry.  
Table 5.9 summarises the percentage of H1299 cells in each stage of the cell cycle 
following treatment with N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 96, for 
48 hours and 72 hours. After 48 hours, treatment of H1299 cells with 0.5 μM N-(6-
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ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 96 significantly increased the sub-
G0/G1 population (p = 0.006). There is also a significant decrease in the number of cells in 
the S phase of the cell cycle (p = 0.017). The sub-G0/G1 population increases by 
approximately two-fold when the concentration of N-(6-ferrocenyl-2-naphthoyl)-glycine-
glycine ethyl ester 96 is increased to 1.0 μM. At this higher concentration, the increase in 
the sub-G0/G1 peak is accompanied by a concomitant decrease in the G0/G1 (p = 0.001) 
and S phase (p = 0.005) cell populations. Similar observations were made following 
treatment for 72 hours; there is a significant increase in the sub-G0/G1 population of H1299 
cells treated with 0.5 μM (p = 0.032) and 1.0 μM (p = 0.006) N-(6-ferrocenyl-2-naphthoyl)-
glycine-glycine ethyl ester 96.  
 
Table 5.9 Cell cycle distribution of H1299 cells treated with N-(6-ferrocenyl-2-naphthoyl)-
glycine-glycine ethyl ester 96 for 48 h or 72 h, then analysed by flow cytometry.  
 Sub G0/G1 G0/G1 S G2/M 
48 h     
Control 4.6 ± 1.1 40.9 ± 0.7 44.9 ± 1.8 9.6 ± 1.9 
0.5 μM 11.9 ± 0.3** 39.6 ± 2.0 39.2 ± 0.8* 9.4 ± 1.4 
1.0 μM 21.8 ± 1.6** 34.5 ± 0.8** 37.1 ± 1.2** 6.7 ± 1.4 
DMSO Control 5.3 ± 0.9 40.8 ± 0.9 44.4 ± 2.9 9.6 ± 1.3 
     
72 h     
Control 2.4 ± 0.3 46.6 ± 0.4 41.3 ± 0.8 9.7 ± 1.2 
0.5 μM 7.5 ± 1.7* 44.5 ± 2.0 39.2 ± 1.8 8.9 ± 2.0 
1.0 μM 12.2 ±  1.5** 41.5 ± 3.1 37.9 ± 1.6* 8.4 ± 2.3 
DMSO Control 2.2 ± 0.4 47.9 ± 3.1 40.2 ± 3.6 9.7 ± 0.9 
Standard deviations have been calculated using data obtained from three independent 
experiments. Student’s t-test was performed to determine significance: * denotes p < 0.05; 
** denotes p < 0.01, when comparing treatment with control or DMSO control. 
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Figure 5.1 Sample graphs of H1299 cell cycle distribution after 72 hours: (a) control, (b) 
N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 96 (0.5 μM), (c) N-(6-ferrocenyl-
2-naphthoyl)-glycine-glycine ethyl ester 96 (1.0 μM) and (d) DMSO control. The data 
obtained from the flow cytometry was analysed using ModFit software. This software 
calculates the number of diploid cells in G0/G1, S and G2/M phases of the cell cycle, as 
well as cell debris and cell aggregates. Hypodiploid cells appear as a sub-G0/G1 peak.  
 
The cell cycle distribution of H1299 cells treated with N-(6-ferrocenyl-2-naphthoyl)-
sarcosine-glycine ethyl ester 120 for 48 hours and 72 hours, follows a similar pattern (Table 
5.10). After 48 hours, there is a significant increase in the sub-G0/G1 population (p = 
0.040) accompanied by a decrease in the number of cells in S (p = 0.009) phase of the cell 
cycle, following treatment with the lower concentration (0.5 μM) of N-(6-ferrocenyl-2-
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naphthoyl)-sarcosine-glycine ethyl ester 120. Doubling the concentration of N-(6-
ferrocenyl-2-naphthoyl)-sarcosine-glycine ethyl ester 120 to 1.0 μM, also doubles the sub-
G0/G1 population. At this higher concentration, there is also a significant decrease in the 
number of cells in the G0/G1 (p = 0.0004) and S (p = 0.002) phases of the cell cycle. After 
72 hours treatment, there is a significant increase in the sub-G0/G1 population of H1299 
cells treated with 0.5 μM (p = 0.012) and 1.0 μM (p = 0.015) N-(6-ferrocenyl-2-naphthoyl)-
sarcosine-glycine ethyl ester 120.  
 
Table 5.10 Cell cycle distribution of H1299 cells treated with N-(6-ferrocenyl-2-
naphthoyl)-sarcosine-glycine ethyl ester 120 for 48 h or 72 h, then analysed by flow 
cytometry. 
 Sub G0/G1 G0/G1 S G2/M 
48 h     
Control 3.6 ± 0.4 40.5 ± 0.6 46.4 ± 1.3 9.6 ± 1.0 
0.5 μM 11.3 ± 2.8* 37.2 ± 2.0 41.3 ± 1.3** 10.2 ± 2.5 
1.0 μM 19.5 ± 3.0** 34.0 ± 0.7** 38.9 ± 1.4** 7.6 ± 1.3 
DMSO Control 4.7 ± 1.0 39.8 ± 1.6 45.7 ± 2.9 9.8 ± 2.9 
     
72 h     
Control 2.9 ± 0.2 42.4 ± 1.1 43.9 ± 0.1 10.8 ± 1.0 
0.5 μM 6.0 ± 0.7* 41.1 ± 1.0 42.0 ± 1.0 10.8 ± 0.6 
1.0 μM 11.3 ± 1.9* 38.4 ± 0.4* 40.3 ±  0.5** 10.1 ± 1.1 
DMSO Control 2.0 ± 0.4 44.0 ± 1.8 43.0 ± 0.7 11.0 ± 0.7 
Standard deviations have been calculated using data obtained from three independent 
experiments. Student’s t-test was performed to determine significance: * denotes p < 0.05; 
** denotes p < 0.01, when comparing treatment with control. 
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Figure 5.2 Sample graphs of H1299 cell cycle distribution after 72 hours: (a) control, (b) 
N-(6-ferrocenyl-2-naphthoyl)-sarcosine-glycine ethyl ester 120 (0.5 μM), (c) N-(6-
ferrocenyl-2-naphthoyl)-sarcosine-glycine ethyl ester 120 (1.0 μM) and (d) DMSO control. 
The data obtained from the flow cytometry was analysed using ModFit software. This 
software calculates the number of diploid cells in G0/G1, S and G2/M phases of the cell 
cycle, as well as cell debris and cell aggregates. Hypodiploid cells appear as a sub-G0/G1 
peak.  
 
These findings suggest that the N-(6-ferrocenyl-2-naphthoyl) dipeptide derivatives most 
likely inhibit cell proliferation in the H1299 cell line by inducing apoptosis. Similar 
observations have been made for the ferrocenyl derivative, ferrociphenol 27 in the MCF-7 
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breast cancer cell line.
5
 However, further flow cytometry studies that specifically measure 
the levels of early and late apoptotic cells must be conducted to confirm that apoptosis is 
being induced by these novel ferrocenyl-peptide bioconjugates.  
 
5.4. Conclusions 
As part of a secondary SAR study, N-(ferrocenyl)naphthoyl amino acid and dipeptide 
derivatives and N-naphthoyl dipeptide derivatives were evaluated for in vitro anti-
proliferative effect in lung cancer (H1299) and melanoma (Sk-Mel-28) cell lines. This 
study confirmed that the N-(6-ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives 
display a greater potential as anti-cancer agents than the N-(3-ferrocenyl-2-naphthoyl) 
amino acid and dipeptide derivatives. With regard to the two potential lead compounds that 
were identified in the primary SAR study, N-methylation of the C-terminal amino acid 
residue reduces the anti-proliferative effect. Thus, the ability of this nitrogen atom to act as 
a hydrogen bond donor is clearly important for biological activity. The in vitro biological 
activity of N-(6-ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl ester 51 was optimised by 
inverting the stereochemistry of the C-terminal α-carbon atom to give N-(6-ferrocenyl-2-
naphthoyl)-glycine-D-alanine ethyl ester 124. The replacement of either glycine residue in 
N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 96 with the β-alanine and γ-
aminobutyric acid residues does not improve the in vitro biological activity, however, 
replacing the N-terminal glycine residue with sarcosine maintains the observed in vitro anti-
proliferative effect. This could prove to be a valuable modification for future studies, since 
N-methyl derivatives are more resistant to degradation by proteases in vivo.
6
 It has also 
been clearly demonstrated in this secondary SAR study that the redox active ferrocenyl unit 
of these ferrocenyl-peptide bioconjugates is essential for biological activity. For the 
homologous series of N-(ferrocenyl)naphthoyl amino acid derivatives, N-(6-ferrocenyl-2-
naphthoyl)-γ-aminobutyric acid ethyl ester 139 was identified as the most active derivative, 
thus extending the length of the α-amino acid glycine chain by two methylene units 
enhances the biological activity. 
In total, these primary and secondary SAR studies have indentified five ferrocenyl-peptide 
bioconjugates that have an equivalent or more potent anti-proliferative effect in the H1299 
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cell line than the platinum-based anti-cancer drug, cisplatin 1 (1.4 ± 0.1 μM). Four of these 
compounds possess IC50 values that lie in the nanomolar range. Thus, the primary objective 
of this research thesis has been achieved; the anti-proliferative effect of these novel 
ferrocenyl-peptide bioconjugates has been enhanced by more than 30 times, compared to 
the most active N-(ferrocenyl)benzoyl peptide derivative.
7
 In addition, the N-
(ferrocenyl)naphthoyl amino acid and dipeptide derivatives have been shown to be 
effective an inhibiting proliferation in the Sk-Mel-28 cell line. Significant IC50 values 
ranging from 1.06 ± 0.05 μM to 3.74 ± 0.37 μM have been determined for the five most 
potent compounds in the Sk-Mel-28 cell line. Thus, the N-(ferrocenyl)naphthoyl amino acid 
and dipeptide derivatives represent a novel class of bioorganometallic anti-cancer agents 
that show great promise for the treatment of lung cancer and melanoma. 
Finally, cell cycle analysis in the H1299 cell line has shown the two most active ferrocenyl-
peptide bioconjugates, N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 96 and N-
(6-ferrocenyl-2-naphthoyl)-sarcosine-glycine ethyl ester 120 to cause a significant increase 
in the sub-G0/G1 peak, which is suggestive of apoptosis. This observation is encouraging, 
since the production of intracellular ROS has been shown to lead to cancer cell apoptosis.
8
 
In future work, the mode of action of these novel compounds should be investigated and 
further studies to confirm that apoptosis is induced by these novel compounds should also 
be performed. 
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Materials and Methods 
 
Cell cycle assays 
H1299 cells were plated at a density of 2.5 x 10
4
 cells/well in 24-well plates, in RPMI-1640 
media containing 10% FCS. After 24 hours, the cells were treated with the test compound. 
Dimethyl sulfoxide (DMSO) control wells were included in each assay. After 48 and 72 
hours, the media was collected into microcentrifuge tubes and the wells were washed with 
PBS, which was also collected.  Cells were trypsinised and added to the media collected for 
each sample. The tubes were centrifuged at 300 x g for 5 minutes and the media was 
aspirated. The cell pellets were re-suspended in PBS, and each cell suspension was 
transferred to a well of a round bottomed 96 well plate.  The plate was centrifuged at 450 x 
g for 5 minutes and the supernatant aspirated leaving approximately 20 µl in each well. The 
remaining volume was used to re-suspend the cells and 200 µl of ice cold 70 % ethanol was 
added gradually to each well. The plates were then stored at 4 
o
C overnight. After fixing, 
the cells were stained according to the protocol for the Guava Cell Cycle assay. Cells were 
analysed on the Guava EasyCyte (Guava Technologies) and the data was analysed using 
Modfit LT software (Verity). 
 
Statistical Analysis 
Analysis of the response to treatment was performed using the student’s t-test (two-tailed 
with unequal variance) and p-value < 0.05 was considered statistically significant. 
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Appendix I-Abbreviations and Units 
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Abbreviations 
A 
A  absorbance 
ACE  angiotensin-converting enzyme 
Acetone-d6 deuterated acetone 
ACN  acetonitrile 
Ag|AgCl silver/silver chloride (reference electrode) 
Anal.  analysis 
ATCC  American Tissue Culture Centre 
ATP  adenosine triphosphate 
ATR  attenuated total reflection 
AR  androgen receptor 
 
B 
BF4
-  
tetrafluoroborate ion 
Boc  tert-butoxycarbonyl 
BOP benzotriazole-1-yl-oxy-tris-(dimethylamino) phosphonium 
hexafluorophosphate 
Br  bromine 
br.  broad (spectral) 
 
C 
C  carbon; concentration 
Calc.  calculated 
CD  cyclodextrin 
CDCl3  deuterated chloroform 
CF3  trifluoromethyl group 
Cg  centroids 
Cl  chlorine 
CN  nitrile 
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Co   cobalt  
CO2  carbon dioxide 
COSY  correlation spectroscopy 
Cp  cyclopentadienyl 
Cq  quaternary carbon 
Cu  copper 
CV  cyclic voltammetry  
C=O  carbonyl 
 
D 
d  doublet (spectral) 
DACH  trans-R,R-1,2-diaminocyclohexane 
D-Ala  D-alanine 
DCC  1,3-dicyclohexylcarbodiimide 
DCM  dichloromethane 
DCU  Dublin City University 
dd  double doublets (spectral) 
DEPT  distorsionless enhancement by polarisation transfer 
DHT  dihydrotestosterone 
DMSO  dimethylsulfoxide 
DMSO-d6 deuterated dimethylsulfoxide 
DNA  deoxyribonucleic acid 
 
E 
e
-
  electron 
EAT  Ehrlich ascites tumour 
EDC  N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride 
EDTA  ethylenediaminetetraacetic acid 
EEDQ  2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline 
E
0
´  formal redox potential 
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ER  estrogen receptor 
ER(+)  estrogen receptor positive cells 
ER(-)  estrogen receptor negative cells 
ESI  electrospray ionisation 
ESR  electron spin resonance 
Et3N  triethylamine 
EtOH  ethanol 
 
F 
FACS  fluorescence activated cell sorting 
Fc/Fc
+  
ferrocene/ferricenium ion 
FcCOOH ferrocenecarboxylic acid 
FCS  foetal calf serum 
Fe  iron 
Fe(II)  ferrous ion 
Fe(III)  ferric ion 
FT  fourier transform 
 
G 
G0/G1/G2 gap phase 
Ga  gallium 
GABA  γ-aminobutyric acid  
Ge  germanium 
Gly  glycine 
 
H 
H  hydrogen 
H2DCF-DA 2’,7’-dichlorodihydrofluorescein diacetate 
H2O  water 
HBr  hydrogen bromide 
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HBTU O-(1H-benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium 
hexafluorophosphate 
HCl  hydrochloric acid 
HMBC heteronuclear multiple bond correlation 
HMPA  hexamethylphosphoramide 
HMQC heteronuclear multiple quantum coherence 
HO
•  
hydroxyl radical 
HOBt  1-hydroxybenzotriazole 
HPβCD hydroxypropyl-β-cyclodextrin 
HPLC  high performance liquid chromatography 
HPV  human papillomavirus 
HRT  hormone replacement therapy 
HSQC  heteronuclear single quantum coherence 
 
I 
IC50  half maximal inhibitory concentration 
IMS  industrial methylated spirits 
IR  infra red 
 
J 
J  coupling constant (spectral) 
 
K 
KBr  potassium bromide 
 
L 
l  path length (in cm) 
L-Ala  L-alanine 
LC  liquid chromatography 
L-Leu  L-leucine 
236 
 
L-Phe  L-phenylalanine 
 
M 
m  meta; mass 
m  multiplet (spectral) 
M  metal; mitosis phase 
MALDI matrix-assisted laser desorption/ionisation 
MDR  multidrug resistance 
MeOH  methanol 
MgSO4 magnesium sulphate 
MLCT  metal-ligand charge transfer 
Mn  manganese 
Mo  molybdenum 
mp  melting point 
MS  mass spectrometry 
MS/MS tandem mass spectrometry 
MTIC  3-methyl-(triazen-1-yl)imidazole-4-carboxamide 
MTT  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
m/z  mass to charge ratio 
 
N 
N  nitrogen 
NaNO2 sodium nitrite 
NaOH  sodium hydroxide 
NCI  National Cancer Institute 
NHE  normal hydrogen electrode 
Ni  nickel  
NICB  National Institute for Cellular Biotechnology 
Nb  niobium 
N-Me-L-Ala N-methyl-L-alanine 
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NMR  nuclear magnetic resonance 
No.  number 
NSCLC non-small cell lung cancer 
 
O 
O  oxygen 
OD  optical density 
OEt  ethoxy 
OH  hydroxy 
OMe  methoxy 
ORTEP oak ridge thermal ellipsoid plot 
 
P 
p  para 
P  phosphorous 
PBS  phosphate buffered saline 
PEG  polyethyleneglycol 
PCl5  phosphorous pentachloride 
PF6
-  
hexafluorophosphate ion 
P-gp  P-glycoprotein 
PLA  poly-D-lactic acid 
Pt  platinum 
PyBOP benzotriazol-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate 
 
Q 
q  quartet (spectral) 
qt  quintet (spectral) 
QSAR  quantitative structure-activity relationship 
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R 
Rh  rhodium 
RNA  ribonucleic acid 
ROE  rotating-frame overhauser enhancement 
ROESY rotating-frame overhauser effect spectroscopy 
ROS  reactive oxygen species 
rpm  rotations per minute 
RPMI  Roswell Park Memorial Institute 
Ru  ruthenium 
 
S 
s  singlet (spectral) 
S  sulfur; synthesis phase 
SAR  structure-activity relationship 
Sar  sarcosine 
SCE  saturated calomel electrode 
SCLC  small cell lung cancer 
SERM  selective estrogen receptor modulator 
Sn  tin 
SOCl2  thionyl chloride 
 
T 
t  triplet (spectral); lifetime 
TBAP  tetrabutylammonium perchlorate 
t-Bu  tert-butyl group 
Tc  coalescence temperature 
TCD  Trinity College Dublin   
TFA  trifluoroacetic acid 
Ti  titanium 
TMS  tetramethylsilane 
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TOCSY total correlation spectroscopy 
TOF  time of flight 
TRIMEB heptakis-2,3,6-tri-O-methyl-β-CD 
 
U 
UV  ultraviolet 
 
V 
V  vanadium 
Vis  visible 
 
W 
WHO  World Health Organisation 
 
Z 
z  charge 
 
Miscellaneous 
(E)  Entegen (opposite) 
(Z)  Zusammen (together) 
2D  2-dimensional 
2X  2-times 
8-oxo-Gua 8-oxo-7,8-dihydroguanine 
αH  α-hydrogen 
β-Ala  β-alanine 
δ-Ava  δ-amino-n-valeric acid 
ε  extinction coefficient 
λmax  maximum absorbance 
η5-C5H4 substituted cyclopentadienyl ring 
η5-C5H5 unsubstituted cyclopentadienyl ring 
240 
 
ω  dihedral angle 
±  plus/minus 
~  approximately 
≈  almost equal to 
<  less than 
>  greater than 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
241 
 
Units 
A  ampere 
Å  Ångstrom 
cm  centimetre 
cm
-1
  wavenumber(s)/per centimetre 
dm  decimetre 
g  gram 
h  hour 
Hz  hertz 
l  litre 
K  Kelvin 
kg
-1
  per kilogram 
M  molar 
MHz  megahertz 
mg  milligram 
ml  millilitre 
mm  millimetre 
mM  millimolar 
mmol  millimole 
mol  mole 
μl  microlitre 
μm  micrometre 
μM  micromolar 
mV  millivolt 
nm  nanometre 
nM  nanomolar 
o  
degrees 
o
C  degrees Celsius 
ppm  part(s) per million 
s  second 
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V  volt 
δ  chemical shift (ppm) 
%  percentage 
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Appendix II-Publications 
